UMP Healthcare
聯合醫務集團

UMP HEALTHCARE HOLDINGS LIMITED
聯合醫務集團有限公司

(Stock Code 股份代號: 722)

(Incorporated in the Cayman Islands with limited liability
於開曼群島註冊成立之有限公司)

Better Health Better Future



2026 年報
ANNUAL REPORT

CONTENTS 目錄

2 Corporate Information
公司資料

4 Financial Highlights
財務摘要

6 Chairman's Statement
主席報告

10 Co-CEOs' Report
聯席行政總裁報告

15 Management Discussion and Analysis
管理層討論及分析

42 Environmental, Social and Governance Report
環境、社會及管治報告

84 Biographical Details of Directors
董事履歷

94 Corporate Governance Report
企業管治報告

121 Report of Directors
董事會報告

163 Independent Auditor's Report
獨立核數師報告

171 Consolidated Statement of Profit or Loss
綜合損益表

172 Consolidated Statement of Comprehensive Income
綜合全面收入表

173 Consolidated Statement of Financial Position
綜合財務狀況表

175 Consolidated Statement of Changes in Equity
綜合權益變動表

177 Consolidated Statement of Cash Flows
綜合現金流量表

180 Notes to the Consolidated Financial Statements
綜合財務報表附註

305 Financial Summary
財務概要

306 Glossary
詞彙

This annual report is printed on environmentally friendly paper
本年報以環保紙印製

CORPORATE INFORMATION
公司資料

BOARD OF DIRECTORS
董事會

Executive Directors
執行董事

Dr. Sun Yiu Kwong *(Chairman)*
孫耀江醫生*(主席)*

Dr. Sun Man Kin, Michael
(Vice Chairman and Co-Chief Executive Officer)
孫文堅醫生
(副主席兼聯席行政總裁)

Ms. Kwok Cheuk Kwan, Jacquen *(Co-Chief Executive Officer)*
郭卓君女士*(聯席行政總裁)*

Mr. Tsang On Yip, Patrick *BBS*
曾安業先生*銅紫荊星章*

Dr. Lee Pak Cheung, Patrick
李柏祥醫生

Non-executive Director
非執行董事

Ms. Cheng Chi Man
鄭志雯女士

Independent Non-executive Directors
獨立非執行董事

Mr. Lee Luen Wai, John *BBS JP*
李聯偉先生*銅紫荊星章，太平紳士*

Mr. Yeung Tak Bun *BBS JP*
楊德斌先生*銅紫荊星章，太平紳士*

Mrs. Chan Kung Wai Ying, Amy *MH*
陳龔偉瑩女士*榮譽勳章*

AUDIT COMMITTEE
審核委員會

Mr. Lee Luen Wai, John *BBS JP (Chairman)*
李聯偉先生*銅紫荊星章，太平紳士(主席)*

Mr. Yeung Tak Bun *BBS JP*
楊德斌先生*銅紫荊星章，太平紳士*

Mrs. Chan Kung Wai Ying, Amy *MH*
陳龔偉瑩女士*榮譽勳章*

REMUNERATION COMMITTEE
薪酬委員會

Mr. Lee Luen Wai, John *BBS JP (Chairman)*
李聯偉先生*銅紫荊星章，太平紳士(主席)*

Mr. Tsang On Yip, Patrick *BBS*
曾安業先生*銅紫荊星章*

Mrs. Chan Kung Wai Ying, Amy *MH*
陳龔偉瑩女士*榮譽勳章*

NOMINATION COMMITTEE
提名委員會

Dr. Sun Yiu Kwong *(Chairman)*
孫耀江醫生*(主席)*

Mr. Lee Luen Wai, John *BBS JP*
李聯偉先生*銅紫荊星章，太平紳士*

Ms. Kwok Cheuk Kwan, Jacquen
郭卓君女士

Mr. Yeung Tak Bun *BBS JP*
楊德斌先生*銅紫荊星章，太平紳士*

Mrs. Chan Kung Wai Ying, Amy *MH*
陳龔偉瑩女士*榮譽勳章*

AUTHORISED REPRESENTATIVES
授權代表

Ms. Kwok Cheuk Kwan, Jacquen
郭卓君女士

Ms. Tong Mo Ting
唐慕婷女士

COMPANY SECRETARY
公司秘書

Ms. Tong Mo Ting
唐慕婷女士

CORPORATE INFORMATION
公司資料

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS
27th Floor
Wing On House
71 Des Voeux Road Central
Hong Kong

總部及主要營業地點
香港
德輔道中71號
永安集團大廈
27樓

FINANCIAL YEAR END
30 June

財政年度年結日
6月30日

STOCK CODE
722

股份代號
722

BOARD LOT
2,000 shares

每手買賣單位
2,000股股份

ISSUED SHARES
810,955,244 (as at 30 June 2026)

已發行股份
810,955,244(於2026年6月30日)

REGISTERED OFFICE
Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

註冊辦事處
Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS
Conyers Trust Company (Cayman) Limited
Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

開曼群島主要股份過戶登記處
Conyers Trust Company (Cayman) Limited
Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR
Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road, Hong Kong

香港股份過戶登記分處
卓佳證券登記有限公司
香港夏慤道16號
遠東金融中心17樓

AUDITOR
KPMG
Public Interested Entity Auditor registered in accordance with the Accounting and Financial Reporting Council Ordinance

核數師
畢馬威會計師事務所
《會計及財務匯報局條例》下的註冊公眾利益實體核數師

PRINCIPAL BANKERS
Hang Seng Bank Limited
UBS AG
Chong Hing Bank

主要往來銀行
恒生銀行有限公司
瑞士銀行
創興銀行

COMPANY WEBSITE
www.ump.com.hk

公司網站
www.ump.com.hk

FINANCIAL HIGHLIGHTS
財務摘要

		For the year ended/ As at 30 June 截至6月30日止年度／於6月30日			
		2026 2026年	2025 2025年	Increase/(decrease) 增加／(減少)	
(1) Operating results (HK$'000)	**(1) 經營業績(千港元)**				
(a) Revenue	(a) 收入	**716,971**	726,949	(9,978)	(1.4%)
(b) EBITDA (note a)	(b) 未計利息、税項、折舊及攤銷前的利潤(附註a)	**(21,571)**	87,025	(108,596)	(124.8%)
Add back:	加回：				
(i) Impairment of goodwill	(i) 商譽減值	**82,000**	7,553	74,447	985.7%
(ii) Impairment loss of investments in associates	(ii) 聯營公司投資的減值虧損	**902**	300	602	200.7%
(iii) Impairment of items of property, plant and equipment	(iii) 物業、廠房及設備項目的減值	**13,864**	–	13,864	N/A 不適用
(c) Adjusted EBITDA (note b)	(c) 經調整之未計利息、税項、折舊及攤銷前的利潤(附註b)	**75,195**	94,878	(19,683)	(20.7%)
(d) (Loss)/profit before tax	(d) 除税前(虧損)／利潤	**(64,751)**	40,499	(105,250)	(259.9%)
(e) (Loss)/profit for the year	(e) 年內(虧損)／利潤	**(72,725)**	31,916	(104,641)	(327.9%)
(f) (Loss)/profit attributable to:	(f) 以下各方應佔(虧損)／利潤：				
Owners of the Company	本公司擁有人	**(74,639)**	31,440	(106,079)	(337.4%)
Non-controlling interests	非控股權益	**1,914**	476	1,438	302.1%
		(72,725)	31,916	(104,641)	(327.9%)
(2) Per share data (HK cents)	**(2) 每股數據(港仙)**				
(a) (Loss)/Earnings per share – basic	(a) 每股(虧損)／盈利－基本	**(9.42)**	3.98	(13.40)	(336.3%)
(b) (Loss)/Earnings per share – diluted	(b) 每股(虧損)／盈利－攤薄	**(9.42)**	3.98	(13.40)	(336.3%)
(c) Dividends per share	(c) 每股股息				
– Proposed final	－擬派末期	**1.40**	1.90	(0.50)	(26.3%)
– Paid interim	－已付中期	**1.40**	1.40	0.0	0.0%
Total	總計	**2.80**	3.30	(0.50)	(15.2%)

Note a: EBITDA represented profit for the year before interest income, finance cost, income tax expense and depreciation (excluded depreciation of right-of-use assets) and amortisation.

附註a： 未計利息、税項、折舊及攤銷前的利潤代表本年度除利息收入、融資成本、所得税費用及折舊(不包括使用權資產折舊)及攤銷前的利潤。

Note b: EBITDA adjusted by one-off impairment of goodwill, impairment loss of investments in associates and impairment of items of property, plant and equipment.

附註b： 經一次性商譽減值、聯營公司投資的減值虧損及物業、廠房及設備項目的減值調整後的未計利息、税項、折舊及攤銷前的利潤。

		For the year ended/ As at 30 June 截至6月30日止年度／於6月30日			
		2026 2026年	2025 2025年	Increase/(decrease) 增加／(減少)	
(3)	**Key ratios (%)** **(3) 主要比率(%)**				
(a)	EBITDA/Revenue (a) 未計利息、税項、折舊及攤銷前的利潤／收入	**(3.0%)**	12.0%	(15.0%) points	百分點
(b)	Adjusted EBITDA/Revenue (b) 經調整未計利息、税項、折舊及攤銷前的利潤／收入	**10.5%**	13.1%	(2.6%) points	百分點
(c)	Net (loss)/profit margin (c) 純(虧損)／利率	**(10.1%)**	4.40%	(14.5%) points	百分點
(d)	Return on shareholders' funds (d) 股東權益回報率	**(11.7%)**	4.2%	(15.9%) points	百分點
(4)	**Financial Position (HK$'000)** **(4) 財務狀況(千港元)**				
(a)	Total assets (a) 總資產	**990,713**	1,095,325	(104,612)	(9.6%)
(b)	Cash, bank balances and deposits (b) 現金、銀行結餘及存款	**331,320**	302,836	28,484	9.4%
(c)	Net current assets (c) 流動資產淨額	**292,670**	267,681	24,989	9.3%
(d)	Shareholders' funds (d) 股東權益	**640,212**	742,632	(102,420)	(13.8%)

CHAIRMAN'S STATEMENT
主席報告

To Our Shareholders and Partners,

The financial year 2026 was a year of both challenges and progress for UMP Healthcare Holdings Limited. Against an evolving economic and healthcare landscape, we remained focused on delivering accessible, high-quality healthcare services while advancing our long-term strategy of building an integrated healthcare platform that serves the needs of patients, corporate clients and healthcare partners.

Reinforcing Our Position in Hong Kong

Hong Kong remains the foundation of our business and the cornerstone of our future growth. During the year, we continued to enhance patient experience through service improvements, brand refresh initiatives and the opening and upgrading of selected medical centres across our network.

We also welcome ongoing developments in Hong Kong's healthcare regulatory framework. The implementation of the regulatory regime under Cap. 633 is expected to further enhance professionalism, transparency and governance within the private healthcare sector, supporting the long-term development of a trusted and sustainable healthcare environment.

At the same time, healthcare policy in Hong Kong is placing increasing emphasis on community-based care, earlier intervention and better coordination across different levels of healthcare services. These developments are consistent with UMP's long-standing focus on delivering comprehensive healthcare services through our network of family medicine, specialist and allied healthcare professionals.

Aligning with Evolving Healthcare Priorities

For many years, UMP has invested in health screening, vaccination services, chronic disease management programmes, corporate wellness initiatives and integrated healthcare solutions. We believe the growing emphasis on prevention and long-term health management creates significant opportunities for healthcare providers with strong clinical, specialist and managed care capabilities.

各位股東及合作夥伴：

對聯合醫務集團有限公司而言，2026財政年度是充滿挑戰與進展的一年。面對不斷演變的經濟及醫療格局，我們依然專注於提供可及、優質的醫療服務，同時推進長期戰略，致力構建一個能夠滿足患者、企業客戶及醫療合作夥伴需求的綜合醫療平台。

鞏固在香港的地位

香港仍是我們業務的基石，亦是我們未來增長的基石。年內，我們透過改善服務、推行品牌煥新舉措，以及在我們的網絡內開設與升級選定醫療中心，持續提升患者體驗。

我們亦對香港醫療保健監管架構的持續發展表示歡迎。預期實施第633章項下的規管制度將進一步提升私營醫療界別的專業水平、透明度及管治，從而支持建立值得信賴且可持續發展的醫療環境之長遠發展。

與此同時，香港的醫療政策日益重視基層社區護理、提早介入以及不同層面醫療服務之間更佳的協調。此等發展與聯合醫務長久以來致力透過我們的家庭醫學、專科及專職醫療人員網絡提供全面醫療保健服務的方針一致。

配合不斷轉變的醫療保健重點

多年來，聯合醫務一直投資於健康篩查、疫苗接種服務、慢病管理計劃、企業健康推廣倡議以及綜合醫療保健解決方案。我們相信，對預防及長期健康管理的日益重視，將為具備強大臨床、專科及管理式醫療護理能力的醫療保健服務提供者帶來重大機遇。

The national policy direction of the forthcoming 15th Five-Year Plan (十五五規劃) places greater emphasis on preventive medicine, chronic disease management and healthy ageing. These priorities align closely with UMP's longstanding commitment to helping individuals proactively manage their health throughout different stages of life.

即將出台的十五五規劃的國家政策方向更著重於預防醫學、慢性病管理及健康老齡化。該等優先事項與聯合醫務一直以來致力於協助個人在人生不同階段主動管理自身健康的承諾高度契合。

Looking ahead, we see significant opportunities to further expand specialist services and strengthen care coordination across our healthcare network. As populations age and chronic diseases become more prevalent, integrated models of care that promote collaboration among family physicians, specialists and allied healthcare professionals are becoming increasingly important.

展望未來，我們看到重大機遇，可進一步拓展專科服務並加強我們整個醫療網絡的護理協調。隨着人口老化及慢病日益普及，促進家庭醫生、專科醫生與專職醫療人員相互協作的綜合護理模式變得愈發重要。

Expanding Our Presence in Chinese Mainland

Chinese Mainland remains an important pillar of our long-term growth strategy. During the year, we advanced our development plans in the Greater Bay Area, highlighted by the establishment of our community healthcare centre in Foshan.

拓展中國內地業務

中國內地仍是我們長期增長策略的重要支柱。年內，我們推進了大灣區的發展計劃，其中以在佛山設立社區醫療中心為亮點。

We view the Foshan project as an important milestone in strengthening UMP's presence in the PRC market. In addition to expanding our operational footprint, the project supports our efforts to build the UMP brand, deepen local partnerships and establish a foundation for future growth across the Greater Bay Area and other regions in Chinese Mainland.

我們視佛山項目為加強聯合醫務在中國市場地位的重要里程碑。除了擴大我們的營運足跡外，該項目亦有助於我們建立聯合醫務品牌、深化本地合作夥伴關係，並為整個大灣區及中國內地其他地區的未來增長奠定基礎。

We also continued to develop our Third-Party Administration ("TPA") business by leveraging our expertise in healthcare network management and medical benefits administration. We believe the growing integration of healthcare and insurance services across the region will continue to create attractive opportunities for this business segment. Building on our strengths in healthcare delivery and network management, we aim to further strengthen our position as a value-added TPA service provider for insurers, corporate clients and members.

我們亦憑藉在醫療網絡管理及醫療福利行政管理方面的專業知識，持續拓展第三方管理(「TPA」)業務。我們相信，該地區醫療與保險服務的日益融合，將繼續為此業務分部創造具吸引力的機遇。憑藉我們在醫療保健服務提供及網絡管理方面的優勢，我們的目標是進一步鞏固作為保險公司、企業客戶及會員的增值TPA服務提供商的地位。

CHAIRMAN'S STATEMENT
主席報告

As healthcare and insurance services become increasingly interconnected, we expect closer collaboration with commercial insurance partners to create new opportunities for growth and innovation. Through closer engagement with insurers and other industry participants, we hope to contribute to the ongoing evolution of a value-based care ecosystem that promotes better health outcomes, enhances patient experience and improves the efficient utilisation of healthcare resources. At the same time, we will continue to expand our healthcare network in Chinese Mainland in a prudent and disciplined manner, extending our reach to a broader patient population, strengthening our relationships with key stakeholders and supporting the long-term development of UMP's healthcare platform across the region.

隨着醫療與保險服務的連繫日益緊密，我們預期與商業保險夥伴開展更緊密的合作，將為增長與創新創造新機遇。透過與保險公司及其他行業參與者更緊密合作，我們期望為價值導向型護理生態系統的持續演進作出貢獻，從而促進更好的健康成效、提升患者體驗，並提高醫療資源的有效利用。與此同時，我們將繼續以審慎自律的方式拓展在中國內地的醫療網絡，將服務範圍擴大至更廣泛的患者群體，加強我們與主要持份者的關係，並支持聯合醫務的醫療平台在整個地區的長期發展。

Continuing Our Digital Transformation

Digitalisation remains a key enabler of our future growth. We continued to invest in technology and digital infrastructure to improve operational efficiency, strengthen service quality and enhance the patient journey.

As healthcare delivery continues to evolve, we believe digital platforms, data analytics and technology-enabled healthcare solutions will play an increasingly important role in supporting both clinical excellence and operational effectiveness. These investments will strengthen our ability to deliver integrated and personalised healthcare services across our network.

持續推進數碼轉型

數碼化依然是我們未來增長的關鍵推動力。我們繼續投資於科技及數碼基礎設施，以提高營運效率、提升服務質素及改善患者就醫體驗。

隨着醫療服務提供模式持續演進，我們相信數碼平台、數據分析及科技賦能的醫療解決方案，將在支持卓越臨床表現及營運效益方面發揮日益重要的作用。該等投資將增強我們在整個網絡中提供綜合及個人化醫療保健服務的能力。

Looking Ahead

We believe our people will continue to be one of the Group's most important assets. As our business grows across Hong Kong and Chinese Mainland, we remain committed to attracting, developing and retaining high-calibre healthcare and management professionals. Through continued investment in talent development, we aim to maintain service quality, enhance patient experience and foster long-term relationships with the patients and communities we serve.

During the year, the Group recognised a one-off non-cash goodwill write-off which had a material impact on reported profit. However, this adjustment is principally an accounting treatment and does not affect the Group's cash position, liquidity or underlying operations. The Board remains confident in the long-term prospects of our business and the strength of our strategic direction.

未來展望

我們相信，員工將繼續是本集團最重要的資產之一。隨着我們的業務在香港及中國內地不斷增長，我們始終致力於吸引、培養和留聘高質素的醫療保健及管理專業人才。透過持續投資人才發展，我們旨在維持服務質素、提升患者體驗，並與我們所服務的患者及社區建立長期關係。

年內本集團確認一筆一次性非現金商譽撇銷，對呈報溢利產生重大影響。然而，此項調整主要屬會計處理，並不影響本集團的現金狀況、流動資金或相關業務。董事會對我們業務的長期前景及我們戰略方向的實力依然充滿信心。

While macroeconomic uncertainties may persist, demand for quality healthcare services continues to be supported by demographic trends, rising health awareness and increasing expectations for better healthcare outcomes. With our established network, trusted brand and growing presence across Hong Kong and the Greater Bay Area, we believe UMP is well positioned to pursue sustainable growth and create long-term value for our stakeholders.

雖然宏觀經濟的不確定性可能持續存在，但人口結構趨勢、健康意識提高以及對更佳醫療成效的期望不斷提升，持續為優質醫療服務的需求提供支持。憑藉我們穩固的網絡、值得信賴的品牌，以及在香港與大灣區不斷擴展的業務版圖，我們相信聯合醫務已處於有利位置，追求可持續增長並為我們的持份者創造長期價值。

Acknowledgement

On behalf of the Board, I would like to express my sincere appreciation to our management team, healthcare professionals, employees, business partners and shareholders for their dedication, trust and continued support throughout the year.

致謝

本人謹代表董事會，對我們的管理團隊、醫護專業人員、員工、業務夥伴及股東在過去一年的奉獻、信任及持續支持致以衷心感謝。

Together, we will continue to strengthen our healthcare platform, pursue sustainable growth and deliver long-term value to our patients, partners and shareholders.

我們將攜手繼續強化我們的醫療平台、追求可持續增長，並為我們的患者、合作夥伴及股東創造長期價值。

Dr. SUN Yiu Kwong
Chairman

孫耀江醫生
主席

Hong Kong

香港

CO-CEOs' REPORT
聯席行政總裁報告

Joint Statement of the Co-Chief Executive Officers

Dear Shareholders,

FY2026 was a year of transformation and investment for UMP Healthcare Holdings Limited. Against a challenging operating environment, we continued to strengthen the foundations of our business through brand enhancement, digital transformation, service integration and regional expansion. During the year, we successfully completed a number of important strategic initiatives, including the Group's corporate rebranding programme, the implementation of our new clinical management platform, the launch of a new member application, the opening of our Foshan community healthcare centre in the Greater Bay Area and the further integration and expansion of our self-owned healthcare service centres. These initiatives reinforce UMP's position as an integrated healthcare services provider and support our long-term vision of delivering accessible, high-quality healthcare services that encompass both preventive care and treatment.

Performance Highlights

For the year ended 30 June 2026, the Group reported revenue of approximately HK$717.0 million, representing a decrease of 1.4% compared to FY2025. The Group recorded adjusted EBITDA of approximately HK$75.2 million. During the year, the Group recognised non-cash impairment charges relating to goodwill and intangible assets which contributed to a loss attributable to shareholders of approximately HK$74.6 million. While these accounting adjustments had a significant impact on reported results, they do not affect the Group's cash position or operational capabilities. The year also included investments in digital infrastructure, healthcare network enhancement and regional expansion initiatives, most notably the establishment of our Foshan community healthcare centre.

聯席行政總裁聯合報告

各位股東：

2026財政年度是聯合醫務集團有限公司轉型及投資的一年。面對充滿挑戰的經營環境，我們繼續透過品牌提升、數碼轉型、服務整合及區域拓展，加強業務基礎。年內，我們成功完成多項重要策略舉措，包括集團企業品牌重塑計劃、全新臨床管理平台的實施、新會員應用程式的推出、大灣區佛山社區醫療中心的開設，以及自營醫療服務中心的進一步整合和擴建。這些舉措鞏固聯合醫務作為綜合醫療服務供應商的定位，並支持我們致力提供便捷、優質及以預防和治療兼備的醫療服務之長遠願景。

業績摘要

截至2026年6月30日止年度，本集團錄得收益約717.0百萬港元，較2025財政年度減少1.4%。本集團錄得經調整EBITDA約75.2百萬港元。年內，本集團就商譽及無形資產確認非現金減值支出，導致股東應佔虧損約74.6百萬港元。儘管有關會計調整對呈報業績造成重大影響，但並不影響本集團的現金狀況及營運能力。年內，本集團亦持續投資於數碼基建、醫療網絡優化及區域拓展項目，其中以佛山社區醫療中心的設立最具代表性。

Strengthening the UMP Brand

One of the most significant achievements during FY2026 was the successful completion of the Group's corporate rebranding programme. In September 2025, we officially launched UMP's new corporate identity and logo, reflecting the transformation of the Group into a modern integrated healthcare solutions platform. We also continued to strengthen consistency across our healthcare network. During the year, all physiotherapy centres were brought under the ProCare brand, creating a more unified service identity and customer experience. Beyond improving brand recognition, the rebranding programme supports our strategy of building a connected healthcare ecosystem that facilitates cross-referrals, improves patient engagement and enhances collaboration among different service lines.

強化聯合醫務品牌

2026財政年度其中一項最重要的成就，是成功完成本集團的企業品牌重塑計劃。於2025年9月，我們正式推出聯合醫務全新企業形象及品牌標誌，反映本集團已轉型為現代化綜合醫療解決方案平台。我們亦持續提升旗下醫療網絡的品牌一致性。年內，所有物理治療中心均已納入ProCare品牌之下，為客戶帶來更一致的服務體驗及品牌形象。品牌重塑計劃不僅有助提升品牌知名度，更配合我們建立互聯醫療生態系統的策略方向，促進跨服務轉介、加強病人參與度，以及提升不同醫療服務範疇之間的協作效益。

Advancing Digital Transformation

Digitalisation remains one of the most important strategic priorities of the Group. During FY2026, we completed the adoption of our new Clinical Management System and further expanded the application and data analytics capabilities of our Electronic Pre-Authorisation platform across the Group. We also launched a new UMP Member App providing appointment management, network provider search, healthcare benefits visibility and electronic claims submission functionality, with the aim of enhancing the overall member experience.

推進數碼轉型

數碼化持續為本集團最重要的策略重點之一。於2026財政年度，我們完成全新臨床管理系統的全面應用，並進一步擴展電子預先授權平台於集團內的使用範圍與數據分析。我們亦推出全新的聯合醫務會員應用程式，提供預約管理、網絡醫療服務供應商搜尋、醫療福利查閱及電子索償提交等功能，致力提升會員體驗。

UMP occupies a unique position within the healthcare ecosystem as both a healthcare service provider and administrator of corporate healthcare schemes. This enables us to gather valuable first-hand insights into healthcare utilisation patterns and patient behaviour. Combined with our extensive healthcare provider network, we are uniquely positioned to pilot, refine and implement digital initiatives efficiently across multiple healthcare settings. Looking ahead, we will continue to explore artificial intelligence applications, including medical card recognition, workflow automation and intelligent document processing, to improve service efficiency and patient experience.

聯合醫務於醫療生態系統中具有獨特定位，既是醫療服務提供者，亦負責企業醫療計劃管理工作。此定位使我們能夠掌握寶貴的一手醫療使用數據及病人行為洞察。結合集團龐大的醫療服務網絡，我們具備優勢在不同醫療場景中測試、優化及推行各項數碼創新措施。展望未來，我們將繼續探索人工智能技術的應用，包括醫療卡識別、流程自動化及智能文件處理，以提升服務效率及病人體驗。

CO-CEOs' REPORT
聯席行政總裁報告

Enhancing Healthcare Infrastructure

During the year, we continued to optimise and integrate our healthcare platform. Key developments included the opening of a new Specialist Centre in Causeway Bay and the continued consolidation of selected medical operations. We also relocated our central laboratory to a self-owned property in Sheung Wan, laying the groundwork for future accreditation initiatives and strengthening our diagnostic services capabilities. These initiatives support our long-term strategy of strengthening our presence in Hong Kong through the development of a more integrated healthcare ecosystem. By carefully observing changes in healthcare demand and patient behaviour, we continue to adapt our service mix and enhance collaboration among primary care, specialist, diagnostic and rehabilitation services.

We also see opportunities to further develop premium specialist services to meet the growing demand for high-quality and personalised healthcare solutions. By leveraging our existing facilities, clinical capabilities and healthcare network, we aim to broaden our premium specialist offerings and strengthen collaboration with leading specialists, healthcare partners and insurance companies serving premium customer segments. We believe these initiatives will enhance UMP's position in the premium healthcare market while fostering deeper and more sustainable partnerships across our healthcare ecosystem.

Foshan: An Important Milestone in Chinese Mainland Development

A major milestone in FY2026 was the establishment and development of UMP's community healthcare centre in Foshan. Although the centre remained at an early stage of development and incurred start-up costs during the year, it achieved significant operational progress. The centre successfully obtained the General Outpatient Department and Community Health Service Center Licence (綜合門診部及社區衛生服務中心牌照), enabling it to provide Basic Public Health Services. In May 2026, it also obtained approval to provide vaccination services and is currently the only private medical institution in Foshan authorised to offer such services.

優化醫療基建

年內，我們持續優化及整合集團醫療平台。主要發展包括銅鑼灣新專科中心投入服務，以及若干醫療業務的持續整合。我們亦將中央化驗所遷往位於上環的自置物業，為未來申請相關認證奠定基礎，並提升診斷服務能力。上述舉措配合集團長遠策略，致力透過建立更完善的綜合醫療生態系統，鞏固我們於香港的業務基礎。透過密切觀察醫療需求及病人行為的變化，我們持續優化服務組合，並加強基層醫療、專科服務、診斷檢測及復康服務之間的協同效應。

我們亦看到進一步發展高端專科服務的機遇，以滿足市場對優質及個人化醫療服務日益增長的需求。透過善用現有設施、臨床能力及醫療網絡，我們致力拓展高端專科服務範疇，並加強與領先專科醫生、醫療合作夥伴及服務高端客戶群的保險公司的合作。我們相信，這些舉措將有助鞏固聯合醫務於高端醫療市場的地位，並促進醫療生態系統內更深入及長遠的合作夥伴關係。

佛山：中國內地業務發展的重要里程碑

2026財政年度其中一項重要里程碑，是聯合醫務佛山社區醫療中心的成立及發展。儘管該中心仍處於發展初期，並於年內產生開辦成本，惟其營運發展已取得顯著進展。該中心成功取得《綜合門診部及社區衛生服務中心牌照》，可提供國家基本公共衛生服務項目。於2026年5月，中心獲批准提供疫苗接種服務，現時為佛山市唯一獲授權提供相關服務的私營醫療機構。

The development of the Foshan community healthcare centre represents an important step in deepening the Group's understanding of the healthcare system in Chinese Mainland. Building on the foundations we have established in Beijing, Shanghai and Guangzhou, as well as our growing participation in the operation of international departments within leading Tier 3 Class A hospitals, this development will further advance the Group's expansion in Chinese Mainland and enhance our reach across the local healthcare market.

佛山社區醫療中心的發展標誌著本集團深入了解中國內地醫療體系的重要一步。憑藉已於北京、上海及廣州建立的業務基礎，以及逐步在三甲醫院國際部的參與運營，此項發展將進一步推進本集團在中國內地的業務拓展，並提升我們於當地市場的覆蓋範圍。

Looking ahead, our focus in the Chinese Mainland extends beyond the provision of clinical services. We are actively exploring opportunities in healthcare administration and third-party administration ("TPA") services that are tailored to local market needs and aligned with national healthcare policy directions. Supported by the TPA team stationed in the Foshan healthcare centre, our objective is to develop a locally adapted model that integrates healthcare delivery, health management and insurance support, thereby creating a comprehensive healthcare ecosystem and supporting the sustainable growth of our Mainland operations.

展望未來，我們在中國內地的發展重點並不限於臨床醫療服務。我們正積極探索符合當地市場需求及國家醫療政策方向的醫療管理及第三方管理服務(「TPA」)機遇，並以佛山綜合醫療中心的TPA團隊提供支援，致力建立一套具本地特色的綜合模式，融合醫療服務、健康管理及保險支援，打造完善的醫療生態系統，並推動中國內地業務的可持續發展。

Strengthening Healthcare Connectivity

During FY2026, we achieved an important milestone through the commencement of eHealth data sharing using our latest Clinical Management System. Strengthening connectivity with government healthcare infrastructure remains one of the Group's key priorities. Enhanced integration with public healthcare systems improves continuity of care, strengthens patient experience and positions UMP to participate in future healthcare initiatives. These efforts support our long-term vision of advancing primary healthcare, preventive care and chronic disease management.

加強醫療互聯互通

於2026財政年度，我們透過全新臨床管理系統成功開展與醫健通(eHealth)的數據共享，達成重要里程碑。加強與政府醫療基建的互聯互通仍然是本集團一個重要策略方向。深化與公共醫療系統的整合，有助提升醫療服務連續性、改善病人體驗，並有利聯合醫務參與未來各項醫療發展計劃。相關工作亦配合集團推動基層醫療、預防醫學及慢性疾病管理的長遠願景。

CO-CEOs' REPORT
聯席行政總裁報告

Looking Forward

The investments made during FY2026 have strengthened the foundations for future growth. Through enhancement of our brand, digital infrastructure, healthcare network, government connectivity and Greater Bay Area presence, we have continued to build an integrated healthcare ecosystem supporting our long-term vision. We will also continue to deepen collaboration with specialist medical groups and healthcare partners, while investing in the training and professional development of healthcare personnel, to broaden our service capabilities, strengthen care coordination and enhance the delivery of high-quality healthcare services. While market conditions remain challenging, we remain confident in our ability to adapt to changing healthcare needs and capture opportunities arising from primary healthcare development, preventive medicine, healthcare digitalisation and regional healthcare integration.

Our Shared Commitment

Together, we remain committed to strengthening UMP's integrated healthcare ecosystem through clinical excellence, digital innovation, preventive healthcare and sustainable growth. We will also deepen our collaboration with insurance companies by leveraging the Group's strengths in healthcare services, healthcare network management and health management to promote greater integration between healthcare and insurance services. In addition, we will enhance cross-border healthcare connectivity and continuity of coverage, helping our insurance partners strengthen access to healthcare networks across the Greater Bay Area and Chinese Mainland while delivering a more seamless and high-quality healthcare experience for their members.

On behalf of the Board and management team, we express our sincere appreciation to our healthcare professionals, employees, business partners and shareholders for their trust, dedication and continued support.

Dr. Michael Sun
Vice Chairman &
Co-Chief Executive Officer

Ms. Jacquen Kwok
Executive Director &
Co-Chief Executive Officer

Hong Kong

展望未來

2026財政年度所作出的各項投資，已為本集團未來發展奠定更穩固基礎。透過品牌升級、數碼基建優化、醫療網絡發展、政府醫療系統互聯互通，以及大灣區業務拓展，我們持續建設完善的綜合醫療生態系統，以支持集團的長遠發展願景。我們亦將持續深化與專科醫療集團及醫療合作夥伴的合作，持續投資於醫護人才培訓及專業發展，以拓展服務能力、加強醫療服務協調，並提升優質醫療服務的提供水平。儘管市場環境仍然充滿挑戰，我們對集團適應醫療需求轉變及把握未來機遇的能力充滿信心，包括基層醫療發展、預防醫學普及、醫療數碼化及區域醫療融合所帶來的增長機遇。

攜手承諾

我們將繼續致力透過臨床專業、數碼創新、預防醫療及可持續發展，完善聯合醫務的綜合醫療生態系統。我們亦將深化與保險公司的合作，充分發揮本集團於醫療服務、醫療網絡管理及健康管理方面的優勢，促進醫療與保險服務的協同發展，並加強跨境醫療服務及保障銜接，協助保險合作夥伴提升大灣區以至中國內地的醫療服務連通性及會員體驗。

我們謹代表董事會及管理團隊，衷心感謝所有醫護人員、員工、業務夥伴及股東一直以來的信任、支持及貢獻。

孫文堅醫生
副主席兼
聯席行政總裁

郭卓君女士
執行董事兼
聯席行政總裁

香港

OUR BUSINESS

UMP Healthcare Holdings Limited operates an integrated private-healthcare platform, combining its self-operated core clinical assets with selected strategic partnerships to create synergies across its business lines. This light-asset operating model enables the Group to broaden its service offerings and market reach while maintaining prudent capital commitments and operational flexibility.

UMP's business scope consists of the following three business lines:

1. Hong Kong & Macau Corporate Healthcare Solutions

Our Hong Kong and Macau corporate healthcare solution services refer to the business of designing and administrating healthcare benefits plans and solutions tailored for contract clients in the region. The extension of third party administration ("TPA") service (including hotline and pre-approval services) to our insurance company clients and corporate clients is an important offering among UMP's corporate healthcare solutions. Building on its established TPA track-record, the Group continues to strengthen its positioning as a value-added TPA service provider for insurers, corporate clients and their members, and deepens collaboration with insurance partners to advance a value-based-care ecosystem that aims for better health outcomes, improved patient experience and more efficient healthcare-resource utilisation. UMP aims to provide convenient, reliable, coordinated, comprehensive and affordable healthcare services through the well-established, and multi-disciplinary UMP Network.

As at 30 June 2026, the UMP Network comprises over 1,000 points of service located across Hong Kong, Macau and Chinese Mainland.

The Group's contract clients comprise (i) insurance companies, which enter into contracts with the Group for healthcare services for their policyholders or employees of their policyholders and (ii) corporations, which enter into contracts with the Group for healthcare services for their employees and/or their dependents. In designing healthcare benefits plans, the Group works closely with each client to tailor the benefits structure to that client's specific circumstances, taking into account industry characteristics and prevailing health concerns, the desired scope of coverage, workforce demographics and budget. Plans are reviewed and refined over time as a client's needs evolve.

我們的業務

聯合醫務集團有限公司營運一個綜合私營醫療保健平台，結合其自營核心臨床資產與精選策略合作夥伴關係，在旗下各業務線之間創造協同效應。該輕資產營運模式使本集團能擴闊其服務範疇及市場覆蓋，同時維持審慎的資本承擔及營運靈活性。

聯合醫務的業務範疇包括以下三條業務線：

1. 香港及澳門企業醫療保健解決方案

我們的香港及澳門企業醫療保健解決方案服務，是為此地區的合約客戶設計和管理度身訂制的醫療保健福利計劃和解決方案的業務。為我們的保險公司客戶及企業客戶提供第三方管理服務(包括熱線及預先批核服務)，是聯合醫務企業醫療保健解決方案的重要一環。基於其在第三方管理領域既有良好往績，本集團持續鞏固自身作為面向保險公司、企業客戶及其公司成員的增值第三方管理服務提供者此定位，並加深與保險合作夥伴合作，推動建構旨在實現更佳健康成效、提升患者體驗以及更有效率利用醫療保健資源基於價值護理的生態系統。集團通過完善的多專科UMP網絡，提供便捷、可靠、協調、全面且價格實惠的醫療保健服務。

於2026年6月30日，UMP網絡包括分佈於香港、澳門及中國內地逾1,000個服務點。

本集團的合約客戶包括(i)保險公司，即與本集團簽訂合約，為其保單持有人或保單持有人的僱員提供醫療保健服務的保險公司；及(ii)企業，即與本集團簽訂合約，為其僱員及／或其僱員家屬提供醫療保健服務的企業。在設計醫療保健福利計劃時，本集團與各客戶緊密合作，經考慮行業特點及普遍受關注的健康問題、預期的保障範圍、員工團隊勞動力特徵及預算後，因應有關客戶的具體情況訂製福利架構。由於客戶需要會改變，故計劃會與時俱進地予以檢討及優化。

2. Hong Kong & Macau Clinical Services

UMP provides medical and dental services, medical imaging and laboratory services and other auxiliary medical services to patients. For medical services, the Group provides (i) general practice services, which serves as the first point of contact for patients and (ii) specialist services covering more than 20 different specialties. To scale specialist capacity without incurring heavy in-house specialist-recruitment overheads, the Group works with external specialist medical providers, giving patients access to a broad panel of specialists while keeping its cost base flexible. For dental services, UMP provides both primary dental care and secondary dental care.

Medical imaging and laboratory services are integral part to the care pathway, and UMP delivers them on a one-stop basis through its ProCare network. Its centres are equipped with advanced imaging equipment and testing facilities including PET-CT, MRI, CT Scan, ultrasound, mammography and X-ray, we provide extensive and reliable medical diagnosis and laboratory services. UMP can provide a wide range of imaging and laboratory services at our self-owned centres. As at 30 June 2026, the Group owned and operated 6 integrated medical and advanced imaging centres and 1 central medical laboratory.

During FY2026, UMP provided other auxiliary medical including physiotherapy, Traditional Chinese Medicine, dietetic services and nursing care services. All physiotherapy centres were rebranded under the ProCare identity during the year, giving patients a consistent service experience across the network.

3. Chinese Mainland Healthcare Services

The Group's Chinese Mainland Healthcare Services comprise outpatient services, such as family medicine, delivered through clinics the Group owns and operates in Beijing, Shanghai and the Greater Bay Area. The Group also expanded its TPA services to healthcare facilities in Chinese Mainland.

2. 香港及澳門臨床服務

聯合醫務向患者提供醫療及牙科服務、醫學影像及化驗服務以及其他輔助醫療服務。醫療服務方面，本集團提供(i)全科醫療服務，為患者的首個接觸點；及(ii)專科服務，覆蓋超過20個不同專科。為在不產生高昂內部專家招聘開銷前提下擴大專科能力，本集團與外部專科醫療供應商合作，讓患者能接觸廣泛專科醫生網絡，同時保持其成本基礎靈活。牙科服務方面，聯合醫務提供基本牙科護理及第二層牙科護理。

醫學影像及化驗服務為護理流程中不可或缺一環，聯合醫務透過其普康網絡提供一站式相關服務。其中心具備先進的影像設備及測試設施，包括正電子電腦斷層掃描、磁力共振成像、電腦斷層掃描、超聲波、乳房造影及X光，提供廣泛而可靠的醫療診斷及化驗服務。聯合醫務可以在旗下中心提供一系列影像及化驗服務。於2026年6月30日，本集團擁有及經營6間綜合醫療及先進影像中心及1間中央醫療化驗所。

於2026財政年度，聯合醫務提供其他輔助醫療，當中包括物理治療、中醫、營養服務與護理服務等。在本年度，所有物理治療中心均重塑為普康旗下品牌，在聯網內為患者提供一致的服務體驗。

3. 中國內地醫療保健服務

本集團的中國內地醫療保健服務包括門診服務(例如家庭醫學)，透過本集團在北京、上海及大灣區擁有及營運的診所提供。本集團亦將其第三方管理服務擴展至中國內地的醫療保健設施。

The following table sets out the revenue, operating profit and number of visits by our business lines for FY2026 and FY2025 for comparison:

下表載列我們2026財政年度以及2025財政年度的業務線收入、經營利潤及就診次數以供比較：

Revenue by business lines

按業務線劃分的收入

		Year ended 30 June 截至6月30日止年度			
		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元	Increase/(decrease) 增加／(減少) HK$'000 千港元	% 百分比
Hong Kong & Macau:	*香港及澳門：*				
Corporate Healthcare Solution Services	企業醫療保健解決方案服務	**266,258**	266,481	(223)	(0.1%)
Clinical Healthcare Services	臨床醫療保健服務	**562,030**	558,263	3,767	0.7%
Chinese Mainland:	*中國內地：*				
Clinical Healthcare Services	臨床醫療保健服務	**40,166**	38,988	1,178	3.0%
Total revenue before elimination of inter-business lines sales	**業務線間的銷售抵銷前的收入合計**	**868,454**	863,732	4,722	0.5%
Reconciliation:	*調節：*				
Elimination of inter-business lines sales	業務線間銷售抵銷	**(151,483)**	(136,783)	(14,700)	10.7%
TOTAL REVENUE	**總收入**	**716,971**	726,949	(9,978)	(1.4%)

Operating profit by business lines **按業務線劃分的經營利潤**

		Year ended 30 June 截至6月30日止年度			
		2026 2026年	2025 2025年	Increase/(decrease) 增加／(減少)	
		HK$'000 千港元	HK$'000 千港元	HK$'000 千港元	% 百分比
Hong Kong & Macau:	*香港及澳門：*				
Corporate Healthcare Solution Services	企業醫療保健解決方案服務	**42,943**	44,997	(2,054)	(4.6%)
Clinical Healthcare Services	臨床醫療保健服務	**16,411**	20,063	(3,652)	(18.2%)
Chinese Mainland:	*中國內地：*				
Clinical Healthcare Services	臨床醫療保健服務	**(7,419)**	7,576	(14,995)	(197.9%)
TOTAL OPERATING RESULTS	**總經營業績**	**51,935**	72,636	(20,701)	(28.5%)

Number of visits by business lines **按業務線劃分的就診人數**

		Year ended 30 June 截至6月30日止年度		Increase/ (decrease)
		2026 2026年	2025 2025年	增加／(減少)
Provision of corporate healthcare solution services in Hong Kong and Macau	**於香港及澳門提供企業醫療保健解決方案服務**	**1,102,512**	1,217,311	(114,799)
Medical	*醫療*	*1,081,579*	*1,195,862*	*(114,283)*
Dental	*牙科*	*20,933*	*21,449*	*(516)*
Provision of clinical healthcare services in Hong Kong and Macau	**於香港及澳門提供臨床醫療保健服務**	**183,324**	199,487	(16,163)
Medical	*醫療*	*152,032*	*169,961*	*(17,929)*
Dental	*牙科*	*31,292*	*29,526*	*1,766*
Chinese Mainland Clinical Healthcare Services	**中國內地臨床醫療保健服務**	**35,683**	32,216	3,467
TOTAL	**合計**	**1,321,519**	1,449,014	(127,495)

BUSINESS REVIEW

The financial year FY2026 unfolded against a mixed macro-economic backdrop across Hong Kong, Macau and the Chinese Mainland, characterised by uneven corporate spending sentiment, evolving public-health regulatory requirements and cyclical weakness in certain service-lines. While the Group upheld its diversified-business-model resilience and maintained prudent capital discipline, overall segment performance softened compared to FY2025.

Amid this environment, management focused on consolidating operations, driving efficiency and advancing selected strategic priorities, weighing near-term profitability against the longer-term work of building the Group's healthcare ecosystem. Revenue from the corporate healthcare solutions segment held broadly steady and cushioned the Group's top line, although the segment's operating profit moderated.

Alongside clinic rationalisation and rebranding in Hong Kong, the Group made meaningful strategic headway in the Chinese Mainland during the year. The Foshan community healthcare centre progressed through its early development phase – a stage that continues to carry start-up costs – and took on a materially larger role within the Group. With selected hotline operations and IT back-office functions migrated to Foshan during the year, the centre now serves as a centralised back-end support hub for the Group as a whole, concentrating scale-sensitive functions in a single, lower-cost location while building capability that can support further Mainland expansion. This builds on the Group's existing operational foundations in Beijing, Shanghai and the GBA as part of its disciplined Mainland market-development approach.

During the year, the Group also recognised one-off non-cash impairment charges in respect of goodwill and a self-owned property. These accounting adjustments affected reported profit for FY2026 but had no impact on the Group's underlying cash flow, liquidity or core operating performance. The goodwill impairment was recognised following management's reassessment of the recoverable amount of the relevant cash-generating unit of the Group, while the property impairment reflected prevailing market conditions and valuation considerations. Management considers these charges to be non-recurring in nature and unrelated to the Group's day-to-day operating performance.

業務回顧

2026財政年度於香港、澳門及中國內地交織的宏觀經濟背景下展開，背景特徵包括企業支出意向不一，公共衞生監管要求不斷演變，以及部分服務線出現週期性疲軟。儘管本集團保持多元化商業模式的韌性，並維持審慎資本原則，惟整體分部表現較2025財政年度有所放緩。

在此環境下，管理層專注於鞏固業務、提高效益及推進選定策略重點，在短期盈利能力與構建本集團醫療保健生態系統的長期工作之間作出權衡。企業醫療保健解決方案分部的收入大致保持平穩，儘管該分部的經營利潤有所放緩，仍為本集團的收入提供緩衝。

年內，在香港整合診所及重塑品牌之時，本集團於中國內地亦取得具意義的策略進展。佛山社區醫療中心度過其早期發展階段(該階段仍持續產生初創成本)，並在本集團內部擔當更顯著重大的角色。年內，隨選定熱線營運及資訊科技後勤職能遷移至佛山，該中心現作為本集團整體的集中後勤支援樞紐，將容易受規模影響的職能集中於單一、成本較低的地點，同時建立能力支援進一步拓展內地市場。此乃建基於本集團於北京、上海及大灣區的現有營運，為審慎內地市場發展方針一部分。

年內，本集團亦就商譽及一項自有物業確認一次性非現金減值支出。有關會計調整影響2026財政年度的報告利潤但對本集團的基礎現金流量、流動資金或核心經營業績並無影響。商譽減值在管理層重新評估本集團相關現金產生單位的可收回金額後確認，而物業減值則反映當時市場狀況及估值所考慮因素。管理層認為，有關費用屬於非經常性質，且與本集團的日常經營表現無關。

Hong Kong & Macau Corporate Healthcare Solutions

For FY2026, this segment saw moderated operating profit when compared with FY2025, amid cautious corporate spending sentiment. The segment nevertheless remained resilient and continued to deliver important patient-referral flows into the Group's clinical network.

- **Revenue Performance:** Despite challenging operating environment, overall segment revenue for FY2026 was broadly comparable to that recorded in FY2025. While the Group retained its key corporate clients and maintained stable uptake of healthcare benefit programmes, growth was capped by restrained corporate discretionary spending and price competition in the market.

- **Profitability Performance:** While the segment faced upward pressure on operating costs during the year, its revenue base remained steady. These increased service delivery costs resulted in some margin compression, partially tempering the segment's operating profitability.

(i) Challenging Macroeconomic Environment

The Hong Kong economy in FY2026 was still characterized by significant volatility, influencing corporate decision-making and operational priorities. Key environmental factors included:

- **Corporate Cost Sensitivity:** Economic uncertainty continued to drive corporate scrutiny over operational expenditures.

- **Talent Retention:** Despite cost pressures, competition for skilled staff persisted, and comprehensive benefit packages remained an important lever for employers in attracting and retaining people.

Employers therefore faced the dilemma of controlling costs while maintaining investment in employee healthcare benefits. To address these competing demands amid a challenging market environment, the Group skillfully tailored its diversified healthcare packages to provide flexible and cost-effective solutions that satisfied corporate clients' evolving needs within reasonable budget constraints.

香港及澳門企業醫療保健解決方案

於2026財政年度，受審慎企業支出意向的影響，該分部較2025財政年度的經營利潤有所放緩。然而，該分部仍保持韌性，並繼續為本集團的臨床網絡提供重要的病人轉介流量。

- **收入表現**：儘管經營環境充滿挑戰，2026財政年度的整體分部收入與2025財政年度錄得者大致相若。儘管本集團留住主要企業客戶，且醫療保健福利計劃的採用率保持穩定，惟企業可自由支配支出及市場價格競爭限制增長。

- **盈利能力表現**：儘管該分部年內面臨營運成本上升壓力，惟其收入來源保持穩健。服務交付成本上升，導致部分利潤率受壓，在一定程度上抑制該分部業務的盈利能力。

(i) 充滿挑戰的宏觀經濟環境

香港經濟於2026財政年度呈現顯著波動，影響企業決策及營運重心。主要的環境因素包括：

- **企業成本敏感度**：經濟不確定性繼續促使企業對營運開支的審查。

- **人才挽留**：儘管成本壓力存在，爭奪技術人才情況持續，而全面的福利待遇仍屬僱主吸引及留聘人才的重要方法。

因此，僱主面臨兩難局面，既要控制成本，又要繼續投資僱員醫療保健福利。為在充滿挑戰的市場環境中應對相互競爭的有關需求，本集團巧妙訂製多元醫療保健組合，以提供靈活且具成本效益的解決方案，在合理的預算限制內滿足企業客戶不斷轉變的需要。

(ii) Strategic & Operational Achievements

- **Healthcare Package Portfolio Optimization:** We continued to refine enhanced and modular plan options designed for various industries and company sizes. This "tailor-made" approach allowed clients to enrich employee benefits while maintaining strict control over their benefits budget.

- **Ecosystem Development:** We further expanded our roster of strategic business partners beyond core insurance providers to include wellness tech firms and specialist outpatient centres by continuously enhancing the strategy of building a one-stop healthcare ecosystem.

- **Third-Party Administration Strengthening:** Ongoing investments in our TPA platform delivered greater operational efficiency, faster claims processing and enhanced data analytics capabilities. This not only improved the member experience but also provided our corporate and insurance partners with valuable insights into healthcare trends and cost drivers.

(iii) Sales Strategic Initiatives

The primary challenge encountered was reduction in corporate headcounts within certain sectors, which created volatility for enrolment-driven products. The Group responded on three fronts:

- **Add-on sales:** The Group offered existing clients to upgrade the cover provided to their remaining employees through complementary add-on services, supporting client satisfaction and retention. Its packages also include optional services charged on a per-use basis, giving clients greater flexibility.

- **Focus on SME Market:** We increased our focus on the small and medium enterprise sector, which showed resilient demand for structured benefits packages.

- **Pursuing New Corporate and Insurance mandates:** The Group continued to pursue large corporates and insurers seeking comprehensive healthcare solutions, drawing on its established position in the Hong Kong market.

(ii) 策略與營運成就

- **醫療保健方案組合優化**：我們繼續精進推出針對不同行業及企業規模的更強大模組化計劃方案。此「量身定制」方式使客戶能夠加強僱員福利，同時嚴格控制福利預算。

- **生態系統拓展**：透過持續強化打造一站式醫療生態系統的策略，我們進一步擴大了與核心保險供應商以外的策略業務夥伴合作名單，新增健康科技公司及專科門診中心。

- **第三方管理強化**：通過持續投資第三方管理平台，我們提升了營運效率、加快理賠處理速度，並增強數據分析能力。此舉不僅改善會員體驗，亦為企業及保險公司合作夥伴提供有關醫療保健趨勢及成本驅動因素的寶貴洞察。

(iii) 銷售策略舉措

面對的首要挑戰是若干行業企業員工人數減少，導致入院類產品波動。本集團於三個方面回應：

- **附加銷售**：本集團向現有客戶提供透過互補的附加服務，提升為其留任僱員提供的保障範圍，從而獲客戶信納並有助挽留客戶。其組合亦包括按次收費的自選服務，為客戶提供更大靈活性。

- **聚焦中小企業市場**：中小企業市場展現對結構化福利計劃的穩健需求，故我們加大對中小企業市場的關注。

- **爭取新企業及保險委聘**：本集團憑藉其在香港市場的既有地位，繼續爭取為尋求全面醫療保健解決方案的大型企業及保險公司服務。

(iv) Development of Mainland Inpatient and Outpatient Healthcare Network & Supporting Infrastructure

The Group maintains collaborative arrangements with designated hospitals in Chinese Mainland to facilitate cross-border healthcare access for members covered under the Group's Hong Kong and Macau healthcare packages.

- **Designated inpatient hospitals:** The Group has strengthened inpatient service support for members of contracted clients through partnerships with designated hospitals, particularly Tier 3 Class A hospitals (三甲醫院), in Chinese Mainland.

- **Foshan centralised backend support hub:** The Foshan community healthcare centre acts as the Group's centralised backend hub for TPA operations, handling hotline support, claims administration and data processing, which lifts operational efficiency and shortens service turnaround times.

(v) Technology Deployment

Digital transformation milestones achieved during the year included wider adoption of the Electronic Pre-approval ("EPA") platform, the launch of the UMP Member App and upgrades to corporate client portals. The Group also commenced evaluating practical use cases for AI-powered tools, including claim document processing and workflow automation. These digital advancements enhance the speed, accuracy and transparency of claims processing, reinforcing client satisfaction and supporting the retention of corporate clients.

(iv) 內地住院及門診醫療網絡與配套基礎設施發展

本集團與中國內地指定醫院維持合作安排，以便為本集團香港及澳門醫療保健方案涵蓋的成員提供跨境醫療保健服務。

- **指定住院醫院**：本集團透過與中國內地的指定醫院(尤其三甲醫院)建立合作關係，加強對合約客戶成員住院服務支援。

- **佛山中央後勤支援樞紐**：佛山社區醫療中心作為本集團第三方管理業務的中央後勤樞紐，處理熱線支援、理賠管理及資料處理服務，可提升營運效率並縮短服務周轉時間。

(v) 技術部署

年內實現的數碼轉型里程碑包括更廣泛採用電子化預先審批(「電子化預先審批」)平台，推出UMP會員應用程式(UMP Member App)，以及升級企業客戶入門網站。本集團亦為人工智能驅動工具開始評估實際應用場景(包括理賠文件處理及工作流程自動化)。數碼上進步會提升理賠處理速度、準確度及透明度，從而令客戶更為滿意並有助於留住企業客戶。

Hong Kong & Macau Clinical Services

Demand for general practice ("GP") and specialist practice ("SP") services remained robust in FY2026, while IME service demand declined. As a result, segment revenue was broadly in line with FY2025, although operating profit fell 18.2%. The financial results were driven by the following:

- Within the medical services segment, revenue from GP and SP before elimination of inter-business lines sales increased by 1.7% and 3.4%, respectively, demonstrating resilient market demand and consolidating the Group's position as a preferred local healthcare provider. In contrast, IME revenue declined and contributed less to overall revenue, as market demand normalised after the exceptional uplift recorded in previous years.

- The dental segment delivered solid growth, with revenue before elimination of inter-business lines sales rising by 7.4% and patient visits increasing by 9.7%. The local dental market faced ongoing headwinds, including shifting consumer lifestyles and growing patient outflow seeking complex dental treatments in Shenzhen. The Group proactively navigated these market changes by enhancing operational efficiency and optimising service strategies to sustain stable profit contributions while operating in a competitive landscape. The Group remains focused on retaining patient loyalty and delivering high-quality dental care.

- The Group's imaging centres continued to scale their operations, contributing to a 4.3% annual revenue increase despite intense market competition and industry-wide margin pressure. Prior investments in advanced diagnostic technology have strengthened clinical capabilities and improved patient throughput. While depreciation on capital investments continued to weigh on short-term profitability, the Group expects improved investment yields over the long term. Through continuous process optimisation, enhanced connectivity with specialist medical groups and service expansion, the Group further solidified its market position in diagnostic imaging to meet rising demand for high-quality diagnostic services.

香港及澳門臨床服務

2026財政年度，全科醫療(「全科醫療」)及專科醫療(「專科醫療」)服務需求保持強勁，移民體檢服務需求則有所下降。因此，儘管經營利潤下跌18.2%，惟分部收入與2025財政年度大致相符。財務業績主要受以下因素帶動：

- 在醫療服務分部內，來自全科醫療及專科醫療的收入(業務線間的銷售抵銷前)分別增加1.7%及3.4%，反映市場需求具備韌性，並鞏固本集團作為首選本地醫療保健提供者的地位。相反，由於市場需求在過往年度錄得異常增長後回復正常，移民體檢收入有所下降，對整體收入的貢獻亦有所減少。

- 牙科分部穩健增長，業務線間的銷售抵銷前的收入增加7.4%，就診量亦增長9.7%。本地牙科市場持續面臨逆境，當中包括消費者生活方式轉變，以及愈來愈多患者前往深圳尋求複雜牙科治療造成流失。本集團積極應對此等市場轉變，提升營運效率及優化服務策略，於競爭激烈的環境中營運時維持穩定的溢利貢獻。本集團將繼續專注保持患者忠誠度，並提供優質的牙科護理。

- 儘管面對激烈的市場競爭及全行業的利潤受壓，惟本集團的影像中心業務規模持續擴展，帶動年度收入增長4.3%。過往對先進診斷技術的投資增強臨床實力，並提高患者流量。儘管資本投資折舊持續對短期盈利能力構成壓力，惟本集團預期長期投資收益率將有所改善。透過持續優化流程、加強與專科醫療集團聯繫以及擴展服務，本集團進一步鞏固其在影像診斷領域的市場地位，從而滿足對優質診斷服務日益增長的需求。

The increase in demand of GP and SP services was due to:

1. **Cross-segment referral synergy:** The Group continued to benefit from patient referrals generated by its Corporate Healthcare Solution segment, with expanded capacity from growth in the Group's own and partnered SP providers supporting activity levels across both GP and SP clinical services, though corporate spending on employee clinical healthcare services has tightened for FY2026.

2. **Operational adjustments and government initiatives:** The Group recalibrated its GP service capacity during the year and allocated additional resources to government-led healthcare initiatives, supported by connectivity to the Government's eHealth data-sharing system.

3. **Specialist organisation collaboration:** In respect of specialist services, reliable collaborative arrangements with specialist clinical organisations delivered enhanced support throughout the year, enabling expanded delivery of specialist-related services.

Against this backdrop, the Group continued to strengthen its clinical service capabilities and operating platform through a number of strategic initiatives during FY2026.

(i) Revisit Workflow for Operational Efficiency & Cost Saving

The Group conducted comprehensive reviews of end-to-end operational workflows across its medical and imaging centres to drive operational efficiency and deliver sustainable cost savings. Key initiatives included optimising staff rostering to lower manpower expenses, enforcing tightened vendor management to lower procurement cost on drugs and consumables and stringent inventory control to minimise medical consumable wastage, and implementing robust pharmaceutical management systems to mitigate overstocking and expired inventory losses. In addition, the relocation and renewal of clinic premises at lower rental terms strengthened the Group's cost-control framework, improved overall cost efficiency and lifted per-clinic profitability.

全科醫療及專科醫療服務需求增加，原因乃：

1. **跨分部轉介協同效應**：本集團繼續受惠於其企業醫療保健解決方案業務分部帶來的患者轉介，而本集團自有及合夥專科醫療提供者增長擴大服務能力，儘管企業於2026財政年度在僱員臨床醫療保健服務方面的支出有所收緊，亦支持全科醫療及專科醫療臨床服務的業務活動水平。

2. **業務調整與政府舉措**：年內，憑藉與政府電子健康數據共享系統(eHealth)的連接，本集團重新校準全科醫療服務能力，並將更多資源分配至政府主導的醫療保健項目。

3. **與專科機構合作**：在專科服務方面，年內因與專科臨床機構訂立可靠合作安排而獲得更多支持，從而擴大所提供專科相關服務範圍。

在此背景下，本集團於2026財政年度透過多項策略舉措，持續鞏固臨床服務能力及營運平台。

(i) 重新審視工作流程，以提升營運效率及節省成本

本集團全面審視醫療及影像中心的端對端營運工作流程，以提升營運效率並實現可持續節約成本。主要舉措包括盡力改善員工排班以降低人力資源開支，強制收緊管理供應商方法以降低藥品及耗材的採購成本，強制嚴格管控存貨以盡力減少浪費醫療耗材，以及推行健全的醫藥管理制度，以減少過量庫存或過期存貨造成的損失。此外，按更低租金條款搬遷與續租診所已鞏固本集團的成本控制架構，提升整體成本效益，並提高每間診所的盈利能力。

(ii) Immigration Examination Services

IME business moderated further in FY2026 on lower service volumes, following the peak in IME demand in prior years, while the Group maintained consistent service quality standards.

(iii) Deployment of New Clinical Medical System

The Group launched a new integrated clinical medical platform by the end of FY2025 and continued to roll it out and refine it through FY2026. The system has produced measurable gains in administrative efficiency: an intuitive booking interface improves the patient experience, end-to-end drug management and real-time inventory tracking tighten stock control, and patient records are administered more systematically and accurately. The investment underpins the Group's longer-term efficiency and service quality.

(iv) Deepening Government Partnerships

The Group expanded its participation in government tenders for outsourced medical and diagnostic services. This diversifies revenue, raises utilisation of the Group's advanced equipment and reinforces its standing as a trusted partner to the public healthcare system. Participation also brings the Group closer to government healthcare authorities and institutions, opening further scope for collaboration and strengthening its ability to support evolving public healthcare needs.

(v) Alignment with the Government's primary healthcare strategy

The Group continued advancing its community-centric primary healthcare initiatives, including health screening, vaccination programmes and chronic disease education. Its district-based service portfolio is closely aligned with the Government's primary healthcare strategy and regional policy focus on preventive care, chronic disease management and healthy ageing. As the new Private Healthcare Facilities Ordinance (Cap. 633), with an aim to safeguard patient safety and patients' rights, raises industry standards for professionalism, transparency and governance, the Group's longstanding focus on quality healthcare services and corporate governance positions it well to benefit from increased patient confidence and opportunities for public-private collaboration.

(ii) 移民體檢

繼過去數年移民體檢需求達致高峰後，受服務量下降影響，移民體檢業務於2026財政年度進一步放緩，惟本集團仍維持一貫的服務質素標準。

(iii) 使用新的臨床醫療系統

本集團於2025財政年度結束前推出一個新的綜合臨床醫療平台，並於2026財政年度期間繼續推出並完善。該系統在行政效率方面帶來可計量收益：簡易的預約界面改善患者體驗，端對端藥品管理及實時存貨追蹤加緊存貨控制；而患者記錄亦以更具系統及準確的方式管理。該項投資鞏固本集團的長遠效率及服務質素。

(iv) 加深與政府的合作夥伴關係

我們增加參與政府外包醫療及診斷服務的招標。此舉可使收入來源多元，提高本集團先進設備的使用率，並鞏固其作為公營醫療系統可靠合作夥伴之地位。參與招標亦拉近本集團與政府醫療保健機構及組織的距離，拓展進一步合作範圍，並加強其支援不斷演變公營醫療需要的能力。

(v) 與政府基層醫療策略對接

本集團繼續推動以社區為本的基層醫療保健服務，當中包括健康篩查、疫苗接種及慢病教育。其區域服務組合與政府的基層醫療保健策略以及在預防保健、慢病管理及健康頤年方面的區域政策重點緊密一致。鑑於新《私營醫療機構條例》(第633章)為保障患者安全與患者權利而提升行業在專業水平、透明度及管治方面的標準，本集團長期以來重視優質醫療保健服務及企業管治，能使其擁有優勢，可受惠於患者信心增強以及公私營協作帶來的機遇。

Further, The Group continued aligning its service offerings with evolving public-sector healthcare dynamics. As public hospital fees rise under the government's fiscal policy framework, the Group's private services have become a more cost-effective and efficient alternative for individual and corporate clients, strengthening market attractiveness and driving patient traffic to its service centres.

(vi) Deepening Collaboration with Service Providers

The Group broadened its specialist healthcare offerings through strategic collaborations with leading specialist medical groups such as Pedder Healthcare Group. The partnership extends the Group's service reach and diversifies its comprehensive healthcare offerings, enabling the Group to address a broader spectrum of patient clinical needs.

Chinese Mainland Healthcare Services

FY2026 still brought a complex operating environment for the Group's Mainland clinical-healthcare businesses. IME volumes continued to moderate amid sustained high geopolitical tensions. Nevertheless, management maintained a disciplined, targeted expansion posture, concentrating resources on priority geographies rather than unfocused nationwide roll-out.

(i) Strategic Adjustments & Operational Enhancements

Workflow optimisation continued across all operating sites. Selected IT support, customer hotline and business development functions were centralised and relocated to Foshan, shortening service turnaround time to the Group and improving overall administrative efficiency. The Foshan operations also provided a stable workforce supply, supporting business continuity, operational scalability and the Group's long-term growth initiatives.

此外，本集團繼續調整其服務範疇，以配合不斷轉變的公營醫療動態。在政府財政政策框架下公立醫院收費上調之際，本集團的私營服務已成為個人及企業客戶更具成本效益且高效的另一選擇，從而增強市場吸引力，並帶動其服務中心的就診人流。

(vi) 加深與服務提供者合作

本集團透過與仁德醫健集團等領先的專科醫療集團策略合作，拓展其專科醫療保健服務。此次合作擴大本集團的服務覆蓋範圍，並豐富其綜合醫療保健服務組合，使本集團能滿足患者更廣泛的臨床需要。

中國內地醫療保健服務

2026財政年度，本集團內地臨床醫療保健業務的經營環境依然複雜。在地緣政治緊張局勢持展下，移民體檢業務量繼續放緩。儘管如此，管理層仍保持審慎且目標明確的擴展態勢，將資源集中於重點區域，而非缺乏重點的全國發展。

(i) 策略調整與營運提升

所有營運站地點的工作流程持續優化。選定的資訊科技支援、客戶熱線及業務拓展職能均集中遷至佛山，縮短本集團處理服務時間，並提升整體行政效率。佛山業務亦供應穩定的勞動力，支持業務持續發展、營運規模擴大以及本集團的長期增長舉措。

(ii) Service Expansion & Regional Diversification

The Group maintained its established operational bases in Shanghai and Beijing, with a continued strategic focus on the GBA, notably Foshan and Guangzhou. In parallel, the Group developed its TPA services in the Chinese Mainland by strengthening collaborations with Tier III Class A hospitals such as Shanghai East Hospital (上海東方醫院), thereby enhancing connectivity across the healthcare ecosystem and broadening service offerings for clients. The expansion of the Group's regional footprint enhanced service coverage, improved accessibility for clients and diversified sources of business. These developments further strengthened the Group's operational resilience and supported its strategy of building a more diversified and sustainable healthcare platform.

(ii) 服務擴張與區域多元化

本集團繼續維持在上海及北京既有的營運基地，並持續將策略重心聚焦於大灣區，尤其在佛山及廣州。同時，本集團透過加強與上海東方醫院等三甲醫院的合作，在中國內地發展了其第三方管理服務，從而增強整個醫療保健生態系統的對接並擴大為客戶提供的服務範圍。擴大本集團區域業務分佈已增加服務覆蓋範圍，提升客戶可及性，並使業務來源多元。有關發展進一步增強本集團的營運韌性，並支持其建立更多元及可持續醫療保健平台的策略。

(iii) Establishment of New Medical Centre in Foshan

In alignment with evolving government healthcare policies that prioritise community-based care, early intervention and chronic disease management, the Group proactively explored new opportunities across primary healthcare and preventive medicine. Recognising the GBA as a strategically important high-growth market with rising demand for accessible, high-quality healthcare services, the Group continued to strengthen its regional presence through a disciplined and targeted expansion strategy. The Group closely monitored national primary care reform directions, and the Foshan community healthcare centre pilot serves as its flagship exploratory initiative tailored to such policy priorities.

The establishment of this Foshan pilot centre further strengthens the Group's market presence and lends greater credibility to the execution of its primary healthcare strategy within the GBA and the Group's other operating locations.

(iii) 在佛山設立新醫療中心

為配合政府優先考慮社區醫療、早期療育及慢性病管理的醫療政策演變，本集團積極探索基層醫療及預防疾病的新機遇。鑑於大灣區乃策略上意義重大的高增長市場，區內對便捷、優質醫療保健服務的需求日益殷切，本集團透過審慎而具針對的擴展策略，持續加強其於區內的業務佈局。本集團密切監察國家基層醫療改革的走向，而佛山社區醫療保健中心試點為針對有關政策重點而訂製的旗艦探索舉措。

設立佛山試點中心進一步鞏固本集團的市場地位，並使其在大灣區及本集團其他營運地區執行基層醫療策略一事更有可能實現。

OUTLOOK

Despite headwinds including macroeconomic volatility, intensifying competition and shifting corporate and consumer healthcare spending patterns, management remains cautiously optimistic about the Group's strategic positioning.

For FY2027, the Group will align its service development roadmap with Hong Kong's healthcare regulatory requirements and with the strategic priorities outlined in China's 15th National Health Plan. Drawing on its mature corporate healthcare ecosystem and robust clinical expertise, the Group sees targeted growth opportunities, especially in preventive care and long-term health management. Backed by its solid operational foundation, the Group is well poised to capture emerging industry opportunities and further consolidate its market foothold. Our priorities are:

(i) Operational Efficiency and Cost Discipline

The Group will capitalise on its cost-efficient, asset-light hybrid operating model to safeguard profitability and drive sustainable returns. It will pursue targeted organic growth aligned with core competencies while retaining agility to seize market recovery opportunities. The Group will also continue to partner with professional healthcare providers to deliver quality clinical services and maintain institutional links with Mainland hospitals to support cross-border TPA arrangements for the Group's existing corporate and insurance scheme members.

(ii) Scaling the Foshan Back-office Hub

The Group will further scale up shared-service functions from its Foshan backend hub. Drawing on the operational infrastructure laid down at the Foshan Healthcare Centre, the facility supports the Group's TPA backend operations and cross-border healthcare access arrangements for scheme members. As the Group's strategic offshore support base, Foshan will continue to leverage the GBA's cost-effective talent pool for labour intensive work spanning data processing, claims administration and customer service support. Moving routine backend workflows to the hub will deliver sustainable cost savings and provide the capacity to absorb a growing client base and rising service volumes.

展望

儘管面對宏觀經濟波動、競爭加劇以及企業與消費者醫療保健支出模式轉變等逆境，管理層對本集團的策略定位仍抱持審慎樂觀態度。

在2027財政年度，本集團將調整其服務發展路線圖至符合香港的醫療監管規定以及中國第十五個國民健康規劃中概述的策略重點。憑藉成熟的企業醫療保健生態系統及深厚的臨床專業知識，本集團能發現目標增長機遇，尤其在預防保健及長期健康管理方面。憑藉穩固的營運基礎，本集團已蓄勢待發，可掌握行業新興機遇，並進一步鞏固其市場地位。我們優先處：

(i) 營運效率與成本管控

本集團將利用其高成本效益、輕資產混合營運模式，保障盈利能力並推動可持續回報。其追求與核心能力契合的自然增長目標，同時保持靈活，以掌握市場復甦機遇。本集團亦將繼續與專業醫療保健提供者合作，提供優質臨床服務，並與內地醫院於機構層面上維持聯繫，以支持為本集團現有企業及保險計劃成員而設的跨境第三方管理安排。

(ii) 擴展佛山後勤樞紐

本集團將進一步擴展其佛山後勤樞紐的共用服務職能。憑藉佛山社區醫療保健中心所建立營運基礎設施，該設施為本集團的第三方管理後勤營運及計劃成員的跨境就醫安排提供支援。作為本集團的策略離岸支援基地，佛山將繼續善用大灣區具成本效益的人才庫，以進行涵蓋數據處理、理賠管理及客戶服務支援等勞動密集型工作。將例行後勤工作流程遷至該樞紐將可持續節省成本，並提供能力吸納不斷擴大的客源及與日俱增的服務量。

(iii) Technology-Enabled Innovation

Digital system upgrades will continue, including further enhancements to the UMP Member App, promoting use of the EPA platform and continued optimisation of eHealth-integrated workflows. In particular, deeper EPA penetration will digitalise end-to-end service procedures, improve operational convenience, lift member satisfaction and strengthen collaboration with insurance partners and corporate clients. The Group will also identify and roll out targeted AI use cases to automate manual processes and secure lasting efficiency gains.

(iii) 技術賦能創新

數碼系統升級將會持續，包括進一步改善UMP會員應用程式(UMP Member App)，推廣使用電子化預先審批平台，以及持續優化與醫健通整合的工作流程。尤其，加深電子化預先審批滲透率將實現端對端服務流程數碼化，使營運更便利，令會員更滿意，並加強與保險合作夥伴及企業客戶合作。本集團亦將物色並推行目標人工智能應用案例，以實現手動流程自動化並確保效率持久提升。

(iv) Network and Service Growth

Preventive-care initiatives will remain an important priority, as they represent a sustainable approach to mitigating long-term healthcare-cost burdens for both clients and the broader healthcare ecosystem. Within Hong Kong and Macau, the Group will keep track of government-led public-private partnership programmes and service-tender opportunities and will consider participating through appropriate third-party collaboration arrangements. For Chinese Mainland operations, it will maintain targeted regional resource allocation, advance the Foshan community-healthcare-centre pilot in a prudent manner, continue to build institutional clinical-referral partnerships and closely keep abreast of evolving regulatory requirements. Building on its well established TPA and corporate healthcare solution capabilities, the Group is vigorously expanding its commercial insurance and TPA service businesses across Chinese Mainland. Leveraging its robust healthcare service system, the Group will continue to collaborate with the International Medical Departments ("IMDs") of hospitals in the Chinese Mainland to broaden its TPA service network, capture market opportunities and expand patient referral services, further realising synergies with the Group's existing service network.

(iv) 網絡及服務增長

預防保健方案將繼續為關鍵重點，就客戶及較大型醫療保健生態系統而言，有關方案為一種緩解長期醫療成本負擔的可持續方法。在香港及澳門，本集團將密切關注政府帶領的公私營協作計劃及服務招標機遇，並考慮透過適當的第三方合作安排參與其中。就中國內地業務而言，本集團將繼續按目標及區域分配資源，審慎推進佛山社區醫療保健中心試點，持續建立機構臨床轉介合作夥伴關係，並密切關注不斷轉變的監管規定。憑藉成熟的第三方管理及企業醫療保健解決方案能力，本集團正大力拓展其在中國內地的商業保險及第三方管理服務業務。憑藉其堅實的醫療保健服務體系，本集團將繼續與中國內地醫院的國際醫療部門(International Medical Department，「國際醫療部」)合作，以擴大其第三方管理服務網絡、掌握市場機遇及擴大患者轉介服務，進一步實現與本集團現有服務網絡之協同效應。

(v) Specialist Collaboration and Product Development

The Group will deepen its collaborations with specialist medical groups and clinical organisations, extending the range of specialist services available to patients without carrying heavy in-house recruitment costs, and will consider further partnerships that broaden clinical coverage, support referral flows within its network or strengthen capability in priority specialties. It will also explore the development of new healthcare plan offerings, including concierge-style services and other value-added solutions, to better address the evolving needs of corporate and individual clients.

(vi) Working with Government and Serving the Community

Deepening connectivity with government healthcare initiatives will remain a strategic priority for the Group. In Hong Kong and Macau, the Group will continue to participate in government-led public-private partnership programmes, healthcare schemes and service tenders with the objective of becoming a key healthcare partner in supporting public healthcare initiatives. The Group will also continue its community-based screening, vaccination and chronic disease management programmes, complementing broader public health objectives. In Chinese Mainland, the Group will closely monitor healthcare policy developments and primary care reforms, aligning its services with government priorities and pursuing opportunities for further collaboration.

Looking ahead, the Group will continue to pursue opportunities that enhance service quality, operational efficiency and market reach. Through a combination of strategic alliances, technology-enabled solutions and targeted regional initiatives, the Group aims to strengthen its position for sustainable long-term development.

(v) 專科合作與產品開發

本集團將加深與專科醫療集團及臨床機構合作，在毋須承擔沉重內部招聘成本的情況下，擴大向患者提供的專科服務範疇，並將考慮進一步展開合作夥伴關係，其或可擴大臨床覆蓋、支持網絡內轉介流或增強重點專科能力。其亦將探索開發新型醫療保健計劃產品，當中包括禮賓式服務及其他增值解決方案，以更妥善迎合企業及個人客戶不斷轉變的需要。

(vi) 與政府合作，服務社區

加深與政府醫療保健計劃對接仍屬本集團的策略重點。在香港及澳門，本集團將繼續參與由政府帶領的公私營協作計劃、醫療保健計劃及服務招標，旨在成為支持公營醫療計劃的重要醫療保健夥伴。本集團亦將繼續推行社區篩查、疫苗接種及慢病管理計劃，以配合更廣泛的公共衛生目標。在中國內地，本集團將密切監察醫療保健政策的發展及基層醫療改革，使其服務緊貼政府的重點方向，並尋求進一步合作的機會。

展望未來，本集團將持續尋求可提升服務品質、營運效率以及增加市場覆蓋範圍的機會。透過結合策略聯盟、技術賦能解決方案及針對性區域的舉措，本集團旨在鞏固其地位，以實現可持續長期發展。

FINANCIAL REVIEW
FY2026 compared to FY2025

Revenue
During FY2026, we primarily generated revenue from (i) the provision of corporate healthcare solutions to Contract Customers in Hong Kong and Macau, (ii) the provision of clinical healthcare services to Self-paid Patients in Hong Kong and Macau and (iii) the provision of clinical healthcare services in Chinese Mainland.

During the period under review, the Group reported a total revenue of approximately HK$717.0 million, represented a decrease of 1.4% as compared to that of FY2025. Such decrease was mainly attributable to the drop in volume of Immigration Medical Examinations (IME).

Professional Services Expenses
Professional services expenses is one of the key operating expense which primarily comprise fees paid to Doctors, Dentists and Auxiliary Services Providers for Medical Services, Dental Services, medical imaging and laboratory services and Auxiliary Services rendered within the UMP Network, as well as fees paid to third party laboratories and medical imaging centres for services rendered to the Group.

Professional services expenses in FY2026 increased by approximately HK$5.6 million, representing an increase of 2.2% as compared to that in FY2025. Professional services expenses maintained at 36.6% to the total revenue (FY2025: 35.4%). The increase in professional services expenses was due to the increase in demand of consultation services during the financial year.

財務回顧
2026財政年度與2025財政年度比較

收入
於2026財政年度，我們的收入主要來自(i)於香港及澳門向合約客戶提供企業醫療保健解決方案；(ii)於香港及澳門向自費患者提供臨床醫療保健服務及(iii)於中國內地提供臨床醫療保健服務。

於回顧期間，本集團錄得總收入約717.0百萬港元，較2025財政年度減少1.4%。該減少主要由於移民體檢的用量下降。

專業服務費用
專業服務費用乃主要經營開支之一，主要包括就醫生、牙醫及輔助服務提供者於UMP網絡內提供的醫療服務、牙科服務、醫學影像及化驗服務以及輔助服務而向其支付的費用，以及就第三方化驗及醫學影像中心向本集團提供的服務而向其支付的費用。

2026財政年度專業服務開支增加約5.6百萬港元，較2025財政年度增加2.2%。專業服務開支維持於佔總收入的36.6%（2025財政年度：35.4%）。專業服務開支增加乃由於本財政年度的診症服務需求上升。

Employee Benefit Expense

Employee benefit expense primarily comprise salaries and related costs, equity-settled share-based payment expense, as well as pension scheme contributions for nurses and administrative personnel, and also include those of the Directors and key management personnel.

Employee benefit expenses in FY2026 recorded an amount of approximately HK$184.6 million, representing an increase of approximately HK$4.6 million and 2.5% as compared to that in FY2025. Employee benefit expenses principally included staff costs for clinical medical service frontline staff and the corporate staff expenses. Employee benefit expenses represented at about 25.7% to the total revenue (FY2025: 24.8%). The increase in employee benefit expenses was mainly attributable to the initial operation of a new integrated healthcare centre in Foshan.

僱員福利開支

僱員福利開支主要包括護士及行政人員以及董事及主要管理人員的薪金及相關成本、以權益結算的股份支付開支以及退休金計劃供款。

2026財政年度僱員福利開支錄得約184.6百萬港元，較2025財政年度增加約4.6百萬港元及2.5%。僱員福利開支主要包括臨床醫療服務前線員工的員工成本以及企業員工開支。僱員福利開支佔總收入約25.7%（2025財政年度：24.8%）。僱員福利開支增加主要由於佛山一家新綜合醫療中心屬營運初期所致。

Earning before Interest, Tax, Depreciation and Amortisation ("EBITDA")

During the year ended 30 June 2026, the Group reported an EBITDA loss of approximately HK$21.6 million, represented a decrease of HK$108.6 million as compared to the EBITDA of approximately HK$87.0 million in FY2025. Excluding impairment of goodwill, impairment loss of investments in associates and impairment of items of property, plant and equipment, the Group core business reported an EBITDA ("Adjusted EBITDA") of approximately HK$75.2 million (FY2025: HK$94.9 million), which represented a decrease of 20.7% from FY2025. The decrease in Adjusted EBITDA was mainly due to start-up and ramp-up costs of initial operation of a new integrated healthcare centre in Foshan and drop in volume of IME.

未計利息、稅項、折舊及攤銷前的利潤（「EBITDA」）

於截至2026年6月30日止年度，本集團錄得EBITDA虧損約21.6百萬港元，較2025財政年度的EBITDA約87.0百萬港元減少約108.6百萬港元。撇除商譽減值、於聯營公司的投資減值虧損以及物業、廠房及設備項目減值，本集團核心業務錄得EBITDA（「經調整EBITDA」）約75.2百萬港元（2025財政年度：94.9百萬港元），較2025財政年度減少20.7%。經調整EBITDA減少主要由於佛山一家新綜合醫療中心於營運初期產生的開業及投產成本及移民體檢的用量下降所致。

Depreciation and Amortisation

Depreciation and amortisation, which comprises of depreciation of the right-of-use assets and depreciation and amortisation of other non-current assets.

(i) Right-of-use assets

Depreciation of Right-of-use assets decreased by 8.4% from HK$61.4 million for FY2025 to HK$56.2 million for FY2026, which was mainly relating to the completion of lease contracts and reduction of lease contracts as a result of centres consolidation.

(ii) Property, plant and equipment and intangible assets

Depreciation of property, plant and equipment and intangible assets decreased by 7.0% from HK$44.4 million for FY2025 to HK$41.3 million for FY2026, which was in line with business development.

Other Expenses

Other expenses primarily comprise provision of impairment loss and general overhead expenses such as utilities, operating and other administrative expenses such as professional fees, repair and maintenance expenses incurred with respect to the Group's offices and medical equipment, printing expenses and bank charges.

Other expenses in FY2026 recorded an amount of approximately HK$167.5 million, representing an increase of approximately HK$89.6 million and 1.2 times as compared to that in FY2025. The increase was mainly attributable to non-cash one-off impairment on goodwill, impairment on items of property, plant and equipment. Other expenses represented at about 23.4% to the total revenue (FY2025: 10.7%).

Net Profit

During the year ended 30 June 2026, the loss for the year 2026 reported approximately HK$72.7 million (FY2025: profit for the year of HK$31.9 million) represented a drop of approximately HK$104.6 million. The drop in profit for the year was mainly attributable to non-cash one-off impairment on goodwill, impairment on items of property, plant and equipment and start-up and ramp-up costs of initial operation of a new integrated healthcare centre in Foshan.

折舊及攤銷

折舊及攤銷包括使用權資產折舊以及其他非流動資產之折舊及攤銷。

(i) 使用權資產

使用權資產折舊由2025財政年度的61.4百萬港元減少8.4%至2026財政年度的56.2百萬港元，這主要與租賃合約完結以及因整合醫療中心而使租賃合約減少有關。

(ii) 物業、廠房及設備及無形資產

物業、廠房及設備及無形資產折舊由2025財政年度的44.4百萬港元減少7.0%至2026財政年度的41.3百萬港元，這與業務發展一致。

其他開支

其他開支主要包括減值虧損撥備及日常開銷，例如水電、經營及其他行政開支(例如專業費用、與本集團辦公室及醫療設備相關的維修及保養開支、印刷費及銀行收費)。

2026財政年度錄得其他開支約167.5百萬港元，較2025財政年度增加約89.6百萬港元及1.2倍。該增加主要由於非現金一次性商譽減值以及物業、廠房及設備項目減值所致。其他開支佔總收入約23.4%(2025財政年度：10.7%)。

淨利潤

於截至2026年6月30日止年度，2026年錄得虧損約72.7百萬港元(2025財政年度：年內利潤31.9百萬港元)，下跌約104.6百萬港元。年內利潤下跌乃主要由於非現金一次性商譽減值、物業、廠房及設備項目減值，以及佛山一家新綜合醫療中心於營運初期產生的開業及投產成本所致。

KEY FINANCIAL POSITION ITEMS

Right-of-use assets

Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. The recognised right-of-use assets are depreciated on a straight-line basis over the shorter of the estimated useful life and the lease term.

As at 30 June 2026, the right-of-use assets recorded at approximately HK$88.2 million (FY2025: HK$96.5 million), the change in FY2026 was mainly resulted from the additions of new lease amounted to approximately HK$53.5 million net off to the depreciation charge of approximately HK$56.2 million. As at 30 June 2026, the right-of-use assets represented about 8.9% of the Group's total assets (FY2025: 8.8%).

Goodwill

Goodwill primarily represents the excess of the aggregate of the consideration over the fair value of the identifiable assets acquired and liabilities assumed. After initial recognition, goodwill is measured at cost less any accumulated impairment losses.

As at 30 June 2026, the goodwill was recorded at approximately HK$76.3 million (FY2025: HK$156.6 million). The change in FY2026 was resulted from impairment of HK$76 million and HK$6 million which were recognised in Hong Kong Medical Services CGU and Hong Kong Dental Services CGU, respectively. As at 30 June 2026, the goodwill represented about 7.7% of the Group's total assets (FY2025: 14.3%).

Investments at fair value through other comprehensive income, financial assets at fair value through profit or loss and financial assets at amortised cost

Investments at fair value through other comprehensive income, financial assets at fair value through profit or loss and financial assets at amortised cost primarily represent unlisted equity investments at fair value, listed equity and debt investments at fair value and investment funds. Certain equity investments are designated at fair value through other comprehensive income as the Group considers these investments to be strategic in nature.

主要財務狀況項目

使用權資產

使用權資產按成本減去任何累計折舊和任何減值虧損後的金額計量，並就租賃負債的任何重新計量進行調整。使用權資產的成本包括已確認的租賃負債金額、已產生的初始直接成本以及在開始日期或之前已作出的租賃付款減已收到的任何租賃優惠。已確認的使用權資產以直線法按估計可使用年期和租期之較短者計提折舊。

於2026年6月30日，錄得使用權資產約88.2百萬港元(2025財政年度：96.5百萬港元)，2026財政年度的變動乃主要由於增訂新租賃約53.5百萬港元扣除折舊支出約56.2百萬港元所致。於2026年6月30日，使用權資產佔本集團總資產約8.9%(2025財政年度：8.8%)。

商譽

商譽主要指總代價超出所收購可識別資產及所承擔負債公允價值的部分。初始確認後，商譽按照成本減任何累計減值虧損計量。

於2026年6月30日，錄得商譽約76.3百萬港元(2025財政年度：156.6百萬港元)。2026財政年度有所變動，緣於分別在香港醫療服務現金產生單位及香港牙科服務現金產生單位確認76百萬港元及6百萬港元減值。於2026年6月30日，商譽佔本集團總資產約7.7%(2025財政年度：14.3%)。

按公允價值計入其他全面收入的投資、按公允價值計入損益的金融資產及按攤銷成本計量的金融資產

按公允價值計入其他全面收入的投資、按公允價值計入損益的金融資產及按攤銷成本計量的金融資產主要代表按公允價值計量的非上市股本投資、按公允價值計量的上市股本及債務投資及投資基金。若干股本投資已指定為按公允價值計入其他全面收入，原因為本集團認為有關投資屬策略性質。

(i) Investments at fair value through other comprehensive income

As at 30 June 2026, the investments at fair value through other comprehensive income amounted to approximately HK$37.0 million (FY2025: HK$40.3 million), the change in FY2026 was resulted in fair value change of the investment.

(ii) Financial assets at fair value through profit or loss

As at 30 June 2026, the financial assets at fair value through profit or loss amounted to approximately HK$36.6 million (FY2025: HK$38.9 million), the change in FY2026 was resulted in decrease in investment and the fair value change during the year.

As at 30 June 2026, the total value of the investments at fair value through other comprehensive income and the financial assets at fair value through profit or loss represented about 3.7% of the Group's total assets (FY2025: 3.5%).

(i) 按公允價值計入其他全面收入的投資

於2026年6月30日，按公允價值計入其他全面收入的投資金額約37.0百萬港元（2025財政年度：40.3百萬港元），2026財政年度的變動乃由於投資公允價值變動所致。

(ii) 按公允價值計入損益的金融資產

於2026年6月30日，按公允價值計入損益的金融資產金額約36.6百萬港元（2025財政年度：38.9百萬港元），2026財政年度的變動乃由於年內投資減少及公允價值變動所致。

於2026年6月30日，按公允價值計入其他全面收入的投資及按公允價值計入損益的金融資產之總值佔本集團總資產約3.7%（2025財政年度：3.5%）。

LIQUIDITY AND FINANCIAL RESOURCES

流動資金及財務資源

		As at 30 June 於6月30日	
		2026	2025
		2026年	2025年
		HK$'000	HK$'000
		千港元	千港元
Current Assets	流動資產	**556,779**	536,805
Current Liabilities	流動負債	**264,109**	269,124
Net Current Assets	流動資產淨值	**292,670**	267,681
Current Ratio	流動比率	**2.11**	1.99

The Group's current ratio was 2.11 as at 30 June 2026 (30 June 2025: 1.99), reflecting a strong liquidity in its financial position. Working capital position of the Group remains strong.

於2026年6月30日，本集團的流動比率為2.11（2025年6月30日：1.99），反映其財務狀況的強大流動性。本集團的營運資金狀況仍然強勁。

The Group has historically funded its operations primarily by cash generated from operating activities. Upon the listing of the shares of the Company on the Stock Exchange, the Group intended to satisfy its liquidity requirements using a combination of cash generated from operating activities, net proceeds from the Global Offering and the net considerations received from the series of transactions. As of 30 June 2026, the Group had free cash and bank deposits of approximately HK$329.5 million (30 June 2025: HK$301.1 million).

本集團過往主要透過經營活動所得現金支持其業務營運。本公司股份於聯交所上市後，本集團擬動用經營活動所得現金、全球發售所得款項淨額及一連串交易已收代價淨額來滿足其流動資金需求。於2026年6月30日，本集團的不受制約現金及銀行存款約為329.5百萬港元（2025年6月30日：301.1百萬港元）。

As of the date of this report, the Group did not have any bank borrowings or outstanding bank loans and did not enter into any bank loan facilities.

截至本報告日期，本集團並無任何銀行借款或未償還銀行貸款，亦無訂立任何銀行貸款融資。

GEARING RATIO

The gearing ratio expressed as a percentage of loans from non-controlling shareholders of subsidiaries divided by consolidated total equity of the Group as at 30 June 2026 as about 7.1% (30 June 2025: 7.1%).

資本負債比率

於2026年6月30日，以來自附屬公司非控股股東的貸款除以本集團綜合權益總額的百分比表示的資本負債比率約為7.1%（2025年6月30日：7.1%）。

CAPITAL STRUCTURE

There has been no change in the capital structure of the Company during the year ended 30 June 2026. The capital of the Company comprises ordinary shares and other reserves.

資本結構

截至2026年6月30日止年度，本公司的資本結構並無變動。本公司的資本包括普通股及其他儲備。

SIGNIFICANT INVESTMENTS HELD

Save for the Investments at fair value through other comprehensive income, financial assets at fair value through profit or loss and financial assets at amortised cost held by the Group, as elaborated in further details in the section headed "FINANCIAL REVIEW" of this report, the Group did not hold any significant investment as at 30 June 2026.

持有的重大投資

除本集團持有的按公允價值計入其他全面收入的投資、按公允價值計入損益的金融資產及按攤銷成本計量的金融資產（詳見本報告「財務回顧」一節）外，本集團於2026年6月30日並無持有任何重大投資。

MATERIAL ACQUISITION OR DISPOSAL OF SUBSIDIARIES AND ASSOCIATES

Save as disclosed in this report, there was no material acquisition or disposal of subsidiaries undertaken by the Group during FY2026.

重大收購或出售附屬公司及聯營公司

除本報告披露者外，本集團於2026財政年度並無重大收購或出售附屬公司。

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in this report, the Group did not have any specific future plan for material investments or capital assets as of 30 June 2026.

重大投資或資本資產的未來計劃

除本報告披露者外，本集團於2026年6月30日並無任何重大投資或資本資產的具體未來計劃。

CAPITAL EXPENDITURE

The capital expenditure during the year was primarily related to deposits paid for and expenditures on additions of property, plant and equipment for the Group's Medical, Dental, and Auxiliary Services centres. For FY2026, the Group incurred capital expenditure in an aggregate amount of approximately HK$25.9 million (FY2025: HK$5.2 million).

資本開支

年內資本開支主要涉及為本集團的醫療、牙科及輔助服務中心添置物業、廠房及設備所支付的保證金及開支。於2026財政年度，本集團產生資本開支合共約25.9百萬港元（2025財政年度：5.2百萬港元）。

INDEBTEDNESS

Contingent Liabilities

As at 30 June 2026, the Group did not have any material contingent liabilities.

債務

或有負債

於2026年6月30日，本集團並無任何重大或有負債。

Capital Commitment

As at 30 June 2026, the Group has material capital commitments of approximately HK$3.2 million in relation to the acquisition of property, plant and equipment (FY2025: HK$6.1 million).

資本承擔

於2026年6月30日，本集團有關於購置物業、廠房及設備的重大資本承擔約3.2百萬港元（2025財政年度：6.1百萬港元）。

TREASURY MANAGEMENT

The Group employs a conservative approach to cash management and risk control. To achieve better risk control and efficient fund management, the Group's treasury activities are centralised.

During FY2026, the Group's receipts were mainly denominated in Hong Kong dollars and Renminbi. Payments were mainly made in Hong Kong dollars and Renminbi. Cash was generally placed in short-term deposits denominated in Hong Kong dollars.

The objective of the Group's treasury policies is to minimise risks and exposures due to the fluctuations in foreign currency exchange rates and interest rates. The Group does not have any significant interest rate risk at present as the Group did not have any bank borrowings or outstanding bank loans and did not enter into any bank loan facilities.

庫務管理

本集團在現金管理及風險控制方面以審慎穩健為先。為了實現更佳的風險控制及有效的資金管理，本集團集中進行庫務活動。

在2026財政年度，本集團的收款主要以港元及人民幣計值。付款主要以港元及人民幣作出。現金一般存作港元計值的短期存款。

本集團財務政策的目標是盡量減少因外幣匯率及利率波動而帶來的風險及敞口。由於本集團並無任何銀行借款或未償還銀行貸款，亦無訂立任何銀行貸款融資，本集團目前並無任何重大的利率風險。

RISK MANAGEMENT

Foreign Currency Risk

During the reporting period, the Group undertook certain transactions in foreign currencies, which exposed the Group to foreign currency risk, primarily relating to the Renminbi against Hong Kong dollars.

The Group did not use any derivative contracts to hedge against its exposure to currency risk. The management manages the currency risk by closely monitoring the movement of the foreign currency rates and will consider hedging against significant foreign exchange exposure when the need arises.

Credit Risk

The credit risk of the Group's financial assets arises from default of the counterparty, with a maximum exposure equal to the carrying amounts of these instruments.

The Group trades only with recognised and creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and concentrations of credit risk are managed by customer/counterparty.

PLEDGE OF ASSETS

As at 30 June 2026, the Group has pledged certain deposits with an aggregate carrying amount of HK$1.8 million (30 June 2025: HK$1.8 million) in connection with a surety bond issued by a bank in favour of respective independent third parties for potential disruption of Medical and Dental Services.

EMPLOYEE AND REMUNERATION POLICY

As at 30 June 2026, the Group had a total of 494 full-time employees (30 June 2025: 452 full-time employees). For FY2026, the staff cost (including Directors' remuneration in the form of salaries and other benefits) was approximately HK$184.6 million (FY2025: HK$180.0 million).

風險管理

外匯風險

於報告期內，本集團進行了若干外幣交易，令本集團承擔外匯風險，主要與人民幣兑港元有關。

本集團並無使用任何衍生工具合約來對沖其貨幣風險。管理層通過密切留意外幣匯率的走向管理貨幣風險，並在需要時會考慮對沖重大外匯風險。

信貸風險

本集團金融資產的信貸風險源自交易對手違約，最大風險相等於有關工具的賬面值。

本集團僅與認可及信譽可靠的第三方進行買賣。本集團之政策為所有有意按信貸條款進行買賣之客戶均須接受信貸審核程序。此外，本集團持續監控應收款項結餘，集中信貸風險由客戶／交易方管理。

資產抵押

於2026年6月30日，本集團已抵押若干賬面總值合共1.8百萬港元(2025年6月30日：1.8百萬港元)的存款，乃涉及由一間銀行就潛在醫療及牙科服務干擾而向有關獨立第三方發出的履約保證。

僱員及薪酬政策

於2026年6月30日，本集團共有494名全職僱員(2025年6月30日：452名全職僱員)。於2026財政年度，員工成本(包括以薪金及其他福利形式發放的董事薪酬)約為184.6百萬港元(2025財政年度：180.0百萬港元)。

The Group ensures that the pay levels of its employees are competitive and employees are rewarded on a performance-related basis, together with reference to the profitability of the Group, prevailing remuneration benchmarks in the industry, and market conditions within the general framework of the Group's remuneration system.

本集團確保其僱員的薪金水平具競爭力，僱員按工作表現基準獲得獎勵，且經參考本集團的盈利能力、行業內現行的薪酬基準以及本集團薪酬體系整體框架內的市場狀況。

In addition, the Company also adopted the 2023 Share Option Scheme on 24 November 2023, where eligible persons are entitled to subscribe for the Shares for their contribution to the Group. The Company has not granted any share options under the 2023 Share Option Scheme since its adoption. The Post-IPO Share Option Scheme was terminated on 24 November 2023. As at 30 June 2026, there were 10,200,000 share options under the Post-IPO Share Option Scheme remained outstanding. Under the Post-IPO Share Option Scheme, 1,000,000 share options were lapsed or forfeited and no share options were granted or exercised during FY2026.

此外，本公司亦於2023年11月24日採納2023年購股權計劃，而合資格人士因彼等對本集團作出貢獻而有權認購股份。本公司自採納2023年購股權計劃起概無據此授出任何購股權。首次公開發售後購股權計劃已於2023年11月24日終止。於2026年6月30日，首次公開發售後購股權計劃下的10,200,000份購股權仍未行使。於2026財政年度，首次公開發售後購股權計劃下的1,000,000份購股權已失效或沒收而概無該計劃下的購股權獲授出或行使。

The Company has also adopted the Share Award Scheme to provide an incentive and reward to selected participants for their contribution or potential contribution to the Group. During FY2026, 3,650,000 share award were granted and vested under the Share Award Scheme. No share award was lapsed or forfeited under the Share Award Scheme during FY2026.

本公司亦採納股份獎勵計劃，以就選定參與者對本集團作出貢獻或潛在貢獻而向彼等提供獎勵及回報。於2026財政年度，3,650,000份股份獎勵根據股份獎勵計劃授出及歸屬。於2026財政年度，根據股份獎勵計劃，概無任何股份獎勵失效或被沒收。

The remuneration of the Directors are reviewed by the Remuneration Committee and approved by the Board, according to the relevant Director's experience, responsibility, workload and the time devoted to the Group, the Company's operating results and comparable market statistics.

董事薪酬由薪酬委員會檢討並由董事會批准，乃根據相關董事的經驗、職責、工作量及於本集團投放的時間、本公司的經營業績及可資比較市場數據決定。

FINAL DIVIDEND

The directors proposed the payment of a final dividend of HK1.40 cents per Share for FY2026 (FY2025: HK1.90 cents), subject to the approval of the Shareholders at the 2026 AGM. Such proposed dividend is expected to be distributed on Friday, 8 January 2027 to the Shareholders whose names appear on the register of members of the Company on Friday, 11 December 2026.

末期股息

董事建議派發2026財政年度之末期股息為每股1.40港仙（2025財政年度：1.90港仙），惟須待股東於2026年股東週年大會上批准，方可作實。該項建議股息預期於2027年1月8日（星期五）向於2026年12月11日（星期五）名列本公司股東名冊的股東派付。

OUR VISION & MISSION

我們的願景和使命

To be your trusted healthcare partner

to provide comprehensive, diversified and coordinated care for everyone

成為值得信賴的醫療保健夥伴

為每個人提供全面、多元化、貼心的護理



OUR VALUES
我們的價值觀



ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
環境、社會及管治報告

1. ABOUT THE REPORT

Report Overview

This Environmental, Social and Governance Report (the "Report" or the "ESG Report") provides an overview of the initiatives, plans and performance of UMP Healthcare Holdings Limited (the "Company", "UMP", the "Group" or "We", together with its subsidiaries) in Environmental, Social and Governance ("ESG") and demonstrates its commitment to sustainable development. UMP's fundamental goal in ESG is to foster sustainable development that aligns with our corporate objectives while addressing the needs of the environment, society, and economy.

Reporting Framework

This Report has been prepared in accordance with the ESG Reporting Code as set out in the Appendix C2 of the listing rules of the Hong Kong Exchanges and Clearing Limited ("HKEX").

Reporting Scope

This Report covers UMP's ESG management approach and performance for the period from 1 July 2025 to 30 June 2026 ("Reporting Period" or "FY2026"), aligning with the reporting period of our financial year. The information set out in this ESG Report aims to provide key ESG information and data relevant to our operations. Unless otherwise specified, the contents reported cover our operations in Chinese Mainland, Hong Kong and Macau. Environmental data only covers our operations in Hong Kong as the relevant figures for our operations in Chinese Mainland and Macau are considered relatively insignificant to the Group.

1. 關於本報告

報告概述

本環境、社會及管治報告(「報告」或「環境、社會及管治報告」)概述聯合醫務集團有限公司(「本公司」、「聯合醫務」、「本集團」或「我們」,連同其附屬公司)在環境、社會及管治(「環境、社會及管治」)方面的舉措、計劃及績效,並展示其對可持續發展的承諾。聯合醫務在環境、社會及管治方面的根本目標是促進符合我們企業目標的可持續發展,同時滿足環境、社會及經濟的需求。

報告框架

本報告乃根據香港交易及結算所有限公司(「港交所」)上市規則附錄C2所載的環境、社會及管治報告守則編製。

匯報範圍

本報告涵蓋聯合醫務於2025年7月1日至2026年6月30日期間(「報告期間」或「2026財政年度」)的環境、社會及管治管理方針及表現,與我們的財政年度報告期一致。本環境、社會及管治報告所載資料旨在提供與我們營運有關的主要環境、社會及管治資料及數據。除另有指明外,所匯報的內容涵蓋我們於中國內地、香港及澳門的營運。環境數據僅涵蓋我們於香港的業務,因為我們中國內地及澳門業務的相關數據對本集團而言影響較小。



Reporting Principles

The Report follows the Reporting Principles stipulated in the HKEX ESG Reporting Code as follows:

匯報原則

本報告按港交所環境、社會及管治報告守則中訂明的匯報原則如下：

Materiality: ***重要性：***	A materiality assessment was conducted to identify material issues during the Reporting Period, thereby adopting the confirmed material issues as the focus for the preparation of this ESG Report. The materiality of issues was reviewed and confirmed by the Board. Please refer to the section headed "Stakeholder Engagement" for further details. 於報告期間進行了重要性評估，以識別重要議題，從而以該等經確認的重要議題作為編製本環境、社會及管治報告的重心。董事會已審閱並確認各項議題的重要性。進一步詳情請參閱「持份者參與」一節。
Quantitative: ***量化：***	The Group discloses KPIs in quantitative terms for evaluation of the Group's ESG performance. Supplementary notes are added along with quantitative data disclosed in this ESG Report to explain any standards, methodologies, and source of conversion factors used during the calculation of emissions and energy consumption. 本集團以量化方式披露關鍵績效指標，以評估本集團的環境、社會及管治表現。本環境、社會及管治報告中披露的量化數據已添加補充說明，以解釋於計算排放量及能源消耗時所用的任何標準、方法及轉換因子的來源。
Balance: ***平衡：***	The ESG Report impartially describes the Group's performance in order to provide a balanced overview for the reader of this Report. 環境、社會及管治報告不偏不倚地描述本集團的表現，以便為本報告的讀者提供一個平衡的概覽。
Consistency: ***一致性：***	The approach adopted for the preparation of this ESG Report was substantially consistent with the previous year, and explanations were provided regarding data with changes in the scope of disclosure and calculation methodologies. 本環境、社會及管治報告採用的編製方法與上一年度基本一致，並對披露範圍及計算方法的數據變動進行了解釋。

Information relating to the Group's corporate governance practices can be found in the Corporate Governance Report of its Annual Report.

有關本集團企業管治常規的資料，可參閱年報中的「企業管治報告」。

Forward-looking Statements

This ESG Report contains forward-looking statements which are based on the current expectations, estimations, projections, beliefs, and assumptions of the Group about the business and the markets in which it operates. These forward-looking statements are not guarantees of future performance and are subject to market risks, uncertainties, and factors beyond the control of the Group. Therefore, actual outcomes may differ from the assumptions made and the statements contained in this ESG Report.

前瞻性陳述

本環境、社會及管治報告包含前瞻性陳述，該等陳述乃基於本集團目前對其經營的業務及經營所在的市場的預期、估計、預測、信念及假設。該等前瞻性陳述並非未來表現的保證，且受市場風險、不確定因素及本集團無法控制的因素影響。因此，實際結果可能與本環境、社會及管治報告中所作的假設及陳述有所不同。

Opinion and Feedback

We expect that our ESG approach will continue to develop, in line with the evolving global sustainability issues and stakeholder expectations. Your feedback on the ESG Report is welcomed for the ongoing improvement of our ESG performance. Should you have any enquiries or suggestions, please feel free to contact us by emailing ir@ump.com.hk.

意見及反饋

我們預期我們的環境、社會及管治方針將持續進步，以符合瞬息萬變的全球可持續發展議題及持份者期望。歡迎　閣下對環境、社會及管治報告提出意見，使我們能夠持續改善我們的環境、社會及管治表現。 閣下如有任何疑問或建議，歡迎隨時發送電子郵件至ir@ump.com.hk與我們聯繫。

2. SUSTAINABILITY FRAMEWORK

Our ESG Strategy and Approach

The Board highlights integrating ESG objectives into our daily operations to improve our sustainability performance. Our strategy includes evaluating, prioritising, and managing ESG-related material issues to ensure our corporate actions align with environmental and social interests.

To enhance our reporting, we conducted a materiality survey among stakeholders this year, refining our assessment through measurement systems, external ratings, and stakeholder feedback. Our primary challenge remains balancing economic growth with environmental sustainability.

As a healthcare company, UMP recognises the interconnectedness of climate, economies, societies, supply chains, and lives. We address sustainability challenges by focusing on four areas: maintaining patient trust, creating a harmonious working environment, safeguarding the planet, and enhancing communities. We are committed to sustainable innovation and actively support 11 United Nations Sustainable Development Goals (SDGs) for a better future.

2. 可持續發展框架

我們的環境、社會及管治策略及方針

董事會強調將環境、社會及管治目標融入我們的日常營運，以改善我們的可持續發展表現。我們的策略包括評估、優先處理及管理重大的環境、社會及管治相關議題，以確保我們的企業行動符合環境及社會利益。

為加強我們的匯報工作，我們今年對持份者進行重要性調查，通過計量制度、外部評分及持份者回饋來完善我們的評估。我們的首要挑戰依然是在經濟成長與環境可持續發展之間取得平衡。

作為一家醫療服務公司，聯合醫務深明氣候、經濟、社會、供應鏈與人們的生活息息相關。我們在應對可持續發展挑戰上重點關注以下四個領域：維護病人信任、創造和諧的工作環境、保護地球以及改善社區。我們致力創新可持續發展解決方案，同時積極支持11項聯合國可持續發展目標，以創造更美好的未來。



Enhancing Communities
改善社區

- We believe in giving back to the communities we serve. By engaging in community outreach and support initiatives, we aim to improve health outcomes and overall quality of life, fostering stronger, healthier communities;
- We provide accessible healthcare services to underserved populations and support initiatives that address health disparities, such as the free 3D Mammograms Program and discounted charges for those with low income or financial difficulties;
- We support health education programs about preventive and lifestyle medicine, and collaborate with local organisations to promote community health and well-being.
- 我們相信回饋社區的精神。透過參與社區外展及支援活動，我們的目標是改善健康成果及整體生活品質，促進更強大、更健康的社區；
- 我們為弱勢群體提供可及的醫療服務，支持解決健康差距的倡議，例如為低收入或有經濟困難人士提供3D乳房造影計劃(3D Mammograms Program)及優惠收費；
- 我們支持預防醫療和生活方式醫學的健康教育計劃，並與地區組織合作推動社區健康與福祉。

Creating a Harmonious Working Environment
創造和諧的工作環境

- The well-being of our people encompasses a wide range of considerations, involving attention to physical, social, mental, and psychological aspects, with the goals of fostering happiness and cultivating human potential;
- We promote equal opportunities for all staff and ensure a zero-tolerance policy for discrimination;
- We provide fair wages and address pay equity, support professional development, and foster a healthy and inclusive workplace for all employees;
- We take steps to ensure the safety of the working environment.
- 僱員福祉包含多方面考量，其涉及對身體、社交、精神及心理等各方面的關注，並以培養幸福感及人類潛能為目標；
- 我們致力促進所有員工機會平等，並確保零容忍歧視政策；
- 我們提供合理和公平的薪酬，支持專業發展，並促進健康及充滿包容的工作環境；
- 我們採取步驟確保安全的工作環境。



Maintaining Trust of Our Patients
維護病人信任

- We prioritise patient trust through effective governance and uphold high ethical standards to ensure we always act responsibly;
- Integrity guides our interactions with stakeholders, and feedback and complaint mechanisms are in place to ensure their voices are heard;
- We train our workforce to deliver safe and quality services;
- We make an effective contribution to improving public health and reducing health risks;
- We implement ethical guidelines and complaint mechanisms that empower patients and ensure their voices are heard.
- 我們透過有效的管治，以維護患者的信任。我們秉持高道德標準，確保我們負責任行事；
- 我們本著誠信與持份者互動溝通，設立反饋投訴機制，確保他們的意見被聽取；
- 我們培訓員工提供安全及優質的服務；
- 我們為改善公共衛生及降低健康風險作出有效的貢獻；
- 我們實施維護患者權益的道德標準及申訴機制，確保他們的意見被聽取。







Safeguarding the Planet
保護地球

- We recognise that our planet urgently needs radical and lasting action to protect our communities, businesses and the natural environment from the damaging effects of climate change;
- We harness technology for improved healthcare delivery and patient outcomes, and invest in research and development for medical advancement and innovation;
- We implement sustainable practices in service delivery, reduce waste and resource consumption through digitalisation, and utilise environmentally friendly medical supplies;
- We collaborate with organisations, governments, and stakeholders to promote sustainable healthcare practices, knowledge sharing, and expertise exchange.
- 我們肯定我們迫切需要採取具有根本性和持久性的行動，以保護我們的社區、企業及自然環境免受氣候變化的破壞性影響；
- 我們利用科技改善醫療保健服務及療效，並投資於研發工作，以推進醫學進步及創新；
- 我們在提供服務的過程中實施可持續做法，透過數碼化減少廢物和資源消耗，並利用環保醫療用品；
- 我們與組織、政府及持份者合作，推動可持續的醫療保健實踐、分享知識及交流專業技術。









Major Awards and Recognitions

"Excellence ESG Enterprise Awards 2025" by HK01 & ESG and Sustainable Development Forum

"Listed Company Awards of Excellence" presented by Hong Kong Economic Journal *(Awarded for the fourth consecutive year)*

主要獎項與成就

榮獲香港01及ESG及可持續發展論壇頒發「傑出ESG企業大獎2025」

榮獲信報頒發《上市公司卓越大獎》*(連續4年獲此殊榮)*







Stakeholder Engagement

Stakeholder engagement helps us advance sustainable development. We value stakeholder trust and work with them on important ESG issues. Our business processes must interact and communicate with stakeholders to meet their requirements and expectations. Below are the key communication channels with our stakeholders:

持份者參與

持份者參與有助我們推進可持續發展。我們重視持份者的信任，並與彼等齊心協力處理重要的環境、社會及管治議題。我們在業務過程中必須與持份者互動溝通，方可符合彼等的要求及期望。以下是我們與持份者的主要溝通渠道：

Investors **投資者**	• Annual general meetings and other general meetings 股東週年大會及其他股東大會 • Annual reports and interim reports 年度及中期報告 • Circulars and announcements 通函及公告 • Company website 公司網站
Employees **僱員**	• Training and team-building activities 培訓及團隊建設活動 • Grievance mechanism 申訴機制 • Company intranet 公司內聯網
Suppliers and contractors **供應商及承包商**	• Supplier review and rating system 供應商評估及評分系統 • Regular communication 定期溝通
Customers **客戶**	• UMP Service Point app 「UMP服務點」應用程式 • Customer hotline 客戶熱線 • Feedback surveys 意見調查 • Virtual Care System 視像診症
Government and regulatory authorities **政府及監管機構**	• Email and circulars 電郵及通告 • Response to inquiries from government departments 回應政府部門查詢
Community **社區**	• Cooperation with social enterprises 與社會企業合作 • Health education and community services 健康教育及社區服務 • ESG Report 環境、社會及管治報告

Materiality Assessment

Material issues in this Report refer to what may have a significant impact on the Group's business operations or have an actual impact on stakeholders. To identify and prioritise these issues, the Group conducts a materiality assessment every year, presenting the findings in the form of a materiality matrix.

重要性評估

本報告中所指的重要議題是指可能對本集團的業務營運造成重大影響或對持份者造成實際影響的議題。為了識別該等議題並排定優先處理的次序，本集團每年均進行重要性評估，並以矩陣圖的形式呈現重要性評估結果。

MATERIALITY MATRIX
重要性矩陣圖



Environment 環境	Social 社會	Governance 管治
1 Climate Change 氣候變化	8 Employee Care 關懷僱員	15 Technology Innovation 科技創新
2 Non-Hazardous Waste Management 無害廢棄物管理	9 Occupational Health and Safety 職業健康與安全	16 Data Protection and Privacy 資料保護及私隱
3 Medical Waste Management 醫療廢棄物管理	10 Labour Standards 勞工準則	17 Supply Chain Management 供應鏈管理
4 Energy Management 能源管理	11 Development and Training 發展及培訓	18 Business Ethics 商業道德
5 Environment Protection 保護環境	12 Service Quality and Safety 服務質素和安全	
6 Resources Management 資源管理	13 Accessibility to Health Care 醫療保健的可及性	
7 Packaging Materials 包裝材料	14 Community Contributions 貢獻社區	

3. THE ESG GOVERNANCE STRUCTURE

Board Statement

The Board takes overall responsibility for the Group's ESG strategy, overseeing the development of the approach, execution and associated reporting. The Board discusses the Group's progress against its ESG ambitions and reviews key topics such as sustainability objectives, climate risks and opportunities, patient experience and employee sentiment. The Board is regularly updated with the latest ESG matters, including public health concerns, energy policy, patient rights and employee well-being. Board members receive ESG-related training as part of their induction and ongoing development. They seek further opportunities to build their skills and experience in this area. The Board sets strategies, priorities, initiatives, goals, and targets, and oversees the sustainability performance of the Group.

Compliance with ESG-related Regulations

The Board is committed to complying with relevant laws and regulations that pertain to our business operations, including the registration and licensing of clinics, processing of radioactive substances and apparatuses, clinical waste treatment, marketing and promotion of healthcare products and services, possession and distribution of drugs, and the protection of customer and patient privacy.

3. 環境、社會及管治架構

董事會聲明

董事會全面負責本集團的環境、社會及管治策略，監督方針的制定、執行及相關報告。董事會討論本集團在實現其環境、社會及管治目標方面的進展，並審視可持續發展目標、氣候風險與機會、患者體驗及僱員情緒等重要議題。董事會定期獲匯報最新的環境、社會及管治事宜，包括公共衛生問題、能源政策、患者權益及僱員福利。董事會成員接受有關環境、社會及管治的培訓，作為彼等履職及持續發展的一部分。彼等尋求更多機會來增進其在此領域的技能及經驗。董事會訂立策略、優先處理的次序、措施、目標及指標，並監督本集團的可持續發展表現。

遵守環境、社會及管治規例

董事會致力遵守與我們業務營運相關的法律及法規，包括診所註冊及牌照、放射性物質及儀器的處理、醫療廢棄物的處理、醫療保健產品及服務的營銷及推廣、藥物的管有及分銷，以及客戶及患者私隱的保護等。



ESG Working Group

The Group has established the ESG Working Group ("Working Group"). This Working Group comprises core members from the Group and is responsible for collecting relevant information for preparing ESG Reports. The Working Group reports to the Board and assists in identifying and evaluating the Group's ESG risks and opportunities. Below are the responsibilities of the Working Group:

- Has an overarching role in supporting the Board on matters of sustainability; overseeing the identification of material ESG issues, implementation of sustainability initiatives, reviewing the related policies and practices and assessing and making recommendations on governance, strategy, planning, and risks;
- Evaluates sustainability performance and progress made against sustainability targets;
- Identifies sustainability-related risks and opportunities within core business units;
- Ensures sustainability measures are effectively executed;
- Provides feedback to the Board on sustainability-related achievements and progress.

環境、社會及管治工作小組

本集團已成立環境、社會及管治工作小組(「工作小組」)。該工作小組由本集團的核心成員組成,負責收集相關資訊以準備環境、社會及管治報告。工作小組向董事會報告,並協助識別和評估集團的環境、社會及管治風險和機遇。以下是工作小組的職責:

- 在可持續發展事宜上擔當全方位支援董事會的角色;監督對重大的環境、社會及管治議題的識別工作、落實可持續發展措施、檢討相關政策及實踐,以及評估有關管治、策略、規劃及風險並提出建議;
- 評估可持續發展表現以及在實現可持續發展目標方面取得的進展;
- 識別核心業務單位內與可持續發展相關的風險和機遇;
- 確保可持續發展措施的有效執行;
- 就可持續發展相關的成就及進展向董事會提供反饋意見。

4. ENHANCING COMMUNITY

We have a long-standing commitment to support the communities in which we operate. We aim to provide people with the skills and knowledge to thrive in the post-pandemic environment, and transition to a sustainable future.

Community Engagement

Our mission is to offer trusted and affordable services to individuals from all walks of life. We aim to go beyond providing our patients with healthcare services but also promote public health within the communities we serve. We hold ourselves to the highest standards of quality and strive to make a positive impact on the overall well-being of those we cater to.

Access to healthcare is a fundamental component of a healthy society that promotes health equity. It ensures that everyone has equal opportunities to receive proper medical care, regardless of their socioeconomic status, race, or gender. By improving accessibility to healthcare, we can also achieve significant cost savings for both individuals and society.

World Vision Hong Kong – Global 6K for Water

As part of its commitment to global health and community well-being, UMP joined this meaningful event to raise awareness about the global water crisis, a challenge that affects an estimated 2.2 billion people who still lack access to safely managed drinking water. In many communities, the burden of collecting water falls heavily on women and children, who often walk long distances to collect water that is contaminated. Through this initiative, the UMP team came together in the spirit of solidarity, using the power of sport to advocate for clean water and a healthier future for those most in need. Our participation reflects our ongoing dedication to empathy, action, and making a lasting global impact.

4. 改善社區

我們長遠致力支持我們營運所在的社區。我們矢志提供技能及知識，讓大眾在疫情後繁榮昌盛，並邁向可持續的未來。

社區參與

我們的使命是為各個社會階層的個人提供值得信賴及可負擔的服務。我們的目標不僅是為患者提供醫療保健服務，還要促進我們所服務社區的公共衛生。我們堅持最高的質量標準，並努力為我們所服務對象的整體福祉帶來正面影響。

在一個健康社會裡，人人享有醫療保健是促進健康公平的基本要素。健康公平是確保任何人均有平等機會獲得適當的醫療護理，無論其社會經濟地位、種族或性別如何。通過改善醫療保健的可及性，我們亦能夠為個人及整個社會節省大量成本。

香港世界宣明會－Global 6K for Water慈善跑活動

作為對全球健康和社區福祉承諾的一部分，聯合醫務參與了這項意義深遠的活動，旨在提升大眾對全球水資源危機的關注。全球約有22億人仍無法獲得安全管理的飲用水。在許多社區，取水的重擔往往落在婦女和兒童身上，他們需要長途跋涉去取用受污染的水源。透過這項倡議，聯合醫務團隊團結一致，利用運動的力量，為最需要幫助的人群爭取安全飲用水和更健康的未來。我們的參與體現了企業對同理心、行動力以及創造持久全球影響的決心。

Corporate Recycling Day – Used Clothes Collection

As part of its ongoing sustainability and community engagement initiatives, the Group has participated in Corporate Recycling Day, installing dedicated collection bins at our Head Office to gather used clothing. The drive encouraged staff to adopt eco-conscious habits by giving pre-loved garments a second life and diverting textiles from landfills. Team members warmly embraced the initiative, contributing generously to support local circular economy efforts. The experience proved both impactful and rewarding, reinforcing our collective commitment to a greener, more sustainable future.

企業回收日—舊衣回收

作為持續推動可持續發展及社區參與措施的一環，本集團參與「企業回收日」活動，於總辦事處設置專用回收箱以收集舊衣。該活動通過賦予舊衣二次生命、減少將之送入堆填區，鼓勵員工培養環保習慣。團隊成員踴躍支持該活動，慷慨捐贈舊衣，支持本地循環經濟。此次活動成效顯著、令人欣慰，鞏固我們建構更環保、更可持續發展未來的共同承諾。

Hong Kong Anti-Cancer Society

UMP is pleased to offer members of the Hong Kong Anti-Cancer Society a special discounted price of HK$7,600 for PET-CT scans at ProCare Advanced Medical Imaging Centre in Central, reinforcing its dedication to cancer awareness and early detection. This initiative is designed to improve access to advanced diagnostic services, giving individuals the opportunity to gain timely and accurate health insights. UMP continues to champion preventive healthcare and stands with the community in the ongoing fight against cancer.

香港防癌會

聯合醫務欣然為香港防癌會會員提供於中環之普康先進醫學影像中心進行PET-CT正電子電腦斷層掃描的特別優惠，每次費用為7,600港元，進一步體現我們對癌症關注與早期檢測的承諾。此項計劃旨在提升大眾對先進診斷服務的可及性，讓市民能夠及早獲得準確的健康資訊。聯合醫務將繼續積極推廣預防醫療，並與社區一同攜手抗癌，守護健康。

Support for the Wang Fuk Court fire

In response to the Wang Fuk Court fire in 2025, UMP extended complimentary medical consultation services to individuals affected by the incident. By providing accessible healthcare support during a challenging period, we sought to assist the local community and reinforce our commitment to social responsibility and community care.

宏福苑火災支援

因應2025年宏福苑火災事件，聯合醫務向受災人士提供免費醫療諮詢服務。我們於此艱難時期提供便利醫療支援，致力協助本地社區，並鞏固對社會責任及社區關懷的承諾。

5. CREATING A HARMONIOUS WORKING ENVIRONMENT

UMP recognises that human resources are its most valuable asset and a fundamental source of competitive advantage, forming the foundation for its sustainable development. As a result, the Group is dedicated to enhancing its employment policies to attract, nurture, and retain talented individuals. It upholds a people-oriented approach, valuing and safeguarding the legitimate rights and interests of all employees, while implementing effective labour management practices to ensure their occupational health and safety. During the Reporting Period, the Group was not aware of any non-compliance with any relevant laws and regulations in relation to compensation and dismissal, recruitment, and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare, that would have a significant impact on the Group. The summary of workforce by categories is disclosed in the Key Performance Indicators Summary Table below.

Talent Attraction and Retention

We put great emphasis on attracting and retaining talent. We recruit the best talent via multiple hiring channels and offer competitive remuneration with a wide range of benefits. Employee performance and remuneration are periodically reviewed based on an individual's overall contributions and market conditions, to ensure we can motivate colleagues in a way that is authentic to our culture and values. Our aim is to offer just and favorable conditions of work including the right to reasonable working hours, fair working conditions and pay. In addition, we encourage internal promotion to offer extra opportunities for employees to develop their full potential. Our approach will help colleagues have clarity on performance expectations, awareness of development opportunities and access to resources. The employee turnover rate analysis is detailed in the Key Performance Indicators Summary Table below.

5. 創造和諧的工作環境

聯合醫務深明人力資源是其最寶貴的資產，是其競爭優勢的核心源泉，亦是其可持續發展的根基。因此，本集團致力加強其僱傭政策，以吸引、培育及挽留優秀人才。本集團堅持以人為本，重視並保障所有僱員的合法權益，同時實施有效的勞動管理常規，確保僱員的職業健康與安全。於報告期間，本集團並不知悉任何違反有關薪酬及解僱、招聘及晉升、工作時數、假期、平等機會、多元化、反歧視，以及其他待遇及福利等對本集團有重大影響的相關法律及規例的情況。各類別員工結構之概要已披露於下方關鍵績效指標摘要表。

人才吸引及挽留

我們非常重視吸引及挽留人才。我們通過多種招聘渠道招募最優秀的人才，並提供具競爭力的薪酬及各種福利。我們根據個人的整體貢獻及市場狀況，定期評核僱員的表現及薪酬，以確保我們能夠以符合公司文化及價值觀的方式激勵同事。我們的目標是提供公正且良好的工作條件，包括合理的工作時間、公平的工作條件及薪資的權利。此外，我們鼓勵內部晉升，為僱員提供更多機會充分發揮潛能。我們的做法將有助同事了解對其工作表現的期望、認識發展機會以及獲得資源。員工流失率之分析詳情載於下方關鍵績效指標摘要表。

Fair Employment

Our Employment Policy provides guidance on respecting and promoting equal opportunity. The Policy states our commitment to offer equal opportunities to job candidates, equal remuneration for men and women for work of equal value, and mandates the need for a harassment and discrimination-free environment. We have established objective performance indicators for annual performance evaluation. The supervisor will engage with the employee on a two-way communication to discuss his/her performance for advancement. Employees regularly receive feedback on their work performance and capabilities to make progress and enhance team competitiveness.

We only allow reasonable and substantiated terminations of employment. Dismissals, when required, are based on reasonable and lawful grounds and are conducted in accordance with applicable laws and regulations. Prior verbal or written warnings will be issued to provide a fair opportunity to employees for improvement.

Prevention of Child Labour and Forced Labour

We adhere to relevant statutory requirements and strictly prohibit all forms of forced labour and child labour. During the recruitment process, the Human Resources Department will verify the applicant's identity documents and ensure that they have reached the minimum age for employment. The Group stipulates the working days and rest time for employees in the employment contract to eliminate forced labour, and carefully monitor the employee working hours and schedules to ensure they work voluntarily and freely. When overtime is required, employees are properly compensated as required by law.

Managers are responsible for ensuring compliance with the Group's policies to eliminate human trafficking and modern slavery by raising concerns on abnormal work conditions or behaviours. If any child labour or forced labour is found, the Group will immediately stop all work of the identified child labour or forced labour. Follow-up investigations will be conducted to find out the reasons and modify the employment management measures to rectify the loopholes.

公平就業

我們的僱傭政策就尊重及促進平等機會提供指引。我們於該政策中承諾為求職者提供平等機會，實現男女同工同酬，並規定必須創造一個無騷擾及歧視的環境。我們為年度績效評估制定客觀績效指標。主管與下屬會進行雙向溝通，討論僱員績效以助其進步。僱員定期聽取有關其工作表現及能力的反饋，以取得進步並加強團隊的競爭力。

我們只會容許在合理及有充分理據的情況下作出解僱。倘若有必要作出解僱，其必須是基於合理及合法的理據，並根據適用的法律及法規作出。我們會事先向僱員發出口頭或書面警告，讓彼等有公平的機會進行改善。

防止童工及強制勞工

我們遵守相關的法定要求，嚴格禁止任何形式的強制勞工及童工。在招聘過程中，人力資源部會核實應徵者的身份證明文件，並確保彼等已達到最低就業年齡。本集團在僱傭合約中訂明僱員的工作日及休息時間，以杜絕強制勞工，並仔細監督僱員的工作時間及安排，確保彼等乃自願及自由地工作。需要加班時，僱員可依法獲得適當補償。

經理有責任提出對異常工作條件或行為的疑慮，以杜絕人口販運及現代奴役，從而確保本集團的政策獲得遵守。倘若發現任何童工或強制勞工的情況，本集團會立即停止所有已查明屬實的童工或強制勞工。後續將會進行調查，以找出原因及修改僱傭管理措施，糾正漏洞。

Other Employee Benefits

To motivate employees to support our goals, we offer competitive remuneration and merit bonuses, including share options and share awards schemes. Staff benefits include comprehensive medical insurance, employees' compensation insurance, directors' and officers' liability insurance and mandatory provident fund for employees. Employees are also entitled to annual leave and maternity leave, paternity leave, marriage leave. Staff are also provided with complimentary flu vaccinations.

To encourage work-life balance and ensure well-being among employees, the Group has clear policies outlining overtime working arrangements. We are devoted to creating career development opportunities and fostering a sense of unity amongst employees across the Group.

Employee benefits are reviewed annually to reflect performance and contributions, as well as to maintain parity with market trends.

Investing in People

We aim to build a dynamic environment where our colleagues can develop skills and undertake experiences that help them fulfil their potential. Our human capital management strategy places priority on equipping our people with continuing education and personal development opportunities. New employees receive induction training to familiarise themselves with our values, strategy, purpose and corporate culture. For existing employees, a number of training programmes, including in-house seminars, training workshops and talks, are provided to facilitate continuous improvement in their technical capabilities and personal development.

As the way we work and the way we learn has changed, driven by the adoption of hybrid work styles and digital capabilities, we use a range of resources to help colleagues take ownership of their development and career, including knowledge sharing of online resources. For analysis of percentage of employees trained and average training hours per employee, please refer to the Key Performance Indicators Summary Table below.

其他僱員福利

為鼓勵僱員支持我們的目標，我們提供具競爭力的薪酬及績效花紅，包括購股權及股份獎勵計劃。員工福利包括綜合醫療保險、僱員補償保險、董事及主要人員責任保險及為僱員而設的強制性公積金。僱員亦可享有年假、產假、侍產假及婚姻假。員工亦可獲提供免費流感疫苗接種。

為鼓勵工作與生活平衡並確保僱員身心健康，本集團已明確制定關於加班工作安排的政策。我們竭力為僱員創造事業發展機會，並培養集團上下團結一心的精神。

僱員福利乃每年檢討一次，以反映績效及貢獻，以及為了與市場趨勢保持一致。

人才投資

我們的目標是建立一個充滿活力的環境，讓同事能夠發展技能及獲得經驗，幫助彼等發揮潛能。我們的人力資本管理策略著重為僱員提供持續教育及個人發展的機會。新入職僱員接受入職培訓，以認識我們的價值觀、策略、目標及企業文化。對於現職僱員，我們提供多項培訓計劃，包括內部研討會、培訓工作坊及講座，以促進僱員在技術能力及個人發展方面的持續進步。

在混合工作模式及數碼技術的驅動下，我們的工作及學習模式已有改變，因此，我們借助一系列資源幫助同事掌握自己的發展路向及職涯發展，包括共享線上學習資源。有關受訓員工百分比及每名員工平均培訓時數之分析，請參閱下方關鍵績效指標摘要表。

Furthermore, we encourage employees to expand their work contacts within the Group and to take advantage of career development opportunities. Employees will have the chance to pursue development in other businesses of the Group, and the policy also allows us to optimise workforce deployment by transferring capable employees to the most suitable service areas.

此外，我們鼓勵僱員擴大集團內的工作聯繫，並把握職業發展機會。僱員將有機會到本集團其他業務發展，而我們亦能藉此政策將有能力的僱員調往最合適的服務領域，從而優化人力資源配置。

Developing a Culture of Safety

Our continued success depends on the well-being of our people. To create a safe and healthy work environment, we have implemented a comprehensive occupational health and safety management system that safeguards our employees and workers.

培育安全文化

我們的持續成功取決於我們僱員的福祉。為營造一個安全及健康的工作環境，我們已實施一套能保障僱員的全面職業健康與安全管理系統。

Infection control is a priority in every clinic. Our clinics are equipped with personal protection and preventive equipment, including hand-washing facilities, adequate masks, and sharps disposal containers. All clinic staff have been educated on health and safety procedures and are encouraged to proactively raise awareness of infection control and report potential risks to the person in charge of the clinic.

感染控制是每間診所的重點工作。診所已配備個人防護及預防設備，包括洗手設施、足夠的口罩及利器處置容器。所有診所職員均已學習了健康及安全步驟，我們同時亦鼓勵彼等主動提高有關控制感染的意識，並向診所負責人報告潛在風險。

We require all employees to practise safe medical procedures. Special medical equipment such as irradiation apparatus can only be operated by certified staff. Clinic staff are regularly trained to use medical equipment properly and to keep updated with the changes. All employees are also required to follow the workplace safety rules. The occupational fatality rate has all along been zero during the past three years. Work Injuries statistics are outlined in the Key Performance Indicators Summary Table below.

我們要求所有僱員執行安全醫療程序。輻照儀器等特殊醫療設備僅可由經過認證的職員操作。診所職員定期接受正確使用醫療設備的培訓，以跟上科技變化。所有僱員亦須遵守工作場所安全規則。過去三年中，職業死亡率俱為零。工傷統計資料列於下方關鍵績效指標摘要表。

Other than clinic-related matters, employees are required to be familiarised with protocols for maintaining a clean, orderly, and safe work area that is hazard-free, and performing work in a safe manner so as not to jeopardise oneself or others. They have adequate knowledge of the Emergency Plan, Evacuation Procedures, Procedures for Life Safety Threats, and other general safety issues in the event of an emergency to ensure safety.

除診所相關事宜外，僱員亦必須熟悉有關保持工作範圍整潔、有序、安全及無害的程序，並在安全的情況下工作，以免危及自身或其他人。彼等充分了解緊急應變計劃、疏散程序、應對生命安全威脅的程序、以及其他在緊急情況下的一般安全問題，以確保安全。

The Group strictly complied with all relevant laws and regulations on occupational health and safety, including but not limited to the Occupational Safety and Health Ordinance and the Occupational Safety Law or such other related legislation in Hong Kong and Chinese Mainland.

本集團嚴格遵守所有有關職業健康與安全的法律及法規，包括但不限於香港及中國內地《職業安全及健康條例》及《安全生產法》或此類其他相關法規。

KEY PERFORMANCE INDICATORS SUMMARY TABLE

關鍵績效指標摘要表

Staff Statistics 員工統計	FY2026 2026財政年度		FY2025 2025財政年度	
a) Workforce by category and turnover analysis 按類別劃分的員工及離職率分析				
Workforce 員工	Headcount (No.) 員工人數	% 百分比	Headcount (No.) 員工人數	% 百分比
By Gender 按性別				
Female 女性	449	79%	79%	78%
Male 男性	117	21%	119	22%
By Age Group 按年齡組別				
Below 30 30歲以下	138	24%	117	22%
30 – 40 30-40歲	219	39%	199	37%
41 – 50 41-50歲	113	20%	155	21%
Above 50 50歲以上	96	17%	108	20%
By Geographic Region 按地區				
Hong Kong 香港	395	70%	419	78%
Chinese Mainland 中國內地	166	29%	114	21%
Macau 澳門	5	1%	6	1%
By Employee Type 按僱傭類型				
Full Time 全職	494	87%	452	84%
Part Time 兼職	72	13%	87	16%

Staff Statistics 員工統計	FY2026 2026財政年度		FY2025 2025財政年度	
Turnover analysis 離職率分析[1]		% 百分比		% 百分比
By Gender 按性別				
Female 女性		39%		29%
Male 男性		50%		20%
By Age Group 按年齡組別				
Below 30 30歲以下		43%		26%
30 – 40 30-40歲		38%		30%
41 – 50 41-50歲		38%		17%
Above 50 50歲以上		50%		33%
By Geographic Region 按地區				
Hong Kong 香港		50%		32%
Chinese Mainland 中國內地		22%		11%
Macau 澳門		20%		0%
b) Employee Training Hours 員工培訓時數	**Average Training Hours 平均培訓時數**	**Employees Trained 僱員受訓百分比 (%)**	**Average Training Hours 平均培訓時數**	**Employees Trained 僱員受訓百分比 (%)**
By Gender 按性別				
Female 女性	15.5	39%	0.4	21%
Male 男性	15.5	45%	0.8	54%
By Employment Type 按僱傭類別				
General Employee 基層僱員	16.5	47%	0.3	11%
Middle Management 中級管理層	11.8	25%	0.6	29%
Senior Management 高級管理層	3.7	23%	2.7	200%
c) Work Injuries 工傷	**Number of Work-related fatalities 因工亡故**	**Lost days due to work injury 因工傷損失工作日數**	**Number of Work-related fatalities 因工亡故**	**Lost days due to work injury 因工傷損失工作日數**
All employees 全體員工	0	13.5	0	0

Note:

1. Employee turnover rate is calculated by the number of employees left during the Reporting Period/Total number of employees at 30 June 2026 × 100%.

附註：

1. 僱員流失率按報告期間離職僱員人數除以於2026年6月30日的僱員總人數乘以100%計算。

6. MAINTAINING TRUST OF OUR PATIENTS

We operate in a way that upholds high standards of corporate governance. We strive to maintain the unwavering trust that society has on us, including being transparent in our approach to fulfilling different obligations. We also seek to ensure we respect stringent standards of the healthcare industry in our workplace and our supply chains, and continually work to improve our compliance management capabilities.

6. 維護病人信任

我們的營運方式秉持高標準的企業管治。我們努力維護社會對我們堅定不移的信任，包括以透明的方式履行不同義務。我們亦致力確保我們在工作場所及供應鏈中尊重醫療保健行業的嚴格標準，並持續努力提升我們的合規管理能力。

Upholding the Highest Standards of Business Ethics

Anti-corruption

The Group is committed to acting with integrity and has a risk management framework and policies that are designed to govern, monitor and report unlawful behaviour. We have a zero-tolerance approach towards all forms of corruption and observe high standards of business ethics. Our Anti-corruption Policy sets out the minimum standard of conduct which applies to all directors, officers, and employees of the Group. Compliance with this policy is obligatory, and any violation thereof may result in disciplinary action, including potential employment termination and the imposition of civil or criminal sanctions. As part of our efforts to strengthen anti-corruption practices and promote employee awareness, we have arranged annual anti-corruption training sessions for our directors and employees this year, with the training being conducted by the Independent Commission Against Corruption and other professional training provider(s).

堅持最高標準的商業道德

反貪污

本集團承諾秉持誠信行事，並設有風險管理架構及政策，以規範、監控及舉報任何違法行為。我們對所有形式的貪污行為採取零容忍態度，並恪守高標準的商業道德。我們的反貪污政策訂立了適用於本集團所有董事、高級人員及僱員的最低操守標準。該政策須予強制遵守，而任何違反該政策的行為均可處以紀律處分，其可能包括終止僱傭關係以及民事或刑事制裁。為了加強反貪污實踐及提高僱員的反貪污意識，我們今年已為董事及員工安排年度反貪污培訓課程，相關培訓由廉政公署或其他專業培訓機構提供。

Whistle-blowing Mechanism

Our whistle-blowing channel encourages our colleagues and other stakeholders to raise concerns confidentially and, anonymously if preferred, subject to laws and regulations. We offer an email address providing colleagues and stakeholders the confidence to speak up when they observe unlawful or unethical behaviour. Their concerns are delivered through the most effective route. We always listen to the concerns of individuals and have a zero tolerance for acts of retaliation.

舉報機制

我們鼓勵同事及其他持份者在遵守法律及法規的前提下，利用我們的舉報渠道以保密及匿名的方式提出疑慮。我們提供電子郵件地址，讓同事及持份者在發現不合法或不道德的行為時能暢所欲言。彼等的疑慮會透過最有效的途徑送達。我們必然聆聽每個人的疑慮，並對報復行為採取零容忍態度。

Concerns are investigated proportionately and independently, with actions taken where appropriate. These can include disciplinary actions, dismissals, and adjustments to variable pay and performance ratings. We ensure that whistle-blowers are protected from unfair dismissal, victimisation, or unwarranted disciplinary action. There were no concluded legal cases regarding corrupt practices brought against the Group or its employees during FY2026.

我們會對疑慮進行相稱且獨立的調查，並在適當情況下採取行動。該等行動可包括紀律處分、解僱、以及調整薪資及績效評分。我們確保舉報者受到保護，不會遭受不公平的解僱、傷害或不必要的紀律處分。於2026財政年度，並無針對本集團或其僱員提出而已審結的貪污相關法律案件。

Achieving Mutual Growth with Suppliers

The Group has established a robust supply chain management system to ensure that our suppliers adhere to relevant environmental and social laws and regulations, as well as our internal supplier selection policy.

We evaluate supplier performance based on several criteria, including product quality, delivery time, brand reputation, and environmental and social considerations. Suppliers with higher performance ratings are prioritised when sourcing specific goods or services.

Additionally, the preferred supplier list is reviewed annually to ensure that supplier performance continuously aligns with UMP's procurement standards. UMP utilises a centralised procurement system to streamline the ordering and distribution of medical supplies to each UMP Medical Centre. We source medicines and medical equipment from qualified pharmaceutical companies and suppliers of medical consumables, ensuring compliance with all applicable laws and regulations. Each centre is accountable for managing its own inventory of drugs and medical consumables. This approach effectively controls procurement quality and costs, while also minimising the risk of corruption and bribery.

To support our local economy and minimise transportation-induced carbon emissions, we prefer local suppliers. During the Reporting Period, we had around 400 suppliers which were located in Hong Kong.

Building Patient Confidence

We consider patient experience as the core of our operations, and we constantly engage with our patients to identify and understand their needs. Our conduct approach guides us to deliver the best quality, and it is embedded in the way we provide our professional services and the way we care for our patients.

Quality Assurance

Our Quality Assurance and Safety ("QAS") Committee, comprising medical practitioners and senior management, is responsible for monitoring the performance of our clinics and providing suggestions on clinical governance, clinical risk, and continuous development of clinical and professional services. The QAS Committee also formulates policies and procedures regarding the healthcare and medical services offered by the Group.

與供應商共同成長

本集團已建立健全的供應鏈管理系統，以確保供應商遵守相關的環境及社會法律及法規，以及我們的內部供應商遴選政策。

我們根據多項標準評估供應商的表現，包括產品質量、交付時間、品牌聲譽、以及環境及社會因素。在採購特定貨品或服務時，我們優先考慮表現評分較高的供應商。

此外，我們每年檢討我們的優先供應商名單，以確保供應商的表現持續符合聯合醫務的採購標準。聯合醫務採用中央採購系統，以簡化訂購醫療用品及將其分發至各聯合醫務中心的程序。我們從合資格製藥公司及醫療消耗品供應商採購藥物及醫療設備，以確保符合所有適用法律及法規。每個醫務中心負責管理自身的藥物及醫療消耗品庫存。此方式能有效控制採購的質量及成本，同時亦能將貪污受賄的風險降至最低。

為支持當地經濟，並將運輸導致的碳排放量降至最低，我們傾向選用當地供應商。於報告期間，我們有大約400個來自香港的供應商。

建立患者信心

我們將患者求診體驗視為營運的核心，並持續與患者溝通，以找出並了解彼等的需要。我們的行為方針引導我們提供最佳質量，並將其融入我們的專業服務及照顧患者的實踐之中。

質量保證

我們的質量保證及安全(「質量保證及安全」)委員會由醫療從業人員及高級管理人員組成，負責監控我們診所的表現，並就臨床管治、臨床風險、以及臨床及專業服務的持續發展提供建議。質量保證及安全委員會亦針對本集團所提供的醫療保健及醫療服務，制定相關政策及程序。

In addition, we have implemented a service quality management approach in our day-to-day business operations. This approach strictly monitors operations from patient registration to clinical consultation procedures and efficiency management. It also stipulates our internal guidelines and procedures which are regularly reviewed to ensure they remain up to date.

此外，我們已在日常業務營運中實施服務質量管理方針。此方針嚴格監控從患者登記到臨床診症程序的運作及效率管理。其亦訂明了內部指引及程序，而我們會對此定期檢討，確保與時並進。

Clinic Hygiene and Infection Control

To ensure a healthy and comfortable clinical environment, we prioritise environmental hygiene in our medical centres. Other than efficient ventilation and lighting systems, our clinics are equipped with a special suction apparatus to reduce aerosols in the air. Personal protective equipment ("PPE") is used and is always kept in sufficient stock at our clinics. Patient triage and placement procedures are in place to prevent the transmission of disease within clinics. Reusable medical equipment is sterilised, and sufficient sanitary and hand-washing facilities are available to all patients and staff. Hand hygiene tips and cough etiquette posters are also displayed at our clinics as a reminder for all. We provide clinic infection control training to clinic staff to prevent epidemic diseases and further reduce the risk of communicable diseases. Surgical masks and other necessary protective equipment are also provided to frontline staff to safeguard their health. Any waste generated at the clinics is properly disposed of as an important clinical infection control.

診所衛生及感染控制

為確保健康及舒適的診症環境，我們首要目標是要維持我們醫療中心的環境衛生。除了高效的通風及照明系統外，我們的診所亦配備特殊抽吸器，以減少空氣中的氣溶膠。我們的診所備有充足的個人防護裝備以供使用。我們已制定患者分流及安置程序，以防止疾病於診所內傳播。可重複使用的醫療設備均經過消毒，而所有患者及職員均獲提供足夠的衛生及洗手設施。我們的診所亦張貼了潔手告示及咳嗽禮儀海報，提醒大家留神注意。我們為診所職員提供診所感染控制培訓，以預防流行性疾病傳播及進一步降低傳染病的風險。我們亦為前線職員提供外科口罩及其他必要的防護裝備，以保障彼等的健康。任何於診所產生的廢棄物均會妥善處理，此亦是臨床感染控制的重要一環。

Professional Practitioners

All of our medical practitioners hold valid certifications and qualifications to provide relevant medical treatments and handle drug and pharmacy matters. Doctors, dentists, and certain auxiliary service providers are required to comply with applicable codes of professional conduct or discipline.

專業的醫療從業人員

我們所有醫療從業人員均持有有效的執業證書及資格，可提供相關醫療服務以及處理藥物及配藥事宜。醫生、牙醫及若干輔助服務提供者必須遵守適用的專業操守或紀律守則。

To ensure that all practitioners are competent in providing quality healthcare services, we have a process in place that involves more than one senior executive from UMP to identify qualified and suitable practitioners. The recruitment process begins with a review of the candidate's background by the Human Resources Department, followed by a video or face-to-face meeting with the respective unit. The Co-Chief Executive Officers are also involved in the hiring decision-making process. Professional qualifications and certificates are collected and kept on record.

為確保所有醫療從業人員均勝任提供優質的醫療保健服務，我們已制定一套程序，由多於一名聯合醫務的高級管理人員參與物色合資格且適當的醫療從業人員。招聘過程首先從人力資源部審查應徵者背景開始，然後由相關部門進行視像或面對面會談。聯席行政總裁亦會參與招聘的決策過程。過程中所收取的專業資格及證書副本將予保存，以作記錄。

Our practitioners are provided with the necessary resources to enhance their skills and knowledge. Our dedicated team conducts regular clinical visits to engage with our affiliated practitioners and ensure consistency of quality. We periodically review our policies on practitioner selection, remuneration, and training with the senior management team to ensure that we deliver clinical care in accordance with industry standards and promote sustainable business operations.

我們為醫療從業人員提供必要資源提升彼等的技能及知識。我們的專責團隊定期到訪診所與我們的聯屬醫療從業人員交流，確保質量保持一致。我們定期與高級管理團隊一同檢視醫療從業人員的甄選、薪酬及培訓政策，以確保我們所提供的臨床護理符合行業標準，並促進可持續的業務營運。

Patient Engagement

We listen to patients' feedback so that we know where we can take proactive measures to improve. We have established various communication platforms to engage with patients and provide them with enhanced services. Through our websites, social media pages, and mobile apps, "UMP Service Point" and "UMP Member App", service users can access the latest information on doctor availability, types of healthcare services offered, and the location and operating hours of our medical centres.

患者溝通

我們聆聽患者的意見，以了解我們自身可於哪些方面採取積極的改善措施。我們已建立不同的溝通平台，以便與患者溝通，為彼等提供更優質的服務。透過我們的網站、社交媒體網頁及流動應用程式「UMP服務點」及「UMP會員應用程式」，用戶可獲取有關醫生應診時間、所提供醫療保健服務類型，以及醫療中心位置及營業時間等的最新資訊。

Complaint Handling Procedures

When faced with complaints, we remain open and acknowledge our flaws, and we will resolve conflicts promptly and fairly. We aim to be consistent in how we track, record and manage complaints. Following our Complaints and Incident Reporting guidelines, all first-hand complaints about the clinics are to be directed to the respective clinic-in-charge. Feedback or suggestions can be submitted via the UMP hotline or website. Any complaints that relate to medical practice are handled by Clinic Chain Operation Department and will be investigated thoroughly and impartially.

投訴處理程序

遇到投訴時，我們會保持開放態度，承認自身的過失，並迅速及公平地解決問題。我們的目標是在追蹤、記錄及管理投訴上保持一致。根據我們的投訴及意外報告指引，所有與診所有關的第一手投訴均應直接提交予相關診所負責人處理。任何意見或建議亦可透過聯合醫務熱線或網站提出。任何與醫療有關的投訴均由醫務中心營業部處理，所有調查均會獲得徹底及公正對待。

Given the nature of our business, we did not receive any product recalls related to safety or health during the Reporting Period.

鑑於我們的業務性質，我們於報告期間並無收到任何與安全或健康相關的產品回收。

Advertising and Labelling

We are committed to providing transparent and accurate information to assist customers in making informed purchasing decisions. We strictly adhere to all relevant regulations and industry guidelines. To promote responsible marketing practices, we have implemented a strict internal review system for our promotional materials and labelling. We use marketing and promotional materials that support customer understanding and provide information on products and services that is clear, fair and not misleading. We are proud to report that there were no significant cases of non-compliance during the Reporting Period with respect to our products and services.

廣告及標籤

我們致力提供透明及準確的資訊，以協助客戶作出明智的採購決定。我們嚴格遵守所有相關法規及行業指引。為推廣負責任的營銷手法，我們對宣傳資料及標籤實施嚴格的內部審核制度。我們使用能幫助客戶了解有關產品及服務的營銷及宣傳材料，當中提供清晰、不偏不倚及無誤導成分的資訊。於報告期間，本集團並無發現其產品及服務重大不合規的情況。

Protecting Data Privacy and Intellectual Property

At UMP, we are dedicated to upholding customer rights, respecting intellectual property rights, and safeguarding patients' data privacy. We maintain strict confidentiality regarding patients' medical status. Transparency is key in how we handle personal data for our customers and stakeholders. Our practices align with the Personal Data (Privacy) Ordinance ("PDPO"), directing how we collect, handle, and disclose personal and medical information.

To prevent unauthorised disclosure of confidential data, we oversee our data storage systems diligently. Access to sensitive information is restricted solely to essential personnel as outlined in our Employee Handbook. Regular employee training sessions reinforce data privacy and security protocols, while privacy personnel report directly to top management on related risks.

In case of any reportable incidents, we have procedures in place for timely actions, including notifying regulators and data subjects as required by privacy laws. Regular reviews and risk assessments enhance our privacy controls. We adapt to evolving data privacy laws by monitoring the regulatory landscape closely to ensure compliant responses to changes.

保護資料私隱及知識產權

在聯合醫務，我們致力維護客戶權益、尊重知識產權及保障患者的資料私隱。我們對患者的醫療狀況嚴格保密。透明度是我們處理客戶及持份者個人資料的關鍵。我們的做法符合《個人資料(私隱)條例》(「私隱條例」)有關如何收集、處理及披露個人及醫療資料的規定。

為防止機密資料在未經授權的情況下外洩，我們嚴格監管我們的資料儲存系統。我們的員工手冊已訂明，只有「必要人員」才可存取敏感資料。資料私隱及安全規範乃透過定期的僱員培訓課程獲得加強，而相關風險則由私隱保障人員直接向最高管理層匯報。

倘若發生任何須予匯報的事件，我們會依程序及時採取行動，包括按照私隱法規定通知監管機構及資料當事人。我們在私隱權方面的控制乃透過定期檢討及風險評估予以加強。我們密切注視監管環境，適應不斷演變的資料私隱法律，以確保能合規地應對變化。

Intellectual Property Rights

We attach great importance to the Company's intellectual property rights and respect the intellectual property rights of third parties. Over the years, the Group had registered a myriad of trademarks for its services offered in Hong Kong and Chinese Mainland, covering diverse domains such as family doctor services, payment application, internal training courses and branches of different professional centre. The Group maintains a Trademark Register which keeps records of the registration number, mark image, class number, owner's name and expiry date. The Group will take legal action and consult with legal experts if there are any violations of the intellectual property rights that the Company owns. We will continue to strengthen intellectual property application and protection.

During the Reporting Period, the Group was not aware of any incidents of non-compliance with related laws and regulations concerning health and safety, advertising, labelling, and privacy matters relating to products and services provided and methods of redress that would have a significant impact on the Group.

7. SAFEGUARDING THE PLANET

Our plan of carbon reduction illustrates our commitment and strategies to achieve the global ambition of net-zero by 2050. We also collaborate proactively with our business partners and customers to identify green energy alternatives, and innovative solutions to reduce carbon emissions and promote sustainability throughout the industry. We will continue to monitor the corresponding changes within the regulatory landscape and actively support the government's decarbonisation plans and initiatives.

Our Environmental Targets

We have established targets that direct our business practices and measure our ESG performance. These targets are designed to help us achieve our environment goals. We acknowledge this is a journey that requires regular reassessment to take into account for climate scenarios, improved data and changes in reporting standards, as well as to reflect real world developments and trends.

知識產權

我們高度重視本公司的知識產權，並尊重第三方知識產權。多年來，本集團已就其在香港及中國內地提供的服務註冊多項商標，其涵蓋廣泛領域，包括家庭醫生服務、支付應用、內部培訓課程及不同的專業醫務中心分店等。本集團備存一份商標登記冊，當中記錄登記號碼、標記圖像、類別號碼、擁有者姓名及有效期。倘若發現任何侵犯本公司知識產權的行為，本集團將採取法律行動及諮詢法律專家意見。我們將繼續加強知識產權的應用及保護。

於報告期間，本集團並不知悉任何違反有關所提供產品和服務的健康與安全、廣告、標籤及私隱事宜以及補救方法等對本集團有重大影響的相關法律及規例的情況。

7. 保護地球

我們的減碳計劃體現了我們支持全球於2050年之前實現淨零排放的承諾及策略。我們亦主動與業務夥伴及客戶合作，發掘綠色替代能源及創新解決方案，以減少碳排放並促進整個行業的可持續發展。我們將繼續關注監管環境的相應變化，並積極支持政府的減碳計劃及倡議。

我們的環境目標

我們已制定各項目標，並以該等目標作為指引，指導我們如何經營業務，以及如何衡量我們在環境、社會及管治方面的表現。該等目標旨在幫助我們實現環境的可持續發展。我們深明這是一個過程，需要經過定期評估檢討，以計及氣候情境、數據改進及報告準則的修訂，以及反映現實世界的發展及趨勢。

Below outlines our metrics to assess our progress in reducing intensity by 2030, using 2023 as the base year:

以下概述了我們評估2030年降低密度進展的指標，以2023年為基準年：

Target Area 目標領域	2030 Target 2030年目標	Base Year 基準年度
GHG Emission Intensity 溫室氣體排放密度	Decrease by 5% 減少5%	2023 2023年
Electricity Consumption Intensity 耗電密度	Decrease by 5% 減少5%	2023 2023年
Non-hazardous Waste Intensity 無害廢棄物密度	Decrease by 5% 減少5%	2023 2023年

Emissions and Waste Management

Greenhouse Gas ("GHG") Emissions

GHG emissions are widely regarded as a significant contribution to climate change and global warming. As their consequential impact on the environment and all lives on earth intensifies, the Group is committed to lowering its emissions and exploring its options on cleaner energy sources.

During the Year, as the Group did not own or operate any vehicles or combustion equipment, no Scope 1 GHG emissions were recorded. Electricity is the largest contributor to our GHG emissions. Healthcare facilities require significant energy: medical equipment as well as air-filtration and air-conditioning units run continuously at many clinics. Improved operational efficiency will result from the introduction of various new energy-efficient and renewable technologies. To further manage GHG emissions, we have taken different measures on the efficient use of energy with further information documented in the section "Optimising Resources".

During the year, although patient numbers dropped slightly, energy use saw a moderate increase due to the establishment of new medical centres and the continued transition to electronic filing systems. The Group will closely monitor GHG emissions and implement relevant measures to reduce our carbon footprint.

排放及廢棄物管理

溫室氣體排放

溫室氣體排放被廣泛認為是導致氣候變化及全球變暖的重要因素。由於溫室氣體排放對環境及地球上所有生命造成日益嚴重的影響，故本集團致力降低其排放量並探討其他更潔淨的能源選項。

於本年度，由於本集團並未擁有或營運任何車輛或燃燒設備，故未錄得範圍1溫室氣體排放。電力是我們最大的溫室氣體排放來源。醫療保健設施需要大量能源：許多診所的醫療設備及空氣過濾和空調機組均持續運轉。透過引入各種新興節能及可再生技術，將有助提高運轉效率。為進一步管理溫室氣體排放，我們已採取不同措施以有效善用能源，更多資訊載於「善用資源」一節。

本年度，雖然就診人數稍微減少，但受新醫療中心設立以及持續轉型至電子檔案系統的影響，能源使用量錄得輕微上升。本集團將密切監測溫室氣體排放，並採取相關措施減少碳足跡。

Summary of GHG Emissions *溫室氣體排放概覽*

Types of GHG Emissions[2] 溫室氣體排放類型[2]	Unit[4] 單位[4]	FY2026 2026財政年度	FY2025 2025財政年度
Indirect GHG Emissions (Scope 2) 間接溫室氣體排放(範圍2) • Purchased Electricity 外購電力	tCO_2e 公噸二氧化碳當量	1,228.30	945.72
Intensity[3] 密度[3]	tCO_2e/visiting patient 每名求診患者的人均公噸二氧化碳當量	0.00093	0.00065

Notes:

2. GHG emissions data is presented in terms of tonne of carbon dioxide equivalent.

3. In FY2026, the number of visiting patients under the reporting scope was 1,321,519 (FY2025: 1,449,014). The data is also used for calculating other intensity data.

4. GHG emission is calculated based on, including but not limited to, "The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard" issued by the World Resources Institute and the World Business Council for Sustainable Development, "How to prepare an ESG Report – Appendix 2: Reporting Guidance on Environmental KPIs" issued by the Stock Exchange, the "2025 Sustainability Report" published by HK Electric Investments Limited and the "CLP 2025 Sustainability Report" published by CLP Holdings Ltd.

附註：

2. 溫室氣體排放數據以公噸二氧化碳當量表示。

3. 於2026財政年度，報告範圍內求診患者人數為1,321,519人(2025財政年度：1,449,014人)。該數據亦用於計算其他密度數據。

4. 溫室氣體排放量的計算依據為(包括但不限於)世界資源研究所及世界可持續發展工商理事會發佈的《溫室氣體議定書：企業會計及報告準則》(The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard)、聯交所發佈的《如何編製環境、社會及管治報告－附錄2：環境關鍵績效指標報告指引》、港燈電力投資有限公司刊發的《2025年可持續發展報告》及中電控股有限公司刊發的《中電2025年可持續發展報告》。

Hazardous Waste

We recognise the importance of safe and effective waste management. We follow established local protocols and guidelines to minimise the risk of accidents or exposure to hazardous materials. In terms of disposing of clinical waste, the Group strictly abides by environmental policies and regulations including the Code of Practice on Clinical Waste Management in Hong Kong. UMP is experienced in handling clinical waste in a safe, legal, and professional manner to avoid potential risks to the environment and human health caused by improper disposal.

Prior to collection, clinical waste is segregated and placed in appropriately labelled garbage bins and bags, while chemical waste is categorised and disposed of in labelled containers that are specifically designed to be leakproof and puncture resistant. The Code for the Disposal of Medical Waste specifies the categories of medical waste, including syringes, contaminated pads, cotton balls, human tissue samples from examinations, dental amalgam, and expired medicines, and provides staff with specific procedures to properly manage and dispose of medical waste.

有害廢棄物

我們深明實施安全有效的廢棄物管理的重要性。我們遵循本地程序及指引，以盡量減少事故發生或有害物質暴露的風險。在處置醫療廢棄物方面，本集團嚴格遵守各項環境政策及法規，包括香港《醫療廢物管理工作守則》。聯合醫務在安全、合法及專業處理醫療廢棄物方面擁有豐富經驗，避免因處置不當而對環境及人類健康造成潛在風險。

在收集之前，醫療廢棄物會被分類並放置於貼有適當標籤的垃圾箱及袋子中，化學廢棄物則會在分類後放置於經過專門設計、並具有防漏及防刺穿功能的標籤容器中。《處理醫療廢棄物守則》訂明各項醫療廢棄物的類別，包括注射器、受污染的墊片、棉花球、檢驗產生的人體組織樣本、牙用銀汞合金及過期藥物，並為職員提供正確管理及處置醫療廢棄物的具體程序。

Medical Waste should be sealed, labelled, and stored in designated locations in our medical centres for collection by a licensed waste collector for further processing. We keep detailed medical waste records with tracking information, such as delivery date and address, quantity, and name of licensed collector. All clinic staff are required to receive training to ensure proper implementation of these procedures. We regularly monitor the disposal of both clinical and chemical waste to ensure that they are handled correctly and safely.

醫療廢棄物應予密封、貼上標籤、並存放於我們醫務中心的指定地點，以便持牌廢棄物收集商收集作進一步處理。我們備存詳細的醫療廢棄物紀錄，並標記追蹤資料，如交付日期及地址、數量、及持牌收集商的名稱等。所有診所職員均須接受培訓，以確保有關程序獲妥善執行。我們定期監察醫療廢棄物及化學廢棄物的處置，以確保其得到正確及安全處理。

Summary of Hazardous Waste

有害廢棄物概覽

Category of Waste 廢棄物類別	Unit 單位	FY2026 2026財政年度	FY2025 2025財政年度
Total Hazardous Waste 有害廢棄物總量	Tonnes 公噸	4.61	7.08
Intensity 密度	Tonnes/visiting patient 每名求診患者的人均公噸	0.0000035	0.0000049

Non-hazardous Waste

Our non-hazardous waste includes paper and general waste. Most of the waste is temporarily stored in a specified location and then recycled by licensed contractors. To reduce the amount of non-hazardous waste, the Group has adopted the following measures:

無害廢棄物

我們的無害廢棄物包括紙張及一般廢棄物。大部分廢棄物會暫時存放於指定地點，然後交由持牌外判商回收。為減少無害廢棄物的產生量，本集團已採取以下措施：

- Educate staff to reduce unnecessary material consumption and disposal
  教育員工減少不必要的材料消耗及棄置
- Employ electronic systems for administrative purposes to minimise paper usage
  採用電子系統進行行政管理，以減少紙張使用量
- Disseminate internal communications through emails and electronic messages instead of printed materials
  在內部通訊方面以電子郵件及電子訊息取代印刷資料
- Reduce the amount of single-use plastic use for non-clinical purposes
  減少非醫療用途的即用即棄塑膠使用量

Due to the implementation of a new clinical management system in 2025, the Group progressively adopted electronic record storage. As part of this transition, legacy paper records were reviewed and disposed of where appropriate, resulting in a temporary increase in office paper waste during FY2026. Notwithstanding this one-off disposal exercise, the Group recorded a decrease in the generation of non-hazardous waste in FY2026, reflecting the effectiveness of its ongoing waste reduction initiatives.

於2025年，由於實施新診所管理系統，本集團逐步採用電子紀錄儲存方式。作為該轉型的一環，舊有紙本記錄經審閱後，已於適當情況下予以棄置，導致2026財政年度辦公室廢紙數量暫時增加。儘管進行了此一次性棄置工作，本集團於2026財政年度所產生的無害廢棄物仍錄得下降，反映其持續減廢措施行之有效。

Summary of Non-hazardous Waste *無害廢棄物概覽*

Category of Waste 廢棄物類別	Unit 單位	FY2026 2026財政年度	FY2025 2025財政年度
Office Paper 辦公用紙	Tonnes 公噸	10.08	2.09
General Waste[5] 一般廢棄物[5]	Tonnes 公噸	280.19	632.59
Total non-hazardous waste 無害廢棄物總量	Tonnes 公噸	290.27	634.68
Intensity 密度	Tonnes/visiting patient 每名求診患者的人均公噸	0.00022	0.00044

Note:

5. The weight of the general waste is calculated using an assumed density of 311.73 kg/m³.

附註：

5. 一般廢棄物總量的換算是根據廢棄物假設密度311.73 kg/m³計算。

Optimising Resources

We share finite resources with our community and planet. We recognise the need to pursue a more circular approach to the operation of our cities. While the transition to a circular environment and economy will take time and require collaboration with all stakeholders in the community, we are developing a resource management plan with specific improvement measures and initiatives to help prepare us for net zero and beyond.

Energy Management

Electricity consumed in offices and clinics is the major form of energy use in our business. A significant portion of UMP's electricity consumption is attributed to the general lighting and the use of medical equipment, such as high-temperature disinfection and X-ray imaging apparatus. To reduce our energy consumption, we are continuously exploring energy-saving measures in our daily operations, such as installing LED lighting systems in some medical centres and prioritising energy-efficient medical equipment to improve energy efficiency.

In order to optimise the management of energy consumption, we have already launched a Smart Energy Monitoring Solution at our ProCare Integrated Medical Imaging and Laboratory Centre (Tsim Sha Tsui) which enables real-time monitoring of energy usage and provides intricate analysis of energy consumption patterns. By leveraging this technology, we can identify areas of superfluous energy usage and implement targeted strategies to enhance energy efficiency.

善用資源

我們與社區及地球共享著有限的資源。我們意識到有必要在營運所在城市中採用更循環的方式經營業務。儘管過渡至循環環境及經濟的過程需時，並且需要與所有社區持份者合作，惟我們正制定資源管理計劃，其中包含具體改善措施及倡議，以幫助我們為淨零甚至更低排放做好準備。

能源管理

我們業務中主要使用的能源類型為辦公室及診所電力。聯合醫務的耗電量有很大部分來自一般照明及醫療設備使用，例如高溫消毒及X光影像儀。為減少能源消耗，我們在日常營運中不斷探索節能措施，例如在部分醫務中心安裝LED照明系統以及優先選用具能源效益的醫療設備，以提高能源效率。

為了優化能源消耗的管理，我們已在普康綜合醫學影像及化驗中心（尖沙咀）推出智能能源監控解決方案，實時監控能源的使用情況，並提供精細的能源消耗模式分析。利用此項技術，我們能夠確定能源使用過剩的區域，並實施針對性策略，以提高能源效率。

Furthermore, the Group is actively promoting centralised information management and digitising operations by utilising IT systems to reduce paper consumption. Clinical management and administrative work, including the Group's eClaims system, have been digitalised to further minimise our paper consumption.

另外，本集團正積極推行中央資料管理，利用IT系統進行數碼化營運，以減少紙張消耗。臨床管理及行政工作(包括本集團的「康橋」電子理賠系統)現已實現數碼化，以進一步將紙張消耗減至最少。

Summary of Energy Consumption

能源消耗概覽

Types of Energy Consumption 能源消耗類型	Unit 單位	FY2026 2026財政年度	FY2025 2025財政年度
Indirect energy consumption 間接能源消耗 • Purchased electricity 外購電力	MWh 兆瓦時	2,401.34	1,900.6
Total energy consumption 能源總耗量	MWh 兆瓦時	2,401.34	1,900.6
Intensity 密度	MWh/visiting patient 每名求診患者的人均兆瓦時	0.0018	0.0013

The moderate increase in electricity consumption is primarily due to the establishment of new medical centres and the continued transition to electronic filing systems.

用電量輕微增長乃主要由於設立新醫療中心，以及持續轉型至電子檔案系統。

Water Management

The Group prioritises water saving initiatives that have greater reduction potential. We look for pragmatic methods to improve water efficiency and reduce wastage from the source and promote circularity. We explored the potential application of highly efficient water restrictors. Matching with existing water facilities, water restrictors can help improve water efficiency. The implementation of water restrictors is simple and easy, without the need to replace current water facilities. We also implemented the following water conservation measures that support water efficiency:

水資源管理

本集團優先採取節水潛力較大的節水措施。我們尋求以務實的方法來提高用水效率，從源頭減少浪費，並促進循環再用。我們研究了高效節水器的應用潛力。配合現有的用水設施，節水器可有助提高用水效率。節水器的實行簡單方便，不需更換現有的用水設施。我們亦實施了以下節水措施，有助改善用水效率：

- Inspect and maintain water pipes regularly
  定期檢查及維護水管
- Raise employee awareness of water conservation
  提高僱員節約用水意識
- Study the possibility of wastewater reuse or recycling
  研究廢水再利用或回收的可能性

Notably, UMP has not been documenting water consumption data for the past few years, as the management fees encompassed this service.

特此註明，聯合醫務於過去幾年一直並無記錄用水量數據，原因是此服務已包含於管理費中。

Use of Packaging Materials

Ensuring medication safety and quality requires appropriate packaging with clear labelling for identification. At UMP, we use various packaging types, including medicinal bottles, pill pouches, ointment jars, dropper bottles, and plastic bags for medicines and topical ointments. Report folders and bags are used for imaging services, while specimen containers serve laboratory needs.

To reduce plastic waste and support environmental preservation, we are exploring a digital storage system to replace wet film. We encourage referral doctors to use MEDEX WED, USB, or CD instead of printing wet films.

During the Reporting Period, X-ray bag usage continued to decrease due to the wider use of digital storage in place of wet films.

使用包裝材料

藥物需要適當的包裝，才能確保安全及質量；其應附有清晰可見的標籤以利識別。在聯合醫務，我們使用各式各樣的包裝，包括藥物瓶、藥丸袋、藥膏罐、滴管瓶及適合裝載藥物及外用藥膏的塑膠袋。報告文件夾及文件袋適用於影像服務，而標本容器則滿足化驗室的需求。

為減少塑膠廢棄物及支持環境保護，我們正探討採用數位儲存系統取代X光顯影片。我們鼓勵轉介醫生使用MEDEX WED、USB或CD來取代列印X光顯影片。

於報告期間，由於使用數位儲存取代X光顯影片的情況愈加普遍，X光袋的使用量持續減少。

Summary of Use of Packaging Materials

包裝材料使用概覽

Index 索引	Unit 單位	FY2026 2026財政年度	FY2025 2025財政年度
Packaging Materials 包裝材料 • X-ray bag X光袋	kg 公斤	1,098	1,300
Intensity 密度	kg/visiting patient 每名求診患者的人均公斤	0.00083	0.00090

Environmental and Natural Resources

Since the Group's business is mainly engaged in the healthcare market and has relatively little impact on the environment and natural resources, we have formulated relevant policies to reduce greenhouse gas emissions, waste generation and energy consumption and other corresponding measures to protect natural resources and the environment.

We continue to strengthen our environmental monitoring and early warning system so that we can effectively address environmental emergencies.

環境及天然資源

由於本集團業務主要從事醫療保健市場，對環境及天然資源影響較小，因此我們制定了相關政策，減少溫室氣體排放、廢棄物產生及能源消耗，以及其他相應措施，以保護自然資源與環境。

我們繼續加強環境監測預警體系建設，以有效處理突發環境事件。

Combating Climate Change

Climate-related Governance

The Board has overall oversight of the Group's ESG matters, including climate-related risks and opportunities. Relevant management functions support the Board by monitoring the Group's ESG performance, regulatory developments and climate-related matters that may affect the Group's operations.

Climate-related matters are considered as part of the Group's ESG and risk management processes. Where relevant, management considers the potential operational implications of climate-related matters, including disruption to healthcare facilities and services arising from extreme weather, changes in energy and operating costs, and evolving regulatory requirements.

The Group's approach is proportionate to the nature and scale of its operations. Climate-related matters are considered alongside other operational, financial, regulatory and business risks when management assesses matters that may affect the Group.

Strategy

Climate-related Risks and Opportunities

The Group provides healthcare services through medical centres, imaging and laboratory facilities and other healthcare operations. Its operations depend on the continued availability of premises, medical equipment, electricity, transportation, employees and third-party suppliers and service providers. Accordingly, climate change may affect the Group principally through disruption caused by extreme weather events and, over time, through changes in regulatory requirements, energy costs and other operating expenses.

For the purpose of assessing climate-related risks, the Group considers the following time horizons:

應對氣候變化

氣候相關管治

董事會全面監督本集團的環境、社會及管治事宜(包括氣候相關風險與機遇)。相關管理部門透過監測本集團環境、社會及管治的表現、監管動向以及可能影響本集團營運的氣候相關事宜，為董事會提供支援。

氣候相關事宜被視為本集團環境、社會及管治及風險管理流程的一部分。於適當情況下，管理層會考慮氣候相關事宜對營運的潛在影響，包括極端天氣對醫療設施及服務造成的中斷、能源及營運成本的變動，以及不斷演變的監管規定。

本集團的方針與其營運性質及規模相稱。當管理層評估可能影響本集團的事宜時，會將氣候相關事宜與其他營運、財務、監管及業務風險一併予以考慮。

策略

氣候相關風險與機遇

本集團透過醫務中心、影像及化驗設施及其他醫療保健業務提供醫療保健服務。其營運依賴於場所、醫療設備、電力、交通、僱員以及第三方供應商及服務提供者之持續供應。因此，氣候變化可能主要透過極端天氣事件所造成的中斷，並透過監管規定、能源成本及其他營運開支的變動，於一段時間後對本集團造成影響。

為評估氣候相關風險，本集團考慮以下時間範圍：

Time Horizon 時間範圍	Definition 定義
Short-term 短期	1 to 3 years 1至3年
Medium-term 中期	3 to 5 years 3至5年
Long-term 長期	5 to 10 years 5至10年

These time horizons broadly reflect the periods considered in the Group's operational planning and longer-term business considerations.

該等時間範圍大致反映本集團於營運規劃及較長期業務考量中所考慮的時間。

The Group aims to enhance its business resilience to climate change. We have refined our risk assessment procedures to analyze potential impacts on our operation and value chain. In FY2026, the Group conducted a qualitative climate scenario analysis to better understand both physical risks and transition risks.

本集團旨在提升其應對氣候變化的業務韌性。我們已完善風險評估程序，以分析對本集團營運及價值鏈的潛在影響。於2026財政年度，本集團進行了定性氣候情境分析，以更深入了解實體風險及過渡風險。

To analyze these risks, we utilize climate scenarios such as the Shared Socio-economic Pathways ("SSPs") developed by the Intergovernmental Panel on Climate Change ("IPCC") and the climate scenarios of the Network of Central Banks and Supervisors for Greening the Financial System ("NGFS"). This approach allows us to gain a better understanding of the resilience of our business strategies under various climate projections, enhancing our ability to address the long-term impacts of climate change on our core operations.

為分析該等風險，我們採用政府間氣候變化專門委員會(「IPCC」)所制定之共享社會經濟路徑(「SSPs」)及中央銀行和監管機構綠色金融網絡(「NGFS」)所提出的氣候情境。此舉有助我們更好地了解本集團的業務策略在不同氣候預測下之韌性，從而提升我們應對氣候變化對核心營運所造成長期影響的能力。

Physical Risk **實體風險**		
Climate scenario 氣候情境	Low risk scenario 低風險情境	High risk scenario 高風險情境
	SSP1-1.9	SSP5-8.5
Scenario description 情境說明	• Rapid global phase-out of fossil fuels. Net-zero global carbon dioxide emissions by around 2050. Renewable energy becomes dominant, with widespread electrification. • 全球迅速淘汰化石燃料。於2050年前後實現全球二氧化碳淨零排放。可再生能源佔有主導地位，電氣化範圍更為廣泛。 • Large-scale afforestation. • 大規模造林。 • Rapid development and implementation of low-carbon technologies, including energy storage, hydrogen, and carbon capture and storage. • 迅速開發並應用低碳技術，包括儲能、氫氣以及碳捕獲及封存。 • Extensive global cooperation, stringent and effective climate policies, consumer behaviour shifting towards low-carbon alternatives. • 廣泛的全球合作、嚴格且高效的氣候政策及消費者行為轉向低碳替代品的轉變。	• Reliance on abundant, globally connected fossil fuel resources. • 依賴儲量豐富、全球互聯的化石燃料資源。 • Active technological innovation, but primarily focused on energy extraction and consumption efficiency rather than low-carbon alternatives. • 積極進行技術創新，但主要著重於能源開採及消耗效率，而非低碳替代方案。 • No effective global carbon pricing or stringent international climate agreements. • 缺乏有效的全球碳定價或嚴謹的國際氣候協議。 • Global income disparities narrow and investment in human capital increases. • 全球收入差距縮小，對人力資本的投資增加。
Expected temperature rise 預計氣溫上升	With a temperature rise of less than 2°C in 2100. 2100年的氣溫上升少於2°C。	With a temperature rise of 4.4°C in 2100. 2100年的氣溫上升4.4°C。

Transition Risk **過渡風險**		
Climate scenario 氣候情境	High risk scenario 高風險情境	Low risk scenario 低風險情境
	Net Zero 2050 2050年淨零排放	Current policies 當前政策
Scenario description 情境說明	• Implement stringent climate policies immediately, with global carbon dioxide emissions reaching net zero around 2050. • 立即實施嚴格的氣候政策，於2050年前後達成全球二氧化碳淨零排放。 • Carbon prices reached elevated levels as early as 2020 (approximately US$100 per tonne of CO_2 equivalent) and continued to rise rapidly. Thus increased the costs of carbon-intensive goods and services, transforming consumption and production patterns. • 碳價早在2020年已升至高位（約每噸二氧化碳當量100美元），並繼續迅速上漲。這導致高碳商品及服務成本增加，進而改變消費及生產模式。 • Carbon Dioxide Removal ("CDR") technologies are deployed to accelerate decarbonisation, though their scale is constrained by sustainability limitations. • 儘管二氧化碳移除（「碳移除」）技術的規模受可持續性限制，其部署可加快脫碳過程。	• Currently implemented policies are preserved without adding any new emission reduction commitments or measures. • 目前實施的政策被保留，而並無增添任何新的減排承諾或措施。 • Slow change to technology, fossil fuels remain dominant in the energy system and renewable energy growing but insufficient to disrupt the existing system. • 技術變革速度放緩，化石燃料仍在能源系統中佔主導地位，可再生能源雖正在增長但仍不足以對現有系統造成衝擊。 • Carbon pricing is low, failing to effectively promote deep decarbonisation. • 碳定價偏低，未能有效促進深度脫碳。
Expected temperature rise 預期氣溫上升	Global warming is limited to below 1.5°C by 2100 (50% probability). 於2100年前將全球升溫控制在1.5°C以內（概率為50%）。	Global temperature rise exceeds 3°C by 2080. 於2080年前全球氣溫上升超過3°C。

We assess the potential impacts of climate risks on the Group's operational activities, the level of risk impact, and the Group's mitigation measures based on climate scenarios. The potential climate-related risks faced by the Group are set out below:

我們基於氣候情境，評估氣候風險對本集團營運活動、風險影響程度，以及本集團的減緩措施。本集團面臨的潛在氣候相關風險載列如下：

Risk 風險	Classification 分類	Potential Impact 潛在影響	Time Horizon 時間範圍	Management Approach 管理方針
Coastal inundation 沿海淹沒	Physical – Acute 實體—急性	Coastal flooding may affect premises, infrastructure and accessibility in exposed locations, potentially resulting in temporary service disruption or damage to assets. 沿海淹沒可能影響位於易受災地區的場所、基礎設施及可及性，並可能導致服務暫時中斷或資產受損。	Short to long term 短至長期	The Group monitors severe weather conditions and may implement appropriate contingency and business continuity arrangements. Insurance coverage and emergency procedures are considered where appropriate. 本集團監察惡劣天氣情況，並可能實施適當之應變及業務連續性安排。在適當情況下，亦會考慮保險保障及緊急應變程序。
Surface flooding 地面水浸	Physical – Acute 實體—急性	Heavy rainfall and flooding may affect low-lying premises, transportation and access to healthcare facilities and may lead to temporary service interruption or additional repair and maintenance costs. 暴雨及水浸可能影響低窪地區的場所、交通及前往醫療保健設施的通道，並可能導致服務暫時中斷或產生額外的維修及保養成本。	Short to long term 短至長期	Relevant facilities may adopt emergency and contingency arrangements and coordinate with landlords, property managers and service providers where necessary. 有關設施可能採取緊急及應變安排，並於必要時與業主、物業經理及服務提供者進行協調。

Risk 風險	Classification 分類	Potential Impact 潛在影響	Time Horizon 時間範圍	Management Approach 管理方針
Extreme wind and typhoons 極端風力及颱風	Physical – Acute 實體—急性	Typhoons and strong winds may affect premises, utilities, transport and supply arrangements, potentially disrupting normal healthcare services. 颱風及強風可能影響場所、水電供應、交通及供應安排，導致正常醫療保健服務受阻。	Short to long term 短至長期	The Group monitors weather warnings and may adjust operating arrangements, implement emergency procedures and coordinate with employees and suppliers in response to severe weather. 本集團監察天氣警告，並可能據此調整營運安排、實施應急程序，以及協調僱員及供應商應對惡劣天氣。
Forest fire 山火	Physical – Acute 實體—急性	Wildfires may affect accessibility, infrastructure or premises in affected areas and may temporarily disrupt operations. 山火可能影響受影響地區之可及性、基礎設施或場所，並可能暫時中斷營運。	Medium to long term 中至長期	The Group monitors relevant local conditions and may implement appropriate emergency and business continuity measures where operations are affected. 本集團監察相關當地情況，並於營運受影響所在地點實施適當之應急及業務連續性措施。
Changes in climate-related regulation and reporting requirements 氣候相關規例及報告要求的變動	Transition – Policy and regulatory 過渡—政策及規例	More extensive climate-related regulation or reporting requirements may increase compliance, data collection and administrative requirements. 更為廣泛的氣候相關規例或報告要求可能增加合規、數據收集及行政方面的要求。	Short to medium term 短至中期	The Group monitors relevant regulatory developments and reviews its reporting and data collection processes where appropriate. 本集團監察相關監管動態，並於適當情況下檢討其報告及數據收集流程。

Risk 風險	Classification 分類	Potential Impact 潛在影響	Time Horizon 時間範圍	Management Approach 管理方針
Energy and utility costs 能源及水電成本	Transition – Market 過渡—市場	Changes in electricity prices and energy-related policies may affect operating costs, particularly for healthcare facilities and medical equipment requiring continuous electricity consumption. 電價及能源相關政策的變動可能影響營運成本，特別是對於需要持續用電的醫療保健設施及醫療設備。	Medium to long term 中至長期	Energy consumption is monitored as part of the Group's environmental management practices, and energy efficiency may be considered when equipment or facilities are renewed or upgraded in the ordinary course of business. 本集團監察能源消耗作為環境管理常規的一部分，且於日常業務過程中更新或升級設備或設施時，可將能源效益納入考量。
Supply chain and stakeholder expectations 供應鏈及持份者的期望	Transition – Market 過渡—市場	Climate-related requirements affecting suppliers and service providers may contribute to changes in procurement costs, while stakeholder expectations regarding environmental performance may continue to evolve. 氣候相關要求影響供應商及服務提供者，採購成本可能因而發生變動，而持份者對環境表現之期望亦可能持續變化。	Medium to long term 中至長期	The Group monitors relevant market developments and may consider environmental factors as part of supplier and procurement management where appropriate. 本集團監察相關市場動態，並於適當情況下，將環境因素納入供應商及採購管理考量。

Based on the assessment conducted for the Reporting Period, climate-related risks are currently considered to be of a lower priority relative to the Group's principal operational, financial and regulatory risks. Nevertheless, the Group will continue to monitor whether changes in climate conditions, regulation or its business activities materially alter its exposure.

根據報告期內進行之評估，相較於本集團之主要營運、財務及監管風險，氣候相關風險目前被認為優先次序較低。然而，本集團將繼續監察氣候狀況、規例或其業務活動之變動會否重大改變其風險敞口。

The Group has not identified any climate-related opportunity that would require a material change to its business model during the Reporting Period. Potential benefits associated with energy efficiency, digitalisation and more efficient use of resources are generally considered as part of normal operational and business improvement rather than as separate climate-related initiatives.

於報告期內，本集團並未識別出任何需要對其業務模式作出重大變更之氣候相關機遇。與能源效益、數碼化及更有效率地利用資源相關之潛在效益，通常被視為正常營運及業務改進的一部分，而非獨立之氣候相關舉措。

Business Model and Value Chain

The Group's exposure to physical climate risks is principally concentrated in its healthcare premises, medical and diagnostic facilities and supporting infrastructure. Extreme weather events may affect facility access, utilities, employees, suppliers and transportation, which may in turn affect the delivery of healthcare services.

商業模式及價值鏈

本集團面臨的實體氣候風險主要集中於其醫療保健場所、醫療及診斷設施以及配套基礎設施。極端天氣事件可能影響設施的可及性、水電、僱員、供應商及交通，進而可能影響醫療保健服務的提供。

Transition risks are more broadly associated with purchased electricity, facility operation, medical equipment and supplies, third-party service providers and evolving regulatory requirements.

過渡風險主要涵蓋外購電力、設施營運、醫療設備及用品、第三方服務提供者，以及不斷變化的監管要求等更廣泛層面。

Based on the Group's current assessment, climate-related matters have not resulted in a material change to the Group's business model. The Group does not currently have a standalone climate-related transition plan. Climate-related considerations are instead addressed, where relevant, through existing operational, environmental, business continuity and risk management processes.

根據本集團目前的評估，氣候相關事宜並無對本集團之業務模式造成重大變動。本集團目前並無獨立之氣候相關過渡計劃，而是透過現有營運、環境、業務連續性及風險管理程序，在適當情況下處理氣候相關考量。

Current and Anticipated Financial Effects

During the Reporting Period, the Group did not separately identify climate-related matters as a material standalone driver of its financial position, financial performance or cash flows.

目前及預期財務影響

於報告期內，本集團並無將氣候相關事宜單獨識別為對其財務狀況、財務表現或現金流量構成重大獨立驅動因素。

Physical climate risks could potentially affect revenue where healthcare services are temporarily interrupted and could result in additional operating expenses, including repair and maintenance, insurance and other business continuity costs. Transition risks could potentially affect utility expenses, compliance costs and the cost of medical supplies and services.

實體氣候風險可能會在醫療保健服務暫時中斷時對收入造成潛在影響，並可能造成額外經營開支，包括維修及保養、保險及其他業務連續性相關成本。過渡風險亦可能對水電開支、合規成本，以及醫療用品及服務成本造成影響。

The Group has not separately quantified the financial effects attributable to individual climate-related risks because such effects are generally intertwined with other operational factors and are subject to uncertainties regarding the timing, location, frequency and severity of climate events, regulatory developments and future market conditions. Accordingly, quantitative information on such effects is not considered separately identifiable or sufficiently reliable at this stage.

本集團並未獨立量化由個別氣候相關風險造成的財務影響，因該等影響一般與其他營運因素緊密關連，且受到氣候事件發生的時間、地點、頻率及嚴重程度，以及監管發展及未來市場狀況等不確定因素影響，因此，該等影響的量化資料現階段仍未被視為可獨立識別或足夠可靠。

The relevant financial statement items that could potentially be affected include revenue, operating expenses, property, plant and equipment and cash flows associated with the Group's healthcare operations. Based on information currently available, the Group has not identified climate-related matters that would require a material change to its current investment, financing or operating strategy.

可能受到影響的相關財務報表項目包括收入、經營開支、物業、廠房及設備，以及與本集團醫療保健業務相關的現金流量。根據目前可獲得的資料，本集團並未識別須對其目前的投資、融資或營運策略作出重大調整的氣候相關事宜。

Climate Resilience and Scenario Analysis

During the Reporting Period, the Group conducted a qualitative assessment of its exposure to physical and transition climate risks under different climate pathways. The assessment considered scenarios broadly representing a lower-emissions transition and a higher-emissions pathway, with reference to the SSPs developed by the IPCC.

氣候韌性及情景分析

於報告期間，本集團就不同氣候路徑下所面臨的實體風險及過渡氣候風險進行定性評估。該評估參考政府間氣候變化專門委員會制定的共享社會經濟路徑，並考慮大致反映較低排放過渡路徑及較高排放路徑的氣候情景。

Under a lower-emissions scenario, more rapid policy and market transition may increase exposure to transition risks, including evolving regulatory requirements, energy-related policies and stakeholder expectations. However, the Group's operations are not carbon-intensive in nature and such risks are currently expected to be managed primarily through normal regulatory compliance and operational planning.

在較低排放情景下，隨著政策變化及市場轉型加快，本集團面臨更大過渡風險，包括監管規定及能源相關政策變化以及持份者期望提升。然而，本集團的營運性質並非高碳排放，該等風險目前亦預期可主要以日常監管合規及營運規劃進行管理。

Under a higher-emissions scenario, the frequency or severity of physical climate hazards may increase over the longer term. The Group's previously identified risks, including coastal inundation, flooding, extreme wind, typhoons and forest fire, may therefore become more relevant to individual facilities depending on their location and exposure.

在較高排放情景下，實體氣候危害於較長期可能會有更高的發生頻率或嚴重程度。因此，本集團過往識別的風險，包括海岸水災、洪水氾濫、極端強風、颱風及山火，個別設施視乎其地理位置及暴露程度可能更易受到影響。

The scenario analysis is qualitative and does not represent a forecast of future climate conditions or financial performance. It considers the Group's principal healthcare operations and the short-, medium- and long-term time horizons described above. Key uncertainties include the future frequency and severity of extreme weather events, location-specific exposure, changes in regulation and energy prices, and the effectiveness of adaptation measures taken by infrastructure operators, landlords and other third parties.

該情景分析屬定性分析，並不構成對未來氣候狀況或財務表現的預測。該分析涵蓋本集團的主要醫療保健業務，以及上述的短、中及長期時間範圍。主要的不確定因素包括極端天氣事件於未來的發生頻率及嚴重程度、特定地點的暴露程度、監管規定及能源價格變動，以及基礎設施營運商、業主及其他第三方所採取適應措施的成效。

Based on this assessment, the Group has not identified a need for a material change to its current business model or strategy as a result of climate-related risks. The Group will continue to monitor developments through its existing risk management and operational processes.

根據該評估，本集團並未識別任何因氣候相關風險而需要對現行業務模式或策略作出重大改變的情況。本集團將繼續透過現有風險管理及營運程序監察相關發展情況。

Risk Management

Climate-related risks are considered within the Group's broader risk management and ESG processes rather than through a separate standalone climate risk management system.

風險管理

氣候相關風險乃納入本集團更廣泛的風險管理以及環境、社會及管治程序中進行考量，而非以獨立的氣候風險管理系統進行管理。

In identifying and assessing climate-related risks, management may consider information including severe weather events and warnings, previous operational incidents, conditions affecting healthcare premises and infrastructure, energy consumption, relevant regulatory developments and communications with landlords, suppliers and other service providers.

在識別及評估氣候相關風險時，管理層可考慮多項資料，包括惡劣天氣事件及警告、過往營運事故、影響醫療保健場所及基礎設施的狀況、能源消耗情況、相關監管發展以及與業主、供應商及其他服務提供者溝通的情況。

Climate-related risks are assessed primarily on a qualitative basis, taking into consideration their nature, likelihood and potential impact on service continuity, premises, employees, operating costs and the Group's financial performance. Risks are considered alongside other business risks when determining their relative priority.

氣候相關風險主要按定性基準進行評估，並綜合考慮其性質、發生可能性，以及對服務持續性、營運場所、僱員、經營成本及本集團財務表現的潛在影響。在釐定風險的相對優次時，氣候相關風險會與其他業務風險一併考慮。

Based on the Group's current assessment, climate-related risks are presently considered lower priority than its principal operational, financial and regulatory risks. The Group nevertheless monitors relevant developments and may reassess the nature and priority of such risks if there are material changes to its operations or external environment.

根據本集團目前的評估，氣候相關風險的優次現仍視作低於其主要營運、財務及監管風險。然而，本集團將持續監察相關發展情況並在其業務營運或外部環境出現重大變化時，重新評估有關風險的性質及優次。

Potential climate-related opportunities are considered through the Group's ordinary business and operational planning processes. These may include opportunities associated with energy efficiency, resource efficiency and digitalisation. No climate-related opportunity was separately assessed as material to the Group during the Reporting Period.

本集團從日常業務及營運規劃程序中考量潛在的氣候相關機遇，其中可能包括提升能源效益、資源使用效益及數碼化等方面的機遇。於報告期間，本集團並無識別任何被獨立評估為對本集團有重大影響的氣候相關機遇。

Metrics and Targets

Greenhouse Gas Emissions

The Group monitors and reports its greenhouse gas emissions and energy consumption as part of its environmental performance. Details of the Group's Scope 1 and Scope 2 greenhouse gas emissions, together with the applicable calculation methodologies and environmental performance data, are set out in the relevant sections of this Report.

指標及目標

溫室氣體排放

本集團監察及匯報其溫室氣體排放及能源消耗情況，並將其納入環保績效的一部分。有關本集團的範圍1及範圍2溫室氣體排放量，連同適用的計算方法及環境績效數據的詳情均載於本報告相關章節。

The Group's existing environmental targets and its progress against such targets are disclosed under "Our Environmental Targets". The Group has not established any additional climate-specific transition target under this section during the Reporting Period.

本集團現有的環境目標及實現相關目標方面取得的進展於「我們的環境目標」一節披露。於報告期間，本集團並無於本節下制定任何額外的氣候相關過渡目標。

Climate-related Financial Metrics

The Group has not separately quantified the amount or percentage of assets or business activities vulnerable to climate-related transition risks, physical risks or aligned with climate-related opportunities. Given the nature of the Group's operations and the interaction between climate-related matters and other operational factors, the information necessary to make a sufficiently reliable allocation is not currently reasonably available without undue cost or effort.

氣候相關財務指標

本集團並未獨立量化易受氣候相關過渡風險及實體風險影響，或與氣候相關機遇相符的資產或業務活動的金額或百分比。鑑於本集團業務性質，且氣候相關因素與其他營運因素之間互相關連，目前未能於無須付出不必要成本或精力的情況下，合理獲得作出足夠可靠分配的必要資料。

The Group will continue to assess the relevance and availability of such information as its climate-related reporting processes develop.

隨著氣候相關匯報程序發展，本集團將持續評估有關資料的相關性及可用性。

Capital Deployment

The Group does not separately classify capital expenditure, financing or investment as climate-related where such expenditure forms part of its ordinary facility management, equipment replacement or operational improvement activities. No material capital deployment specifically attributable to climate-related risks or opportunities was separately identified during the Reporting Period.

資本部署

本集團並無將日常設施管理、設備更換或營運改善活動所涉及的資本開支、融資及投資獨立分類為氣候相關項目。於報告期間亦無識別任何特別歸因於氣候相關風險或機遇的重大資本部署。

Remuneration

Climate-related performance metrics are not currently incorporated into the Group's remuneration arrangements. Climate-related matters are managed through the Group's broader ESG, operational and risk management processes.

薪酬

本集團目前並無將氣候相關績效指標納入薪酬安排。氣候相關事宜乃由本集團更廣泛的環境、社會及管治、營運及風險管理程序進行管理。

Internal Carbon Price

The Group does not currently apply an internal carbon price in its operational or investment decision-making. Having regard to the nature of its healthcare services business and its current emissions profile, the Group has not identified internal carbon pricing as a necessary management tool at this stage.

內部碳價格

本集團目前並無於營運或投資決策中採用內部碳價格。鑑於其醫療保健服務業務的性質及目前的排放情況，本集團認為現階段採用內部碳定價作為管理工具並非必要。

BIOGRAPHICAL DETAILS OF DIRECTORS
董事履歷

BOARD OF DIRECTORS
Executive Directors

Dr. Sun Yiu Kwong ("Dr. Sun"), aged 83, is a founding member of the Group and the Chairman of the Company. He was appointed as a Director on 23 April 2015 and re-designated as an executive Director on 29 August 2015. He is primarily responsible for the overall formulation, supervision and guidance of business strategies, planning and development of the Group. He is the Chairman of the Nomination Committee of the Company. Dr. Sun is also a director of various companies of the Group.

With over 45 years of experience in family medicine practice, Dr. Sun is a Founder Fellow of the Hong Kong College of Family Physicians. He is a Clinical Associate Professor (honorary) in Faculty of Medicine, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong and an Honorary Clinical Assistant Professor in Department of Family Medicine and Primary Care, The University of Hong Kong. Dr. Sun is one of the pioneer Hong Kong doctors to participate in the healthcare development and training of medical professionals in the PRC.

Dr. Sun is the father of Dr. Michael Sun, the Vice Chairman, executive Director and Co-Chief Executive Officer, the father-in-law of Mr. Patrick Tsang, an executive Director and the uncle of Ms. Cheng, a non-executive Director. He is the sole shareholder and one of the directors of East Majestic Group Limited. He is also the sole shareholder and director of EM Team Limited.

He obtained a Bachelor of Medicine, Bachelor of Surgery from the University of Hong Kong in November 1967 and became a Fellow of the Hong Kong College of Family Physicians in September 1987 and a Fellow of the Hong Kong Academy of Medicine in the specialty of Family Medicine in December 1993. He was also registered as a specialist in Family Medicine in March 1998.

董事會
執行董事

孫耀江醫生(「**孫醫生**」),83歲,為本集團創始人之一,並為本公司主席;於2015年4月23日獲委任為董事,2015年8月29日調任為執行董事;主要負責制定、監督及指引本集團的整體業務策略、規劃及發展,並擔任本公司提名委員會主席。孫醫生亦為本集團多間公司的董事。

孫醫生擁有逾45年的家庭醫學臨床經驗,為香港家庭醫學學院的創辦院士、香港中文大學醫學院賽馬會公共衛生及基層醫療學院名譽臨床副教授及香港大學家庭醫學及基層醫療學系名譽臨床助理教授。孫醫生是香港醫生中參與中國醫療保健業務發展及醫護人員培訓的領導人物之一。

孫醫生為副主席、執行董事兼聯席行政總裁孫文堅醫生的父親、執行董事曾安業先生的岳父及非執行董事鄭女士的姑丈。彼為East Majestic Group Limited的唯一股東及董事之一。彼亦為EM Team Limited的唯一股東及董事。

孫醫生於1967年11月獲得香港大學內外全科醫學士學位,於1987年9月成為香港家庭醫學學院院士及於1993年12月成為香港醫學專科學院院士(家庭醫學);亦於1998年3月註冊成為家庭醫學專科醫生。

Dr. Sun Man Kin, Michael ("Dr. Michael Sun"), aged 48, is the Vice Chairman and Co-Chief Executive Officer of the Company. He was appointed as a Director on 18 August 2015 and re-designated as an executive Director on 29 August 2015. He is a specialist in Radiology and along with Ms. Jacquen Kwok, he is responsible for building, consolidating, and strengthening professional network of the Group and the overall guidance of planning and development of the Group. Dr. Michael Sun has over 15 years of experience in medicine and has been the chief radiologist of the Group since July 2012. He is currently a radiologist, a director and a shareholder of ProCare Medical Imaging and Laboratory Centre Limited, a non-wholly owned subsidiary of the Company. He is also a consultant radiologist of the Group and a director of various members of the Group.

孫文堅醫生(「孫文堅醫生」),48歲,為本公司副主席兼聯席行政總裁。彼於2015年8月18日獲委任為董事並於2015年8月29日調任為執行董事。彼乃放射科專科醫生;與郭卓君女士合力負責建立、鞏固並加強本集團的專業網絡,並就本集團的規劃及發展提供整體指引。孫文堅醫生擁有逾15年的醫學經驗,自2012年7月起一直為本集團的首席放射科醫生,目前為本公司非全資附屬公司普康醫學影像及化驗中心有限公司的放射科專科醫生、董事及股東,亦為本集團的放射科顧問及本集團多間成員公司的董事。

Dr. Michael Sun is the son of Dr. Sun, the Chairman of the Company and executive Director, the brother-in-law of Mr. Patrick Tsang, an executive Director and the cousin of Ms. Cheng, a non-executive Director. He is also a director of East Majestic Group Limited.

孫文堅醫生為本公司主席兼執行董事孫醫生之子、執行董事曾安業先生的內弟及非執行董事鄭女士的表哥。彼亦為East Majestic Group Limited的董事。

Dr. Michael Sun obtained a Bachelor of Medicine, Bachelor of Surgery from the University of Hong Kong in December 2002. He became a Fellow of the Royal College of Radiologist in October 2007 and a Fellow of the Hong Kong College of Radiologists in October 2010. He also became a Fellow of the Hong Kong Academy of Medicine in the specialty of Radiology in June 2010.

孫文堅醫生於2002年12月獲得香港大學內外全科醫學士學位。於2007年10月成為英國皇家放射科學醫學院院士,於2010年10月成為香港放射科醫學院院士,亦於2010年6月成為香港醫學專科學院院士(放射科)。

BIOGRAPHICAL DETAILS OF DIRECTORS
董事履歷

Ms. Kwok Cheuk Kwan, Jacquen ("Ms. Jacquen Kwok"), aged 58, is the Co-Chief Executive Officer of the Company. She was appointed as a Director on 5 November 2014 and re-designated as an executive Director on 29 August 2015. She is a member of the Nomination Committee of the Company. Along with Dr. Michael Sun, she is responsible for the overall guidance of planning and development of the Group and initiating and leading business projects in collaboration with medical insurance companies and corporate customers. Ms. Jacquen Kwok is also responsible for internal operations to enhance operational efficiency and develop the Group's corporate expansion in Hong Kong and Chinese Mainland. Ms. Jacquen Kwok is one of the key members in establishing the administration arm of the Group. She has over 25 years of experience in health schemes management and providers network administration to support the healthcare plan's implementation in the Group's network. She is actively involved in developing the infrastructure of the Group such as information technology platforms and medical network facilities. In the recent years, Ms. Jacquen Kwok is also leading and managing corporate development, merger and acquisition investments, and business expansion for the Group.

郭卓君女士(「郭卓君女士」)，58歲，為本公司聯席行政總裁；於2014年11月5日獲委任為董事，並於2015年8月29日調任為執行董事。彼為本公司提名委員會成員。彼與孫文堅醫生合力負責就本集團的規劃及發展提供整體指引，並負責領導和推進與醫療保險公司及機構客戶合作業務項目及其運作。郭卓君女士亦負責內部營運，以提高經營效率，並在香港及中國內地推動本集團的企業擴展。郭卓君女士為本集團管理部門的主要創始人之一，於保健計劃管理方面擁有逾25年的經驗，並為本集團醫療計劃的營運和醫務網絡的管理，提供管理支持。郭卓君女士積極推動本集團基礎設施(例如資訊技術平台及醫療網絡設施)等發展。近年，郭卓君女士亦帶領本集團企業發展，管理及參與本集團的併購投資以及業務擴展。

Ms. Jacquen Kwok obtained a Bachelor of Arts in International Business Studies (Hons) from the City University of Hong Kong in November 1991 and obtained a Bachelor of Laws from Peking University in July 1996. She also obtained a Master of Science in Management (Health Services Management) from the Hong Kong Polytechnic University in November 2003.

郭卓君女士於1991年11月獲得香港城市大學國際商業學榮譽文學士學位，於1996年7月獲得中國北京大學法學學士學位，亦於2003年11月獲得香港理工大學醫療服務管理學理學碩士學位。

Mr. Tsang On Yip, Patrick *BBS* **("Mr. Patrick Tsang")**, aged 55, was appointed as a Director on 18 August 2015 and re-designated as an executive Director on 29 August 2015. He is a member of the Remuneration Committee of the Company. Mr. Patrick Tsang is primarily responsible for providing strategic directions on co-operations with different business stakeholders in China and globally. He is a director of CTFE. He is also a director of The GBA Healthcare Holdings Limited, a wholly owned subsidiary of CTFE and a substantial shareholder of the Company. Mr. Patrick Tsang has over 25 years of international capital markets experience, and was previously managing director, head of Asia Fixed Income Capital Markets at Deutsche Bank AG, Hong Kong Branch, where he worked from 2003 to 2012.

曾安業先生*銅紫荊星章*(「**曾安業先生**」),55歲,於2015年8月18日獲委任為董事並於2015年8月29日獲調任為執行董事。彼為本公司薪酬委員會成員。曾安業先生主要針對與國內及全球不同業務夥伴的合作制訂策略方向。曾先生為周大福企業的董事;亦為大灣區醫療控股有限公司(周大福企業全資附屬公司及本公司主要股東)的董事。曾安業先生於國際資本市場擁有逾25年的經驗,曾於2003年至2012年任職德意志銀行香港分行,擔任董事總經理,主管亞洲固定收益資本市場業務。

Mr. Patrick Tsang is the vice chairman and an executive director of CTF Media & Entertainment Limited (stock code: 1097), an executive director of Melbourne Enterprises Limited (stock code: 158), a non-executive director of CTF Services Limited (stock code: 659), Giordano International Limited (stock code: 709) and SJM Holdings Limited (stock code: 880), all being companies listed on the Main Board of the Stock Exchange. From June 2015 to May 2022, Mr. Patrick Tsang was a non-executive director of Greenheart Group Limited (stock code: 94), and from November 2012 to August 2022, Mr. Patrick Tsang was a non-executive director of Integrated Waste Solutions Group Holdings Limited (stock code: 923), both being companies listed on the Main Board of the Stock Exchange.

曾安業先生為周大福媒體娛樂有限公司(股份代號:1097)副主席及執行董事、萬邦投資有限公司(股份代號:158)執行董事、周大福創建有限公司(股份代號:659)、佐丹奴國際有限公司(股份代號:709)及澳門博彩控股有限公司(股份代號:880)非執行董事,該等公司均為聯交所主板上市公司。曾安業先生於2015年6月至2022年5月期間為綠心集團有限公司(股份代號:94)的非執行董事,以及於2012年11月至2022年8月期間為綜合環保集團有限公司(股份代號:923)的非執行董事,均為聯交所主板上市公司。

Mr. Patrick Tsang is the son-in-law of Dr. Sun, the Chairman and an executive Director, the brother-in-law of Dr. Michael Sun, an executive Director, Vice Chairman and Co-Chief Executive Officer of the Company and the cousin-in-law of Ms. Cheng, a non-executive Director.

曾安業先生為本公司主席兼執行董事孫醫生的女婿,執行董事、副主席兼聯席行政總裁孫文堅醫生的姐夫及非執行董事鄭女士的表姐夫。

Mr. Patrick Tsang obtained a Bachelor of Arts in Economics from Columbia College of Columbia University in New York, USA in May 1994.

曾安業先生於1994年5月獲得美國紐約哥倫比亞大學哥倫比亞學院經濟學文學士學位。

BIOGRAPHICAL DETAILS OF DIRECTORS
董事履歷

Dr. Lee Pak Cheung, Patrick ("Dr. Patrick Lee"), aged 61, was appointed as an executive director on 28 February 2018. He joined the Group in 2003. He was appointed as the Dental Director for the Group since 2014, primarily responsible for supervising the dental practice of the Group and advising on the continuing training of dental professionals and development of clinical and professional services. Dr. Patrick Lee is one of the major contributors in the Group's dental centre chain, he keeps an active practice to nurture and inspire his dental colleagues. Dr. Patrick Lee also performs a key role in business development and quality assurance in the Group's dental centre chain. Dr. Patrick Lee obtained a Bachelor of Dental Surgery from the University of Hong Kong in 1988. He became a member of the faculty of general dental practitioners (UK) of the Royal College of Surgeons of England in 1995 and a member in general dental surgery of the Royal College of Surgeons of Edinburgh in 1997. In 1999, he became a Fellow of the Royal Australasian College of Dental Surgeons. In 2007, he was granted a Diploma of Membership in General Dentistry by the College of Dental Surgeons of Hong Kong. Dr. Patrick Lee currently also serves as dental consultant for the Group.

李柏祥醫生(「李柏祥醫生」),61歲,已於2018年2月28日獲委任為執行董事。彼於2003年加入本集團。彼自2014年起獲委任為本集團牙科總監,主要負責監督本集團牙科業務,並就牙科專業人士的持續培訓以及臨床及專業服務的發展提供意見。李柏祥醫生為本集團連鎖牙科中心作出重要貢獻,同時還積極培育及激勵牙科同僚。彼亦在本集團連鎖牙科中心的業務發展及品質保證方面發揮着關鍵作用。李柏祥醫生於1988年獲香港大學頒授牙醫學士學位,於1995年成為英國皇家外科醫學院牙醫全科學系院員,並於1997年成為英國愛丁堡皇家外科醫學院牙醫全科院員。彼於1999年成為澳紐皇家牙科醫學院院士。於2007年,彼獲頒授香港牙科醫學院牙科院員資格。李柏祥醫生現時亦為本集團的牙科顧問。

Non-executive Director

Ms. Cheng Chi Man ("Ms. Cheng"), aged 45, was appointed as a non-executive Director of the Company on 21 November 2025. She is an executive director of New World Development Company Limited (stock code: 17), a vice-chairman and executive director of Chow Tai Fook Jewellery Group Limited (stock code: 1929), and the chairman and a non-executive director of Giordano International Limited (stock code: 709), all are listed public companies in Hong Kong. She was an independent director of Primavera Capital Acquisition Corporation, a company previously listed on the New York Stock Exchange, up until her resignation in December 2022. She is also the chief executive officer of Rosewood Hotel Group and an independent non-executive director of The Hongkong and Shanghai Banking Corporation Limited. Ms. Cheng holds a Bachelor of Arts Degree in Applied Mathematics with a concentration in Economics from Harvard University in the U.S.A. She is a member of the Council of The Chinese University of Hong Kong and a member of The Standing Committee on Disciplined Services Salaries and Conditions of Service of the Hong Kong Special Administrative Region. She is also the Vice-Governor of Guangdong Youth Development Foundation. Ms. Cheng is a member of the Thirteenth Guangdong Provincial Committee of The Chinese People's Political Consultative Conference of The People's Republic of China. Ms. Cheng is the niece of Dr. Sun, the Chairman of the Company and executive Director, the cousin of Dr. Michael Sun, the Vice Chairman, executive Director and Co-Chief Executive Officer and the cousin-in-law of Mr. Patrick Tsang, an executive Director.

非執行董事

鄭志雯女士(「鄭女士」)，45歲，於2025年11月21日獲委任為本公司非執行董事。彼為香港上市公眾公司新世界發展有限公司(股份代號：17)執行董事、周大福珠寶集團有限公司(股份代號：1929)副主席兼執行董事及佐丹奴國際有限公司(股份代號：709)的主席兼非執行董事。彼曾為前紐約證券交易所上市公司Primavera Capital Acquisition Corporation獨立董事，直至2022年12月辭任。彼亦為瑰麗酒店集團首席行政總裁及香港上海滙豐銀行有限公司獨立非執行董事。鄭女士持有美國哈佛大學應用數學文學士學位，主修經濟。彼為香港中文大學校董會成員、香港特別行政區紀律人員薪俸及服務條件常務委員會委員。彼亦為廣東省青少年發展基金會副理事長。鄭女士為中華人民共和國人民政治協商會議第十三屆廣東省委員會委員。鄭女士為本公司主席兼執行董事孫醫生的外甥女、副主席、執行董事兼聯席行政總裁孫文堅醫生的表妹及執行董事曾安業先生的妻子的表妹。

BIOGRAPHICAL DETAILS OF DIRECTORS
董事履歷

Independent Non-executive Directors

Mr. Lee Luen Wai, John *BBS JP* **("Mr. John Lee")**, aged 77, was appointed as an independent non-executive Director on 6 November 2015. He is the chairman of Audit Committee, the chairman of Remuneration Committee and a member of the Nomination Committee of the Company. Mr. John Lee is an independent non-executive director of New World Development Company Limited (stock code: 17), an associate of CTFE. Mr. John Lee is also an executive director and the deputy chairman of both Lippo China Resources Limited (stock code: 156) and Hongkong Chinese Limited (stock code: 655). All aforementioned companies are listed on the Main Board of the Stock Exchange. He is the deputy chairman and executive director of Lippo Limited (stock code: 226), which was delisted from the Main Board of the Stock Exchange on 25 September 2025.

Mr. John Lee is a Fellow of The Institute of Chartered Accountants in England and Wales, the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants. He was a partner of Pricewaterhouse (now known as PricewaterhouseCoopers) in Hong Kong and has extensive experience in corporate finance and capital markets. Mr. John Lee is an Honorary Fellow of the City University of Hong Kong, a Justice of Peace in Hong Kong and an awardee of the Bronze Bauhinia Star by the Government of the Hong Kong Special Administrative Region.

Mr. John Lee is active in public service. Over the years, he served as a member or chairman of different government boards and committees in Hong Kong, including a member of the Hong Kong Hospital Authority, the chairman of the Hospital Governing Committee of the Queen Elizabeth Hospital and the Chairman of the Hospital Governing Committee of the Hong Kong Children's Hospital.

獨立非執行董事

李聯偉先生*銅紫荊星章、太平紳士*(「**李聯偉先生**」),77歲,於2015年11月6日獲委任為獨立非執行董事。彼為本公司審核委員會主席、薪酬委員會主席及提名委員會成員。李聯偉先生為周大福企業的聯繫人新世界發展有限公司(股份代號:17)的獨立非執行董事。李聯偉先生亦為力寶華潤有限公司(股份代號:156)及香港華人有限公司(股份代號:655)執行董事兼副主席。上述公司均為聯交所主板上市公司。彼為力寶有限公司(股份代號:226)副主席兼執行董事,該公司已於2025年9月25日從聯交所主板退市。

李聯偉先生為英格蘭及威爾斯特許會計師公會、英國特許公認會計師公會及香港會計師公會資深會員。彼曾為香港羅兵咸會計師事務所(現稱羅兵咸永道會計師事務所)合夥人之一,於企業融資及資本市場方面擁有豐富經驗。李聯偉先生為香港城市大學榮譽院士、香港太平紳士,並獲香港特別行政區政府頒授銅紫荊星章。

李聯偉先生積極參與公共事務,在過去多年,彼曾於香港擔任多個不同政府委員會的委員或主席,其中包括香港醫院管理局委員、伊利沙伯醫院管治委員會主席及香港兒童醫院的醫院管治委員會主席。

Mr. Yeung Tak Bun *BBS JP* **("Mr. Yeung")**, aged 60, was appointed as an independent non-executive Director on 24 November 2023. He is a member of the Audit Committee and the Nomination Committee of the Company. He holds a Bachelor of Science in Electrical Engineering from the University of Texas (Austin) in the U.S., a Master of Science in Electrical Engineering from Purdue University in the U.S., and an Executive MBA from the Kellogg School of Management of the University of Northwestern in the U.S. in conjunction with the Hong Kong University of Science and Technology. Mr. Yeung started his career in the Silicon Valley, California in 1987 and had worked for several high-tech companies. Mr. Yeung held senior management positions in several multinational corporations with operations throughout Asia.

楊德斌先生*銅紫荊星章、太平紳士*(「**楊先生**」),60歲,於2023年11月24日獲委任為獨立非執行董事。彼為本公司審核委員會及提名委員會成員。彼持有美國德州大學(奧斯汀總校)電機工程理學士學位、美國普渡大學電機工程理學碩士學位,以及美國西北大學凱洛管理學院及香港科技大學聯辦的行政人員工商管理碩士學位。楊先生在1987年於加州矽谷開展事業,曾任職多家高科技公司。楊先生曾於數家業務遍及亞洲的跨國公司擔任高級管理職位。

When Mr. Yeung was the Chief Corporate Development Officer of the Hong Kong Science and Technology Parks Corporation in 2009, he was responsible for the development strategy of the Science Park, global partnership, incubation programme for start-ups, nurturing bio-tech, green-tech, IT and electronics enterprises, and initiated the science park corporate venture fund. During mid-2015 to mid-2018, Mr. Yeung was appointed as the Government Chief Information Officer, head of department, and a Justice of the Peace, by the Hong Kong SAR Government. Mr. Yeung was responsible for formulation of policies and strategies for Hong Kong's information industry in development of the digital economy, e-government, cyber-security, and formulation of the blueprint for developing Hong Kong into the world's leading smart city.

在楊先生於2009年擔任香港科技園公司的首席企業發展總監時,彼負責制定科學園的發展策略,建立全球合作夥伴網絡,孵化初創企業,培養生物科技、綠色科技、資訊科技及電子企業,及建立科技園創投基金。於2015年年中至2018年年中,楊先生獲香港特別行政區政府委任為政府資訊科技總監、部門首長及太平紳士。楊先生負責制定香港資訊業在數碼經濟、電子政府、網絡安全及制定香港成為世界領先的智慧城市發展藍圖的政策及策略。

Mr. Yeung co-founded Intelli Global Corporation in late 2018 with international smart city and big data experts to provide top-level design and big data/artificial intelligence relate products that foster city governments and companies around the world in managing cities with new smart city concepts, improving the quality of life, reducing management costs and improving urban governance efficiency. Mr. Yeung is currently the Chief Executive Officer of and Strategic Adviser to Intelli Global Corporation.

於2018年末,楊先生聯合國際級智慧城市及大數據科學家創立數睿科技國際有限公司,提供智慧城市頂層設計和大數據/人工智能相關產品,協助全球各地城市政府和企業利用新型智慧城市理念管理城市,提高生活品質,降低管理成本及提升城市治理效率。楊先生現任數睿科技國際有限公司行政總裁及戰略顧問。

BIOGRAPHICAL DETAILS OF DIRECTORS
董事履歷

Mr. Yeung holds the public positions of being a member at the Expert Group of the Chief Executive Policy Unit and a Member of the Digital Economy Development Committee of the HKSAR Government. He is a Council Member of the Hong Kong University of Science and Technology and the President of Greater Bay Area International Information Technology Industry Association and the Founding Chairman of the Institute of Big Data Governance. In addition, Mr. Yeung serves as an independent non-executive director of companies which are listed on the Stock Exchange, including Yau Lee Holdings Limited (stock code: 406) and Chinasoft International Limited (stock code: 354). He also serves as an independent non-executive director of POA Bank Limited, which is a wholly-owned subsidiary of Lufax Holding Ltd (listed on the New York Stock Exchange (NYSE: LU) and The Stock Exchange of Hong Kong Limited (stock code: 6623)) and a member of Ping An Insurance (Group) Company of China, Ltd. (listed on The Stock Exchange of Hong Kong Limited (stock code: 2318) and on the Shanghai Stock Exchange (SSE: 601318)). From October 2018 to December 2023, Mr. Yeung was an independent non-executive director of Lansen Pharmaceutical Holdings Limited (delisted from the Stock Exchange).

楊先生現任特首政策組專家組及香港特別行政區政府數字化經濟發展委員會的成員。彼為香港科技大學校董會成員及大灣區國際信息科技協會的會長及大數據治理公會的創會主席。此外，楊先生為聯交所上市公司獨立非執行董事，包括有利集團有限公司(股份代號：406)及中軟國際有限公司(股份代號：354)。彼亦為POA Bank Limited的獨立非執行董事，POA Bank是陸金所控股有限公司(在紐約證券交易所(NYSE: LU)和香港聯合交易所有限公司(股份代號：6623)上市)的全資子公司，也是中國平安保險(集團)股份有限公司(在香港聯合交易所有限公司(股份代號：2318)和上海證券交易所(上交所：601318)上市)的成員公司。楊先生於2018年10月至2023年12月期間為朗生醫藥控股有限公司(已從聯交所退市)的獨立非執行董事。

Mrs. Chan Kung Wai Ying, Amy *MH* **("Mrs. Amy Chan")**, aged 70, was appointed as an independent non-executive Director of the Company on 21 November 2025. She is a member of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company. She holds a Master of Arts from Leicester Polytechnic University, the United Kingdom. Mrs. Amy Chan has worked in KPMG from 1989 to 1993 and headed the firm's business development department. From 1993 to 2009, Mrs. Amy Chan served as the Chief Manager, Public Affairs of the Hospital Authority, gaining extensive expertise in managing external relations within the healthcare sector. From 2007 to 2009, she was the Chief of the first Greater China office of the Hospital Authority and was responsible for the strategic planning and management of initiatives related to Greater China. Currently, Mrs. Amy Chan serves as the Chairman of both the Child Development Matching Fund ("CDMF") and the Child Development Initiative Alliance ("CDIA"). In 2009, Mrs. Amy Chan began her involvement as a director at the CDMF at its inception stage to support the Hong Kong Special Administrative Region ("HKSAR") Government's Child Development Fund which is designed to combat intergenerational poverty as well as youth development. In 2014, Mrs. Amy Chan founded the CDIA with other community-minded individuals and became the chairperson in 2016.

Mrs. Amy Chan also actively contributes to healthcare and other community services. She is a Founding Director of the Hong Kong Stroke Fund and an advisor for the WeRISE Project, a community rehabilitation initiative that supports stroke patients and their families. She is also the Founding Chairman of the Charitable Foundation of Love and a board member of the Quality Mentorship Network. Mrs. Amy Chan was awarded the HKSAR Medal of Honour in 2025.

陳龔偉瑩女士*榮譽勳章*(「**陳龔偉瑩女士**」),70歲,於2025年11月21日獲委任為本公司獨立非執行董事。彼為本公司審核委員會、薪酬委員會及提名委員會的成員。彼持有英國萊斯特理工大學的文學碩士學位。陳龔偉瑩女士於1989年至1993年在畢馬威會計師事務所工作,並擔任該事務所的業務拓展部主管。自1993年至2009年,陳龔偉瑩女士任職醫院管理局公共事務總經理,在醫療行業中累積了管理對外關係的豐富專業知識。自2007年至2009年,彼擔任醫院管理局首任中國事務處的主管,負責有關大中華地區的策略規劃及項目管理。目前,陳龔偉瑩女士擔任兒童發展配對基金(「兒童發展配對基金」)及青少年發展企業聯盟(「青少年發展企業聯盟」)主席。於2009年,陳龔偉瑩女士在兒童發展配對基金創辦初期擔任董事,以支持香港特別行政區(「香港特別行政區」)政府為應對跨代貧窮及扶育下代而成立的兒童發展基金。於2014年,陳龔偉瑩女士與一群志同道合的社區人士共同創立青少年發展企業聯盟,並於2016年出任主席。

陳龔偉瑩女士亦積極參與醫療及其他社區服務。彼為香港中風基金會的創會董事及社區康復計劃「風起航」的顧問,旨在支援中風患者及其家人。彼亦為愛聯基金會創會主席,同時亦為優質師友網絡的董事會成員。陳龔偉瑩女士於2025年獲香港特別行政區頒發榮譽勳章。

CORPORATE GOVERNANCE REPORT
企業管治報告

The Company is committed to maintaining high standards of corporate governance and transparency. The Company believes that high standards of corporate governance provide a solid foundation for the Group to manage business risks, enhance transparency and maintain high standards of accountability. The corporate governance principles of the Company emphasise sound internal control and aim to protect Shareholders' interests in general.

本公司致力維持高水平的企業管治及透明度。本公司認為，高水平的企業管治為本集團管理經營風險、提高透明度及保持高度問責提供了堅實的基礎。本公司的企業管治原則著重健全的內部監控，旨在維護股東整體利益。

CORPORATE PURPOSE, CULTURE AND VALUES

Our corporate culture is built on the values of expertise, compassion, innovation, trust, and efficacy. We strive to be experts in our field, providing the highest quality care to our patients. We treat our patients with compassion and empathy, recognizing the importance of the human connection in healthcare. We embrace innovation and creativity to improve patient outcomes and enhance the patient experience. We understand that trust is the foundation of our relationship with our patients, their families, and our community, and we act with integrity, honesty, and transparency in all our dealings. We are committed to delivering effective and efficient care, measuring and evaluating our performance to continuously improve the quality of care we provide. Our corporate culture is built on the principles of ethical and responsible decision-making, transparency, and accountability, ensuring that our actions are always in the best interests of our patients, our employees, and our stakeholders.

企業宗旨、文化及價值觀

我們的企業文化建基於專業、關懷、創新、信任及成果的價值觀之上。我們致力成為業內專家，為患者提供最優質的醫療服務。我們以關懷及同理心對待患者，並明白人與人之間的聯繫在醫療保健中的重要性。我們崇尚以創新及創意改善患者的治療效果及提升患者的求診體驗。我們深知，信任是我們與患者、患者家屬及社區之間的關係基礎，因此我們在所有醫患相處中，秉承正直、誠實及透明的原則。我們致力提供高效率及高效益的醫療服務，衡量及評估我們的表現，以不斷提高我們的醫療服務品質。我們的企業文化建基於合乎道德及負責任的決策、透明、及問責的原則之上，確保我們的行事始終符合患者、僱員及持份者的最佳利益。

CORPORATE GOVERNANCE

The Company has complied with the code provisions of the Corporate Governance Code during FY2026.

企業管治

本公司於2026財政年度已遵守企業管治守則的守則條文。

BOARD OF DIRECTORS

Board Composition

The Board currently comprises nine Directors, consisting of five executive Directors, one non-executive Director and three independent non-executive Directors, namely Dr. Sun Yiu Kwong as Chairman, Dr. Sun Man Kin, Michael as Vice Chairman, Co-Chief Executive Officer, Ms. Kwok Cheuk Kwan, Jacquen, as Co-Chief Executive Officer, Mr. Tsang On Yip, Patrick *BBS* and Dr. Lee Pak Cheung, Patrick as executive Directors; Ms. Cheng Chi Man as non-executive Director; and Mr. Lee Luen Wai, John *BBS JP*, Mr. Yeung Tak Bun *BBS JP* and Mrs. Chan Kung Wai Ying, Amy *MH* as independent non-executive Directors.

董事會

董事會組成

董事會現時由九名董事組成，包括五名執行董事、一名非執行董事及三名獨立非執行董事，分別為執行董事孫耀江醫生（主席）、孫文堅醫生（副主席、聯席行政總裁）、郭卓君女士（聯席行政總裁）、曾安業先生*銅紫荊星章*及李柏祥醫生；非執行董事鄭志雯女士；以及獨立非執行董事李聯偉先生*銅紫荊星章，太平紳士*、楊德斌先生*銅紫荊星章，太平紳士*及陳龔偉瑩女士*榮譽勳章*。

Biographical details of the Directors and their relationships, where applicable, are contained in the section headed "Biographical Details of Directors" of this annual report.

董事履歷詳情及彼等之間的關係(如適用)載於本年報「董事履歷」一節。

The Company has maintained on its website and on the website of the Stock Exchange an updated list of its Directors identifying their roles and functions, and whether they are independent non-executive Directors. Independent non-executive Directors are identified as such in all corporate communications that disclose the names of Directors.

本公司一直在其網站及聯交所的網站上提供其最新董事名單,列明其職位和職責,以及是否為獨立非執行董事。於披露董事姓名的所有公司通訊中,已明確識別獨立非執行董事身份。

Board Independence Evaluation

The Company has established a Board Independence Evaluation Mechanism which sets out the processes and procedures to ensure a strong independent element on the Board, which allows the Board effectively exercises independent judgment to better safeguard Shareholders' interests.

董事會獨立性評估

本公司已制定董事會獨立性評估機制,有關機制列明相關過程及程序,以確保董事會有強大的獨立元素,能夠有效地作出獨立判斷,以更好地維護股東利益。

The objectives of the evaluation are to improve Board effectiveness, maximise strengths, and identify the areas that need improvement or further development. The evaluation process also clarifies what actions of the Company need to be taken to maintain and improve the Board performance.

評估的目的是要提高董事會效率,發揮最大優勢,以及識別出需要改進或進一步發展的地方。評估過程亦釐清本公司需要採取哪些行動,以保持並提高董事會的表現。

The Board has conducted a review and considered that the Board Independence Evaluation Mechanism has been properly implemented for FY2026 and is effective.

董事會已檢討並認為董事會獨立性評估機制於2026財政年度已獲得妥善實施且行之有效。

Board Diversity Policy

The Board adopted a board diversity policy setting out the approach to achieve diversity on the Board. The Company considered diversity of Board members can be achieved through consideration of a number of aspects, including but not limited to the gender, age, cultural, educational background and professional experience of the Board members. The appointment of Directors will be based on the Group's own business model and specific needs, having due regard to the benefits of diversity of the Board.

董事會多元化政策

董事會採納董事會多元化政策,其中載有達致董事會成員多元化的方法。本公司認為,透過考慮多方面因素可達致董事會成員多元化,包括但不限於董事會成員的性別、年齡、文化、教育背景及專業經驗。董事的委任均以本集團業務模型及特別需要為原則,並充分顧及董事會多元化的裨益。

The Company believes that the current Board composition is well-balanced and of a diverse mix appropriate for the business of the Company. The Board currently has three female Directors and in compliance with Board gender diversity requirement under Rule 13.92 of the Listing Rules. We will continue to strive to enhance female representation and achieve an appropriate balance of gender diversity. The Board has reviewed the Board Diversity Policy for FY2026 and is of the view that the Board Diversity Policy has been properly implemented and is effective.

本公司相信，目前董事會的組成相當均衡，且多元化的背景切合本公司業務所需。董事會目前有三名女性董事，符合上市規則第13.92條的董事會性別多元化要求。我們將繼續努力提高女性比例，務求在性別多元化中取得適當平衡。董事會已於2026財政年度檢討董事會多元化政策，並認為董事會多元化政策已獲得妥善實施且行之有效。

Workforce Diversity Policy

The Board adopted a workforce diversity policy setting out the approach to achieve diversity on the workforce. The Company values the diversity of its employees and is committed to establishing a diverse and inclusive workplace.

員工多元化政策

董事會已採納員工多元化政策，其中列明實現員工多元化的方針。本公司重視員工多元化，並致力建立多元共融的工作環境。

As at 30 June 2026, the gender ratio in the senior management of the Group was approximately 20% female and approximately 80% male and the gender ratio in the workforce (excluding senior management) of the Group was approximately 80% female and approximately 20% male. The Group treats every employee equally and equal opportunities for different genders. In particular, the recruitment process of the Group shall not involve any discrimination on the grounds of race, disability, gender, sexual orientation, family responsibilities, marital status, age or other discriminatory factors. It is relatively more challenging for the Group to achieve equal gender ratio across all business units of the Group due to the characteristics and work types of different business units. The Group will continue to enhance diversity in different levels of workforce.

於2026年6月30日，本集團的高級管理人員性別比例為女性約20%及男性約80%，以及本集團的員工(不包括高級管理人員)性別比例為女性約80%及男性約20%。本集團平等對待每一位僱員，並為不同性別僱員提供平等機會。本集團尤其在招聘過程中不會基於種族、殘疾、性別、性取向、家庭責任、婚姻狀況、年齡或其他歧視性因素而作出任何歧視行為。由於各業務單位的特性及工作類型均有不同，要在本集團所有業務單位實現男女比例平等相對更具挑戰性。本集團將繼續提升各級僱員的多元化程度。

Board Performance Review

Under Code Provision B.1.4 of the Corporate Governance Code, the Company is required to conduct a Board's performance review at least every two years. As FY2026 was the first year of the current review cycle, no Board performance review was conducted during FY2026. The Board reviewed the plan of conducting the Board performance review, which is scheduled to be conducted in FY2027.

董事會表現評核

根據企業管治守則的守則條文第B.1.4條，本公司須至少每兩年對董事會表現進行評核。由於2026財政年度為本評核週期首年，故2026財政年度並無進行董事會表現評核。董事會已審閱有關進行董事會表現評核的計劃，並擬定於2027財政年度進行評核。

Board Skills Matrix

The Board recognizes that an appropriate balance of skills, experience, knowledge and diversity is essential to the effective governance and long-term success of the Group. The Nomination Committee reviewed the composition of the Board to ensure that it possesses a broad range of competencies relevant to the Group's strategic objectives, business operations and future development.

The Board comprises members with extensive experience and expertise in healthcare services, medicine, business management, finance, corporate governance, technology and risk management. Such a combination of skills enables the Board to provide effective leadership, oversight and strategic guidance to the Group.

董事會技能表

董事會深知，於技能、經驗、知識及多元化取得適當平衡，對本集團有效管治及長遠成功至關重要。提名委員會已審視董事會成員組合，以確保其具備與本集團策略目標、業務營運及未來發展相關的廣泛能力。

董事會成員在醫療保健服務、醫學、業務管理、財務、企業管治、科技及風險管理皆具備豐富經驗及專業知識。憑藉該等能力組合，董事會得以向本集團提供有效的領導、監督及策略指引。

	Executive Directors 執行董事					Non-executive Director 非執行董事	Independent Non-executive Directors 獨立非執行董事		
Directors' Skills and Experience 董事技能及經驗	Dr. Sun Yiu Kwong 孫耀江醫生	Dr. Sun Man Kin, Michael 孫文堅醫生	Ms. Kwok Cheuk Kwan, Jacquen 郭卓君女士	Mr. Tsang On Yip, Patrick 曾安業先生	Dr. Lee Pak Cheung, Patrick 李柏祥醫生	Ms. Cheng Chi Man 鄭志雯女士	Mr. Lee Luen Wai, John 李聯偉先生	Mr. Yeung Tak Bun 楊德斌先生	Mrs. Chan Kung Wai Ying, Amy 陳龔偉瑩女士
Healthcare Industry 醫療保健行業	✓	✓	✓	✓	✓		✓		✓
Medical/Dental and Clinical Expertise 醫科／牙科及臨床專業知識	✓	✓			✓				
Business and Strategic Management 業務及策略管理	✓	✓	✓	✓		✓		✓	✓
Finance and Accounting 財務及會計				✓		✓	✓		
Corporate Governance and Regulatory Compliance 企業管治及監管合規							✓		
Risk Management and Internal Control 風險管理及內部監控		✓			✓		✓		✓
Human Resources and Remuneration 人力資源及薪酬		✓	✓						
Information Technology and Digital Transformation 資訊科技及數碼轉型			✓					✓	
Hong Kong and Mainland China Market Experience 香港及中國內地市場經驗	✓		✓	✓		✓	✓	✓	✓

The key skills and experience represented on the Board include:

董事會具備的關鍵技能及經驗包括：

Skills and Experience 技能及經驗	Description 描述
Healthcare Industry 醫療保健行業	Knowledge of the healthcare sector, healthcare services management, healthcare market dynamics and industry development 醫療保健行業知識、醫療保健服務管理、醫療保健市場動態及行業發展
Medical/Dental and Clinical Expertise 醫科／牙科及臨床專業知識	Medical/Dental qualifications and experience in medical/Dental practice, patient care, clinical governance and healthcare quality standards 醫科／牙科資格以及於醫科／牙科執業、患者護理、臨床管治及醫療保健質量標準方面的經驗
Business and Strategic Management 業務及策略管理	Corporate leadership, business development, strategic planning and operational management 企業領導、業務發展、策略規劃及營運管理
Finance and Accounting 財務及會計	Financial management, accounting, budgeting, investment evaluation and capital allocation 財務管理、會計、預算編制、投資評估及資本配置
Corporate Governance and Regulatory Compliance 企業管治及監管合規	Listed company governance, regulatory compliance, Listing Rules and board effectiveness 上市公司管治、監管合規、上市規則及董事會效率
Risk Management and Internal Control 風險管理及內部監控	Enterprise risk management, internal controls, compliance and business continuity 企業風險管理、內部監控、合規及業務持續性
Human Resources and Remuneration 人力資源及薪酬	Talent management, succession planning, remuneration and workforce development 人才管理、繼任計劃、薪酬及人力資源開發
Information Technology and Digital Transformation 資訊科技及數碼轉型	Digital healthcare, healthcare technology, AI applications, cybersecurity and innovation 數碼醫療保健、醫療保健科技、人工智能應用、網絡安全及創新
Hong Kong and Mainland China Market Experience 香港及中國內地市場經驗	Knowledge of the healthcare, business and regulatory environments in Hong Kong, Macau and Mainland China 對香港、澳門及中國內地醫療保健、業務及監管環境的認識

The Board is satisfied that its current composition provides an appropriate balance of skills, experience and perspectives necessary to support the Group's strategy, oversee its operations and deliver sustainable value to shareholders and stakeholders. The Nomination Committee will continue to review the Board Skills Matrix periodically and identify any gaps in skills or experience to support future Board succession planning and Director appointments.

董事會信納，其現有組合具備技能、經驗及觀點的適當平衡，足以支持本集團策略、監督其營運及為股東及持份者創造可持續價值。提名委員會將繼續定期檢討董事會技能表及找出技能或經驗方面的差距，以支持董事會未來的繼任計劃及董事委任。

Chairman and Chief Executive Officer

Code Provision C.2.1 of the Corporate Governance Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing. The Company has been in compliance with Code Provision C.2.1 of the Corporate Governance Code with Dr. Sun Yiu Kwong serving as the Chairman of the Board and Dr. Sun Man Kin, Michael and Ms. Kwok Cheuk Kwan, Jacquen serving as the Co-Chief Executive Officer.

主席及行政總裁

企業管治守則的守則條文第C.2.1條訂明，主席與行政總裁的角色應有區分，並不應由一人同時兼任。主席與行政總裁的責任應當清楚劃分並以書面方式列明。本公司已遵守企業管治守則的守則條文第C.2.1條，其中孫耀江醫生擔任董事會主席，而孫文堅醫生及郭卓君女士則擔任聯席行政總裁。

Independent Non-executive Directors

During FY2026, the Board at all times met the requirements of the Listing Rules relating to the appointment of at least three independent non-executive Directors representing one third of the Board with one of whom possessing appropriate professional qualifications or accounting or related financial management expertise. The Company has received written annual confirmation from each of the independent non-executive Directors in respect of his independence in accordance with the independence guidelines set out in Rule 3.13 of the Listing Rules. The Company is of the view that all independent non-executive Directors are independent.

獨立非執行董事

於2026財政年度，董事會一直遵守上市規則有關委任最少三名獨立非執行董事(相當於董事會三分之一席位)且當中最少一名擁有適當專業資格或會計或相關財務管理專長的規定。本公司已收到各獨立非執行董事之年度書面確認，確認其符合上市規則第3.13條所載的獨立指引。本公司認為所有獨立非執行董事均屬獨立人士。

Roles of the Board and Management

The Board oversees the management, business, strategic directions and performance of the Group. It is collectively responsible for the management and operation of the Company. The Board is the ultimate decision making body of the Company except for matters requiring the approval of the Shareholders in accordance with the Articles, the Listing Rules or other applicable laws and regulations.

The Board delegates day-to-day operations of the Group to the management of the Company. The Board and the management have clearly defined authorities and responsibilities under various internal control and check and balance mechanisms.

董事會及管理層的角色

董事會監察本集團的管理、業務、策略方針及表現。董事會共同負責本公司的管理及營運。除根據細則、上市規則或其他適用法例及法規須獲股東批准的事宜外，董事會為本公司的最終決策機關。

董事會將本集團的日常運作轉授本公司的管理層。在各項內部監控及制衡機制下，董事會及管理層具有明確界定的授權及職責。

CORPORATE GOVERNANCE REPORT
企業管治報告

Corporate Governance Functions

The Board plays a major role in the supervision of corporate governance to ensure that the Company maintains a sound governance framework and the long-term sustainable Shareholders' value by way of, among others:

(a) to develop and review the Company's policies and practices on corporate governance;

(b) to review and monitor the training and continuous professional development of the Directors and senior management;

(c) to review and monitor the Company's policies and practices in compliance with legal and regulatory requirements;

(d) to develop, review and monitor the code of conduct and compliance manual (if any) applicable to employees and the Directors; and

(e) to review the Company's compliance with Appendix C1 of the Listing Rules (Corporate Governance Code and Corporate Governance Report).

During the year, the Board has reviewed the Company's policies and practices on corporate governance, and reviewed and monitored the training and continuous professional development of directors and senior management. The Board has also reviewed and ensured compliance of the relevant legal and regulatory requirements, the code of conducts, the code and the disclosure in the Corporate Governance Report.

企業管治職能

董事會於監督企業管治職能方面擔當主要角色，以確保本公司維持健全的管治框架及長期可持續的股東價值，方法(其中包括)如下：

(a) 制定及檢討本公司的企業管治政策及常規；

(b) 檢討及監察董事及高級管理人員的培訓及持續專業發展；

(c) 檢討及監察本公司在遵守法律及監管規定方面的政策及常規；

(d) 制定、檢討及監察僱員及董事適用的操守準則及合規守冊(如有)；及

(e) 檢討本公司遵守上市規則附錄C1(企業管治守則及企業管治報告)的情況。

年內，董事會已審閱本公司的企業管治政策及常規，並審閱及監察董事及高級管理人員的培訓和持續專業發展。董事會亦已審閱並確保遵守相關法律及法規要求，行為守則、守則及企業管治報告中的披露。

Board Meetings and Supply of and Access to Information

Under code provision C.5.1 of the Corporate Governance Code, the Board should meet regularly and Board meetings should be held at least four times a year at approximately quarterly intervals and under code provision C.2.7 of the Corporate Governance Code, the Chairman of the Board should at least annually hold meetings with the independent non-executive Directors without the other Directors present. During FY2026, the Board held four meetings and Directors' attendance records are set out below:

董事會會議及資料提供及使用

根據企業管治守則的守則條文第C.5.1條，董事會應定期開會，董事會會議應每年召開至少四次，大約每季一次，而根據企業管治守則的守則條文第C.2.7條，董事會主席亦應至少每年與獨立非執行董事舉行一次其他董事避席的會議。於2026財政年度內，董事會已舉行四次會議，各董事的出席紀錄載列如下：

Directors	董事	Meeting(s) Attended/Held 出席／舉行會議次數
Executive Directors	*執行董事*	
Dr. Sun Yiu Kwong *(Chairman)*	孫耀江醫生*(主席)*	4/4
Dr. Sun Man Kin, Michael *(Vice Chairman and Co-Chief Executive Officer)*	孫文堅醫生*(副主席兼聯席行政總裁)*	4/4
Ms. Kwok Cheuk Kwan, Jacquen *(Co-Chief Executive Officer)*	郭卓君女士*(聯席行政總裁)*	4/4
Mr. Tsang On Yip, Patrick	曾安業先生	4/4
Dr. Lee Pak Cheung, Patrick	李柏祥醫生	4/4
Non-executive Directors	*非執行董事*	
Ms. Cheng Chi Man *(Note 1)*	鄭志雯女士*(附註1)*	3/3
Dr. Lee Kar Chung, Felix *(Note 2)*	李家聰博士*(附註2)*	1/1
Independent Non-executive Directors	*獨立非執行董事*	
Mr. Lee Luen Wai, John	李聯偉先生	4/4
Mr. Yeung Tak Bun	楊德斌先生	4/4
Mrs. Chan Kung Wai Ying, Amy *(Note 3)*	陳龔偉瑩女士*(附註3)*	3/3
Dr. Li Kwok Tung, Donald *(Note 4)*	李國棟醫生*(附註4)*	0/1

In addition, the Chairman held a meeting with the independent non-executive Directors without the presence of executive Directors.

此外，主席曾與獨立非執行董事舉行一次執行董事避席的會議。

Notes:

1. Ms. Cheng Chi Man was appointed as a non-executive Director with effect from 21 November 2025.
2. Dr. Lee Kar Chung, Felix ceased to be a non-executive Director with effect from 21 November 2025.
3. Mrs. Chan Kung Wai Ying, Amy was appointed as an independent non-executive Director with effect from 21 November 2025.
4. Dr. Li Kwok Tung, Donald ceased to be an independent non-executive Director with effect from 21 November 2025.

附註：

1. 鄭志雯女士由2025年11月21日起獲委任為非執行董事。
2. 李家聰博士由2025年11月21日起不再擔任非執行董事。
3. 陳龔偉瑩女士由2025年11月21日起獲委任為獨立非執行董事。
4. 李國棟醫生由2025年11月21日起不再擔任獨立非執行董事。

Notice incorporating the agenda for each regular Board meeting is given to all Directors at least 14 days in advance. For other Board meetings and Board committee meetings, reasonable notice will be given. All Directors or Board committee members are given the opportunity to include matters for discussion in the agenda. Meeting agenda and accompanying meeting papers are sent to all relevant Directors at least 3 days in advance of every regular Board meeting or committee meeting.

所有董事會常規會議通告及議程均在召開會議至少14天前送達全體董事，至於召開其他董事會會議及董事會轄下委員會會議，則予以發出合理通知。全體董事或董事會轄下委員會成員均有機會提呈商討事項列入會議議程。會議議程及隨附會議文件在舉行各董事會常規會議或委員會會議日期至少3天前送達全體相關董事。

The Company Secretary assists the Chairman of the Board and the chairmen of Board committees in preparing meeting agendas and ensures that the Corporate Governance Code as well as all applicable laws and regulations are duly complied with. Minutes of Board meetings and Board committee meetings are recorded in sufficient details of the matters considered and decisions reached at the relevant meetings. Draft and final versions of the minutes in respect of Board meetings and Board committee meetings are sent to all Directors or Board committee members respectively for comment and records within a reasonable time after the relevant meetings. All minutes are properly kept by the Company Secretary and are available for the Directors' and Board committee members' inspection.

公司秘書協助董事會主席及各董事會轄下委員會主席編製會議議程，並確保妥為遵守企業管治守則及所有適用的法例及規例。董事會會議及董事會轄下委員會會議上所考慮的事宜及達致的決定均會詳細記錄於會議紀錄內。董事會會議及董事會轄下委員會會議紀錄的初稿及最終定稿於會議後一段合理時間內先後發送全體董事或董事會轄下委員會成員，初稿供董事或董事會轄下委員會成員給予意見，最終定稿供其存檔之用。所有會議紀錄由公司秘書備存，以供各董事或董事會轄下委員會成員查閱。

All Directors are entitled to have access to timely information in relation to the Company's business and make further enquiries or retain independent professional advisors where necessary. The management provides all relevant explanation and information to the Board so as to give the Board the information it needs to discharge its responsibilities. During FY2026, the management has provided all members of the Board with adequate information giving a balanced and understandable assessment of the Company's performance, position and prospects.

所有董事均可以適時掌握本公司業務資料，並在需要時作進一步查詢或尋求獨立專業意見。管理層會向董事會提供所有相關說明及資料，給予董事會相關資料以助其履行職責。於2026財政年度，管理層已向董事會全體成員提供足夠資訊，載列有關本公司的表現、狀況及前景的公正及易於理解的評估。

GENERAL MEETINGS

During FY2026, the Company has convened and held one annual general meeting ("AGM") and one extraordinary general meeting ("EGM"). Attendance records of the Directors at the general meetings are set out as follows:

股東大會

於2026財政年度內，本公司已召開及舉行一次股東週年大會(「股東週年大會」)及一次股東特別大會(「股東特別大會」)。董事於股東大會的出席紀錄載列如下：

Name of Directors	董事姓名	Number of meeting attended/held 出席／舉行會議次數 AGM 股東週年大會	EGM 股東特別大會
Executive Directors	*執行董事*		
Dr. Sun Yiu Kwong *(Chairman)*	孫耀江醫生*(主席)*	1/1	1/1
Dr. Sun Man Kin, Michael *(Vice Chairman and Co-Chief Executive Officer)*	孫文堅醫生*(副主席兼聯席行政總裁)*	1/1	1/1
Ms. Kwok Cheuk Kwan, Jacquen *(Co-Chief Executive Officer)*	郭卓君女士*(聯席行政總裁)*	1/1	1/1
Mr. Tsang On Yip, Patrick	曾安業先生	0/1	0/1
Dr. Lee Pak Cheung, Patrick	李柏祥醫生	1/1	1/1
Non-executive Directors	*非執行董事*		
Ms. Cheng Chi Man *(Note 1)*	鄭志雯女士*(附註1)*	0/0	0/1
Dr. Lee Kar Chung, Felix *(Note 2)*	李家聰博士*(附註2)*	0/1	0/0
Independent Non-executive Directors	*獨立非執行董事*		
Mr. Lee Luen Wai, John	李聯偉先生	1/1	1/1
Mr. Yeung Tak Bun	楊德斌先生	1/1	1/1
Mrs. Chan Kung Wai Ying, Amy *(Note 3)*	陳龔偉瑩女士*(附註3)*	0/0	1/1
Dr. Li Kwok Tung, Donald *(Note 4)*	李國棟醫生*(附註4)*	0/1	0/0

Notes:

1. Ms. Cheng Chi Man was appointed as a non-executive Director with effect from 21 November 2025.
2. Dr. Lee Kar Chung, Felix ceased to be a non-executive Director with effect from 21 November 2025.
3. Mrs. Chan Kung Wai Ying, Amy was appointed as an independent non-executive Director with effect from 21 November 2025.
4. Dr. Li Kwok Tung, Donald ceased to be an independent non-executive Director with effect from 21 November 2025.

附註：

1. 鄭志雯女士由2025年11月21日起獲委任為非執行董事。
2. 李家聰博士由2025年11月21日起不再擔任非執行董事。
3. 陳龔偉瑩女士由2025年11月21日起獲委任為獨立非執行董事。
4. 李國棟醫生由2025年11月21日起不再擔任獨立非執行董事。

Directors' Appointment, Re-election and Removal

Each of the executive Directors has entered into a service contract with the Company for a term of three years subject to the provision of retirement and rotation of Directors under the Articles and the provision under the service contract.

Ms. Cheng Chi Man has entered into a letter of appointment with the Company for a term of one year commencing from the date of her appointment, which term shall be automatically renewable for successive terms of one year. She is subject to retirement by rotation in accordance with the Articles and the provision under her letter of appointment.

Mr. Lee Luen Wai, John has entered into a letter of appointment with the Company for a term of three years commencing on the date of his appointment. Thereafter, the appointment is renewable automatically for successive terms of one year. Mr. Yeung Tak Bun and Mrs. Chan Kung Wai Ying, Amy have each entered into a letter of appointment with the Company as an independent non-executive Director for a term of one year commencing from the date of his or her appointment, which term shall be automatically renewable for successive terms of one year. All independent non-executive Directors are subject to the provision of retirement and rotation of Directors under the Articles and the provision under their letters of appointment.

The Articles provide that each Director is subject to retirement from office by rotation and re-election once every three years and that one-third (or the number nearest to but not less than one-third) of the Directors shall retire from office every year at the annual general meeting. Any Director appointed by the Board to fill a casual vacancy shall hold office until the first general meeting after his appointment and be subject to re-election at such meeting while any Director appointed by the Board as additional Director shall be subject to re-election at the next following annual general meeting.

董事的委任、重選及罷免

執行董事已各自與本公司訂立服務合約，為期三年，並須遵守細則所載有關董事輪值退任的條文及服務合約內的條文。

鄭志雯女士已與本公司訂立委任函，任期為自委任日期起計一年。其後，任期將自動重續，每次重續一年，彼須根據細則及委任函內的條文輪值退任。

李聯偉先生已與本公司訂立委任函，任期為自委任日期起計三年。其後，任期將自動重續，每次重續一年。楊德斌先生與陳龔偉瑩女士已各自與本公司訂立有關擔任獨立非執行董事的委任函，任期為自委任日期起計一年，並可自動續期，每次重續一年。所有獨立非執行董事須遵守細則所載有關董事輪值退任的條文及委任函內的條文。

細則規定，各董事須每三年輪值告退一次惟可重選連任，每年為數三分之一(或最接近但不少於三分之一人數)的董事須於股東週年大會上退任。由董事會委任以填補臨時空缺的任何董事，其任期直至其獲委任後的首屆股東大會為止，並須於該大會上重選連任，而由董事會委任的任何新增董事須於下屆股東週年大會上重選連任。

Directors' Training and Professional Development

Every Director keeps abreast of responsibilities as a Director and of the conduct, business activities and development of the Company. Every newly appointed Director receives a comprehensive, formal and tailored induction package covering the statutory and regulatory obligations of Directors, organizational structure, policies, procedures and codes of the Company, terms of reference of board committees and charter of responsibilities of internal audit. The Directors are encouraged to attend seminars and conferences to enrich their knowledge in discharging their duties as a director. The Company Secretary from time to time updates and provides written training materials to the Directors, and organizes seminars on the latest development of the Listing Rules, applicable laws, rules and regulations relating to Directors' duties and responsibilities.

The Company Secretary maintains records of trainings received by the Directors. During FY2026, the Company engaged The Hong Kong Institute of Directors to provide a three-hour online Board Training Programme. Each of the current Directors participated in the Board Training Programme in compliance with the continuous professional development requirements under Rules 3.09F and 3.09G of the Listing Rules.

董事培訓及專業發展

各董事充分了解作為董事的職責以及本公司的經營方式、業務活動及發展。各新委任董事均獲得一份全面、正式及訂製的就任啟導，內容包括董事的法定及監管責任、本公司的組織架構、政策、程序及守則、董事會轄下委員會的職權範圍，以及內部審計責任的憲章。本公司鼓勵董事參加研討會和會議，以豐富董事在履行其職責方面的知識。公司秘書不時向董事更新並提供書面培訓資料，並就有關上市規則最近發展以及適用於董事職務及職責的法例、規則及監管規例等專題舉辦研討會。

公司秘書備存董事接受培訓的紀錄。於2026財政年度，本公司已委聘香港董事學會提供三小時網上董事會培訓課程。各現任董事均已參與董事會培訓課程，以符合上市規則第3.09F條及3.09G條項下的持續專業發展要求。

The trainings received by the current Directors during FY2026 are as follows:

各董事於2026財政年度接受的培訓情況概要載列如下：

Name of Directors	董事名稱	Training Topics [Note] 培訓主題[附註]
Executive Directors	*執行董事*	
Dr. Sun Yiu Kwong *(Chairman)*	孫耀江醫生*(主席)*	✓
Dr. Sun Man Kin, Michael *(Vice Chairman and Co-Chief Executive Officer)*	孫文堅醫生 *(副主席兼聯席行政總裁)*	✓
Ms. Kwok Cheuk Kwan, Jacquen *(Co-Chief Executive Officer)*	郭卓君女士 *(聯席行政總裁)*	✓
Mr. Tsang On Yip, Patrick	曾安業先生	✓
Dr. Lee Pak Cheung, Patrick	李柏祥醫生	✓
Non-Executive Director	*非執行董事*	
Ms. Cheng Chi Man	鄭志雯女士	✓
Independent Non-executive Directors	*獨立非執行董事*	
Mr. Lee Luen Wai, John	李聯偉先生	✓
Mr. Yeung Tak Bun	楊德斌先生	✓
Mrs. Chan Kung Wai Ying, Amy	陳龔偉瑩女士	✓

Mrs. Chan Kung Wai Ying, Amy was appointed as an independent non-executive Director on 21 November 2025 and is a first-time director under Rule 3.09H of the Listing Rules. She is undertaking the director training and has completed 7 hours of training during FY2026.

陳龔偉瑩女士已於2025年11月21日獲委任為獨立非執行董事，並屬上市規則第3.09H條項下的首次董事。彼現正接受董事培訓，並已於2026財政年度完成7小時培訓。

Note:

The Board Training Programme covered the following topics:

(i) Roles, functions and responsibilities of the board, its committees and its directors, and board effectiveness

(ii) Issuers' obligations and directors' duties and key regulatory developments

(iii) Corporate governance and ESG matters

(iv) Risk management and internal controls

(v) Updates on industry specific developments, business trends and strategies

附註：

董事會培訓計劃涵蓋以下主題：

(i) 董事會、其委員會及其董事的角色、職能及責任，以及董事會效率

(ii) 發行人義務及董事職責，以及主要監管發展

(iii) 企業管治及環境、社會及管治事宜

(iv) 風險管理及內部監控

(v) 行業特定發展、業務趨勢及策略的最新資訊

Directors' and officers' Liabilities Insurance

The Company has arranged appropriate directors' and officers' liabilities insurance coverage for the Directors and officers of the Company.

董事及高級人員責任險

本公司已為董事及本公司高級人員投保適當的董事及高級人員責任險。

CODES FOR DEALING IN THE COMPANY'S SECURITIES

The Company has adopted the Model Code as its own code for dealings in the Company's securities by the Directors.

Having made specific enquiry with all Directors, the Company confirmed that the Directors have complied with the Model Code during FY2026.

Relevant employees who are likely to be in possession of inside information of the Group are also subject to compliance with the Code of Conduct for Securities Transactions by Employees on terms that are no less exacting than those set out in the Model Code. To the best knowledge of the Company, there was no incident of non-compliance of the Code of Conduct for Securities Transactions by Employees during FY2026.

買賣本公司證券的守則

本公司已採納標準守則作為董事買賣本公司證券的守則。

經對全體董事作出特定查詢後，本公司確認董事已於2026財政年度遵守標準守則。

可能知悉本集團內幕消息的有關僱員亦須遵守僱員進行證券交易的操守準則，其條款不遜於標準守則所訂標準。就本公司所知，2026財政年度並無出現違反僱員進行證券交易的操守準則的情況。

BOARD COMMITTEES

Remuneration Committee

The Company has established its Remuneration Committee with written terms of reference, which is available at the Company's website at www.ump.com.hk and the Stock Exchange's website at www.hkexnews.hk.

董事會轄下委員會

薪酬委員會

本公司已成立薪酬委員會並制定其書面職權範圍，可於本公司網站(www.ump.com.hk)及聯交所網站(www.hkexnews.hk)瀏覽。

The Remuneration Committee is responsible for making recommendations to the Board on the Company's policy and structure for all Directors' and senior management's remuneration and on the establishment of a formal and transparent procedure for developing such remuneration policies. In arriving at its recommendations to the Board, the Remuneration Committee will consider salaries paid by comparable companies, time commitment and responsibilities and employment conditions elsewhere in the Group. The Committee either determines or makes recommendations to the Board on the remuneration package of individual executive Directors and senior management, and it also makes recommendations to the Board on the remuneration of non-executive Directors. The Remuneration Committee meets at least twice a year and is provided with sufficient resources enabling it to discharge its duties.

薪酬委員會負責就本公司全體董事及高級管理層的薪酬政策及架構，及就設立正規及具透明度的程序制定薪酬政策，向董事會提交建議。薪酬委員會在達致其提供予董事會的建議時，會考慮同類公司支付的薪金、董事及管理層付出的時間及職責及本集團內其他職位的僱用條件。委員會釐定或就個別執行董事及高級管理人員的薪酬待遇向董事會提交建議，亦就非執行董事的薪酬向董事會提交建議。薪酬委員會每年最少舉行兩次會議並獲提供充足資源以履行其職責。

The Remuneration Committee currently comprises three members, including two independent non-executive Directors, namely Mr. Lee Luen Wai, John and Mrs. Chan Kung Wai Ying, Amy, and an executive Director, namely Mr. Tsang On Yip, Patrick. Mr. Lee Luen Wai, John serves as the chairman of the Remuneration Committee. The composition of the Remuneration Committee meets the requirements of chairmanship and independence of the Listing Rules.

薪酬委員會現由三名成員組成，包括兩名獨立非執行董事李聯偉先生及陳龔偉瑩女士及執行董事曾安業先生。李聯偉先生擔任薪酬委員會主席。薪酬委員會的組成符合上市規則中主席和獨立性的規定。

During FY2026, the Remuneration Committee had performed the following works:

於2026財政年度，薪酬委員會已履行以下事務：

- determined and reviewed the remuneration policy of the executive Directors;
- 訂定並審議執行董事的薪酬政策；
- made recommendations to the Board on the remuneration packages (including the granting of share awards) of individual executive Directors and senior management;
- 就個別執行董事及高級管理人員的薪酬待遇(包括股份獎勵的授予)向董事會作出建議；
- made recommendations to the Board on the director's fee for the appointment of Ms. Cheng Chi Man as non-executive Director; and
- 就委任鄭志雯女士為非執行董事後的董事袍金向董事會作出建議；及
- made recommendations to the Board on the director's fee for the appointment of Mrs. Chan Kung Wai Ying, Amy as independent non-executive Director.
- 就委任陳龔偉瑩女士為獨立非執行董事後的董事袍金向董事會作出建議。

The attendance records of the committee members to committee meeting(s) are set out below:

委員會成員出席委員會會議的紀錄載列如下：

Remuneration Committee Members	薪酬委員會成員	Meeting(s) Attended/Held 出席／舉行會議次數
Mr. Lee Luen Wai, John *(Chairman) (Note 1)*	李聯偉先生*(主席)(附註1)*	3/3
Mr. Tsang On Yip, Patrick	曾安業先生	3/3
Mrs. Chan Kung Wai Ying, Amy *(Note 2)*	陳龔偉瑩女士*(附註2)*	1/1
Dr. Li Kwok Tung, Donald *(Chairman) (Note 3)*	李國棟醫生*(主席)(附註3)*	0/2

Notes:

1. Mr. Lee Luen Wai, John was redesignated as the chairman of the Remuneration Committee with effect from 21 November 2025.
2. Mrs. Chan Kung Wai Ying, Amy was appointed as a member of the Remuneration Committee with effect from 21 November 2025.
3. Dr. Li Kwok Tung, Donald ceased to be the chairman of the Remuneration Committee with effect from 21 November 2025.

附註：

1. 李聯偉先生自2025年11月21日起獲調任為薪酬委員會主席。
2. 陳龔偉瑩女士由2025年11月21日起獲委任為薪酬委員會成員。
3. 李國棟醫生由2025年11月21日起不再擔任薪酬委員會主席。

Details of Directors' emoluments for the year are disclosed in note 9 to the consolidated financial statements.

年內的董事薪酬詳情於綜合財務報表附註9披露。

Nomination Committee

The Company has established its Nomination Committee with written terms of reference, which is available at the Company's website at www.ump.com.hk and the Stock Exchange's website at www.hkexnews.hk.

提名委員會

本公司已成立提名委員會並制定其書面職權範圍，可於本公司網站(www.ump.com.hk)及聯交所網站(www.hkexnews.hk)瀏覽。

The Nomination Committee is responsible for regularly reviewing the structure, size and diversity of the Board and making recommendations to the Board on any proposed changes to complement the Company's corporate strategy. Its duties include making recommendations to the Board on the selection of individuals nominated for directorships, the appointment or re-appointment of Directors and succession planning for Directors, reviewing the leadership needs of the Company to ensure the continued ability of the Company to compete effectively. The Committee is also responsible for assessing the independence of independent non-executive Directors and reviewing their annual confirmations on independence. The Nomination Committee meets at least once a year and is provided with sufficient resources to perform its duties.

提名委員會負責定期檢討董事會的架構、規模及多元性，並就任何為配合本公司企業策略而擬作出的變動向董事會提交建議。其職責包括就甄選獲提名人士出任董事、董事委任或重新委任以及董事繼任計劃，向董事會提交建議，並檢視本公司的領導需要，以確保本公司持續有能力有效競爭。委員會亦負責評估獨立非執行董事的獨立性，並審閱彼等就獨立性提交的年度確認書。提名委員會每年最少舉行一次會議並獲提供充足資源以履行其職責。

The Nomination Committee currently comprises five members, including three independent non-executive Directors, namely Mr. Lee Luen Wai, John, Mr. Yeung Tak Bun and Mrs. Chan Kung Wai Ying, Amy, and two executive Directors, namely Dr. Sun Yiu Kwong and Ms. Kwok Cheuk Kwan, Jacquen. Dr. Sun Yiu Kwong serves as the chairman of the Nomination Committee. The composition of the Nomination Committee meets the requirements of chairmanship and independence of the Listing Rules.

提名委員會現由五名成員組成，包括三名獨立非執行董事李聯偉先生、楊德斌先生及陳龔偉瑩女士，及兩名執行董事孫耀江醫生及郭卓君女士。孫耀江醫生擔任提名委員會主席。提名委員會的組成符合上市規則中主席和獨立性的規定。

During FY2026, the Nomination Committee had performed the following works:

於2026財政年度，提名委員會已履行以下事務：

- reviewed the current structure, size and composition of the Board;
- 檢討董事會的現行架構、規模及組成；
- assessed the independence of independent non-executive Directors;
- 評估獨立非執行董事的獨立性；
- made recommendations to the Board on the re-appointment of Directors;
- 就董事的重新委任向董事會作出建議；
- reviewed the current board diversity policy;
- 檢討現行董事會成員多元化政策；
- made recommendations to the Board on the appointment of Ms. Cheng Chi Man as non-executive Director;
- 就委任鄭志雯女士為非執行董事向董事會作出建議；
- made recommendations to the Board on the appointment of Mrs. Chan Kung Wai Ying, Amy as independent non-executive Director; and
- 就委任陳龔偉瑩女士為獨立非執行董事向董事會作出建議；及
- made recommendations to the Board on changes to the composition of the Board committees.
- 就董事會轄下委員會的組成變動向董事會作出建議。

The Board adopted the policy of the nomination of Directors in December 2018 (the "Director Nomination Policy"). Pursuant to the Director Nomination Policy, the nomination committee of the Board shall nominate suitable candidates to the Board for it to consider and make recommendations to Shareholders for election as directors at general meetings of the Company or to appoint as Directors to fill casual vacancies or as an addition to the existing Board, for details of which, please refer to the Company's website at www.ump.com.hk.

董事會於2018年12月採納董事提名政策(「董事提名政策」)。根據董事提名政策，董事會轄下提名委員會須向董事會提名適合人選供其考慮，並就於本公司股東大會上選舉或委任董事以填補臨時空缺或作為現董事會的增補向股東作出推薦建議。詳情請參閱本公司網站www.ump.com.hk。

During the year, the Board reviewed the overall contribution and service to the Company, expertise and professional qualifications of the retiring Directors and recommended them to be re-elected at the Company's forthcoming annual general meeting.

年內，董事會已審閱退任董事對本公司的整體貢獻及服務、彼等的專業知識及專業資格，並建議彼等於本公司的應屆股東週年大會上膺選連任。

The attendance records of the committee members to committee meeting(s) are set out below:

委員會成員出席委員會會議的紀錄載列如下：

Nomination Committee Members	提名委員會成員	Meeting(s) Attended/Held 出席／舉行會議次數
Dr. Sun Yiu Kwong *(Chairman)*	孫耀江醫生*(主席)*	2/2
Ms. Kwok Cheuk Kwan, Jacquen	郭卓君女士	2/2
Mr. Lee Luen Wai, John	李聯偉先生	2/2
Mr. Yeung Tak Bun	楊德斌先生	2/2
Mrs. Chan Kung Wai Ying, Amy *(Note 1)*	陳龔偉瑩女士*(附註1)*	0/0
Dr. Li Kwok Tung, Donald *(Note 2)*	李國棟醫生*(附註2)*	0/2

Notes:

1. Mrs. Chan Kung Wai Ying, Amy was appointed as a member of the Nomination Committee with effect from 21 November 2025.
2. Dr. Li Kwok Tung, Donald ceased to be a member of the Nomination Committee with effect from 21 November 2025.

附註：

1. 陳龔偉瑩女士由2025年11月21日起獲委任為提名委員會成員。
2. 李國棟醫生由2025年11月21日起不再擔任提名委員會成員。

Audit Committee

The Company has established its Audit Committee with written terms of reference, which is available at the Company's website at www.ump.com.hk and the Stock Exchange's website at www.hkexnews.hk.

The Audit Committee reports to the Board and holds regular meetings to assist the Board in discharging its responsibilities for effective financial reporting controls, internal controls and risk management. The Committee monitors the integrity of the Company's financial statements, annual report and accounts and half-year report and reviews significant financial reporting judgments contained in them. It reviews, makes recommendations and reports to the Board on findings relating to the financial statements, reports and accounts, systems of internal control and risk management and compliance issues on an annual basis. The Audit Committee also oversees the Company's relationship with the external auditor, reviews auditor's letter of engagement and makes recommendations to the Board on the appointment and re-appointment of external auditor. It is empowered to review and monitor the external auditor's independence and objectivity and the effectiveness of the audit process in accordance with applicable standards. It reviews external auditor's management letter and any material queries raised by the auditor to the management and the management's response. The Committee meets at least twice a year and is provided with sufficient resources enabling it to discharge its duties.

審核委員會

本公司已成立審核委員會並制定其書面職權範圍，可於本公司網站(www.ump.com.hk)及聯交所網站(www.hkexnews.hk)瀏覽。

審核委員會向董事會匯報，並定期舉行會議，協助董事會履行其職責，確保財務匯報監控、內部監控及風險管理行之有效。委員會監察本公司的財務報表、年度報告及賬目以及半年度報告的完整性，並審閱其中所載有關財務申報的重大意見。其按年檢討有關財務報表、報告及賬目、內部監控及風險管理系統，以及合規事宜的結果，並就此向董事會提交建議及報告。審核委員會亦監察本公司與外聘核數師的關係、檢討核數師的委聘書，並就外聘核數師的委任及重新委任向董事會提交建議。其獲授權檢討及監察外聘核數師是否獨立客觀，以及審核程序根據適用準則是否有效。其亦檢討外聘核數師給予管理層的《審核情況說明函件》及核數師向管理層提出的任何重大疑問，以及管理層作出的回應。委員會每年最少舉行兩次會議並獲提供充足資源以履行其職責。

The Audit Committee currently comprises three members, all of whom are independent non-executive Directors, namely Mr. Lee Luen Wai, John, Mr. Yeung Tak Bun and Mrs. Chan Kung Wai Ying, Amy. Mr. Lee Luen Wai, John serves as the chairman of the Audit Committee. The composition of the Audit Committee meets the requirements of chairmanship and independence of the Listing Rules.

審核委員會現由三名成員組成，全部成員均為獨立非執行董事，分別為李聯偉先生、楊德斌先生及陳龔偉瑩女士。李聯偉先生擔任審核委員會主席。審核委員會的組成符合上市規則中主席和獨立性的規定。

During FY2026, the Audit Committee had performed the following works:

於2026財政年度，審核委員會已履行以下事務：

- reviewed the interim and annual financial statements and made recommendation to the Board;
- 審閱中期及年度財務報表並向董事會提交建議；
- reviewed the annual caps on continuing connected transactions of the Company;
- 檢討本公司持續關連交易年度上限；
- reviewed the remuneration, terms of engagement and the independence of the external auditor and considered the re-appointment of the external auditor;
- 檢討外聘核數師的薪酬、委聘條款及獨立性，並考慮續聘外聘核數師；
- reviewed the arrangements for raising concerns about possible improprieties in financial reporting, internal control or other matters; and
- 檢討有關財務申報、內部監控或其他事項中的可能發生不正當行為提出關注的安排；及
- reviewed the Group's financial controls, risk management and internal control systems and the effectiveness, adequacy of resources and competency.
- 檢討本集團的財務監控、風險管理及內部監控系統以及有效性、資源充足性及能力。

The attendance records of the committee members to committee meeting(s) are set out below:

委員會成員出席委員會會議的紀錄載列如下：

Audit Committee Members	審核委員會成員	Meeting(s) Attended/Held 出席／舉行會議次數
Mr. Lee Luen Wai, John *(Chairman)*	李聯偉先生*(主席)*	3/3
Mr. Yeung Tak Bun	楊德斌先生	2/3
Mrs. Chan Kung Wai Ying, Amy *(Note 1)*	陳龔偉瑩女士*(附註1)*	2/2
Dr. Li Kwok Tung, Donald *(Note 2)*	李國棟醫生*(附註2)*	1/1

Notes:

1. Mrs. Chan Kung Wai Ying, Amy was appointed as a member of the Audit Committee with effect from 21 November 2025.
2. Dr. Li Kwok Tung, Donald ceased to be a member of the Audit Committee with effect from 21 November 2025.

附註：

1. 陳龔偉瑩女士由2025年11月21日起獲委任為審核委員會成員。
2. 李國棟醫生由2025年11月21日起不再擔任審核委員會成員。

DIRECTORS' RESPONSIBILITIES FOR FINANCIAL STATEMENTS

The Board is responsible for the preparation of the financial statements which should give a true and fair view of the state of affairs of the Group and of the financial performance and cash flows for such reporting period. In preparing the financial statements, the Board has adopted generally accepted accounting standards in Hong Kong and suitable accounting policies and applied them consistently, made judgments and estimates that are prudent, fair and reasonable, and prepared the financial statements on a going concern basis. The Board is responsible for ensuring that the Group keeps proper accounting records which disclose with reasonable accuracy at any time the financial position of the Group.

董事對財務報表的責任

董事會負責編製財務報表，財務報表應真實及公平地反映本集團於該報告期內的業務狀況、財務表現及現金流量。於編製財務報表時，董事會已採納並貫徹應用香港公認會計準則及適當的會計政策，作出審慎、公平及合理的判斷及估計，並按持續經營基準編製財務報表。董事會負責確保本集團時常保存妥善的會計紀錄，以於任何時候合理準確披露本集團的財務狀況。

The Board is not aware of any material uncertainties relating to events or conditions which may cast significant doubt over the Group's ability to continue as a going concern. Accordingly, the Board has continued to adopt the going concern basis in preparing the financial statements.

董事會並不知悉與可能對本集團持續經營能力構成重大疑慮之事件或情況有關之任何重大不明朗因素。因此，董事會編製財務報表時已繼續採用持續經營基準。

The auditor is responsible for auditing and reporting its opinion on the financial statements of the Group and the independent auditor's report for FY2026 is set out in the section headed "Independent Auditor's Report" of this annual report.

核數師負責審核本集團的財務報表及匯報其意見，2026財政年度的獨立核數師報告載於本年報「獨立核數師報告」一節內。

DIVIDENDS POLICY

The Board has approved and adopted a dividend policy (the "Dividend Policy"). The Company is endeavor to maintain sufficient operating capital to develop and operate the Group's business, and to provide stable and sustainable returns to the Shareholders.

According to Dividend Policy, in considering the declaration and payment of dividends, the Board should take into account the following factors:

- financial results;
- cash flow situation;
- business conditions and strategies;
- future operations and earnings;
- capital requirements and expenditure plans;
- interests of shareholders;
- any restrictions on payment of dividend; and
- any other factors that the Board may consider relevant.

The Board will also constantly review the Dividend Policy and reserve the discretion to update, revise, modify and/or cancel the Dividend Policy at any time. The Dividend will not in any way constitute a legally binding commitment of the Group in relation to its future dividends and/or will not in any way render the Company obligated to declare dividends at any time or from time to time.

The Board confirmed that all dividend decisions made during FY2026 were made in accordance with the Company's dividend policy.

股息政策

董事會已批准及採納一項股息政策(「股息政策」)。本公司致力維持充足營運資金以發展及經營本集團的業務，並為股東帶來穩定及可持續的回報。

根據股息政策，在考慮宣派及派付股息時，董事會需考慮以下因素：

- 財務業績；
- 現金流狀況；
- 業務狀況及策略；
- 未來營運及盈利；
- 資金需求及支出計劃；
- 股東的利益；
- 任何派付股息的限制；及
- 董事會可能視為相關的任何其他因素。

董事會亦將持續檢討股息政策，並保留酌情權以隨時更新、修改、修訂及／或撤銷股息政策。股息將不會以任何方式構成本集團一項有關其未來股息的具法律約束力承諾及／或將不會以任何方式令本公司負有責任須於任何時間或不時宣派股息。

董事會確認，2026財政年度作出的所有股息決策均符合本公司的股息政策。

INTERNAL CONTROL AND RISK MANAGEMENT

The Board acknowledged its responsibility for the risk management and internal control systems and overseeing their effectiveness. Such systems are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable and not absolute assurance against material misstatement or loss.

The Company has developed and adopted various risk management procedures and controls with defined authority for implementation by key business processes and office functions, including clinic chain operations, business development, financial reporting, human resources, information technology and handling and dissemination of inside information.

All departments conducted internal control assessment regularly to identify risks that potentially impact the business of the Group and various aspects including key operational and financial processes, regulatory compliance and information security.

The management, in coordination with department heads, assessed the likelihood of risk occurrence, provide management plans, and monitor the risk management progress, and reported to the Audit Committee and the Board on all findings and the effectiveness of the systems. The internal audit department is responsible for providing the internal audit function and performing independent review of the adequacy and effectiveness of the risk management and internal control systems.

內部監控及風險管理

董事會承認其須對風險管理及內部監控系統負責，並有責任監察其有效性。有關系統旨在管理而非消除未能達致業務目標的風險，並僅可就重大的失實陳述或損失提供合理而非絕對的保證。

本公司已發展及採納多項風險管理程序及監控連同清晰授權，以執行主要業務程序及辦公室職能，包括診所連鎖經營、業務發展、財務申報、人力資源、資訊科技以及處理及發佈內幕消息。

所有部門定期進行內部監控評估，以識別對本集團業務及多個範疇(包括主要營運及財務程序、監管合規、信息安全)構成潛在影響的風險。

管理層與部門主管互相協調，評估出現風險的可能性、提供管理計劃及監督風險管理進度，並向審核委員會及董事會匯報一切評估結果及有關系統的成效。內部審計部門負責提供內部審計職能以及對風險管理及內部監控系統的充足性及有效性進行獨立審閱。

The key elements of the Group's risk management and internal control structure are as follows:

- well-defined organizational structure with appropriate segregation of duties, limit of authority, reporting lines and responsibilities to minimize risk of errors and abuse;
- establish written policies and procedures for major functions and operations;
- important business functions or activities are managed by experienced, qualified and suitably trained staff;
- continuous monitoring of the market developments, key operating data and performance indicators, timely and up-to-date business and financial reporting, immediate strategic actions are taken where necessary; and
- internal audit function to perform independent appraisal of major operations on an ongoing basis.

A risk-based approach is adopted to ensure that a logistic coverage of the Group's operations and resources are focused on high risk areas. The internal audit function takes the lead to evaluate the risk management and internal control systems of the Group by reviewing the major operations of the Group covering all material controls including financial, operational, compliance controls and risk management, as a separate line of defence. Audit plan for the forthcoming year will be assessed and prioritised according to risk level or impact changes.

Review results and recommendations in the form of written reports are submitted to the Audit Committee for discussion and review. Follow up actions will be taken up by the relevant departments to ensure that findings previously identified have been properly resolved.

In addition, as part of the annual statutory audit, the external auditor considers internal controls relevant to the preparation of the Group's financial statements and communicates any significant control deficiencies identified, if any, to the Audit Committee and the Board.

本集團風險管理及內部監控架構的主要元素如下：

- 明確界定的組織架構，擁有適當的職責區分、限制權力、報告系統及在最大程度減低失誤及濫權風險的責任；
- 已就主要職能及運作制訂書面政策及程序；
- 重要業務職能或活動均由富經驗、具有資格及合適的經培訓人員管理；
- 持續監察市場發展、主要營運數據及業績指標，及時更新業務及財務報告以及在需要時採取即時策略行動；及
- 設立內部審計職能，以持續對主要營運進行獨立評估。

已採納風險為本的方法以確保本集團運作及資源的後勤保障涵蓋高風險範圍。內部審計職能作為獨立防線，領導檢討本集團主要營運以評估本集團風險管理及內部監控系統的工作。檢討涵蓋所有主要控制，包括財務、營運、合規控制以及風險管理。將根據風險等級或影響的變化，評估並優先考慮來年的審計計劃。

檢討結果及建議會以書面報告形式向審核委員會提交以供討論及審閱。後續行動將由相關部門跟進，以確保過去識別的風險問題均已獲妥善處理。

此外，作為法定年度審計的一部分，外聘核數師會考慮與本集團編製財務報表相關的內部監控，並向審核委員會及董事會傳達任何已識別的重大監控缺陷（如有）。

The Company also established a procedure to facilitate employees of the Company to raise, in confidence, concerns about possible improprieties in financial reporting, internal control or other matters of the Company

本公司亦設立程序以便本公司僱員保密提出有關本公司財務申報、內部監控或其他事宜中出現可能發生不正當行為的問題。

During FY2026, the Board, in conjunction with the Audit Committee, conducted a review of the risk assessment and the internal control system of the Group, including the adequacy of resources, staff qualifications and experience, training programmes and budget of the Company's accounting, internal audit and financial reporting function, as well as those relating to the Group's ESG performance and reporting. The Board considered that the Group's risk management and internal control systems for FY2026 was effective and appropriate and no significant control failure has been identified.

於2026財政年度，董事會聯同審核委員會檢視本集團的風險評估及內部監控系統，包括本公司在會計、內部審計及財務匯報職能方面以及與本集團的環境、社會及管治表現及匯報有關的資源、員工資歷及經驗，以及員工所接受的培訓課程及有關預算是否充足。董事會認為本集團於2026財政年度的風險管理及內部監控制度屬有效合適，並無發現任何重大監控失效情況。

AUDITOR'S REMUNERATION

The fees in respect of audit and non-audit services provided to the Company and its subsidiaries by KPMG, the auditor of the Company for FY2026 are set out below:

核數師酬金

於2026財政年度，本公司核數師畢馬威會計師事務所向本公司及其附屬公司提供核數和非核數服務的酬金載列如下：

		HK$'000 千港元
Audit service	核數服務	2,482
Non-audit services	非核數服務	175
		2,657

SHAREHOLDERS' RIGHTS

Convening an extraordinary General Meeting

Article 58 of the Articles of the Company provides that any one or more members of the Company holding at the date of deposit of the requisition not less than one-tenth of the paid up capital of the Company carrying the right of voting at general meetings of the Company shall at all times have the right, by written requisition to the Board or the Company Secretary, to require an extraordinary general meeting to be called by the Board for the transaction of any business specified in such requisition; and such meeting shall be held within 2 months after the deposit of such requisition. If within 21 days of such deposit the Board fails to proceed to convene such meeting, the requisitionist(s) himself (themselves) may do so in the same manner, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to the requisitionist(s) by the Company.

股東權利

召開股東特別大會

本公司細則第58條規定，任何一名或多名於遞呈要求日期持有不少於本公司繳足股本(附帶於本公司股東大會上的投票權)十分之一的本公司股東於任何時間均有權透過向董事會或公司秘書發出書面要求，要求董事會召開股東特別大會，以處理有關要求中指明的任何事項；且該大會應於遞呈該要求後兩個月內舉行。倘遞呈後21日內，董事會未能召開該大會，則遞呈要求人士可自行以同樣方式召開會議，而遞呈要求人士因董事會未能召開大會而合理產生的所有開支應由本公司向遞呈要求人士作出償付。

Putting Forward Proposals at General Meetings

A Shareholder may lodge a notice of his intention to propose any person (other than himself/herself) for election as a Director together with a notice signed by the person to be proposed of his/her willingness to be elected to the head office of the Company or at the registration office where the branch register of members of the Company is kept provided that the minimum length of the period, during which such notice(s) are given shall be at least 7 days and that (if the notices are submitted after the despatch of the notice of the general meeting appointed for such election) the period for lodgment of such notice(s) shall commence on the day after the despatch of the notice of the general meeting appointed for such election and end no later than 7 days prior to the date of such general meeting.

Other than the above concerning a proposal of a person for election as a Director, there are no provisions in the Articles of Association or the Companies Law of the Cayman Islands for putting forward proposals of new resolutions by Shareholders at general meetings. Shareholders may follow the procedures set out above to convene an extraordinary general meeting for any business specified in such written requisition.

於股東大會上提呈建議

股東可就其有意提名任何人士(除彼本身外)參選董事的通知以及經被提名人士簽署表明其願意接受選舉的通知，送交本公司總辦事處或本公司存置股東名冊分冊的登記處，惟提交通知的期間必須至少7天，如通知在指定舉行該選舉的股東大會的通告寄發後提交，提交通知的期間為由指定舉行該選舉的股東大會的通告發送後翌日開始，至不遲於該股東大會舉行日期前7天結束。

除上文有關提名人士參選董事的議案外，公司細則或開曼群島公司法並無有關股東於股東大會動議新決議案的條文。股東可遵照上文所載的程序就於有關書面要求列明的任何事宜召開股東特別大會。

Putting Forward Enquiries to the Board

For putting forward any enquiries to the Board, Shareholders may send written enquiries to the Company. The Company will not normally deal with verbal or anonymous enquiries.

向董事會提出查詢

股東可以書面形式向本公司寄發查詢，藉以向董事會作出任何查詢。本公司一般不會處理口頭或匿名查詢。

Contact Details

Shareholders may send their enquiries or requests as mentioned above to the following:

Address: 27th Floor
Wing On House
71 Des Voeux Road Central
Hong Kong

Fax: (852) 2511 1152
Email: ir@ump.com.hk

聯絡資料

股東可將上述的查詢或要求發送至：

地址： 香港
德輔道中71號
永安集團大廈
27樓

傳真： (852) 2511 1152
電郵： ir@ump.com.hk

For the avoidance of doubt, Shareholders must deposit and send the original duly signed written requisition, notice or statement, or enquiry (as the case may be) to the above address and provide their full name, contact details and identification in order to give effect thereto. Shareholders' information may be disclosed as required by law.

為免生疑問，股東必須將妥為簽署的書面要求、通知或聲明正本或查詢(視情況而定)遞交及寄發至上述地址，並提供其全名、聯絡資料及身份，以使其生效。股東資料可能須按法律規定予以披露。

COMMUNICATION WITH SHAREHOLDERS

The Company considers that effective communication with Shareholders is essential for enhancing investor relations and investor understanding of the Group's business performance and strategies. The Company endeavours to maintain good communication with Shareholders and in particular, through its annual general meeting and other extraordinary general meetings. At the annual general meeting, Directors (or their delegates as appropriate) are available to meet Shareholders and answer their enquiries. The Directors, Company Secretary or appropriate members of senior management, where appropriate, also respond to inquiries from Shareholders and investors on a timely basis.

與股東的溝通

本公司認為，與股東進行有效溝通，乃提升投資者關係及讓投資者了解本集團業務表現及策略的要素。本公司致力與股東維持良好溝通，尤其是透過股東週年大會及其他股東特別大會。於股東週年大會上，董事(或其代表(如適用))將會抽空與股東會面，並回答股東查詢。董事、公司秘書或高級管理層的相關成員亦會在適當情況下適時回答股東及投資者的查詢。

Under the Listing Rules, all resolutions proposed at Shareholders' meetings must be voted by poll except where the chairman of a general meeting, in good faith and in compliance with the Listing Rules, decides to allow resolutions to be voted on by the Shareholders on a show of hands. Details of the poll procedures will be explained during the proceedings of Shareholders' meetings. The poll voting results will be released and posted on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.ump.com.hk.

根據上市規則，於股東大會提呈的所有決議案均須按股數投票方式表決，惟股東大會主席以誠實信用的原則及在遵守上市規則的情況下作出決定，容許決議案由股東以舉手方式表決則除外。投票表決程序的詳情會於股東大會進行期間加以解釋。投票表決的結果會於聯交所網站(www.hkexnews.hk)及本公司網站(www.ump.com.hk)發佈及登載。

To provide effective communication, the Company maintains a website at www.ump.com.hk. All the financial information and other disclosures including, inter alia, annual reports, interim reports, announcements and Articles are available under the section of "Investors" on the Company's website.

為促進有效聯繫，本公司已設立網站www.ump.com.hk。所有財務資料以及其他披露資料(其中包括年報、中期報告、公告及細則)均可於本公司網站「投資者」一欄瀏覽。

Shareholders can direct their questions about their shareholdings to the Company's Share Registrars. To the extent the requisite information of the Company is publicly available, Shareholders and the investment community may at any time make a request for such information. Designated contacts, email addresses and enquiry lines of the Company have been provided in the "Corporate Information" section of this annual report to enable the Shareholders and the investment community to make any enquiry in respect of the Company.

股東可直接向本公司的股份過戶登記處查詢有關其股權事宜。倘要求索取的本公司資料為公開資料，股東及投資大眾可隨時索取有關資料。本公司的指定聯絡人、電郵地址及查詢電話已載於本年報「公司資料」一節內，以便股東及投資大眾提出任何有關本公司的查詢。

Shareholders can refer to the "Shareholders' Communication Policy" posted on our corporate websites for more details. The Board has reviewed the effectiveness and implementation of the Shareholders' Communication Policy and is of the view that the Shareholders' Communication Policy remained effective and has been implemented effectively.

股東可參閱公司網站上登載的「股東通訊政策」以了解更多詳情。董事會已檢討股東通訊政策的有效性及實施情況，並認為股東通訊政策至今依然有效，並已切實執行。

CONSTITUTIONAL DOCUMENTS

During FY2026, the Company has not made any changes to its memorandum and Articles of Association.

章程文件

於2026財政年度，本公司並無對其組織章程大綱及細則作出任何變更。

The Directors are pleased to present their report together with the audited consolidated financial statements for FY2026.

董事欣然呈報2026財政年度的董事會報告及經審核綜合財務報表。

PRINCIPAL ACTIVITIES

The principal activity of the Company is investment holding. Details of the principal activities of its principal subsidiaries are set out in note 1 to the consolidated financial statements.

主要業務

本公司的主要業務為投資控股。其主要附屬公司的主要業務詳情載於綜合財務報表附註1。

BUSINESS REVIEW AND OUTLOOK

A review of the business of the Group during the year and a discussion on the Group's future business development are set out in "Chairman's Statement" on pages 6 to 9 of this annual report, in "Co-CEOs' Report" on pages 10 to 14 of this annual report and in "Management Discussion and Analysis" on pages 15 to 39 of this annual report, which forms part of this report of Directors. The financial risk management objectives and policies of the Group are set out in note 45 to the consolidated financial statements. Besides, the potential risks and uncertainties faced by the Group, key relationship between the Group and its employees, customers and suppliers, the environmental policies of the Group and compliance with the relevant laws and regulations which have significant impact are set out below.

業務回顧及展望

本集團於本年度內的業務回顧及有關本集團未來業務發展的討論載於本年報第6至9頁的「主席報告」、本年報第10至14頁的「聯席行政總裁報告」及本年報第15至39頁的「管理層討論及分析」(其構成本董事會報告一部分)。本集團的財務風險管理目標及政策載於綜合財務報表附註45。此外,本集團所面臨的潛在風險及不明朗因素、本集團與僱員、客戶及供應商的主要關係、本集團的環境政策及遵守帶來重大影響的相關法律法規的情況載列於下文。

KEY RISKS AND UNCERTAINTIES

The Groups' results and operations are subject to various factors with the key risks summarised below:

主要風險及不明朗因素

本集團的業績及營運受多種因素影響,主要風險概述如下:

Strategy Risk

The current macroeconomic uncertainty and sluggish economy may cause episodic disruptions to the medical industry. Our Company must effectively and efficiently allocate resources in order to minimize the risk brought on by the uncertain economic environment. We must also continue to find new strategic angles to improve our operations and business. The sluggish economy may continue to impact global business in the near future. The Group must be prepared to continue being agile in our operations and ready to switch gears to curb any unexpected operational headwinds that might cause significant interruptions to our business. As consumer discretionary spending decreases, we need to be thoughtful about pricing and promotional strategies. At the same time, we should look for opportunities to diversify our revenue streams and create new partnerships to weather the economic downturn.

策略風險

當前宏觀經濟的不確定性以及經濟低迷均可能對醫療行業造成偶發干擾。本公司必須切實且有效地分配資源,將經濟環境的不確定性所帶來的風險降至最低。我們亦必須繼續尋找新的戰略角度,以改善我們的營運及業務。經濟低迷於未來可能會持續影響全球業務一段短時間。本集團必須做好準備,繼續保持靈活經營,並隨時做好轉向準備,以應對任何無法預料,且可能會對我們業務造成重大影響的經營阻力。隨著消費者的可自由支配支出減少,我們在定價及推銷策略上需要深思熟慮。同時,我們應該尋找機會擴闊我們的收入來源,並建立新的合作夥伴關係,以抵禦經濟衰退。

Reputation Risk

The Group's success in Hong Kong depends significantly on the recognition of its brand and reputation as a leading corporate healthcare solutions provider. However, Doctors, Dentists and Auxiliary Services Providers working in the Group may from time to time be subject to complaints, allegations or legal actions regarding the adequacy of patient care, treatment outcome and medical services provided, which may harm the business, results of operations, financial condition, brand and reputation of the Group.

Compliance Risk

The Group's business operations, Doctors, Dentists and Auxiliary Services Providers in the Group's network working in Hong Kong, Macau and Chinese Mainland are subject to extensive laws, regulations and licensing requirements, any failure to comply with such laws, regulations or licensing requirement could harm the Group's business, results of operations, financial condition, brand and reputation.

KEY RELATIONSHIPS BETWEEN THE GROUP AND ITS EMPLOYEES, CUSTOMERS AND SUPPLIERS

The Group fully understands that employees, customers and suppliers are the key to our sustainable and stable development. We are committed to establishing a close relationship with our employees, enhancing cooperation with our suppliers and providing high-quality services to our customers so as to ensure the Group's sustainable development.

ENVIRONMENTAL POLICIES

As a responsible corporation, the Group recognises the importance of good environmental stewardship. In this connection, the Group strictly adopted and implemented policies and procedures to ensure environmental protection. To the best knowledge of the Directors, the Group has complied with all the relevant laws and regulations that have a significant impact on the Group in relation to its business including health and safety, workplace conditions, employment and the environment. During FY2026, no environmental claims, lawsuits, penalties or administrative sanctions were reported to our management.

聲譽風險

本集團在香港取得成功甚為有賴其品牌及作為領先企業醫療保健服務提供者的聲譽獲得認同。然而，在本集團工作的醫生、牙醫及輔助服務提供者可能不時在照護患者的充分性、治療結果及所提供的醫療服務方面遭到投訴、指控或採取法律行動，繼而可能損害本集團的業務、經營業績、財務狀況、品牌及聲譽。

合規風險

本集團的業務經營、本集團網絡內在香港、澳門及中國內地工作的醫生、牙醫及輔助服務提供者須遵守大量法律、法規及發牌規定。若未能遵守該等法律、法規及發牌規定，可能損害本集團的業務、經營業績、財務狀況、品牌及聲譽。

本集團與僱員、客戶及供應商的主要關係

本集團充分意識到僱員、客戶和供應商是我們持續穩定發展的關鍵。我們致力與員工建立密切關係，加強與供應商合作，為客戶提供高品質的服務，從而確保本集團可持續發展。

環境政策

作為負責任企業，本集團認同良好的環境管理工作的重要性。就此，本集團嚴格採取及實施政策及程序以確保環境受到保護。就董事所深知，本集團已遵守對本集團業務方面（包括健康及安全、工作環境狀況、僱傭及環境）有重大影響的所有相關法律及法規。於2026財政年度，我們的管理層概無收到有關環保申索、訴訟、懲罰或行政處罰的匯報。

COMPLIANCE WITH LAWS AND REGULATIONS

The Group's operations are mainly carried out by the Company's subsidiaries in Hong Kong, Macau and Chinese Mainland while the Company is a holding company incorporated in the Cayman Islands with its Shares listed on the Main Board of the Stock Exchange. Our establishments and operations accordingly shall comply with relevant laws and regulations in the Cayman Islands, Hong Kong, Macau and Chinese Mainland. During FY2026, our businesses were in compliance with all the relevant laws and regulations in Cayman Islands, Hong Kong, Macau and Chinese Mainland in all material aspects.

符合法例及法規

本集團的營運主要由本公司的附屬公司於香港、澳門及中國內地進行，而本公司為於開曼群島註冊成立的控股公司，其股份於聯交所主板上市。因此，我們的企業及營運須符合開曼群島、香港、澳門及中國內地的相關法例及法規。於2026財政年度，我們的業務在各重大方面一直符合開曼群島、香港、澳門及中國內地的所有相關法例及法規。

RESULTS AND DIVIDENDS

The profit of the Group for FY2026 and the Group's financial position as at 30 June 2026 are set out in the consolidated financial statements on pages 171 to 174 of this annual report.

The Board proposed the payment of a final dividend of HK1.40 cents per Share for FY2026 (FY2025: HK1.90 cents), subject to the approval of the Shareholders at the 2026 AGM. Such proposed dividend is expected to be distributed on Friday, 8 January 2027 to the Shareholders whose names appear on the register of members of the Company on Friday, 11 December 2026.

Together with the interim dividend of HK1.4 cent per Share paid in April 2026, the total distribution of dividend by the Company for FY2026 will be HK2.80 cents per Share (FY2025: HK3.30 cents per Share).

業績及股息

本集團於2026財政年度的利潤及本集團於2026年6月30日的財務狀況載於本年報第171至174頁的綜合財務報表。

董事會建議派發2026財政年度之末期股息為每股1.40港仙（2025財政年度：1.90港仙），惟須待股東於2026年股東週年大會上批准，方可作實。該項建議股息預期於2027年1月8日（星期五）向於2026年12月11日（星期五）名列本公司股東名冊的股東派付。

連同於2026年4月派付的中期股息每股1.4港仙，本公司就2026財政年度作出的股息分派總額將為每股2.80港仙（2025財政年度：每股3.30港仙）。

CLOSURE OF REGISTER OF MEMBERS

For determining the entitlement to attend and vote at the 2026 AGM, the register of members of the Company will be closed from Tuesday, 17 November 2026 to Friday, 20 November 2026, both days inclusive, during which period no transfer of shares will be registered. In order to qualify as members entitled to attend and vote at the meeting, investors should lodge all transfers of shares accompanied by the relevant share certificates and transfer forms with the Company's branch share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Monday, 16 November 2026. The record date for attending and voting at the meeting is Friday, 20 November 2026.

暫停辦理股份過戶登記手續

為確定有權出席2026年股東週年大會並於會上投票的資格，本公司將於2026年11月17日（星期二）至2026年11月20日（星期五）（包括首尾兩天）暫停辦理股份過戶登記手續，在此期間將不會辦理股份過戶登記手續。為符合作為股東有權出席大會並於會上投票的資格，投資者應不遲於2026年11月16日（星期一）下午4時30分將所有股份過戶文件連同有關股票及過戶表格送達本公司的股份過戶登記分處卓佳證券登記有限公司（地址為香港夏慤道16號遠東金融中心17樓）辦理登記。獲確定為有權出席大會並於會上投票的記錄日期為2026年11月20日（星期五）。

For determining the entitlement to the proposed 2026 final dividend, the register of members of the Company will be closed from Thursday, 10 December 2026 to Friday, 11 December 2026 both days inclusive, during which period no transfer of shares will be registered. In order to qualify for the entitlement to the proposed final dividend, all transfers of shares accompanied by the relevant share certificates and transfer forms must be lodged with the Company's branch share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Wednesday, 9 December 2026.

為確定收取建議2026年末期股息的資格，本公司將於2026年12月10日（星期四）至2026年12月11日（星期五）（包括首尾兩天）暫停辦理股份過戶登記手續，在此期間將不會辦理股份過戶登記手續。為符合資格收取建議末期股息，所有股份過戶文件連同有關股票須不遲於2026年12月9日（星期三）下午4時30分送達本公司之股份過戶登記分處卓佳證券登記有限公司（地址為香港夏慤道16號遠東金融中心17樓）辦理登記。

CHARITABLE DONATIONS

Charitable donations made by the Group for FY2026 amounted to HK$6,300 (FY2025: HK$58,000).

慈善捐款

本集團於2026財政年度的慈善捐款為6,300港元（2025財政年度：58,000港元）。

EVENTS AFTER THE REPORTING PERIOD

There were no material subsequent events undertaken by the Company or by the Group after 30 June 2026 and up to the date of this report.

報告期後事項

於2026年6月30日後及直至本報告日期，概無重大期後事項由本公司或本集團承擔。

FINANCIAL SUMMARY

A summary of the published results and assets, liabilities and non-controlling interests of the Group for the last five financial years, as extracted from the audited financial statements and restated as appropriate, is set out on page 305. This summary does not form part of the audited financial statements.

財務概要

本集團於過去五個財政年度的已公佈業績及資產、負債及非控股權益的概要（摘錄自經審核財務報表及已適當地重列）載於第305頁。該概要並不構成經審核財務報表的一部分。

SHARE CAPITAL AND SHARE OPTIONS

Details of the movements in the share capital, share options and share awards of the Company for FY2026 are set out in notes 35, 36 and 37 to the consolidated financial statements in this annual report.

股本及購股權

本公司股本、購股權及股份獎勵於2026財政年度內的變動詳情載於本年報綜合財務報表附註35、36及37。

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Save for the purchase of shares for the share award scheme (as detailed under Note 37 to the consolidated financial statements), neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities during FY2026.

購買、出售或贖回本公司上市證券

除了就股份獎勵計劃購買股份（詳見綜合財務報表附註37）外，於2026財政年度，本公司及其任何附屬公司概無購買、出售或贖回本公司任何上市證券。

RESERVES AND DISTRIBUTABLE RESERVES

Details of the movements in the reserves of the Group for FY2026 are set out in the section headed "Consolidated Statement of Changes in Equity" of this annual report.

As at 30 June 2026, the Company's reserves available for distribution amounted to HK$487,630,000, of which HK$11,353,000 has been proposed as final dividend for FY2026.

儲備及可供分派儲備

本集團於2026財政年度的儲備變動詳情載於本年報「綜合權益變動表」一節。

於2026年6月30日，本公司的可供分派儲備為487,630,000港元，其中11,353,000港元已建議為2026財政年度的末期股息。

PROPERTY, PLANT AND EQUIPMENT

Details of the movements during the year in the Group's property, plant and equipment are set out in note 14 to the consolidated financial statements in this annual report.

物業、廠房及設備

本集團物業、廠房及設備於年內變動的詳情載於本年報綜合財務報表附註14。

BORROWINGS

During FY2026, the Group did not have any bank borrowings or entering into any bank loan facility and as at 30 June 2026, the Group had no outstanding bank loans, other borrowings or indebtedness.

借款

於2026財政年度，本集團並無任何銀行借款或訂立任何銀行貸款融資，於2026年6月30日，本集團並無未償還銀行貸款、其他借款或債務。

PLEDGE OF ASSETS

Details of pledge of assets during the year are set out in section headed "Pledge of Assets" in the "Management Discussion and Analysis" of this annual report.

資產抵押

年內資產抵押的詳情載於本年報「管理層討論及分析」的「資產抵押」一節。

MAJOR CUSTOMERS AND SUPPLIERS

During FY2026, the revenue attributable to the five largest customers accounted for approximately 17.8% of the Group's revenue for the year and the largest customer included therein accounted for 6.2%. Purchases from the Group's five largest suppliers accounted for less than 30% of the total purchases for the year.

To the best knowledge of the Directors, none of the Directors or any of their close associates (as defined in the Listing Rules) or shareholders of the Company that owned more than 5% of the issued Shares had any direct or indirect interest in the five largest customers or the five largest suppliers of the Group during FY2026.

主要客戶及供應商

於2026財政年度，來自五大客戶的收入佔本集團年內收入約17.8%，而當中最大客戶則佔6.2%。來自本集團五大供應商的採購額佔年內總採購額少於30%。

就董事所知，於2026財政年度，概無董事、彼等的任何緊密聯繫人(定義見上市規則)或擁有已發行股份逾5%的任何本公司股東，於本集團五大客戶或五大供應商中擁有任何直接或間接權益。

REPORT OF DIRECTORS
董事會報告

DIRECTORS
The Directors of the Company during FY2026 and up to the date of this annual report were:

Executive Directors
Dr. Sun Yiu Kwong *(Chairman)*
Dr. Sun Man Kin, Michael
(Vice Chairman and Co-Chief Executive Officer)
Ms. Kwok Cheuk Kwan, Jacquen
(Co-Chief Executive Officer)
Mr. Tsang On Yip, Patrick *BBS*
Dr. Lee Pak Cheung, Patrick

Non-executive Directors
Ms. Cheng Chi Man *(appointed on 21 November 2025)*
Dr. Lee Kar Chung, Felix *(ceased on 21 November 2025)*

Independent non-executive Directors
Mr. Lee Luen Wai, John *BBS JP*
Mr. Yeung Tak Bun *BBS JP*
Mrs. Chan Kung Wai Ying, Amy *MH*
(appointed on 21 November 2025)
Dr. Li Kwok Tung, Donald *GBS JP*
(ceased on 21 November 2025)

Ms. Cheng Chi Man who was appointed as a non-executive Director on 21 November 2025, obtained legal advice from a firm of solicitors qualified to advise on Hong Kong law on 19 November 2025. She has confirmed that she understands her obligations and responsibilities as a director of a listed company under the Listing Rules.

Mrs. Chan Kung Wai Ying, Amy who was appointed as an independent non-executive Director on 21 November 2025, obtained legal advice from a firm of solicitors qualified to advise on Hong Kong law on 18 November 2025. She has confirmed that she understands her obligations and responsibilities as a director of a listed company under the Listing Rules.

董事
於2026財政年度及截至本年報日期，本公司董事為：

執行董事
孫耀江醫生*(主席)*
孫文堅醫生
(副主席兼聯席行政總裁)
郭卓君女士
(聯席行政總裁)
曾安業先生*銅紫荊星章*
李柏祥醫生

非執行董事
鄭志雯女士*(於2025年11月21日獲委任)*
李家聰博士*(於2025年11月21日卸任)*

獨立非執行董事
李聯偉先生*銅紫荊星章，太平紳士*
楊德斌先生*銅紫荊星章，太平紳士*
陳龔偉瑩女士*榮譽勳章*
(於2025年11月21日獲委任)
李國棟醫生*金紫荊星章，太平紳士*
(於2025年11月21日卸任)

鄭志雯女士於2025年11月21日獲委任為非執行董事，於2025年11月19日取得具備香港法律諮詢資格的律師事務所出具的法律意見。她已確認其了解上市規則規定的上市公司董事的義務及責任。

陳龔偉瑩女士於2025年11月21日獲委任為獨立非執行董事，於2025年11月18日取得具備香港法律諮詢資格的律師事務所出具的法律意見。她已確認其了解上市規則規定的上市公司董事的義務及責任。

RE-ELECTION OF DIRECTORS

Pursuant to the Articles of Association, any Director appointed by the Board to fill a casual vacancy shall hold office until the first general meeting of the Company after his appointment and be subject to re-election at such meeting and any Director appointed by the Board as an addition to the existing Board shall hold office only until the next following annual general meeting of the Company and shall then be eligible for re-election. At each annual general meeting, one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting at least once every three years. The details of Directors (as required by the Listing Rules) who will retire and being eligible, offer themselves for re-election at the AGM, will be provided in the accompanying circular. The re-election of each Director will be subject to vote of shareholders of the Company by separate resolutions.

Accordingly, Mr. Tsang On Yip, Patrick, Mr. Lee Luen Wai, John, Mr. Yeung Tak Bun, Ms. Cheng Chi Man and Mrs. Chan Kung Wai Ying, Amy shall retire by rotation at the 2026 AGM and being eligible, offer themselves for re-election.

Each Director has disclosed to the Company the names and the titles and nature of office held in the public companies or organisations prior to the acceptance of the appointment and promised to inform the Company timely of any relevant change. The Company will also require Directors to submit written confirmation twice a year, and update their biographical details, if any.

重選董事

根據公司細則，獲董事會委任以填補臨時空缺的任何董事，其任期直至其委任後首個本公司股東大會止，並可於有關大會上膺選連任。而獲董事會委任作為現屆董事會新增成員的任何董事僅任職至下屆本公司股東週年大會舉行為止，惟屆時符合資格膺選連任。在每屆股東週年大會上，當時三分之一(或倘人數並非三(3)的倍數，則為最接近但不少於三分之一的人數)的董事須輪值告退，惟所有董事須最少每三年於股東週年大會退任一次。按上市規則規定，將於股東週年大會上退任並符合資格且願意重選連任的董事的詳情，將於隨附的通函提供。各董事獲重選連任與否將由本公司股東以通過獨立決議案的方式表決決定。

因此，曾安業先生、李聯偉先生、楊德斌先生、鄭志雯女士及陳龔偉瑩女士均須在2026股東週年大會上退任，且均符合資格並願意重選連任。

各董事已向本公司披露其於接受委任前於公眾公司或機構擔任的職位及職責性質，以及公司或機構名稱，並承諾就任何相關變化適時通知本公司。本公司亦將要求董事每年提交書面確認兩次，並更新其履歷詳情(如有)。

THE BIOGRAPHICAL DETAILS OF THE DIRECTORS

The biographical details of the Directors are set out in pages 84 to 93 of this annual report.

董事履歷詳情

董事的履歷詳情載於本年報第84至93頁。

INDEPENDENCE CONFIRMATIONS FROM INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received written annual confirmation from each of the independent non-executive Directors in respect of his independence in accordance with the independence guidelines set out in Rule 3.13 of the Listing Rules. The Company is of the view that all independent non-executive Directors are independent.

獨立非執行董事的獨立確認書

本公司已接獲獨立非執行董事各自根據上市規則第3.13條所載獨立指引，就其獨立性發出的書面年度確認。本公司認為所有獨立非執行董事均屬獨立人士。

DIRECTORS' SERVICE CONTRACTS

None of the Directors has an unexpired service contract which is not determinable by the Company or any of its subsidiaries within one year without payment of compensation, other than statutory compensation.

董事的服務合約

概無董事與本公司訂立不可由本公司或其任何附屬公司於一年內終止而毋須作出賠償(法定賠償除外)的未屆滿服務合約。

REMUNERATION OF THE DIRECTORS AND SENIOR MANAGEMENT

Details of the Directors' remuneration and the five highest paid employees in the Group are set out in notes 9 and 10 to the consolidated financial statements in this annual report.

董事及高級管理層的薪酬

董事及本集團五名最高薪僱員的薪酬詳情載於本年報綜合財務報表附註9及10。

Details of the remuneration payable to the senior management (excluding Directors) in the Group are as follows:

應付本集團高級管理人員(董事除外)的薪酬詳情如下：

		Number of senior management (FY2026) 高級管理層人數 (2026財政年度)
HK$1,500,001 to HK$2,500,000	1,500,001港元至2,500,000港元	4
HK$1,500,000 or below	1,500,000港元或以下	1
		5

REMUNERATION POLICY

The Group's remuneration policies are based on the merit, qualifications and competence of individual employees and are reviewed by the Remuneration Committee periodically. The emoluments of the Directors are recommended by the Remuneration Committee and are decided by the Board, having regard to the Group's operating results, individual performance and comparable market statistics.

The Company has adopted share option schemes and a share award scheme to motivate and reward its Directors and eligible participants. Details of the schemes are set out in pages 134 to 146 of this report.

None of the Directors waived any emoluments during FY2026.

薪酬政策

本集團的薪酬政策乃基於個別僱員的優點、資歷及能力制定，並由薪酬委員會定期檢討。薪酬委員會就董事的薪酬提出建議並由董事會經計及本集團的經營業績、個人表現及可比較市場統計數據後決定。

本公司已採納購股權計劃及一項股份獎勵計劃，旨在激勵及嘉許其董事和合資格參與者。計劃詳情載於本報告第134至146頁。

概無董事於2026財政年度豁免收取任何薪酬。

NON-COMPETE UNDERTAKINGS

Dr. Sun Yiu Kwong, East Majestic Group Limited and EM Team Limited, our controlling Shareholders, have undertaken to the Company in a deed of non-compete undertaking that, subject to and except as mentioned in the prospectus of the Company dated 17 November 2015, they would not carry on, engage, invest, participate or otherwise be interested in any business which competes or is likely to compete with any of the existing and/or future businesses carried on by any member of the Group in relation to the provision of corporate healthcare solutions and consultancy services in non-UMP medical centres in Hong Kong, Macau and Chinese Mainland.

Each of them has confirmed in writing to the Company of their compliance with the deed of non-compete undertaking for disclosure in this annual report during FY2026. No new business opportunity was informed by them as at 30 June 2026 The independent non-executive Directors have reviewed the implementation of the deed of non-compete undertaking and are of the view that the non-competition undertakings have been complied with by Dr. Sun Yiu Kwong, East Majestic Group Limited and EM Team Limited for FY2026.

不競爭承諾

我們的控股股東孫耀江醫生、East Majestic Group Limited及EM Team Limited已於一項不競爭承諾契據中向本公司承諾，除本公司日期為2015年11月17日之招股章程所述者外並在其規限下，彼等不會在香港、澳門及中國內地開展、從事、投資、參與因在聯合醫務中心以外提供企業醫療保健解決方案及諮詢服務而與本集團任何成員公司所進行任何現有及／或未來的業務構成或可能構成競爭的任何業務，或以其他方式擁有當中權益。

彼等已各自向本公司書面確認彼等於2026財政年度遵守不競爭承諾契據的情況，以供在本年報披露。截至2026年6月30日，彼等並未告知任何新的商業機會。獨立非執行董事已檢討不競爭承諾契據的執行情況，並認為孫耀江醫生、East Majestic Group Limited及EM Team Limited於2026財政年度已遵守不競爭承諾。

DIRECTORS' INTERESTS IN COMPETING BUSINESSES

None of the Directors is or was interested in any business apart from the Group's business, that competes or competed or is or was likely to compete, either directly or indirectly, with the Group's business at any time during FY2026 and up to and including the date of this report.

董事於競爭業務的權益

於2026財政年度內任何時間及截至本報告日期(包括當日)止，概無董事於本集團業務以外與本集團業務直接或間接構成或已構成或可能構成或曾可能構成競爭的任何業務中擁有權益。

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS

As at 30 June 2026, the interests and short positions of the Directors and Chief Executive of the Company in the shares, underlying shares and/or debentures (as the case may be) of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO) or which were required to be entered into the register required to be kept by the Company under Section 352 of the SFO or which were otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code were set out below:

董事及最高行政人員於本公司或其相聯法團的股份、相關股份及債券的權益及淡倉

於2026年6月30日，董事及本公司最高行政人員於本公司或其任何相聯法團(定義見證券及期貨條例第XV部)的股份、相關股份及／或債券(視乎情況而定)中，擁有根據證券及期貨條例第XV部第7及第8分部而須知會本公司及聯交所的權益及淡倉(包括彼等根據該等證券及期貨條例條文而被視作或當作擁有的權益及淡倉)，或須記錄於本公司根據證券及期貨條例第352條須存置的登記冊內的權益及淡倉，或根據標準守則而須知會本公司及聯交所的權益及淡倉如下：

(i) The Company

(i) 本公司

Name of Director 董事姓名	Long/short position 好倉／淡倉	Capacity 身份		Number of Shares/ underlying shares 股份／相關股份數目	Notes 附註	Approximate percentage of shareholding (%) *(Note 3)* 概約持股比例(%) *(附註3)*
Dr. Sun Yiu Kwong **孫耀江醫生**	Long position 好倉	Beneficial owner 實益擁有人		27,006,000		
	Long position 好倉	Interest held by his controlled corporations 權益由其控制法團持有		273,220,989	1	
	Long position 好倉	Beneficial owner 實益擁有人		1,000,000	2	
			Sub-total 小計	301,226,989		37.14
Dr. Sun Man Kin, Michael **孫文堅醫生**	Long position 好倉	Beneficial owner 實益擁有人		23,033,033		
	Long position 好倉	Beneficial owner 實益擁有人		1,000,000	2	
			Sub-total 小計	24,033,033		2.96
Ms. Kwok Cheuk Kwan, Jacquen **郭卓君女士**	Long position 好倉	Beneficial owner 實益擁有人		21,200,000		
	Long position 好倉	Beneficial owner 實益擁有人		1,000,000	2	
			Sub-total 小計	22,200,000		2.73
Mr. Tsang On Yip, Patrick **曾安業先生**	Long position 好倉	Beneficial owner 實益擁有人		4,486,000		
	Long position 好倉	Beneficial owner 實益擁有人		1,000,000	2	
			Sub-total 小計	5,486,000		0.67
Dr. Lee Pak Cheung, Patrick **李柏祥醫生**	Long position 好倉	Beneficial owner 實益擁有人		22,992,556		
	Long position 好倉	Beneficial owner 實益擁有人		1,000,000	2	
			Sub-total 小計	23,992,556		2.95
Mr. Lee Luen Wai, John **李聯偉先生**	Long position 好倉	Beneficial owner 實益擁有人		4,048,081		0.49
			Total 總計	380,986,659		46.94

Notes:

1. Dr. Sun Yiu Kwong is deemed to be interested in the 223,740,989 Shares held by East Majestic Group Limited, being his controlled corporation, and is also deemed to be interested in 49,480,000 Shares held by EM Team Limited, also being his controlled corporation.

2. These Shares represented by the underlying Shares under the options granted by the Company on 26 May 2021 pursuant to the Post-IPO Share Option Scheme.

3. These percentages are calculated on the basis of 810,955,244 issued shares as at 30 June 2026.

附註：

1. 孫耀江醫生被視為於其受控法團East Majestic Group Limited持有的223,740,989股股份中擁有權益，亦被視為於同樣為其受控法團EM Team Limited持有的49,480,000股股份中擁有權益。

2. 該等股份指本公司於2021年5月26日根據首次公開發售後購股權計劃授出的購股權項下的相關股份。

3. 此等百分比乃按於2026年6月30日之810,955,244股已發行股份為基準計算。

(ii) Associated Corporations (within the meaning of the SFO)

Procare Medical Imaging & Laboratory Centre Limited[1]

(ii) 相聯法團(定義見證券及期貨條例)

普康醫學影像及化驗中心有限公司[1]

Name of Director 董事姓名	Long/short position 好倉／淡倉	Capacity 身份	Number of shares 股份數目	Approximate percentage of shareholding (%) 概約持股比例(%)
Dr. Sun Man Kin, Michael 孫文堅醫生	Long position 好倉	Beneficial owner 實益擁有人	625	6.25

Causeway Bay MRI Centre Limited[2]

銅鑼灣磁力共振中心有限公司[2]

Name of Director 董事姓名	Long/short position 好倉／淡倉	Capacity 身份	Number of shares 股份數目	Approximate percentage of shareholding (%) 概約持股比例(%)
Dr. Sun Man Kin, Michael 孫文堅醫生	Long position 好倉	Beneficial owner 實益擁有人	95	6.33

Name of Director 董事姓名	Long/short position 好倉／淡倉	Capacity 身份	United Medical Services (China) Limited[3] Number of shares 股份數目	United Medical Services (China) Limited[3] Approximate percentage of shareholding (%) 概約持股比例 (%)
Mr. Tsang On Yip, Patrick 曾安業先生	Long position 好倉	Interest of controlled corporation 受控制法團權益	20	20

Notes:

(1) UMP Medical Centre Limited, a wholly-owned subsidiary of the Company, holds 62.5% of the entire issued share capital of Procare Medical Imaging & Laboratory Centre Limited.

(2) UMP Medical Centre Limited, a wholly-owned subsidiary of the Company, holds 20% of the entire issued share capital of Causeway Bay MRI Centre Limited.

(3) UMP Medical China Holdings Limited, a wholly-owned subsidiary of the Company, holds 80% of the entire issued share capital of United Medical Services (China) Limited.

附註：

(1) 本公司的全資附屬公司聯合醫務中心有限公司持有普康醫學影像及化驗中心有限公司的全部已發行股本的62.5%。

(2) 本公司的全資附屬公司聯合醫務中心有限公司持有銅鑼灣磁力共振中心有限公司的全部已發行股本的20%。

(3) UMP Medical China Holdings Limited（為本公司之全資附屬公司）持有United Medical Services (China) Limited全部已發行股本之80%。

Save as disclosed above, as at 30 June 2026, none of the Directors or Chief Executive of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

除上文所披露者外，於2026年6月30日，董事或本公司最高行政人員於本公司及其相聯法團（定義見證券及期貨條例第XV部）的股份、相關股份及債券中，概無擁有根據證券及期貨條例第XV部第7及第8分部而須知會本公司及聯交所的任何權益或淡倉（包括彼等根據該等證券及期貨條例條文而被視作或當作擁有的權益或淡倉），或根據證券及期貨條例第352條須記錄於該條所述登記冊的任何權益或淡倉，或根據標準守則已知會本公司及聯交所的權益或淡倉。

SHARE OPTION SCHEMES

The Company terminated the Post-IPO Share Option Scheme and adopted the 2023 Share Option Scheme both with effect from 24 November 2023.

The Pre-IPO Share Option Scheme was only in force during the period from 18 August 2015 to 9 November 2015, and no further options are to be granted. As at 1 July 2025 and 30 June 2026, there was no share option remained outstanding under the Pre-IPO Share Option Scheme.

The number of the Shares that may be issued in respect of all the Share Option Schemes during the year ended 30 June 2026 were 10,200,000 Shares. The dilutive effect of such is approximately 1.3%, being the number of Shares may be issued divided by the weighted average number of Shares for the same period.

Post-IPO Share Option Scheme

The Company adopted the Post-IPO Share Option Scheme on 13 November 2015.

The Board resolved to terminate the Post-IPO Share Option Scheme with effect from 24 November 2023 and no option was available for grant as at 1 July 2025 and 30 June 2026.

During the year ended 30 June 2026, no share options were exercised and vested under the Post-IPO Share Option Scheme. The weighted average closing price of the shares immediately before the dates on which the options were exercised and vested were not applicable.

As at 30 June 2026, the Company had 10,200,000 outstanding share options granted under the Post-IPO Share Option Scheme which shall continue to be valid and exercisable during the prescribed exercise period in accordance with the Post-IPO Share Option Scheme.

購股權計劃

本公司已終止首次公開發售後購股權計劃並採納2023年購股權計劃，自2023年11月24日起生效。

首次公開發售前購股權計劃於2015年8月18日至2015年11月9日期間有效，其後將不再據此進一步授出購股權。於2025年7月1日及2026年6月30日，首次公開發售前購股權計劃下概無仍未行使的購股權。

截至2026年6月30日止年度，就根據所有購股權計劃可發行的股份數目為10,200,000股。其攤薄影響約為1.3%，即可發行的股份數目除以同期的加權平均股份數目。

首次公開發售後購股權計劃

本公司於2015年11月13日採納首次公開發售後購股權計劃。

董事會議決終止首次公開發售後購股權計劃，自2023年11月24日起生效，而於2025年7月1日及2026年6月30日均無可授出的購股權。

截至2026年6月30日止年度，概無購股權根據首次公開發售後購股權計劃獲行使及歸屬。緊接購股權獲行使及歸屬日期前的股份加權平均收市價並不適用。

於2026年6月30日，本公司有10,200,000份根據首次公開發售後購股權計劃已授出但未行使之購股權，該等購股權將根據首次公開發售後購股權計劃在規定行使期間內繼續有效並可予行使。

Details of the Post-IPO Share Option Scheme are as follows:

(a) Purpose

The purpose of the Post-IPO Share Option Scheme is to incentivise and reward the Eligible Persons (as defined in sub-paragraph (b) below) for their contribution to the Group and to align their interests with that of the Company so as to encourage them to work towards enhancing the value of the Company.

(b) Participants

The Board (including any committee or delegate of the Board appointed by the Board to perform any of its functions pursuant to the rules of the Post-IPO Share Option Scheme) may, at its absolute discretion, offer to grant an option to subscribe for such number of Shares as the Board may determine to an employee (whether full-time or part-time) or a director of a member of the Group or associated companies of the Company (the "Eligible Persons").

(c) Total number of securities available for issue

The total number of Shares which may be issued upon exercise of all options to be granted under the Post-IPO Share Option Scheme and any other share option schemes (including but not limited to the Pre-IPO Share Option Scheme) of the Company must not in aggregate exceed 10% of the total number of Shares in issue as at the Listing Date which is 73,600,000 Shares, representing approximately 9.08% issued shares of the Company as at the date of this annual report.

(d) Maximum entitlement of each participant

No options shall be granted to any Eligible Person under the Post-IPO Share Option Scheme and any other Share option schemes of the Company which, if exercised, would result in such Eligible Person becoming entitled to subscribe for such number of Shares as, when aggregated with the total number of Shares already issued or to be issued to him under all options granted to him (including exercised, cancelled and outstanding options) in the 12-month period up to and including the date of offer of such options, exceeds 1% of the Shares in issue at such date.

首次公開發售後購股權計劃詳情如下：

(a) 目的

首次公開發售後購股權計劃的目的旨在鼓勵及獎勵合資格人士(如下文(b)分段所界定)對本集團作出的貢獻，令其利益與本公司利益一致，藉以推動其盡力提升本公司價值。

(b) 參與者

董事會(包括董事會根據首次公開發售後購股權計劃的規則為履行其任何職責而委任的任何董事會轄下委員會或代表)可全權酌情向本集團成員公司或本公司聯營公司的僱員(不論全職或兼職)或董事(「合資格人士」)授出購股權，以認購董事會可釐定有關數目的股份。

(c) 可發行證券總數

根據首次公開發售後購股權計劃及本公司任何其他購股權計劃(包括但不限於首次公開發售前購股權計劃)將予授出的所有購股權獲行使時可發行的股份總數，合共不得超過於上市日期已發行股份總數的10%，即73,600,000股股份，佔本公司於本年報日期的已發行股份約9.08%。

(d) 每名參與者可獲授權益的上限

倘根據首次公開發售後購股權計劃及本公司任何其他購股權計劃向任何合資格人士授出的購股權獲行使時，會致使有關合資格人士有權認購的股份數目，加上其於截至有關購股權要約日期(包括該日)止過去12個月期間所獲授的全部購股權(包括已行使、已註銷及尚未行使的購股權)而已向其發行或將向其發行的股份總數超過該日已發行股份的1%，則不會根據首次公開發售後購股權計劃及本公司任何其他購股權計劃向該名合資格人士授出購股權。

(e) Period within which the option may be exercised

Any vested option which has not lapsed and which conditions have been satisfied or waived by the Board in its sole discretion may, unless the Board determines otherwise in its absolute discretion, be exercised at any time from the next business day after the offer of options has been accepted. Any option which remain unexercised shall lapse upon the expiry of the option period, which period shall be determined by the Board and shall not exceed ten years from the offer date of the option.

(e) 購股權可予行使之期限

除董事會按其絕對酌情權另行釐定外，任何已歸屬而未失效的購股權於達成條件或董事會按其全權酌情決定豁免條件後，可於接納購股權要約後的下一個營業日隨時行使。任何尚未行使的購股權於購股權期限屆滿後將告失效，該期限由董事會釐定，且不得超過購股權要約日期起計十年。

(f) Vesting period of options granted

The Board may in its absolute discretion set a minimum period for which an option must be held and performance targets that must be achieved before an option can be exercised.

(f) 已授出購股權之歸屬期

董事會可全權酌情設定於購股權可予行使前必須持有購股權的最短期限及須達成的表現目標。

(g) Time of acceptance and the amount payable on acceptance of the option

An offer of options shall be open for acceptance in writing or by telex or facsimile transmission or (if the Board agree) by electronic communication received by the Chairman (or a person designated by him with the approval of the Board) for such period (not exceeding 30 days inclusive of, and from, the date of offer) as the Board may determine and notify to the Eligible Person concerned provided that no such offer shall be open for acceptance after the expiry of the duration of the Post-IPO Share Option Scheme. An offer of options not accepted within this period shall lapse.

An amount of HK$1.00 is payable upon acceptance of the grant of an option and such payment shall not be refundable and shall not be deemed to be a part payment of the exercise price.

(g) 接納購股權的期限及接納購股權時應付款項

購股權的要約可於董事會決定並通知有關合資格人士的有關期間(由要約日期起(包括該日)計30日內)供接納，接納方式為以書面形式或通過電報或傳真或(如董事會同意)通過主席(或其在經董事會批准後指定的一名人士)收到的電子通訊的方式接納，惟首次公開發售後購股權計劃期限屆滿後不得作出有關要約。期內不被接納的購股權要約將告失效。

於接納所授出的購股權時須繳付1.00港元，該款項將不予退還，且不應被視為行使價的部分款項。

(h) Basis of determining the exercise price

The exercise price shall be such price as determined by the Board and notified to an option-holder and which shall not be less than the higher of: (i) the closing price of the Shares as stated in the Stock Exchange's daily quotation sheets on the date of offer of the option; (ii) the average of the closing price of the Shares as stated in the Stock Exchange's daily quotation sheets for the five trading days immediately preceding the date of offer of the option; and (iii) the nominal value of the Shares.

(h) 釐定行使價的基準

行使價應為董事會釐定並通知購股權持有人的價格，及不得低於以下的最高者：(i)股份於購股權要約日期於聯交所每日報價表所列的收市價；(ii)股份於緊接購股權要約日期前五個交易日於聯交所每日報價表所列平均收市價；及(iii)股份面值。

(i) Life of the Post-IPO Share Option Scheme

The Post-IPO Share Option Scheme shall expire automatically on the day immediately preceding the tenth anniversary of the Listing Date, subject to early termination provisions in the Post-IPO Share Option Scheme. The Post-IPO Share Option Scheme was terminated by the Board on 24 November 2023.

(i) 首次公開發售後購股權計劃的年期

在首次公開發售後購股權計劃的提前終止條款之規限下，首次公開發售後購股權計劃將自緊接上市日期十週年前一天自動屆滿。首次公開發售後購股權計劃已於2023年11月24日被董事會終止。

The summary below sets out the details of the movement during the year ended 30 June 2026 of all the options granted pursuant to the Post-IPO Share Option Scheme:

以下概要載列根據首次公開發售後購股權計劃授出的所有購股權於截至2026年6月30日止年度的變動詳情：

Name 姓名	Date of grant[1], [2] 授出日期[1], [2] (dd/mm/yyyy) (日/月/年)	Exercise price per Share 每股行使價 (HK$) (港元)	Exercise period[3] 行使期[3] (dd/mm/yyyy) (日/月/年)	Number of Shares issuable under the share options 購股權項下可予發行股份數目				
				As at 1 July 2025 於2025年7月1日	Granted during the year 年內授出	Exercised during the year 年內行使	Forfeited/ lapsed during the year 年內沒收/失效	As at 30 June 2026 於2026年6月30日
Dr. Sun Yiu Kwong *(Chairman and Executive Director)*	26/05/2021	0.772	26/05/2022-25/05/2029	400,000	–	–	–	400,000
	26/05/2021	0.772	26/05/2023-25/05/2029	300,000	–	–	–	300,000
孫耀江醫生*(主席兼執行董事)*	26/05/2021	0.772	26/05/2024-25/05/2029	300,000	–	–	–	300,000
Dr. Sun Man Kin, Michael *(Vice chairman, Co-Chief Executive Officer and Executive Director)*	26/05/2021	0.772	26/05/2022-25/05/2029	400,000	–	–	–	400,000
	26/05/2021	0.772	26/05/2023-25/05/2029	300,000	–	–	–	300,000
	26/05/2021	0.772	26/05/2024-25/05/2029	300,000	–	–	–	300,000
孫文堅醫生*(副主席、聯席行政總裁兼執行董事)*								
Ms. Kwok Cheuk Kwan, Jacquen *(Co-Chief Executive Officer and Executive Director)*	26/05/2021	0.772	26/05/2022-25/05/2029	400,000	–	–	–	400,000
	26/05/2021	0.772	26/05/2023-25/05/2029	300,000	–	–	–	300,000
郭卓君女士*(聯席行政總裁兼執行董事)*	26/05/2021	0.772	26/05/2024-25/05/2029	300,000	–	–	–	300,000
Mr. Tsang On Yip, Patrick *(Executive Director)*	26/05/2021	0.772	26/05/2022-25/05/2029	400,000	–	–	–	400,000
曾安業先生*(執行董事)*	26/05/2021	0.772	26/05/2023-25/05/2029	300,000	–	–	–	300,000
	26/05/2021	0.772	26/05/2024-25/05/2029	300,000	–	–	–	300,000
Dr. Lee Pak Cheung, Patrick *(Executive Director)*	26/05/2021	0.772	26/05/2022-25/05/2029	400,000	–	–	–	400,000
	26/05/2021	0.772	26/05/2023-25/05/2029	300,000	–	–	–	300,000
李柏祥醫生*(執行董事)*	26/05/2021	0.772	26/05/2024-25/05/2029	300,000	–	–	–	300,000
			Sub-total 小計	5,000,000	–	–	–	5,000,000

Name 姓名	Date of grant[1], [2] 授出日期[1], [2] (dd/mm/yyyy) (日/月/年)	Exercise price per Share 每股行使價 (HK$) (港元)	Exercise period[3] 行使期[3] (dd/mm/yyyy) (日/月/年)	Number of Shares issuable under the share options 購股權項下可予發行股份數目 As at 1 July 2025 於2025年7月1日	Granted during the year 年內授出	Exercised during the year 年內行使	Forfeited/ lapsed during the year 年內沒收/失效	As at 30 June 2026 於2026年6月30日
Employees 僱員								
In aggregate 合計	26/05/2021	0.772	26/05/2022–25/05/2029	2,080,000	–	–	–	2,080,000
	26/05/2021	0.772	26/05/2023–25/05/2029	1,560,000	–	–	–	1,560,000
	26/05/2021	0.772	26/05/2024–25/05/2029	1,560,000	–	–	–	1,560,000
			Sub-total 小計	5,200,000	–	–	–	5,200,000
Others 其他								
Dr. Lee Kar Chung, Felix 李家聰博士	26/05/2021	0.772	26/05/2022-25/05/2029	400,000	–	–	(400,000)	–
	26/05/2021	0.772	26/05/2023-25/05/2029	300,000	–	–	(300,000)	–
	26/05/2021	0.772	26/05/2024-25/05/2029	300,000	–	–	(300,000)	–
			Sub-total 小計	1,000,000	–	–	(1,000,000)	–
			Total 總計	11,200,000 (Note 1) (附註1)	–	–	(1,000,000)	10,200,000

Notes:

(1) Dr. Lee Kar Chung, Felix left his position as a non-executive Director upon the expiry of his term of office on 21 November 2025. The total of 1,000,000 share options held by him has been reclassified from the section "Directors" to the section "Others".

(2) The closing price of the Shares immediately before the date on which the share options were granted on 26 May 2021 was HK$0.82 per share.

(3) The vesting period of all the outstanding share options and share options granted is the period beginning on the date of grant and ending on the date immediately before commencement of the exercise period.

附註：

(1) 李家聰博士於2025年11月21日任期屆滿後卸任非執行董事。彼持有之合共 1,000,000份購股權已由「董事」重新分類為「其他」。

(2) 緊接購股權於2021年5月26日獲授出之日前的股份收市價為每股0.82港元。

(3) 尚未行使購股權及已授出購股權的歸屬期為由授出日期開始直至行使期開始的前一日止。

Save as disclosed above, no share option was granted, exercised, forfeited or lapsed under the Post-IPO Share Option Scheme during the year ended 30 June 2026.

除上文披露者外，於截至2026年6月30日止年度，概無購股權根據首次公開發售後購股權計劃授出、行使、被沒收或失效。

2023 Share Option Scheme

The Company adopted the 2023 Share Option Scheme on 24 November 2023. Details of the 2023 Share Option Scheme are as follows:

2023年購股權計劃

本公司於2023年11月24日採納2023年購股權計劃。2023年購股權計劃詳情如下：

(a) Purpose

The purpose of the 2023 Share Option Scheme is to incentivize and reward the Eligible Persons (as defined in sub-paragraph (b) below) for their contribution to the Group and to align their interests with that of the Company so as to encourage them to work towards enhancing the value of the Company.

(a) 目的

2023年購股權計劃旨在激勵及獎勵合資格人士（如下文(b)分段所界定）對本集團作出的貢獻，令其利益與本公司利益一致，藉以鼓勵其盡力提升本公司價值。

(b) Participants

The Board may, at its absolute discretion, invite any person belonging to any of the following classes of persons of any member of the Group, to be an eligible person of the 2023 Share Option to take up an option to subscribe for Shares (the "Eligible Person(s)"):

(i) any director or employee of any member of the Group (the "Employee**(s)**");

(ii) any director or employee of any of the related entity (each, a "Related Entity Participant"); and

(iii) service providers.

(b) 參與者

董事會可全權酌情邀請本集團任何成員公司中屬於下列任何類別的人士作為2023年購股權計劃的合資格人士接納購股權以認購股份（「合資格人士」）：

(i) 本集團任何成員公司的任何董事或僱員（「僱員」）；

(ii) 任何關聯實體的任何董事或僱員（各為一名「關聯實體參與者」）；及

(iii) 服務提供者。

(c) Total number of securities available for issue

The total number of Shares which may be issued upon exercise of all options to be granted under the 2023 Share Option Scheme and any options or awards granted under any other scheme(s) of the Company involving issue of new Shares must not in aggregate exceed 10% of the Shares of the Company in issue as at its adoption date (the "Scheme Mandate Limit") which is 81,095,524 Shares, representing approximately 10% issued Shares of the Company as at the date of this annual report.

Subject to the above, within the Scheme Mandate Limit, the total number of Shares which may be issued upon exercise of all options to be granted to Service Providers under the 2023 Share Option Scheme and any options or awards granted under any other scheme(s) of the Company involving issue of new Shares shall not in aggregate exceed two per cent (2%) of the Shares in issue as at its adoption date (the "Service Provider Sublimit") which is 16,219,104 Shares, representing approximately 2% issued Shares of the Company as at the date of this annual report.

(c) 可發行證券總數

因行使根據2023年購股權計劃授出的所有購股權及根據本公司任何其他涉及發行新股份的計劃授出的任何購股權或獎勵而可能發行的股份總數合共不得超過本公司於採納日期已發行股份的10%(「計劃授權限額」),即81,095,524股股份,佔本公司於本年報日期的已發行股份約10%。

受以上所規限,在計劃授權限額中,因行使根據2023年購股權計劃授予服務提供者的所有購股權及根據本公司任何其他涉及發行新股份的計劃授出的任何購股權或獎勵而可能發行的股份總數合共不得超過於採納日期已發行股份的百分之二(2%)(「服務提供者分項限額」),即16,219,104股股份,佔本公司於本年報日期的已發行股份約2%。

(d) Maximum entitlement of each participant

Subject to the rules of the 2023 Share Option Scheme, where any grant of options to a selected Eligible Person under the 2023 Share Option Scheme would result in the Shares issued and to be issued in respect of all options and awards granted to such person (excluding any options and awards lapsed in accordance with the rules of the relevant scheme(s) of the Company) in the 12-month period up to and including the date of such grant representing in aggregate over 1% of the total number of issued Shares, such grant of options or awards shall be approved by the Shareholders in general meeting.

(d) 每名參與者可獲授權益的上限

受2023年購股權計劃規則所規限,倘向2023年購股權計劃向下的獲選合資格人士授出購股權,將導致因有關人士於截至授出日期(包括該日)止12個月期間內,就所有獲授購股權及獎勵(不包括根據本公司相關計劃規則已失效的任何購股權及獎勵)而發行及將予發行的股份,合共佔已發行股份總數超過1%,則授出購股權及獎勵須經股東於股東大會上批准。

(e) Period with which the option may be exercised

In respect of an option, the period within which an option may be exercised by the option-holder as the Board may in its absolute discretion determine and which shall not be more than 10 years from the offer date of the option.

(e) 購股權可予行使之期限

就購股權而言,董事會可全權酌情釐定由購股權持有人行使購股權的期間,自購股權要約日期起計不超過10年。

(f) Vesting period of option granted

The vesting of any options under the 2023 Share Option Scheme shall be subject to a vesting period to be determined by the Board and the remuneration committee of the Board in their absolute discretion, which shall be specified in the offer letter.

(f) 已授出購股權之歸屬期

2023年購股權計劃項下任何購股權的歸屬須受限於董事會及董事會薪酬委員會全權酌情釐定的歸屬期，且該歸屬期應於要約函件中訂明。

(g) Time of acceptance and the amount payable on acceptance of the option

Offers of options shall be open for acceptance for such period (not exceeding 30 days inclusive of, and from, the offer date) as the Board may determine and notify to the Eligible Persons concerned provided that no such offer shall be open for acceptance after the expiry of the duration of the 2023 Share option Scheme. Offers of options not accepted within this period shall lapse. An amount of HK$1.00 is payable upon acceptance of the grant of an option and such payment shall not be refundable and shall not be deemed to be a part payment of the option price.

(g) 接納購股權的期限及接納購股權時應付款項

購股權要約將於董事可能釐定並通知相關合資格人士的期間（自要約日期（包括該日）起計不超過30日）內可供接納，惟有關要約不得於2023年購股權計劃期限屆滿後接納。於該期間未獲接納的購股權要約將失效。於接納所授出購股權時須繳付1.00港元，該款項將不予退還，且不應被視為購股權價格的部分款項。

(h) Basis of determining the option price

The option price shall be such price as determined by the Board and shall not be less than the higher of:

(i) the closing price of the Shares as stated in the Stock Exchange's daily quotations sheet on the offer date; and

(ii) the average closing price of the Shares as stated in the Stock Exchange's daily quotations sheets for the five business days immediately preceding the offer date.

(h) 釐定行使價的基準

購股權價格應為董事會釐定的價格，且不得低於以下較高者：

(i) 於要約日期，聯交所每日報價表所報的股份收市價；及

(ii) 於緊接要約日期前五個營業日，聯交所每日報價表所報的股份平均收市價。

(i) Life of the 2023 Share Option Scheme

The 2023 Share Option Scheme will expire automatically on the day immediately preceding the tenth anniversary of the adoption date, subject to early termination provisions in the 2023 Share Option Scheme.

(i) 2023年購股權計劃的年期

在2023年購股權計劃的提前終止條款之規限下，2023年購股權計劃將自緊接採納日期十週年前一天自動屆滿。

The Company has not granted any share options under the 2023 Share Option Scheme since its adoption.

本公司自採納2023年購股權計劃起概無據此授出任何購股權。

During the year ended 30 June 2026, no share options were exercised and vested under the 2023 Share Option Scheme. The weighted average closing price of the shares immediately before the dates on which the options were exercised and vested were not applicable.

截至2026年6月30日止年度，概無購股權根據2023年購股權計劃獲行使及歸屬。緊接購股權獲行使及歸屬日期前的股份加權平均收市價並不適用。

The number of options available for grant under the 2023 Share Option Scheme of the Company under the Scheme Mandate Limit at both 1 July 2025 and 30 June 2026 were 81,095,524 respectively.

於2025年7月1日及2026年6月30日，本公司根據計劃授權限額於2023年購股權計劃項下可授出的購股權數目為81,095,524份。

The number of options available for grant under the 2023 Share Option Scheme of the Company under the Service Provider Sublimit at both 1 July 2025 and 30 June 2026 were 16,219,104 respectively.

於2025年7月1日及2026年6月30日，本公司根據服務提供者分項限額於2023年購股權計劃項下可授出的購股權數目為16,219,104份。

SHARE AWARD SCHEME

The Share Award Scheme of the Company was adopted on 30 June 2016 which is valid and effective for a term of ten years from its adoption date, subject to any early termination thereof as determined by the Board.

The purpose of the Share Award Scheme is to recognise the contributions by certain Eligible Persons and to provide them with incentives in order to retain them for the continual operation and development of the Group; and to attract suitable personnel for further development of the Group.

The Board resolved to amend the following key terms of the Share Award Scheme which was effected from 24 November 2023 (the "Amendment Date"):

(a) Duration of the Share Award Scheme

The Share Award Scheme shall be valid and effective for a further term of 10 years commencing on the Amendment Date.

(b) Eligible Persons for the Share Award Scheme

The following classes of persons (other than excluded person) are eligible for being selected for participation in the Share Award Scheme (the "Eligible Person(s)"):

(i) director(s) and employee(s) of the Company or any of its Subsidiaries;

(ii) director(s) and employee(s) of any member of the related entity; and

(iii) service provider(s).

(c) Scheme Limit

The Board shall not make any further award of awarded Shares which will result in the aggregate number of the Shares awarded by the Board under the Share Award Scheme exceeding ten per cent (10%) of the Shares of the Company in issue as at the Amendment Date which is 81,095,524 Shares, representing approximately 10% of the issued Shares as at the date of this annual report.

股份獎勵計劃

本公司於2016年6月30日採納股份獎勵計劃，自採納日期起計十年內有效及生效，惟董事會可決定提前終止該計劃。

股份獎勵計劃的目的是肯定若干合資格參與者所作貢獻及就此給予獎勵，以留聘彼等為本集團持續經營及發展；及吸引合適人員推動本集團進一步發展。

董事會議決修訂股份獎勵計劃的以下關鍵條款，自2023年11月24日(「修訂日期」)起生效：

(a) 股份獎勵計劃之期限

股份獎勵計劃自修訂日期起計10年內有效及生效。

(b) 股份獎勵計劃合資格人士

以下類別的人士(不包括除外人士)有資格獲選參與股份獎勵計劃(「合資格人士」)：

(i) 本公司或其任何附屬公司的董事及僱員；

(ii) 任何關聯實體成員公司的董事及僱員；及

(iii) 服務提供者。

(c) 計劃限額

倘董事會根據股份獎勵計劃授出的股份總數超過於修訂日期本公司已發行股份的百分之十(10%)，即81,095,524股股份，佔於本年報日期已發行股份約10%，則董事會不得進一步授出任何獎勵股份。

The maximum number of Shares which may be awarded to a selected participant under the Share Award Scheme in the 12-month period up to and including the date of such grant shall not in aggregate exceed one per cent (1%) of the issued share capital of the Company.

於截至授出日期(包括該日)止12個月期間內根據股份獎勵計劃可授予一名獲選參與者的股份最高數目合共不得超過本公司已發行股本的百分之一(1%)。

(d) Voting Rights

The trustee shall not exercise the voting rights in respect of any Shares held under the trust including but not limited to the awarded Shares.

(d) 投票權

受託人不得就信託項下所持有的任何股份(包括但不限於獎勵股份)行使投票權。

Pursuant to the terms of the Share Award Scheme, the Company will not issue new Shares in connection with the awards granted under the Share Award Scheme.

根據股份獎勵計劃的條款，本公司不會就根據股份獎勵計劃授出的獎勵發行新股份。

Subject to the provisions of the Share Award Scheme, the Board may, from time to time, at its absolute discretion select any Eligible Person for participation in the Share Award Scheme as a selected participant, and grant such number of awarded Shares to any selected participant and in such number and on and subject to such terms and conditions as it may in its absolute discretion determine.

在股份獎勵計劃的條文規限下，董事會可不時全權酌情挑選任何合資格人士作為獲選參與者參與股份獎勵計劃，並按其可能全權酌情決定的有關數目以及有關條款及條件及在其規限下，向任何獲選參與者授出有關數目的獎勵股份。

A selected participant under the Share Award Scheme shall be entitled to receive the awarded Shares vested in him/her in accordance with the vesting schedule (if any) and subject to the selected participant having satisfied all vesting conditions (if any) as specified in the Share Award Scheme or the grant notice.

根據股份獎勵計劃，獲選參與者有權根據歸屬時間表(如有)領取歸屬於該獲選參與者的獎勵股份，惟獲選參與者須已滿足股份獎勵計劃或授出通知中規定的所有歸屬條件(如有)。

Upon receipt of the grant notice, the selected participant shall confirm acceptance of the awarded Shares being granted to him by signing and returning to the Board the acceptance form attached to the grant notice within 5 business days after the date of the grant notice.

於接獲授予通知後，獲選參與者須於授予通知日期後5個營業日內簽署授予通知所附的接納表格並將之交回董事會，以確認接納其獲授予的獎勵股份。

No consideration is required to be paid upon acceptance of the award by a selected participant.

獲選參與者接納獎勵時無須支付任何代價。

As at 30 June 2026, the details of the share award granted and outstanding under the Share Award Scheme are set out as follow:

於2026年6月30日，股份獎勵計劃項下已授出及尚未行使之股份獎勵詳情載列如下：

		Number of awarded shares 獎勵股份數目				
	Date of grant 授出日期	As at 1 July 2025 於2025年7月1日	Granted during the year 年內授出	Vested during the year 年內歸屬	Forfeited during the year 年內沒收	As at 30 June 2026 於2026年6月30日
Name of director 董事姓名						
Dr. Sun Man Kin, Michael 孫文堅醫生	27 February 2026 2026年2月27日	–	1,000,000	(1,000,000)	–	–
Ms. Kwok Cheuk Kwan, Jacquen 郭卓君女士	27 February 2026 2026年2月27日	–	1,000,000	(1,000,000)	–	–
Five highest paid individuals *(Note 4)* 五名最高薪酬人士*(附註4)*	27 February 2026 2026年2月27日	–	750,000	(750,000)	–	–
Other employees of the Group (excluding five highest paid individuals) (in aggregate) 本集團其他僱員(不包括五名最高薪酬人士)(合計)	27 February 2026 2026年2月27日	–	900,000	(900,000)	–	–
Total 總計		–	3,650,000 *(Notes 1, 3 and 5)* *(附註1、3及5)*	(3,650,000) *(Notes 2)* *(附註2)*	–	–

Notes:

1. The exercise price was set at nil consideration per awarded share.
2. 3,650,000 awarded shares vested on 27 February 2026.
3. The closing price of the Shares immediately before the date on which the awarded shares were granted on 27 February 2026 was HK$0.47 per share.
4. The five highest paid individuals during the year included three directors. 2,000,000 awarded shares were granted to two directors and two individuals of the five highest paid individuals were granted 750,000 awarded shares.
5. Save as disclosed above, no share award was granted during the year ended 30 June 2026.

附註：

1. 每股獎勵股份行使價為零代價。
2. 3,650,000股獎勵股份於2026年2月27日歸屬。
3. 緊接獎勵股份於2026年2月27日獲授出之日前的股份收市價為每股0.47港元。
4. 本年度五名最高薪酬人士中包括三名董事。兩名董事獲授予2,000,000股獎勵股份，而五名最高薪人士中的兩名獲授予750,000股獎勵股份。
5. 除上文披露者外，於截至2026年6月30日止年度內並無授出股份獎勵。

2,100,000 Shares have been purchased under the Share Award Scheme during the year ended 30 June 2026. The total amount paid to acquire the Shares during the year was HK$976,000 (2025: HK$180,000). As at 30 June 2026, 6,419,863 Shares are held by the trustee of the Share Award Scheme for the benefit of the eligible participants for the purpose of the Share Award Scheme.

於截至2026年6月30日止年度內已根據股份獎勵計劃購買2,100,000股股份。年內就收購股份所須支付的款項總額為976,000港元（2025年：180,000港元）。於2026年6月30日，6,419,863股股份乃由股份獎勵計劃之受託人為計劃合資格參與者之福利而持有。

The weighted average closing price immediately before the date on which the awarded Shares were vested was HK$0.48 per Share.

緊接獎勵股份歸屬日前的加權平均收市價為每股0.48港元。

The fair value of the awarded Shares was calculated based on the closing price of the Company's Share at the grant date. The fair value of awarded Shares granted during the year ended 30 June 2026 was approximately HK$1,752,000.

獎勵股份的公允價值乃根據本公司股份於授出日期的收市價計算。於截至2026年6月30日止年度授出的獎勵股份的公允價值約為1,752,000港元。

The number of share awards available for grant under the Share Award Scheme as at 1 July 2025 and 30 June 2026 were 75,830,524 and 72,180,524 respectively.

於2025年7月1日及2026年6月30日根據股份獎勵計劃可供授出的股份獎勵數目分別為75,830,524股及72,180,524股。

Rule 17.07(3) of the Listing Rules was not applicable to the Share Award Scheme as the Company will not issue new Shares in connection with the awards granted under the Share Award Scheme.

上市規則第17.07(3)條不適用於股份獎勵計劃，原因是本公司不會就根據股份獎勵計劃授出的獎勵發行新股份。

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed under the sections headed "Share Option Schemes" and "Share Award Scheme" in this report, at no time during FY2026 was the Company or any of its subsidiaries or fellow subsidiaries a party to any arrangement that would enable the Directors to acquire benefits by means of acquisition of shares in or debentures of the Company or any other body corporate.

董事收購股份或債券的權利

除於本報告「購股權計劃」及「股份獎勵計劃」兩節內所披露者外，於2026財政年度內任何時間，本公司或其任何附屬公司或同系附屬公司概無訂立令董事可藉收購本公司或任何其他法團股份或債券獲利的任何安排。

DIRECTORS' INTERESTS IN TRANSACTIONS, ARRANGEMENTS OR CONTRACTS OF SIGNIFICANCE

Save as disclosed in this annual report, no transactions, arrangements or contracts of significance subsisted in which a Director or an entity connected with a Director was materially interested, whether directly or indirectly, during or at the end of FY2026.

董事於重大交易、安排或合約的權益

除本年報所披露者外，於2026財政年度內或結束時，概無董事或與董事有關連的實體，於仍然存續的重大交易、安排或合約中直接或間接擁有重大權益。

DIRECTORS' PERMITTED INDEMNITY PROVISION

Under the Articles, every Director and officer of the Company acting in relation to any of the affairs of the Company shall be indemnified and secured harmless out of the assets and profits of the Company from and against all actions, costs and damages and expenses which they or any of them shall or may incur or sustain by or omitted in or about the execution of their duties in their respective office or otherwise in relation thereto.

董事的獲准許彌償條文

根據細則，凡就本公司任何事務而行事的董事及本公司高級人員可獲本公司資產及利潤作為彌償及擔保，使其或其任何一人不會因於或就履行其各自職責過程中或與此有關的其他原因而引致或遭受或忽略的任何訴訟、費用及損害及開支而蒙受損害。

The Company has arranged appropriate Directors' and officers' liability insurance coverage for the Directors and officers of the Group.

本公司已就董事及本集團高級人員投購適當的董事及高級人員責任保險。

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 30 June 2026, so far as was known to the Directors of the Company, the following persons/entities (other than the Directors or Chief Executive of the Company) had, or were deemed to have, interests or short positions in the Shares or underlying shares of the Company which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO:

主要股東於本公司股份及相關股份的權益及淡倉

於2026年6月30日，據本公司董事所知，以下人士／實體（董事或本公司最高行政人員除外）於本公司的股份或相關股份中擁有或被視為擁有須根據證券及期貨條例第XV部第2及3分部條文向本公司及聯交所披露的權益或淡倉，或記錄於本公司須根據證券及期貨條例第336條存置的登記冊內的權益或淡倉：

Name of substantial shareholder 主要股東名稱	Long/short position 好倉／淡倉	Capacity 身份	Number of Shares/ underlying shares 股份／相關股份數目	Interests under equity derivatives 股本衍生工具項下之權益	Notes 附註	Approximate percentage of shareholding *(Note 4)* 概約持股比例 *(附註4)* (%)
East Majestic Group Limited	Long position 好倉	Beneficial owner 實益擁有人	223,740,989	–	1	27.58
EM Team Limited	Long position 好倉	Beneficial owner 實益擁有人	49,480,000	–	1	6.10
Cheng Yu Tung Family (Holdings II) Limited	Long position 好倉	Interest held by its controlled corporations 權益由其受控法團持有	123,764,027	–	2	15.26
Cheng Yu Tung Family (Holdings) Limited	Long position 好倉	Interest held by its controlled corporations 權益由其受控法團持有	123,764,027	–	2	15.26
Chow Tai Fook Capital Limited	Long position 好倉	Interest held by its controlled corporations 權益由其受控法團持有	123,764,027	–	2	15.26
Chow Tai Fook (Holding) Limited 周大福(控股)有限公司	Long position 好倉	Interest held by its controlled corporations 權益由其受控法團持有	123,764,027	–	2	15.26
Chow Tai Fook Enterprises Limited 周大福企業有限公司	Long position 好倉	Interest held by its controlled corporation 權益由其受控法團持有	123,764,027	–	2	15.26
The GBA Healthcare Holdings Limited 大灣區醫療控股有限公司	Long position 好倉	Beneficial owner 實益擁有人	123,764,027	–	2	15.26
China Resources Company Limited 中國華潤有限公司	Long position 好倉	Interest held by its controlled corporations 權益由其受控法團持有	91,803,000	–	3	11.32
CR Medical 華潤醫療	Long position 好倉	Beneficial owner 實益擁有人	91,803,000	–	3	11.32

Notes:

1. Dr. Sun Yiu Kwong was deemed to be interested in the 223,740,989 Shares held by East Majestic Group Limited, being his controlled corporation, and was also deemed to be interested in the 49,480,000 Shares held by EM Team Limited, also being his controlled corporation. Dr. Sun's interests in Shares are disclosed in this annual report in the section headed "Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company or its associated Corporations".

2. The GBA Healthcare Holdings Limited was wholly-owned by CTFE, which was wholly-owned by Chow Tai Fook (Holding) Limited ("CTFH"). CTFH was held as to 81.03% by Chow Tai Fook Capital Limited ("CTFC"), which was in turn held as to 48.98% by Cheng Yu Tung Family (Holdings) Limited ("CYTF") and as to 46.65% by Cheng Yu Tung Family (Holdings II) Limited ("CYTFII"). By virtue of the SFO, CTFE, CTFH, CTFC, CYTF and CYTFII were deemed to be interested in the same parcel of Shares in which The GBA Healthcare Holdings Limited was interested.

3. CR Medical was the beneficial owner of the Shares. CR Medical was held as to 35.76% by CRH (Medical) Limited. CRH (Medical) Limited was wholly owned by China Resources Healthcare Group Limited, which was wholly owned by CRH (Healthcare) Limited. CRH (Healthcare) Limited was wholly owned by China Resources (Holdings) Company Limited, which was wholly owned by CRC Bluesky Limited. CRC Bluesky Limited was wholly owned by China Resources Inc., which was wholly owned by China Resources Company Limited. Commotra Company Limited held 0.82% of CR Medical Commotra Company Limited is wholly owned by China Resources (Holdings) Company Limited. By virtue of the SFO, CRH (Medical) Limited, China Resources Healthcare Group Limited, CRH (Healthcare) Limited, China Resources Inc., China Resources (Holdings) Company Limited, CRC Bluesky Limited and China Resources Company Limited were deemed to be interested in the same parcel of Shares in which CR Medical was interested.

4. These percentages are calculated on the basis of 810,955,244 issued shares as at 30 June 2026.

附註：

1. 孫耀江醫生被視為於其受控法團East Majestic Group Limited持有的223,740,989股股份中擁有權益，亦被視為於同樣為其受控法團EM Team Limited持有的49,480,000股股份中擁有權益。孫醫生於股份的權益於本年報「董事及最高行政人員於本公司或其相聯法團的股份、相關股份及債券的權益及淡倉」一節披露。

2. 大灣區醫療控股有限公司由周大福企業全資擁有，而周大福企業由周大福(控股)有限公司(「周大福控股」)全資擁有。周大福控股由Chow Tai Fook Capital Limited(「CTFC」)持有81.03%的股權，而CTFC分別由Cheng Yu Tung Family (Holdings) Limited(「CYTF」)及Cheng Yu Tung Family (Holdings II) Limited(「CYTFII」)持有48.98%及46.65%的股權。根據證券及期貨條例，周大福企業、周大福控股、CTFC、CYTF及CYTFII被視為於大灣區醫療控股有限公司擁有權益的同一批股份中擁有權益。

3. 華潤醫療為股份之實益擁有人。華潤醫療由華潤集團(醫療)有限公司擁有35.76%。華潤集團(醫療)有限公司由華潤健康集團有限公司全資擁有，而華潤健康集團有限公司由華潤集團(健康)有限公司全資擁有。華潤集團(健康)有限公司由華潤(集團)有限公司全資擁有，而華潤(集團)有限公司由CRC Bluesky Limited全資擁有。CRC Bluesky Limited由華潤股份有限公司全資擁有，而華潤股份有限公司由中國華潤有限公司全資擁有。合貿有限公司持有CR Medical Commotra Company Limited的0.82%而CR Medical Commotra Company Limited由華潤(集團)有限公司全資擁有。根據證券及期貨條例，華潤集團(醫療)有限公司、華潤健康集團有限公司、華潤集團(健康)有限公司、華潤股份有限公司、華潤(集團)有限公司、CRC Bluesky Limited及中國華潤有限公司被視為於華潤醫療擁有權益的同一批股份中擁有權益。

4. 此等百分比乃按於2026年6月30日之810,955,244股已發行股份為基準計算。

Other than as disclosed above, as at 30 June 2026, the Directors have not been notified by any person (other than the Directors or Chief Executive of the Company) who had interests or short positions in the Shares or underlying shares of the Company as recorded in the register required to be kept pursuant to Section 336 of the SFO.

除上文所披露者外，截至2026年6月30日，董事並無獲任何人士(董事或本公司最高行政人員除外)通知其於本公司股份或相關股份中擁有根據證券及期貨條例第336條須存置的登記冊所記錄的權益或淡倉。

CONNECTED TRANSACTIONS

Save for certain relevant transactions mentioned in the section headed "Related Party Transactions" under the Notes to the Consolidated Financial Statements, none of such related party transactions constituted a non-exempt connected transaction or a continuing connected transaction of the Company pursuant to Chapter 14A of the Listing Rules. The Company has complied with the disclosure requirements under Chapter 14A of the Listing Rules for the connected transactions set out in this section as and where applicable and relevant.

關連交易

除於綜合財務報表附註下「關聯方交易」一節所述若干相關交易外，概無關聯方交易構成本公司根據上市規則第十四A章的非豁免關連交易或持續關連交易。本公司已於適當時候及按相關情況就本節所載關連交易遵守上市規則第十四A章的披露規定。

Non-exempt Continuing Connected Transactions

The Company has entered into certain non-exempt continuing connected transactions, the annual caps and the actual transaction amounts of which for FY2026 are set out as follows:

非豁免持續關連交易

本公司已訂立若干非豁免持續關連交易，其於2026財政年度的年度上限及實際交易金額載列如下：

	Continuing Connected Transactions 持續關連交易	Connected Persons 關連人士	Annual cap for the year ended 30 June 2026 截至2026年6月30日止年度的年度上限 (HK$'000) （千港元）	Actual transaction Amount for the year ended 30 June 2026 截至2026年6月30日止年度的實際交易金額 (HK$'000) （千港元）
A.	2024 Consultancy Renewal Agreement with Dr. Patrick Lee 與李柏祥醫生的2024年顧問重續協議	Dr. Lee Pak Cheung, Patrick 李柏祥醫生	7,000	4,138
B.	2024 Medical Services Framework Renewal Agreement 2024年醫療服務框架重續協議	CTFE 周大福企業	20,000	12,603
C.	2024 Consultancy Renewal Agreement with Dr. Michael Sun 與孫文堅醫生的2024年顧問重續協議	Dr. Sun Man Kin, Michael 孫文堅醫生	5,000	881

The above non-exempt continuing connected transactions are subject to reporting and announcement requirement but exempt from the independent shareholders' approval requirements. For further details, please refer to the announcements of the Company dated 26 June 2024 and 9 July 2024.

上述非豁免持續關連交易須遵守申報及公告規定但獲豁免遵守獨立股東批准規定。進一步詳情請參閱本公司日期為2024年6月26日及2024年7月9日之公告。

	Continuing Connected Transactions 持續關連交易	Connected Person 關連人士	Annual cap for the period from 1 July 2025 to 30 September 2025 由2025年7月1日至2025年9月30日期間的年度上限 (HK$'000) （千港元）	Actual transaction amount for the period from 1 July 2025 to 30 September 2025 由2025年7月1日至2025年9月30日期間的實際交易金額 (HK$'000) （千港元）
D(i).	Medical Services Agreement 醫療服務協議	Chow Tai Fook Life Insurance Company Limited 周大福人壽保險有限公司	20,000	13,319

The above non-exempt continuing connected transaction is subject to reporting, annual review, announcement and independent Shareholders' approval requirements. For further details, please refer to the announcements of the Company dated 1 October 2022, 7 October 2022 and 16 March 2023 and circulars of the Company dated 24 April 2023.

上述非豁免持續關連交易須遵守申報、年度審核、公告及獨立股東批准規定。進一步詳情請參閱本公司日期為2022年10月1日、2022年10月7日及2023年3月16日之公告以及本公司日期為2023年4月24日之通函。

	Continuing Connected Transactions 持續關連交易	Connected Person 關連人士	Annual cap for the period from 1 October 2025 to 31 December 2025 由2025年10月1日至2025年12月31日期間的年度上限 (HK$'000) (千港元)	Actual transaction amount for the period from 1 October 2025 to 31 December 2025 由2025年10月1日至2025年12月31日期間的實際交易金額 (HK$'000) (千港元)
D(ii).	2025 CTF Life Medical Services Agreement 2025年周大福人壽醫療服務協議	Chow Tai Fook Life Insurance Company Limited 周大福人壽保險有限公司	17,000	15,112

The above non-exempt continuing connected transaction is subject to reporting and announcement requirement but exempt from the independent shareholders' approval requirement. For further details, please refer to the announcement of the Company dated 30 September 2025.

上述非豁免持續關連交易須遵守申報及公告規定但獲豁免遵守獨立股東批准規定。進一步詳情請參閱本公司日期為2025年9月30日之公告。

	Continuing Connected Transactions 持續關連交易	Connected Person 關連人士	Annual cap for the period from 1 January 2026 to 30 June 2026 由2026年1月1日至2026年6月30日期間的年度上限 (HK$'000) (千港元)	Actual transaction amount for the period from 1 January 2026 to 30 June 2026 由2026年1月1日至2026年6月30日期間的實際交易金額 (HK$'000) (千港元)
D(iii).	2026 CTF Life Medical Services Agreement 2026年周大福人壽醫療服務協議	Chow Tai Fook Life Insurance Company Limited 周大福人壽保險有限公司	32,000	26,823

The above non-exempt continuing connected transaction is subject to reporting, annual review, announcement and independent Shareholders' approval requirements. For further details, please refer to the announcements of the Company dated 9 October 2025 and circular of the Company dated 6 November 2025.

上述非豁免持續關連交易須遵守申報、年度審核、公告及獨立股東批准規定。進一步詳情請參閱本公司日期2025年10月9日之公告及本公司日期為2025年11月6日之通函。

	Continuing Connected Transactions 持續關連交易	Connected Person 關連人士	Annual cap for the eleven months period ended 30 June 2026 截至2026年6月30日止11個月期間的年度上限 (HK$'000) (千港元)	Actual transaction amount for the eleven months period ended 30 June 2026 截至2026年6月30日止11個月期間的實際交易金額 (HK$'000) (千港元)
E.	Medical Services Framework Agreement with Pedder Healthcare 與仁德醫健的醫療服務框架協議	Pedder Healthcare Management Limited 仁德醫務健康管理有限公司		
	– Pedder Medical Related Services – 仁德醫療相關服務		50,000	39,607
	– UMP Medical Related Services – 聯合醫務醫療相關服務		30,000	14,087

The above non-exempt continuing connected transaction is subject to reporting and announcement requirement but exempt from the independent shareholders' approval requirement. For further details, please refer to the announcements of the Company dated 31 July 2025 and 14 October 2025.

上述非豁免持續關連交易須遵守申報及公告規定但獲豁免遵守獨立股東批准規定。進一步詳情請參閱本公司日期為2025年7月31日及2025年10月14日之公告。

A. 2024 Consultancy Renewal Agreement with Dr. Patrick Lee

On 26 June 2024, the Company entered into the 2024 Consultancy Renewal Agreement with Dr. Patrick Lee for a term up to 30 June 2027. Details of the 2024 Consultancy Renewal Agreement with Dr. Patrick Lee are set out below:

- Dr. Lee Pak Cheung, Patrick ("Dr. Patrick Lee") shall provide Dental Services to the Group;
- the annual fees charged by Dr. Patrick Lee to the Group shall be negotiated on an arm's length basis, and shall be on normal commercial terms which, from the Group's perspective, are expected to be no less favourable than those which the relevant members of the Group could obtain from independent consultants of similar expertise, experience and reputation for similar role, scope of services and responsibilities; and
- the 2024 Consultancy Renewal Agreement with Dr. Patrick Lee shall commence from the 1 July 2024 until 30 June 2027 and may be renewed by mutual consent of the parties.

The Company has made reference to historical aggregate fees paid by the Group for medical services provided by Dr. Patrick Lee of similar scope of services to ensure that the consultancy fees payable are fair and reasonable to the Company.

Dr. Patrick Lee is an executive Director, and accordingly, a connected person of the Company under Chapter 14A of the Listing Rules. The transactions contemplated under the 2024 Consultancy Renewal Agreement with Dr. Patrick Lee constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The annual cap for the consultancy fees paid by the Company to Dr. Patrick Lee for FY2026 was HK$7,000,000 and the actual amount paid or payable to Dr. Lee Pak Cheung, Patrick was HK$4,138,000.

A. 與李柏祥醫生的2024年顧問重續協議

於2024年6月26日，本公司與李柏祥醫生訂立為期至2027年6月30日的2024年顧問重續協議。與李柏祥醫生的2024年顧問重續協議的詳情載列如下：

- 李柏祥醫生(「李柏祥醫生」)須向本集團提供牙科服務；
- 李柏祥醫生向本集團收取的年度費用須經公平磋商後釐定，且須按一般商業條款訂立，並就本集團而言，預計不遜於本集團的相關成員公司就類似職位、範圍服務及職責從具備類似專業知識、經驗及聲譽的獨立顧問可獲得者；及
- 與李柏祥醫生的2024年顧問重續協議自2024年7月1日起至2027年6月30日止，可經雙方同意後續期。

本公司已參考本集團就李柏祥醫生提供類似服務範圍的醫療服務支付的過往費用總額，以確保應付顧問費用對本公司屬公平合理。

李柏祥醫生為執行董事，因此，根據上市規則第十四A章為本公司關連人士。根據上市規則第十四A章，與李柏祥醫生的2024年顧問重續協議項下擬進行的交易構成本公司的持續關連交易。

於2026財政年度，本公司已付李柏祥醫生顧問費用的年度上限為7,000,000港元，而已付或應付李柏祥醫生的實際金額為4,138,000港元。

B. 2024 Medical Services Framework Renewal Agreement

On 26 June 2024, the Company entered into the 2024 Medical Services Framework Renewal Agreement for a term up to 30 June 2027. Details of the 2024 Medical Services Framework Renewal Agreement are set out below:

- the Group shall provide Medical, Dental and Auxiliary Services to the employees of CTFE and its associates;
- the relevant members of the Group shall enter into individual agreements which prescribe specific terms and conditions, including scope of medical services, service amount, payment method and other terms;
- the terms of, and the service amounts payable under, each individual agreement will be negotiated on a case-by-case and on an arm's length basis, and shall be on normal commercial terms which, from the Group's perspective, are no less favourable than those which the relevant members of the Group could offer to independent third parties, with a comparable scope of services; and
- the 2024 Medical Services Framework Renewal Agreement shall commence from 1 July 2024 to 30 June 2027 (both days inclusive) and may be renewed by mutual consent of the parties.

The management has made reference to the prevailing price of medical services offered by the Group to other customers and the historical service fees the Company received for medical services with a similar scope to ensure that the service amounts payable during the service period are fair and reasonable to the Company.

CTFE is a substantial shareholder of the Company and, accordingly, a connected person of the Company under Chapter 14A of the Listing Rules. The transactions contemplated under the 2024 Medical Services Framework Renewal Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The annual cap for the aggregate fees to be received by the Company from CTFE for FY2026 was HK$20,000,000 and the actual amount received or receivable by the Company was HK$12,603,000.

B. 2024年醫療服務框架重續協議

於2024年6月26日，本公司訂立為期至2027年6月30日的2024年醫療服務框架重續協議。2024年醫療服務框架重續協議的詳情載列如下：

- 本集團應向周大福企業及其聯繫人的僱員提供醫療、牙科及輔助服務；
- 本集團的相關成員公司應訂立個別協議，訂明具體條款及條件，包括醫療服務的範圍、服務金額、付款方式及其他條款；
- 各個別協議的條款及其項下的應付服務金額將按個別情況經公平磋商後釐定，且應按一般商業條款訂立，並就本集團而言，不遜於本集團的相關成員公司就可資比較的服務範圍可向獨立第三方所提供者；及
- 2024年醫療服務框架重續協議自2024年7月1日起至2027年6月30日止（包括首尾兩日），可經雙方同意後續期。

管理層已參考本集團向其他客戶提供的醫療服務之現行價格及本公司就類似範圍醫療服務收取的過往服務費，以確保於服務期間應付的服務金額對本公司屬公平合理。

周大福企業為本公司主要股東，因此，根據上市規則第十四A章為本公司關連人士。根據上市規則第十四A章，2024年醫療服務框架重續協議項下擬進行的交易構成本公司的持續關連交易。

於2026財政年度，本公司將向周大福企業收取費用總額的年度上限為20,000,000港元，而本公司已收或應收的實際金額為12,603,000港元。

C. 2024 Consultancy Renewal Agreement with Dr. Michael Sun

On 26 June 2024, the Company entered into the 2024 Consultancy Renewal Agreement with Dr. Michael Sun for a term up to 30 June 2027. Details of the 2024 Consultancy Renewal Agreement with Dr. Michael Sun are set out below:

- Dr. Sun Man Kin, Michael ("Dr. Michael Sun") shall provide radiologist services to the Group;
- the consultancy fees payable under the 2024 Consultancy Renewal Agreement with Dr. Michael Sun shall be determined by the parties through arm's length negotiation and on normal commercial terms and based on the scope of services rendered by Dr. Michael Sun and with reference to the fees charged by independent consultants of similar expertise, experience and reputation with similar role, scope of services and responsibilities under similar circumstances to ensure that the terms are no less favourable to the Group than terms available by independent consultants; and
- the 2024 Consultancy Renewal Agreement with Dr. Michael Sun shall commence from 1 July 2024 until 30 June 2027 and may be renewed by mutual consent of the parties.

Dr. Michael Sun is an executive Director and is therefore a connected person of the Company pursuant to Rule 14A.07(1) of the Listing Rules. Therefore, the transactions contemplated under the 2024 Consultancy Renewal Agreement with Dr. Michael Sun constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The annual cap for the consultancy fees paid by the Company to Dr. Michael Sun for FY2026 was HK$5,000,000 and the actual amount paid or payable to Dr. Michael Sun was HK$881,000.

C. 與孫文堅醫生的2024年顧問重續協議

於2024年6月26日，本公司與孫文堅醫生訂立2024年顧問重續協議，期限直至2027年6月30日止。與孫文堅醫生的2024年顧問重續協議的詳情載列如下：

- 孫文堅醫生(「孫文堅醫生」)須向本集團提供放射科醫生服務；
- 根據與孫文堅醫生的2024年顧問重續協議應付的顧問費用應經各方公平磋商後按一般商業條款及基於孫文堅醫生所提供的服務範圍以及參考在類似情況下具備類似專業知識、經驗及聲譽的獨立顧問就類似角色、服務範圍及職責所收取的費用釐定，以確保就本集團而言，有關條款不遜於可從獨立顧問獲得的條款；及
- 與孫文堅醫生的2024年顧問重續協議自2024年7月1日起至2027年6月30日止，可經雙方同意後續期。

孫文堅醫生為執行董事，因此，根據上市規則第14A.07(1)條，其為本公司的關連人士。因此，與孫文堅醫生的2024年顧問重續協議項下擬進行的交易根據上市規則第14A章構成本公司的持續關連交易。

於2026財政年度，本公司已付孫文堅醫生顧問費用的年度上限為5,000,000港元，而已付或應付孫文堅醫生的實際金額為881,000港元。

D(i). Medical Services Agreement

- On 1 October 2022, UMP Professional Management Limited ("UMP Professional"), an indirect wholly-owned subsidiary of the Company, entered into a Medical Services Agreement with Chow Tai Fook Life Insurance Company Limited (Formerly known as: FTLife Insurance Company Limited) ("CTF Life") in respect of provision and administration of the Medical Services by UMP Professional (or procure its applicable affiliates) to the insured and/or policyholders of CTF Life ("CTF Life Members") and/or respective family members of policyholders of FTLife including spouse and children ("CTF Life Family Members").

- UMP Professional agreed (or procure its applicable affiliates) to provide and administer medical services to CTF Life Members and/or CTF Life Family Members, including (a) various administrative services including, among others, 24/7 hotline services, third-party administrative services and other ancillary digital support for CTF Life Members and/or CTF Life Family Members ("Administrative Services"); and (b) medical services including, among others, day procedures, diagnostic imaging services, in-patient surgical procedures, medical advice and other relevant services ("Clinical Services") (collectively, the "Medical Services").

- The term of the Medical Services Agreement shall be for three (3) years commencing from the 1 October 2022, unless terminated in accordance with the terms of the Medical Services Agreement.

D(i). 醫療服務協議

- 於2022年10月1日，本公司間接全資附屬公司聯合醫務專業管理有限公司(「聯合醫務專業」)與周大福人壽保險有限公司(前稱富通保險有限公司)(「周大福人壽」)訂立醫療服務協議，內容有關由聯合醫務專業(或促使其適用之聯屬公司)向周大福人壽之受保人及／或保單持有人(「周大福人壽成員」)及／或周大福人壽保單持有人各自之家庭成員(包括配偶及子女)(「周大福人壽家庭成員」)提供及管理醫療服務。

- 聯合醫務專業同意(或促使其適用之聯屬公司)向周大福人壽成員及／或周大福人壽家庭成員提供及管理醫療服務，包括(a)對象為周大福人壽成員及／或周大福人壽家庭成員的不同行政管理服務，包括(除其他服務外)24/7全天候熱線服務、第三方行政管理服務及其他配套數碼支援(「行政管理服務」)；及(b)醫療服務，包括(除其他服務外)日間手術、診斷影像服務、住院手術、醫療建議及其他相關服務(「臨床服務」)(統稱「醫療服務」)。

- 除非根據醫療服務協議之條款終止，否則醫療服務協議之期限為自2022年10月1日起計三(3)年。

- The actual demand for the Medical Services under the Medical Services Agreement has exceeded the original expectations which has resulted in a corresponding increase in the total amount of service fees payable by CTF Life to UMP Professional under such agreement. As such, the aggregate amount of service fees payable by CTF Life to UMP Professional under the Medical Services Agreement are expected to be higher than the level envisaged at the time when the parties entered into the Medical Services Agreement. On 11 May 2023, an extraordinary general meeting approved the annual caps (revised) and the transactions contemplated thereunder.

- 對醫療服務協議項下醫療服務之實際需求已超出原先預期，導致周大福人壽根據該協議應付聯合醫務專業之服務費總額相應增加。因此，預期周大福人壽根據醫療服務協議應付聯合醫務專業之服務費總額將高於雙方訂立醫療服務協議時所預計之水平。於2023年5月11日，在股東特別大會上批准了年度上限(經修訂)及據此擬進行之交易。

- The annual cap for the period from 1 July 2025 to 30 September 2025 received by UMP Professional from CTF Life was HK$20,000,000 and the actual amount received or receivable by UMP Professional was HK$13,319,000.

- 聯合醫務專業向周大福人壽收取之由2025年7月1日至2025年9月30日期間的年度上限為20,000,000港元，而聯合醫務專業已收或應收的實際金額為13,319,000港元。

D(ii). 2025 CTF Life Medical Services Agreement

D(ii). 2025年周大福人壽醫療服務協議

- On 30 September 2025, UMP Professional entered into the 2025 CTF Life Medical Services Agreement with CTF Life in respect of provision and administration of the Medical Services by UMP Professional (or procure its applicable affiliates) to CTF Life Members and/or CTF Life Family Members.

- 於2025年9月30日，聯合醫務專業與周大福人壽訂立2025年周大福人壽醫療服務協議，內容有關由聯合醫務專業(或促使其適用之聯屬公司)向周大福人壽成員及／或周大福人壽家庭成員提供及管理醫療服務。

- The term of the 2025 CTF Life Medical Services Agreement shall be for a period of three months commencing from 1 October 2025 unless terminated in accordance with the terms of the 2025 CTF Life Medical Services Agreement.

- 除非根據2025年周大福人壽醫療服務協議之條款終止，否則2025年周大福人壽醫療服務協議之期限為自2025年10月1日起計之三個月期間。

- The annual cap for the period from 1 October 2025 to 31 December 2025 received by UMP Professional from CTF Life was HK$17,000,000 and the actual amount received or receivable by UMP Professional was HK$15,112,000.

- 聯合醫務專業向周大福人壽收取之由2025年10月1日至2025年12月31日期間的年度上限為17,000,000港元，而聯合醫務專業已收或應收的實際金額為15,112,000港元。

D(iii). 2026 CTF Life Medical Services Agreement

- On 9 October 2025, UMP Professional entered into the 2026 CTF Life Medical Services Agreement with CTF Life in respect of provision and administration of the Medical Services by UMP Professional (or its applicable affiliates) to CTF Life Members and/or CTF Life Family Members for a further term of two years and six months commencing from 1 January 2026.

- The term of the 2026 CTF Life Medical Services Agreement shall be for a period of two years and six months commencing from 1 January 2026 unless terminated in accordance with the terms thereof.

- The annual cap for the period from 1 January 2026 to 30 June 2026 received by UMP Professional from CTF Life was HK$32,000,000 and the actual amount received or receivable by UMP Professional was HK$26,823,000.

CTF Life is an indirect wholly-owned subsidiary of CTF Services Limited which in turn is a subsidiary of CTFE, whereas CTFE is a substantial shareholder of the Company. Hence, CTF Life is a connected person of the Company and the transactions contemplated under the Medical Services Agreement, 2025 CTF Life Medical Services Agreement and 2026 CTF Life Medical Services Agreement constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

D(iii). 2026年周大福人壽醫療服務協議

- 於2025年10月9日，聯合醫務專業與周大福人壽訂立2026年周大福人壽醫療服務協議，內容有關由聯合醫務專業(或其適用之聯屬公司)向周大福人壽成員及／或周大福人壽家庭成員提供及管理醫療服務，該協議自2026年1月1日起續期兩年六個月。

- 除非根據2026年周大福人壽醫療服務協議之條款終止，否則2026年周大福人壽醫療服務協議之期限為自2026年1月1日起計之兩年六個月期間。

- 聯合醫務專業向周大福人壽收取之由2026年1月1日至2026年6月30日期間的年度上限為32,000,000港元，而聯合醫務專業已收或應收的實際金額為26,823,000港元。

周大福人壽為周大福創建有限公司之間接全資附屬公司，而周大福創建有限公司為周大福企業(本公司之主要股東)之附屬公司。因此，周大福人壽為本公司之關連人士，而根據上市規則第14A章，醫療服務協議、2025年周大福人壽醫療服務協議及2026年周大福人壽醫療服務協議項下擬進行之交易構成本公司之持續關連交易。

E. Medical Services Framework Agreement with Pedder Healthcare

On 31 July 2025, the Company entered into the Medical Services Framework Agreement ("Framework Agreement") with Pedder Healthcare Management Limited ("Pedder Healthcare") for a term commencing from 1 August 2025 to 30 June 2028. Details of the Framework Agreement are set out below:

- *Pedder Medical Related Services*

  Pedder Healthcare, its subsidiary or its holding company or a subsidiary of any such holding company and/or its affiliates ("Pedder Healthcare Group") had, on a non-exclusive basis, provided medical related services to the Group, including (i) medical consultation services to plan members under corporate healthcare benefit plans of the Group (as one of the affiliates of the Group's network of healthcare providers; (ii) medical consultation services to the Group through arranging or procuring its medical practitioners to provide medical services (including inpatient and/or outpatient services) to the Group; (iii) clinical administration and personnel support services; (iv) advisory and consulting support services; and (v) other auxiliary services. The services were charged at terms mutually agreed between the relevant parties.

- *UMP Medical Related Services*

  The Group had, on a non-exclusive basis, provided (i) diagnostic, imaging and laboratory tests services; (ii) licensing and/or sub-leases of premises; (iii) medical consultation services to the Pedder Healthcare Group through arranging or procuring its medical practitioners to provide medical services (including inpatient and/or outpatient services) to Pedder Healthcare Group; and (iv) other auxiliary services. The services were charged at terms mutually agreed between the relevant parties.

- The term of the Framework Agreement is two years and eleven months commencing on 1 August 2025 and ending on 30 June 2028.

E. 與仁德醫健的醫療服務框架協議

於2025年7月31日，本公司與仁德醫務健康管理有限公司(「仁德醫健」)訂立醫療服務框架協議(「框架協議」)，由2025年8月1日起至2028年6月30日止。框架協議的詳情載列如下：

- *仁德醫療相關服務*

  仁德醫健、其附屬公司或其控股公司或任何有關控股公司之附屬公司及／或其聯屬公司之任何公司(統稱「仁德醫健集團」)以非獨家方式向本集團提供醫療相關服務，包括(i)向本集團公司醫療保健福利計劃項下的計劃成員提供醫療諮詢服務(作為本集團醫療保健提供者網絡的聯屬公司之一)；(ii)透過安排或獲取其醫療從業人員向本集團提供醫療服務(包括住院及／或門診服務)而向本集團提供醫療諮詢服務；(iii)臨床管理及人事支援服務；(iv)顧問及諮詢支援服務；及(v)其他輔助服務。該等服務以相關方相互協定的條款收費。

- *聯合醫務醫療相關服務*

  本集團已按非獨家方式提供(i)診斷、影像及化驗服務；(ii)物業的牌照辦理及／或分租事宜；(iii)透過安排或促使其醫療從業人員向仁德醫健集團提供醫療服務(包括住院及／或門診服務)而向仁德醫健集團提供醫療諮詢服務；及(iv)其他輔助服務。該等服務以相關方相互協定的條款收費。

- 框架協議年期自2025年8月1日起計至2028年6月30日止為期兩年十一個月。

Pedder Healthcare is a subsidiary of a substantial shareholder of a number of subsidiaries of the Company and thus a connected person of the Company at subsidiary level. The transactions contemplated under the Framework Agreement therefore constitute continuing connected transactions of the Company with connected person at the subsidiary level for the purpose of Chapter 14A of the Listing Rules. Pursuant to Rule 14A.101 of the Listing Rules, the transactions contemplated under the Framework Agreement are subject to the reporting and announcement requirements but are exempt from the circular, independent financial advice and Shareholders' approval requirements under Chapter 14A of the Listing Rules.

仁德醫健為本公司多間附屬公司的主要股東的附屬公司，故於附屬公司層面為本公司之關連人士。因此，就上市規則第14A章而言，框架協議項下擬進行之交易構成本公司與附屬公司層面之關連人士的持續關連交易。根據上市規則第14A.101條，框架協議項下擬進行之交易須遵守申報及公告規定，惟獲豁免遵守上市規則第14A章項下的通函、獨立財務意見及股東批准之規定。

The annual cap for the services provided by Pedder Healthcare Group to the Group for the eleven months period ended 30 June 2026 was HK$50,000,000 and the actual amount paid or payable to Pedder Healthcare Group was HK$39,607,000.

本集團向仁德醫健集團提供之截至2026年6月30日止十一個月的服務年度上限為50,000,000港元，而已付或應付仁德醫健集團的實際金額為39,607,000港元。

The annual cap for the services provided by the Group to Pedder Healthcare Group for the eleven months period ended 30 June 2026 was HK$30,000,000 and the actual amount paid or payable to the Group was HK$14,087,000.

本集團向仁德醫健集團提供之截至2026年6月30日止十一個月的服務年度上限為30,000,000港元，而已付或應付本集團的實際金額為14,087,000港元。

The Company's independent non-executive Directors have reviewed the above non-exempt continuing connected transactions for the year ended 30 June 2026 and confirmed that:

本公司獨立非執行董事已審核上述截至2026年6月30日止年度的非豁免持續關連交易，並確認：

(a) the transactions have been entered into by the Group in the ordinary and usual course of its business;

(a) 該等交易乃由本集團於日常及一般業務過程中訂立；

(b) the transactions have been entered into either (i) on normal commercial terms or (ii) (where there are not sufficient comparable transactions to judge whether they are on normal commercial terms) on terms no less favourable to the Group than terms available to or from (as appropriate) independent third parties; and

(b) 該等交易乃按(i)一般商業條款或(ii)倘沒有足夠的可比較交易判斷該等交易是否按一般商業條款訂立)就本集團而言不遜於向獨立第三方提供或取得(按適用)的條款訂立；及

(c) the transactions have been entered into in accordance with the relevant agreement governing them on terms that are fair and reasonable and in the interests of the Shareholders as a whole.

(c) 該等交易乃根據相關規管協議訂立，條款屬公平合理並符合股東的整體利益。

KPMG, the Company's auditors, were engaged to report on the Group's continuing connected transactions in accordance with Hong Kong Standard on Assurance Engagements 3000 Assurance Engagements Other Than Audits or Reviews of Historical Financial Information and with reference to Practice Note 740 (Revised) Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules issued by the Hong Kong Institute of Certified Public Accountants. KPMG have issued their unqualified letter containing their findings and conclusions in respect of the continuing connected transactions disclosed above by the Group in accordance with Rule 14A.56 of the Listing Rules.

本公司核數師畢馬威會計師事務所受委聘就本集團之持續關連交易，按照香港會計師公會所頒佈的香港核證工作準則3000「歷史財務信息審計或審閱以外的鑒證業務」，以及參照《實務説明》第740號（經修訂）「關於香港《上市規則》所述持續關連交易的核數師函件」進行報告。畢馬威會計師事務所已按上市規則第14A.56條發出無保留信函，包含其對有關本集團於上文披露的持續關連交易作出之調查及結論。

The Company's auditors have reported to the Directors that (i) nothing has come to their attention that causes them to believe that the disclosed continuing connected transactions have not been approved by the Board; (ii) for transactions including the provision of goods or services by the Group, nothing has come to their attention that causes them to believe that the transactions were not, in all material respects, in accordance with the pricing policies of the Group; (iii) nothing has come to their attention that causes them to believe that the disclosed continuing connected transactions were not entered into, in all material respects, in accordance with the relevant agreements governing such transactions; and (iv) with respect to the aggregate amount of each of the above continuing connected transactions, nothing has come to their attention that causes them to believe that the disclosed continuing connected transactions have exceeded the annual cap as set by the Company.

本公司核數師已向董事報告，(i)彼等並不知悉有任何事宜，導致彼等相信董事會未有批准已披露之持續關連交易；(ii)就包括本集團提供產品或服務之交易而言，彼等並不知悉有任何事宜，導致彼等相信該等交易在各重要方面並非按照本集團之定價政策進行；(iii)彼等並不知悉有任何事宜，導致彼等相信該等已披露之持續關連交易在各重要方面並非按照規管該等交易之相關協議進行；及(iv)就上述持續關連交易各自總額而言，彼等並不知悉有任何事宜，導致彼等相信已披露之持續關連交易已超出本公司設定之年度上限。

MANAGEMENT CONTRACTS

The Company has not entered into any contract with any individual, firm or body corporate to manage or administer the whole or any substantial part of any business of the Group during FY2026.

管理合約

於2026財政年度，本公司並無與任何個人、公司或法人團體訂立任何合約以管理或管治本集團全部或大部分業務。

EQUITY-LINKED AGREEMENTS

Save for the Share Option Schemes and Share Award Scheme as disclosed on pages 134 to 146 of this annual report, no equity-linked agreements were entered into by the Company, or existed during FY2026.

股權掛鈎協議

除本年報第134至146頁所披露的購股權計劃及股份獎勵計劃外，於2026財政年度內，本公司並無訂立亦不存在任何股權掛鈎協議。

PRE-EMPTIVE RIGHTS

There are no provision for pre-emptive rights under the Articles of Association or the relevant laws of the Cayman Islands where the Company is incorporated which would oblige the Company to offer new shares on a pro-rata basis to existing Shareholders.

優先購買權

公司細則或開曼群島（即本公司註冊成立地點）相關法例均無規定本公司須按比例向現有股東提呈新股份的優先購買權條文。

SUFFICIENCY OF THE PUBLIC FLOAT

Based on the information publicly available to the Company, and to the best knowledge, information and belief of the Directors, the Directors confirm that the Company had maintained a sufficient public float as required under the Listing Rules during FY2026.

足夠公眾持股量

就本公司所得之公開資料，並根據董事所深知，所悉及所信，董事確認於2026財政年度本公司已維持上市規則所規定之充足公眾持股量。

AUDITOR

KPMG retire and a resolution for their reappointment as auditor of the Company will be proposed at the forthcoming 2026 AGM.

核數師

畢馬威會計師事務所退任，本公司將於應屆2026年股東週年大會上提呈一項有關重新委聘其作為本公司核數師的決議案。

On behalf of the Board
Dr. Sun Yiu Kwong
Chairman

代表董事會
孫耀江醫生
主席

Hong Kong, 24 September 2026

香港，2026年9月24日

To the shareholders of UMP Healthcare Holdings Limited
(Incorporated in the Cayman Islands with limited liability)

致聯合醫務集團有限公司列位股東
(於開曼群島註冊成立之有限公司)

OPINION

We have audited the consolidated financial statements of UMP Healthcare Holdings Limited ("the Company") and its subsidiaries ("the Group") set out on pages 171 to 304, which comprise the consolidated statement of financial position as at 30 June 2026, the consolidated statement of profit or loss, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended and notes, comprising material accounting policy information and other explanatory information.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 30 June 2026 and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with HKFRS Accounting Standards as issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

意見

我們已審計列載於第171至304頁的聯合醫務集團有限公司(「貴公司」)及其附屬公司(以下統稱「貴集團」)的綜合財務報表,此綜合財務報表包括於2026年6月30日的綜合財務狀況表與截至該日止年度的綜合損益表、綜合全面收入表、綜合權益變動表及綜合現金流量表以及附註,包括重大會計政策資料及其他解釋資料。

我們認為,該等綜合財務報表已根據香港會計師公會頒佈的《香港財務報告準則會計準則》真實而中肯地反映了 貴集團於2026年6月30日的綜合財務狀況及截至該日止年度的綜合財務表現及綜合現金流量,並已遵照香港《公司條例》的披露規定妥為擬備。

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") as issued by the HKICPA. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the HKICPA's *Code of Ethics for Professional Accountants* ("the Code"), as applicable to audits of financial statements of public interest entities. We have also fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

意見的基礎

我們已根據香港會計師公會頒佈的《香港審計準則》進行審計。我們在該等準則下承擔的責任已在本報告「*核數師就審計綜合財務報表承擔的責任*」部分中作進一步闡述。根據香港會計師公會頒佈的《*專業會計師道德守則*》(以下簡稱「守則」),其適用於公眾利益實體財務報表的審計。我們並已履行守則中的其他道德責任。我們相信,我們所獲得的審計憑證能充足及適當地為我們的審計意見提供基礎。

KEY AUDIT MATTERS

Key audit matter is the matter that, in our professional judgement, was of most significance in our audit of the consolidated financial statements of the current period. This matter was addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on this matter.

關鍵審計事項

關鍵審計事項是根據我們的專業判斷，認為對本期綜合財務報表的審計最為重要的事項。這事項是在對綜合財務報表整體進行審計並形成意見的背景下進行處理的。我們不對這事項提供單獨的意見。

Assessing potential impairment of goodwill and indefinite-lived intangible assets
評估商譽及無限年期的無形資產之潛在減值

Refer to note 18 to the consolidated financial statements and the accounting policy note 2.4.
請參閱綜合財務報表附註18及會計政策附註2.4。

The Key Audit Matter **關鍵審計事項**	**How the matter was addressed in our audit** **我們的審計如何處理關鍵審計事項**
As at 30 June 2026, the Group has goodwill of HK$76 million and indefinite-lived intangible assets of HK$40 million, representing 11.7% and 6.1% of the Group's net assets, respectively. 於2026年6月30日， 貴集團擁有商譽76百萬港元及無限年期的無形資產40百萬港元，分別相當於 貴集團資產淨值的11.7%及6.1%。 Management performs impairment assessments of the goodwill and indefinite-lived intangible assets which arose from business combinations annually, or more frequently if events or changes in circumstances indicate that it might be impaired. 管理層每年對業務合併所產生之商譽及無限年期的無形資產進行減值評估，或有事件或情況變化顯示其可能出現減值時更頻密地進行減值評估。 In performing such impairment assessments, management compares the carrying value of each of the separately identifiable cash-generating units ("CGUs") to which goodwill and indefinite-lived intangible assets have been allocated with their respective recoverable amounts based on the greater of their fair value less costs of disposal and value in use as determined by discounted cash flow forecasts to determine if any impairment loss should be recognised. 於進行該等減值評估時，為釐定應否確認任何減值虧損，管理層將各項獲分配商譽及無限年期的無形資產之獨立可識別現金產生單位(「現金產生單位」)的賬面值與其各自可收回金額進行比較，可收回金額乃根據公允價值減出售成本及使用價值之較高者按貼現現金流量預測釐定。	Our audit procedures to assess potential impairment of goodwill and indefinite-lived intangible assets included the following: 我們在評估商譽及無限年期的無形資產之潛在減值時採用的審計程序如下： • assessing the management's identification of CGUs and the allocation of assets to each CGU; 評估管理層對現金產生單位的識別方式，以及向各現金產生單位分配的資產； • with the assistance of our valuation specialists, assess the methodology adopted by management in its impairment assessments of goodwill and indefinite-lived intangible assets with reference to the requirements of the prevailing accounting standards; 在我們估值專家的協助下，經參考現行會計準則的要求後，評核管理層在評估商譽及無限年期的無形資產之減值時所採用的方法；

KEY AUDIT MATTERS (Continued) 關鍵審計事項(續)

Assessing potential impairment of goodwill and indefinite-lived intangible assets
評估商譽及無限年期的無形資產之潛在減值

Refer to note 18 to the consolidated financial statements and the accounting policy note 2.4.
請參閱綜合財務報表附註18及會計政策附註2.4。

The Key Audit Matter **關鍵審計事項**	**How the matter was addressed in our audit** **我們的審計如何處理關鍵審計事項**
The preparation of discounted cash flow forecasts for the purpose of assessing potential impairment of goodwill and indefinite-lived intangible assets involves estimating future cash flows generated from business and certain assumptions, including revenue growth rates and discount rates, which can be inherently uncertain. 為評估商譽及無限年期的無形資產之潛在減值而編備貼現現金流量預測時，會涉及估計業務所得的未來現金流量以及若干本身存有不確定因素的假設(包括收入增長率及貼現率)。 We identified the assessment of potential impairment of goodwill and indefinite-lived intangible assets as a key audit matter because the year-end impairment assessments performed by management contain certain judgemental assumptions which could be subject to management bias. 我們將對商譽及無限年期的無形資產之潛在減值評估列為關鍵審計事項，此乃由於管理層於年結評估減值時會納入若干判斷假設，其可能會受管理層之偏見所影響。	• evaluating the key assumptions, including revenue growth rates adopted in the preparation of the cash flow forecasts for the purpose of the impairment assessments of goodwill and indefinite-lived intangible assets, with reference to our understanding of the business, historical trends, available industry information and available market data; 參考我們對業務、歷史趨勢、所取得行業資訊及市場數據的了解後，評核為評估商譽及無限年期的無形資產之減值而編備現金流量預測所採用的主要假設(包括收入增長率)； • with the assistance of our valuation specialist, assessing whether the discount rates applied in the discounted cash flow forecasts prepared for the purpose of assessing potential impairment of goodwill and indefinite-lived intangible assets were within a reasonable range by comparing with companies operating in the same industry; 在我們估值專家的協助下，透過與同業公司進行比較，評核就評估商譽及無限年期的無形資產之潛在減值而編備貼現現金流量預測所採用的貼現率是否屬合理範圍內；

KEY AUDIT MATTERS (Continued) 關鍵審計事項(續)

Assessing potential impairment of goodwill and indefinite-lived intangible assets
評估商譽及無限年期的無形資產之潛在減值

Refer to note 18 to the consolidated financial statements and the accounting policy note 2.4.
請參閱綜合財務報表附註18及會計政策附註2.4。

The Key Audit Matter 關鍵審計事項	How the matter was addressed in our audit 我們的審計如何處理關鍵審計事項
	• comparing the cashflow forecasts prepared at the end of last year for the purpose of impairment assessments with the actual performance of the businesses for the current year to assess how accurate the cash flow forecasts were, making enquiries of management as to the reasons for any significant variations identified and considering if there was any indication of management bias; and 將去年就減值評估而編備的現金流量預測與本年度業務的實際表現進行比較，以評核現金流量預測的準確程度，並向管理層查詢所發現任何重大變動的原因，以及考慮否存在任何管理層偏見的跡象；及 • performing sensitivity analyses on the key assumptions, including revenue growth rate and the discount rates, adopted in the discounted cash flow forecasts on the conclusions reached in the impairment assessments and assessing whether there were any indicators of management bias in the selection of these assumptions. 根據減值評估得出的結論，對貼現現金流量預測採用的主要假設(包括收入增長率及貼現率)進行敏感度分析，並評估在挑選該等假設時是否存在任何管理層偏見的跡象。

INFORMATION OTHER THAN THE CONSOLIDATED FINANCIAL STATEMENTS AND AUDITOR'S REPORT THEREON

The directors are responsible for the other information. The other information comprises all the information included in the annual report, other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon as part of our engagement to audit the consolidated financial statements. We have performed an assurance engagement on the disclosed continuing connected transactions that form part of the other information and provided a separate assurance practitioner's conclusion thereon that is included within the other information.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF THE DIRECTORS FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRS Accounting Standards as issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

The directors are assisted by the Audit Committee in discharging their responsibilities for overseeing the Group's financial reporting process.

綜合財務報表以及其核數師報告以外的信息

董事須對其他信息負責。其他信息包括刊載於年度報告內的所有信息，但不包括綜合財務報表及我們的核數師報告。

我們對綜合財務報表的意見並不涵蓋其他信息，我們亦不對該等其他信息發表任何形式的鑒證結論作為我們審計綜合財務報表的項目的一部分。我們已為作為其他信息一部份的已披露持續關連交易進行鑒證工作，並就此提供載列於其他信息內的獨立鑒證執業人員結論。

結合我們對綜合財務報表的審計，我們的責任是閱讀其他信息，在此過程中，考慮其他信息是否與綜合財務報表或我們在審計過程中所了解的情況存在重大抵觸或者似乎存在重大錯誤陳述的情況。

基於我們已執行的工作，如果我們認為其他信息存在重大錯誤陳述，我們需要報告該事實。在這方面，我們沒有任何報告。

董事就綜合財務報表須承擔的責任

董事須負責根據香港會計師公會頒佈的《香港財務報告準則會計準則》及香港《公司條例》的披露規定擬備真實而中肯的綜合財務報表，並對其認為為使綜合財務報表的擬備不存在由於欺詐或錯誤而導致的重大錯誤陳述所需的內部監控負責。

在擬備綜合財務報表時，董事負責評估　貴集團持續經營的能力，並在適用情況下披露與持續經營有關的事項，以及使用持續經營為會計基礎，除非董事有意將　貴集團清盤或停止經營，或別無其他實際的替代方案。

審核委員會協助董事履行職責，監督　貴集團的財務報告過程。

INDEPENDENT AUDITOR'S REPORT
獨立核數師報告

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. This report is made solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

核數師就審計綜合財務報表承擔的責任

我們的目標，是對綜合財務報表整體是否不存在由於欺詐或錯誤而導致的重大錯誤陳述取得合理保證，並出具包括我們意見的核數師報告。我們僅對全體成員作出報告，除此以外，本報告並無其他用途。我們不會就核數師報告的內容向任何其他人士負上或承擔任何責任。

合理保證是高水平的保證，但不能保證按照《香港審計準則》進行的審計，在某一重大錯誤陳述存在時總能發現。錯誤陳述可以由欺詐或錯誤引起，如果合理預期它們單獨或匯總起來可能影響綜合財務報表使用者依賴綜合財務報表所作出的經濟決定，則有關的錯誤陳述可被視作重大。

在根據《香港審計準則》進行審計的過程中，我們運用了專業判斷，並保持了專業懷疑態度。我們亦：

- 識別和評估由於欺詐或錯誤而導致綜合財務報表存在重大錯誤陳述的風險，設計及執行審計程序以應對這些風險，以及獲取充足和適當的審計憑證，作為我們意見的基礎。由於欺詐可能涉及串謀、偽造、蓄意遺漏、虛假陳述，或凌駕於內部監控之上，因此未能發現因欺詐而導致的重大錯誤陳述的風險高於未能發現因錯誤而導致的重大錯誤陳述的風險。

- 了解與審計相關的內部監控，以設計適當的審計程序，但目的並非對　貴集團內部監控的有效性發表意見。

- 評價董事所採用會計政策的恰當性及作出會計估計和相關披露的合理性。

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Plan and perform the Group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the Group financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the Group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and, where applicable, actions taken to eliminate threats or safeguards applied.

核數師就審計綜合財務報表承擔的責任(續)

- 對董事採用持續經營會計基礎的恰當性作出結論。根據所獲取的審計憑證，確定是否存在與事項或情況有關的重大不確定性，從而可能導致對　貴集團的持續經營能力產生重大疑慮。如果我們認為存在重大不確定性，則有必要在核數師報告中提請使用者注意綜合財務報表中的相關披露。假若有關的披露不足，則我們應當發表非無保留意見。我們的結論是基於核數師報告日止所取得的審計憑證。然而，未來事項或情況可能導致　貴集團不能持續經營。

- 評價綜合財務報表的整體列報方式、結構和內容，包括披露，以及綜合財務報表是否中肯反映相關交易和事項。

- 規劃及執行集團審計，以就　貴集團內實體或業務單位的財務信息獲取充足、適當的審計憑證，作為對　貴集團財務報表形成意見的依據。我們負責就集團審計而執行的審計工作的方向、監督和覆核。我們為審計意見承擔全部責任。

除其他事項外，我們與審核委員會溝通了計劃的審計範圍、時間安排、重大審計發現等，包括我們在審計中識別出內部監控的任何重大缺陷。

我們還向審核委員會提交聲明，說明我們已符合有關獨立性的相關專業道德要求，並與他們溝通有可能合理地被認為會影響我們獨立性的所有關係和其他事項，以及在適用的情況下，已採取的行動以消除威脅及已應用的防範措施。

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

From the matters communicated with the Audit Committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Chui Kin Pong (practising certificate number: P06609).

核數師就審計綜合財務報表承擔的責任(續)

從與審核委員會溝通的事項中，我們確定哪些事項對本期綜合財務報表的審計最為重要，因而構成關鍵審計事項。我們在核數師報告中描述這些事項，除非法律法規不允許公開披露這些事項，或在極端罕見的情況下，如果合理預期在我們報告中溝通某事項造成的負面後果超過產生的公眾利益，我們決定不應在報告中溝通該事項。

出具本獨立核數師報告的審計項目合夥人是徐建邦(執業證書編號：P06609)。

KPMG
Certified Public Accountants

8th Floor, Prince's Building
10 Chater Road
Central, Hong Kong
24 September 2026

畢馬威會計師事務所
執業會計師

香港中環
遮打道十號
太子大廈八樓
2026年9月24日

CONSOLIDATED STATEMENT OF PROFIT OR LOSS
綜合損益表

For the year ended 30 June 2026
截至2026年6月30日止年度

		Notes 附註	**2026 2026年 HK$'000 千港元**	2025 2025年 HK$'000 千港元
REVENUE	**收入**	5	**716,971**	726,949
Other income and gains	其他收入及收益	6	**12,603**	14,181
Professional services expenses	專業服務費用		**(262,639)**	(256,997)
Employee benefit expenses	僱員福利開支		**(184,567)**	(180,015)
Property rental and related expenses	物業租金及相關開支		**(15,436)**	(15,383)
Cost of inventories consumed	已耗存貨成本		**(59,858)**	(56,733)
Depreciation and amortisation	折舊及攤銷		**(97,527)**	(105,806)
Other expenses	其他開支		**(167,498)**	(77,897)
Finance cost	融資成本	8	**(6,304)**	(7,345)
Share of (losses)/profits of:	分佔(虧損)／利潤：			
Joint ventures	合資公司		**(1,426)**	(1,983)
Associates	聯營公司		**930**	1,528
(LOSS)/PROFIT BEFORE TAX	**除稅前(虧損)／利潤**	7	**(64,751)**	40,499
Income tax expense	所得稅費用	11	**(7,974)**	(8,583)
(LOSS)/PROFIT FOR THE YEAR	**年內(虧損)／利潤**		**(72,725)**	31,916
Attributable to:	以下各方應佔：			
Owners of the Company	本公司擁有人		**(74,639)**	31,440
Non-controlling interests	非控股權益		**1,914**	476
			(72,725)	31,916
(LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY	**本公司普通權益持有人應佔每股(虧損)／盈利**	13		
Basic	基本		**HK(9.42) cents港仙**	HK3.98 cents港仙
Diluted	攤薄		**HK(9.42) cents港仙**	HK3.98 cents港仙

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
綜合全面收入表

For the year ended 30 June 2026
截至2026年6月30日止年度

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
(LOSS)/PROFIT FOR THE YEAR	**年內(虧損)／利潤**	**(72,725)**	31,916
OTHER COMPREHENSIVE (LOSS)/ INCOME	**其他全面(虧損)／收入**		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:	於其後期間可能重新分類至損益的其他全面收入：		
Exchange differences on translation of operations outside Hong Kong	折算香港以外業務的匯兑差額	**1,129**	1,564
Other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods:	於其後期間不會重新分類至損益的其他全面(虧損)／收入：		
Changes in fair value of equity investments designated at fair value through other comprehensive income	指定為按公允價值計入其他全面收入之股本投資的公允價值變動	**(2,925)**	9,819
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR, NET OF TAX	**年內其他全面(虧損)／收入，扣除税項**	**(1,796)**	11,383
TOTAL COMPREHENSIVE (LOSS)/ INCOME FOR THE YEAR	**年內全面(虧損)／收入總額**	**(74,521)**	43,299
Attributable to:	以下各方應佔：		
Owners of the Company	本公司擁有人	**(76,435)**	42,823
Non-controlling interests	非控股權益	**1,914**	476
		(74,521)	43,299

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
綜合財務狀況表

As at 30 June 2026
於2026年6月30日

		Notes 附註	**2026** **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
NON-CURRENT ASSETS	**非流動資產**			
Property, plant and equipment	物業、廠房及設備	14	**141,483**	177,928
Right-of-use assets	使用權資產	15(a)	**88,229**	96,506
Goodwill	商譽	16	**76,264**	156,604
Other intangible assets	其他無形資產	17	**40,084**	37,892
Investments in joint ventures	於合資公司的投資	19	**3,753**	5,179
Investments in associates	於聯營公司的投資	20	**2,452**	3,924
Investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資	22	**37,019**	40,272
Deferred tax assets	遞延稅項資產	33	**25,901**	27,848
Deposits and other receivables	保證金及其他應收款項	25	**18,749**	12,367
Total non-current assets	非流動資產總額		**433,934**	558,520
CURRENT ASSETS	**流動資產**			
Inventories	存貨	23	**15,275**	14,612
Trade receivables	貿易應收款項	24	**125,360**	120,684
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	25	**26,443**	37,056
Finance lease receivables	應收融資租賃	15(e)	**–**	1,876
Financial assets at fair value through profit or loss	按公允價值計入損益的金融資產	26	**36,573**	38,864
Amounts due from associates	應收聯營公司款項	27	**3,066**	4,493
Amounts due from joint ventures	應收合資公司款項	27	**424**	26
Amounts due from related companies	應收關聯公司款項	28	**10,715**	10,252
Tax recoverable	可收回稅項		**7,603**	6,106
Cash, bank balances and deposits	現金、銀行結餘及存款	29	**331,320**	302,836
Total current assets	流動資產總額		**556,779**	536,805

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
綜合財務狀況表

As at 30 June 2026
於2026年6月30日

		Notes 附註	**2026** **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
CURRENT LIABILITIES	**流動負債**			
Trade payables	貿易應付款項	30	**71,333**	61,584
Other payables and accruals	其他應付款項及應計費用	31	**62,968**	67,531
Loans from non-controlling shareholders of subsidiaries	來自附屬公司非控股股東的貸款	32	**46,379**	53,174
Amounts due to associates	應付聯營公司款項	27	**399**	522
Amounts due to related companies	應付關聯公司款項	28	**14,683**	9,497
Provision	撥備	34	**3,626**	5,417
Lease liabilities	租賃負債	15(b)	**43,733**	55,519
Tax payable	應付稅項		**20,988**	15,880
Total current liabilities	流動負債總額		**264,109**	269,124
NET CURRENT ASSETS	**流動資產淨額**		**292,670**	267,681
TOTAL ASSETS LESS CURRENT LIABILITIES	**總資產減流動負債**		**726,604**	826,201
NON-CURRENT LIABILITIES	**非流動負債**			
Lease liabilities	租賃負債	15(b)	**53,825**	52,857
Deferred tax liabilities	遞延稅項負債	33	**12,277**	14,923
Provision	撥備	34	**8,179**	6,622
Total non-current liabilities	非流動負債總額		**74,281**	74,402
NET ASSETS	**資產淨額**		**652,323**	751,799
EQUITY	**權益**			
Equity attributable to owners of the Company	**本公司擁有人應佔權益**			
Issued capital	已發行股本	35	**811**	811
Reserves	儲備	38	**639,401**	741,821
			640,212	742,632
Non-controlling interests	非控股權益		**12,111**	9,167
TOTAL EQUITY	**權益總額**		**652,323**	751,799

Sun Yiu Kwong
孫耀江
Director
董事

Kwok Cheuk Kwan, Jacquen
郭卓君
Director
董事

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
綜合權益變動表

Year ended 30 June 2026
截至2026年6月30日止年度

			Attributable to owners of the Company 本公司擁有人應佔											
		Notes 附註	Issued capital 已發行股本 HK$'000 千港元 (note 35) (附註35)	Share premium account 股份溢價賬 HK$'000 千港元	Capital contribution reserve 出資儲備 HK$'000 千港元 (note 38) (附註38)	Shares held under the share award scheme 股份獎勵計劃項下預留的股份 HK$'000 千港元 (note 37) (附註37)	Share-based payment reserve 以股份為基礎的付款儲備 HK$'000 千港元 (note 38) (附註38)	Fair value reserve 公允價值儲備 HK$'000 千港元	Legal reserve 法定儲備 HK$'000 千港元 (note 38) (附註38)	Exchange fluctuation reserve 匯兑波動儲備 HK$'000 千港元	Retained profits 留存利潤 HK$'000 千港元	Total 合計 HK$'000 千港元	Non-controlling interests 非控股權益 HK$'000 千港元	Total equity 權益總額 HK$'000 千港元
At 1 July 2025	於2025年7月1日		811	436,751	37,294	(14,403)	6,545	(10,054)	2,898	(6,212)	289,002	742,632	9,167	751,799
(Loss) for the year	年內(虧損)		–	–	–	–	–	–	–	–	(74,639)	(74,639)	1,914	(72,725)
Other comprehensive loss for the year:	年內其他全面虧損:													
Changes in fair value of equity investments designated at fair value through other comprehensive income	指定為按公允價值計入其他全面收入之股本投資的公允價值變動		–	–	–	–	–	(2,925)	–	–	–	(2,924)	–	(2,924)
Exchange differences on translation of operations outside Hong Kong	折算香港以外業務的匯兑差額		–	–	–	–	–	–	–	1,129	–	1,129	–	1,129
Total comprehensive income for the year	年內全面收入總額		–	–	–	–	–	(2,925)	–	1,129	(74,639)	(76,435)	1,914	(74,521)
Dividends paid/payable to non-controlling interests	已付/應付非控股權益股息		–	–	–	–	–	–	–	–	–	–	(2,190)	(2,190)
Acquisition of non-controlling interest	收購非控股權益		–	–	–	–	–	–	–	–	–	–	(1,107)	(1,107)
Deemed disposal of interest in subsidiaries	視為出售附屬公司權益		–	–	–	–	–	–	–	–	–	–	3,404	3,404
Capital injection from non-controlling interests	非控股權益注資		–	–	–	–	–	–	–	–	–	–	923	923
Final 2025 dividend	2025年末期股息	13	–	–	–	–	–	–	–	–	(15,408)	(15,408)	–	(15,408)
Interim 2026 dividend	2026年中期股息	13	–	–	–	–	–	–	–	–	(11,353)	(11,353)	–	(11,353)
Transfer upon disposal of equity securities designated at fair value through other comprehensive income	出售按公允價值計入其他全面收入的股本證券時轉撥		–	–	–	–	–	185	–	–	(185)	–	–	–
Purchases of shares for the share award scheme	就股份獎勵計劃購買的股份	37	–	–	–	(976)	–	–	–	–	–	(976)	–	(976)
Equity-settled share-based payment arrangements	以權益結算的以股份為基礎的付款安排	36, 37	–	–	–	1,752	(772)	–	–	–	772	1,752	–	1,752
At 30 June 2026	於2026年6月30日		811	436,751	37,294	(13,627)	5,773	(12,794)	2,898	(5,083)	188,189	640,212	12,111	652,323

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
綜合權益變動表

Year ended 30 June 2026
截至2026年6月30日止年度

			Attributable to owners of the Company 本公司擁有人應佔											
		Notes 附註	Issued capital 已發行股本 HK$'000 千港元 (note 35) (附註35)	Share premium account 股份溢價賬 HK$'000 千港元	Capital contribution reserve 出資儲備 HK$'000 千港元 (note 38) (附註38)	Shares held under the share award scheme 股份獎勵計劃項下預留的股份 HK$'000 千港元 (note 37) (附註37)	Share-based payment reserve 以股份為基礎的付款儲備 HK$'000 千港元 (note 38) (附註38)	Fair value reserve 公允價值儲備 HK$'000 千港元	Legal reserve 法定儲備 HK$'000 千港元 (note 38) (附註38)	Exchange fluctuation reserve 匯兌波動儲備 HK$'000 千港元	Retained profits 留存利潤 HK$'000 千港元	Total 合計 HK$'000 千港元	Non-controlling interests 非控股權益 HK$'000 千港元	Total equity 權益總額 HK$'000 千港元
At 1 July 2024	於2024年7月1日		811	436,751	37,294	(15,842)	7,629	(19,873)	2,898	(7,776)	284,050	725,942	18,333	744,275
Profit for the year	年內利潤		–	–	–	–	–	–	–	–	31,440	31,440	476	31,916
Other comprehensive loss for the year:	年內其他全面虧損：													
Changes in fair value of equity investments designated at fair value through other comprehensive income	指定為按公允價值計入其他全面收入之股本投資的公允價值變動		–	–	–	–	–	9,819	–	–	–	9,819	–	9,819
Exchange differences on translation of operations outside Hong Kong	折算香港以外業務的匯兌差額		–	–	–	–	–	–	–	1,564	–	1,564	–	1,564
Total comprehensive income for the year	年內全面收入總額		–	–	–	–	–	9,819	–	1,564	31,440	42,823	476	43,299
Dividends paid/payable to non-controlling interests	已付／應付非控股權益股息		–	–	–	–	–	–	–	–	–	–	(9,642)	(9,642)
Final 2024 dividend	2024年末期股息	12	–	–	–	–	–	–	–	–	(16,219)	(16,219)	–	(16,219)
Interim 2025 dividend	2025年中期股息	12	–	–	–	–	–	–	–	–	(11,353)	(11,353)	–	(11,353)
Purchases of shares for the share award scheme	就股份獎勵計劃購買的股份	37	–	–	–	(180)	–	–	–	–	–	(180)	–	(180)
Equity-settled share-based payment arrangements	以權益結算的以股份為基礎的付款安排	36, 37	–	–	–	1,619	(1,084)	–	–	–	1,084	1,619	–	1,619
At 30 June 2025	於2025年6月30日		811	436,751	37,294	(14,403)	6,545	(10,054)	2,898	(6,212)	289,002	742,632	9,167	751,799

CONSOLIDATED STATEMENT OF CASH FLOWS
綜合現金流量表

Year ended 30 June 2026
截至2026年6月30日止年度

		Notes 附註	**2026 2026年 HK$'000 千港元**	2025 2025年 HK$'000 千港元
CASH FLOWS FROM OPERATING ACTIVITIES	**經營活動的現金流量**			
(Loss)/profit before tax	除税前(虧損)／利潤		**(64,751)**	40,499
Adjustments for:	就下列各項調整：			
Finance cost	融資成本	8	**6,304**	7,345
Share of losses of joint ventures	應佔合資公司虧損		**1,426**	1,983
Share of profits of associates	應佔聯營公司利潤		**(930)**	(1,528)
Bank interest income	銀行利息收入	6	**(4,404)**	(4,904)
Interest income from finance lease	融資租賃的利息收入	6	**(19)**	(107)
Dividend income from investments at fair value through other comprehensive income	按公允價值計入其他全面收入之投資的股息收入	6	**(495)**	(467)
Dividend income from investments at fair value through profit or loss	按公允價值計入損益的投資的股息收入	6	**(138)**	–
Fair value gain on financial assets at fair value through profit or loss, net	按公允價值計入損益的金融資產的公允價值收益淨額	6	**(2,933)**	(2,661)
Write-off of finance lease receivable	撇銷應收融資租賃		**1,184**	–
Impairment of items of property, plant and equipment	物業、廠房及設備項目減值	7	**13,864**	–
Write-off of items of property, plant and equipment	撇銷物業、廠房及設備項目	7	**3,786**	2,132
Gain on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的收益	7	**–**	(39)
Depreciation of property, plant and equipment	物業、廠房及設備折舊	14	**40,965**	44,414
Gain on disposal of leases	出售租賃的收益		**(2,740)**	(331)
Depreciation of right-of-use assets	使用權資產折舊	15	**56,229**	61,392
Amortisation of other intangible assets	其他無形資產攤銷	7	**333**	–
Impairment loss of investment in an associate	投資於一間聯營公司的減值虧損	7	**902**	300
Impairment of goodwill	商譽減值		**82,000**	7,553
Decrease in provision	撥備減少		**(234)**	(1,388)
Equity-settled share-based payment expense	以權益結算以股份為基礎的付款開支	7	**1,752**	1,859
Operating profit before working capital changes	營運資金變動前的經營利潤		**132,101**	156,052

CONSOLIDATED STATEMENT OF CASH FLOWS
綜合現金流量表

Year ended 30 June 2026
截至2026年6月30日止年度

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
(Increase)/decrease in inventories	存貨(增加)／減少	**(586)**	157
(Increase)/decrease in trade receivables	貿易應收款項(增加)／減少	**(4,676)**	10,341
Decrease in prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產減少	**4,659**	12,880
Decrease in finance lease receivables	應收融資租賃減少	**711**	2,135
Decrease/(increase) in amounts due from associates	應收聯營公司款項減少／(增加)	**1,427**	(3,390)
Increase in amounts due from joint ventures	應收合資公司款項增加	**(398)**	(1)
Increase in amounts due from related companies	應收關聯公司款項增加	**(463)**	(8,514)
Increase/(decrease) in trade payables	貿易應付款項增加／(減少)	**9,749**	(14,198)
(Decrease)/increase in other payables and accruals	其他應付款項及應計費用(減少)／增加	**(15,606)**	7,541
Increase in amounts due to associates	應付聯營公司款項增加	**383**	229
Increase in amounts due to related companies	應付關聯公司款項增加	**5,186**	5,127
Cash generated from operations	經營業務產生的現金	**132,487**	168,359
Interest received	已收利息	**4,404**	4,904
Income taxes paid	已付所得稅	**(5,197)**	(21,284)
Net cash inflows from operating activities	**經營活動現金流入淨額**	**131,694**	151,979
CASH FLOWS FROM INVESTING ACTIVITIES	**投資活動的現金流量**		
(Increase)/decrease in bank deposits with original maturities of more than 3 months	原到期日超過3個月的銀行存款(增加)／減少	**(67,191)**	4,224
Dividends received from investments at fair value through other comprehensive income	已收按公允價值計入其他全面收入的投資的股息	**495**	467
Dividends received from investments at fair value through profit or loss	已收按公允價值計入損益的投資的股息	**138**	–
Acquisition of new subsidiaries	收購新附屬公司	**748**	–
Dividends received from associates	已收聯營公司股息	**994**	300
Purchases of items of property, plant and equipment	購買物業、廠房及設備項目	**(22,098)**	(11,639)
Maturity of investments at fair value through profit or loss	按公允價值計入損益的投資到期	**5,224**	–
Addition to intangible assets	添置無形資產	**(1,998)**	–
Capital injection from NCI	非控股權益注資	**923**	–

CONSOLIDATED STATEMENT OF CASH FLOWS
綜合現金流量表

Year ended 30 June 2026
截至2026年6月30日止年度

		Notes 附註	**2026 2026年 HK$'000 千港元**	2025 2025年 HK$'000 千港元
Proceeds from disposal of property, plant and equipment	出售物業、廠房及設備的所得款項		**–**	107
Proceeds from disposal of investment at fair value through other comprehensive income	出售按公允價值計入其他全面收入的投資所得款項		**328**	–
Proceeds from disposal of investments at fair value through profit or loss	出售按公允價值計入損益的投資所得款項		**–**	5,000
Deposits paid for purchases of items of property, plant and equipment	購買物業、廠房及設備項目支付的保證金		**(190)**	6,443
(Increase)/decrease in pledged deposits	抵押存款(增加)／減少		**(36)**	1,041
Net cash (used in)/inflows from investing activities	**投資活動(所用)現金／現金流入淨額**		**(82,663)**	5,943
CASH FLOWS FROM FINANCING ACTIVITIES	**融資活動的現金流量**			
Acquisition of non-controlling interests	收購非控股權益		**3,404**	–
Purchases of shares for the share award scheme	就股份獎勵計劃購買股份	37	**(976)**	(180)
Dividends paid	已付股息		**(26,761)**	(27,572)
Dividends paid to non-controlling interests	已付非控股權益股息		**(2,190)**	(9,642)
Lease payments	租金付款	40(b)	**(56,084)**	(62,606)
Interest paid	已付利息		**(6,304)**	(7,345)
Net cash flows used in financing activities	**融資活動所用現金流量淨額**		**(88,911)**	(107,345)
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	**現金及現金等價物(減少)／增加淨額**		**(39,880)**	50,577
Effect of foreign exchange rate changes, net	外匯匯率變動的影響淨額		**1,137**	1,385
Cash and cash equivalents at beginning of year	年初現金及現金等價物		**248,336**	196,374
CASH AND CASH EQUIVALENTS AT END OF YEAR	**年末現金及現金等價物**	29	**209,593**	248,336

1. CORPORATE AND GROUP INFORMATION

UMP Healthcare Holdings Limited is a limited liability company incorporated in the Cayman Islands. The principal place of business of the Company is located at 27/F., Wing On House, 71 Des Voeux Road Central, Hong Kong.

During the year, the Company and its subsidiaries (collectively referred to as the "Group") were principally engaged in the provision of healthcare services which include:

- corporate healthcare solution services;
- medical and dental services;
- medical imaging and laboratory services;
- other auxiliary medical services; and
- healthcare management services.

The shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 27 November 2015 (the "Listing").

1. 公司及集團資料

聯合醫務集團有限公司乃在開曼群島註冊成立的有限公司。本公司主要營業地點為香港德輔道中71號永安集團大廈27樓。

年內，本公司及其附屬金司(統稱「本集團」)的主要業務為提供醫療保健服務，包括：

- 企業醫療保健解決方案服務；
- 醫療及牙科服務；
- 醫學影像及化驗服務；
- 其他輔助醫療服務；及
- 醫療保健管理服務。

本公司股份於2015年11月27日在香港聯合交易所有限公司(「聯交所」)主板上市(「上市」)。

1. CORPORATE AND GROUP INFORMATION (Continued)

1. 公司及集團資料(續)

Information about subsidiaries

附屬公司資料

Particulars of the Company's principal subsidiaries are as follows:

本公司主要附屬公司之詳情如下：

Name 名稱	Place of incorporation/ registration and business 註冊成立／註冊及營業地點	Issued ordinary/ registered share capital 已發行普通／註冊股本	Percentage of equity interest attributable to the Company 本公司應佔股權比例 2026 2026年	 2025 2025年	Principal activities 主要業務
Flash Mover Limited 東藝有限公司	Hong Kong 香港	HK$10,000 10,000港元	**100**	100	Provision of medical imaging and laboratory services 提供醫學影像及化驗服務
Metro International Clinic Limited 國際文度醫療所有限公司	Macau 澳門	MOP100,000 100,000澳門幣	**69**	69	Provision of medical services 提供醫療服務
Paeon ProCare Oncology Centre Limited 倍康腫瘤治療中心有限公司	Hong Kong 香港	HK$100 100港元	**50**	50	Provision of medical and surgery services 提供醫療及手術科服務
Paeon ProCare Physiotherapy & Fitness Centre Limited 倍康物理治療及體適能中心有限公司	Hong Kong 香港	HK$100 100港元	**75**	75	Provision of medical physiotherapy services 提供醫療物理治療服務
ProCare Integrated Medical Imaging & Laboratory Centre (Tsim Sha Tsui) Limited 普康綜合醫學影像及化驗中心(尖沙咀)有限公司	Hong Kong 香港	HK$105 105港元	**52.23**	52.23	Provision of medical imaging and laboratory services 提供醫學影像及化驗服務
ProCare Medical Imaging & Laboratory Centre (Central-One Chinachem Central) Limited 普康醫學影像及化驗中心(中環－華懋中心1期)有限公司	Hong Kong 香港	HK$2,000,000 2,000,000港元	**75**	75	Provision of medical imaging and laboratory services 提供醫學影像及化驗服務
ProCare Medical Imaging & Laboratory Centre (Kowloon) Limited 普康醫學影像及化驗中心(九龍)有限公司	Hong Kong 香港	HK$1,000 1,000港元	**85**	85	Provision of medical imaging and laboratory services 提供醫學影像及化驗服務
Procare Medical Laboratory Centre Limited 普康醫學化驗中心有限公司	Hong Kong 香港	HK$10,000 10,000港元	**100**	100	Provision of medical laboratory services 提供醫療化驗服務

1. CORPORATE AND GROUP INFORMATION (Continued)

1. 公司及集團資料(續)

Information about subsidiaries (Continued)

附屬公司資料(續)

Name 名稱	Place of incorporation/ registration and business 註冊成立／註冊及營業地點	Issued ordinary/ registered share capital 已發行普通／註冊股本	Percentage of equity interest attributable to the Company 本公司應佔股權比例 **2026** **2026年**	 2025 2025年	Principal activities 主要業務
Procare Medical Imaging & Laboratory Centre (CWB) Limited 普康醫學影像及化驗中心(銅鑼灣)有限公司	Hong Kong 香港	HK$1 1港元	**100**	100	Provision of medical imaging and laboratory services 提供醫學影像及化驗服務
ProCare PET-CT Centre (Hong Kong) Limited 普康正電子掃描中心(香港)有限公司	Hong Kong 香港	HK$100 100港元	**75**	75	Provision of medical imaging services 提供醫學影像服務
Procare Physiotherapy and Rehabilitation Centre (Skyline) Limited 普康物理治療及復康中心(東涌)有限公司	Hong Kong 香港	HK$10,000 10,000港元	**70**	70	Provision of medical physiotherapy services 提供醫療物理治療服務
SkinCentral Limited ("SkinCentral") 善肌聯合皮膚中心有限公司(「善肌」)	Hong Kong 香港	HK$1,000,000 1,000,000港元	**60**	60	Provision of dermatological services 提供皮膚科服務
UMP Central Dental Centre Limited 聯合醫務牙科中心(中環)有限公司	Hong Kong 香港	HK$100 100港元	**90**	90	Provision of dental services 提供牙科服務
UMP Dental Centre Limited 聯合醫務牙科中心有限公司	Hong Kong 香港	HK$10,000 10,000港元	**100**	100	Provision of dental services 提供牙科服務
UMP Medical Centre (Hong Kong) Limited 聯合醫務中心(香港)有限公司	Hong Kong 香港	HK$100 100港元	**100**	100	Provision of medical services 提供醫療服務
UMP Medical Centre (Kowloon Bay) Limited 聯合醫務中心(九龍灣)有限公司	Hong Kong 香港	HK$10,000 10,000港元	**100**	100	Provision of medical services 提供醫療服務
UMP Medical Centre (New Territories) Limited 聯合醫務中心(新界)有限公司	Hong Kong 香港	HK$2 2港元	**100**	100	Provision of medical services 提供醫療服務
UMP Medical Centre Limited 聯合醫務中心有限公司	Hong Kong 香港	HK$100 100港元	**100**	100	Investment holding and provision of medical services 投資控股及提供醫療服務

1. CORPORATE AND GROUP INFORMATION (Continued)

1. 公司及集團資料(續)

Information about subsidiaries (Continued)

附屬公司資料(續)

Name 名稱	Place of incorporation/ registration and business 註冊成立／註冊及營業地點	Issued ordinary/ registered share capital 已發行普通／註冊股本	Percentage of equity interest attributable to the Company 本公司應佔股權比例 2026 2026年	 2025 2025年	Principal activities 主要業務
UMP Preventive Medicine Centre (Central) Limited 聯合醫務預防醫學中心(中環)有限公司	Hong Kong 香港	HK$100 100港元	**100**	75	Provision of medical services 提供醫療服務
UMP Professional Management (Macau) Limited UMP專業管理(澳門)有限公司	Macau 澳門	MOP10,000 10,000澳門幣	**100**	100	Investment holding and provision of corporate healthcare solution 投資控股及提供企業醫療保健解決方案
UMP Professional Management Limited 聯合醫務專業管理有限公司	Hong Kong 香港	HK$50,000,012 50,000,012港元	**100**	100	Investment holding and provision of corporate healthcare solution 投資控股及提供企業醫療保健解決方案
UMP Specialist Medical Centre Limited 聯合醫務專科醫療中心有限公司	Hong Kong 香港	HK$100 100港元	**100**	100	Provision of medical services 提供醫療服務
238 Day Surgery & Endoscopy Centre Limited 238日間手術及內視鏡中心有限公司	Hong Kong 香港	HK$10,000 10,000港元	**68**	68	Provision of day surgery and endoscopy services 提供日間手術及內視鏡檢查服務
238 Specialist Medical Centre Limited 238專科醫療中心有限公司	Hong Kong 香港	HK$10,000 10,000港元	**63**	63	Provision of medical services 提供醫療服務
北京耀東門診部有限公司[a]	PRC 中國	RMB3,500,000 人民幣3,500,000元	**80**	80	Provision of healthcare and medical services 提供醫療保健及醫療服務
上海怡東門診部有限公司[a]	PRC 中國	RMB3,500,000 人民幣3,500,000元	**80**	80	Provision of healthcare and medical services 提供醫療保健及醫療服務
普庫健康管理(上海)有限公司[a]	PRC 中國	RMB1,000,000 人民幣1,000,000元	**100**	100	Provision of corporate healthcare solution 提供企業醫療保健解決方案

1. CORPORATE AND GROUP INFORMATION (Continued)

Information about subsidiaries (Continued)

(a) The Company is a limited liability company under PRC law.

To give details of other subsidiaries would, in the opinion of the directors, result in particulars of excessive length.

2.1 BASIS OF PREPARATION

These consolidated financial statements have been prepared in accordance with HKFRS Accounting Standards (which include all Hong Kong Financial Reporting Standards ("HKFRSs"), Hong Kong Accounting Standards ("HKASs") and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for equity investments and certain other assets which have been measured at fair value. These consolidated financial statements are presented in Hong Kong dollars and all values are rounded to the nearest thousand except when otherwise indicated.

Basis of consolidation

A subsidiary is an entity directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

1. 公司及集團資料(續)

附屬公司資料(續)

(a) 該公司為中國法律下的有限責任公司。

董事認為載列其他附屬公司之詳情會使資料過於冗長。

2.1 編製基準

此等綜合財務報表乃根據香港會計師公會(「香港會計師公會」)頒佈的香港財務報告準則會計準則(包括所有香港財務報告準則(「香港財務報告準則」)、香港會計準則(「香港會計準則」)及詮釋)及香港公司條例之披露規定而編製。除以公允價值計量的股本投資及若干其他資產外，此等綜合財務報表乃根據歷史成本法編製。除另有說明外，此等綜合財務報表以港元列報，而當中所有金額均約整至最接近的千位。

綜合基準

附屬公司為直接或間接由本公司控制的實體。倘本集團透過參與投資對象業務而享有或有權取得投資對象的可變回報，且有能力對投資對象行使權力影響有關回報，則本集團擁有該實體的控制權(即現時賦予本集團指示投資對象相關活動的能力)。

倘本公司直接或間接擁有投資對象投票權或類似權利少於半數，則評估本公司是否有權控制投資對象時，本集團會考慮所有相關事實及情況，包括：

2.1 BASIS OF PREPARATION (Continued)

Basis of consolidation (Continued)

(a) the contractual arrangement with the other vote holders of the investee;

(b) rights arising from other contractual arrangements; and

(c) the Group's voting rights and potential voting rights.

The consolidated financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described above. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it derecognises (i) the assets (including goodwill) and liabilities of the subsidiary, (ii) the carrying amount of any non-controlling interest and (iii) the cumulative translation differences recorded in equity; and recognises (i) the fair value of the consideration received, (ii) the fair value of any investment retained and (iii) any resulting surplus or deficit in profit or loss. The Group's share of components previously recognised in other comprehensive income is reclassified to profit or loss or retained profits, as appropriate, on the same basis as would be required if the Group had directly disposed of the related assets or liabilities.

2.1 編製基準(續)

綜合基準(續)

(a) 與該投資對象其他投票權持有人的合約安排；

(b) 來自其他合約安排的權利；及

(c) 本集團的投票權及潛在投票權。

附屬公司的綜合財務報表的報告期與本公司的相同，並採用一致的會計政策編製。附屬公司的業績乃自本集團取得控制權之日起綜合入賬，直至有關控制權終止當日為止。

損益及其他全面收入的各組成部分歸屬於本集團母公司之擁有人及非控股權益，即使此舉會引致非控股權益出現虧絀結餘。本集團旗下成員公司之間交易所產生的全部集團內公司間資產及負債、權益、收入、支出及現金流量均在綜合賬目時全數對銷。

倘事實及情況顯示上文所述三項控制因素中有一項或多項出現變動，本集團會重新評估其是否控制投資對象。附屬公司的所有權權益變動(未失去控制權)按權益交易入賬。

倘本集團失去一間附屬公司的控制權，則其終止確認(i)該附屬公司的資產(包括商譽)及負債、(ii)任何非控股權益的賬面值及(iii)於權益內記錄的累計折算差額；及確認(i)所收代價的公允價值、(ii)所保留任何投資的公允價值及(iii)損益中任何因此產生的盈餘或虧絀。倘本集團已直接出售相關資產及負債，先前於其他全面收入內確認的本集團應佔部分應重新分類為損益或留存利潤(如適用)。

2.2 CHANGES IN ACCOUNTING POLICIES

The Group has applied the following amendments to HKFRS Accounting Standards as issued by the HKICPA to these financial statements for the current accounting period:

- Amendments to HKAS 21, *The effects of changes in foreign exchange rates – Lack of exchangeability*

None of these developments have had a material effect on how the Group's results and financial position for the current or prior periods have been prepared or presented. The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

2.2 會計政策變動

本集團已對本會計期間之財務報表應用以下由香港會計師公會頒佈之香港財務報告準則會計準則之修訂：

- 香港會計準則第21號之修訂，*外幣匯率變動的影響－缺乏可兌換性*

該等變動概無對本集團編製及呈列本期間或過往期間業績及財務狀況的方式造成重大影響。本集團並無採用於本會計期間尚未生效的任何新準則或詮釋。

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS

Up to the date of issue of these financial statements, the HKICPA has issued a number of new or amended standards, which are not yet effective for the year ended 30 June 2026 and which have not been adopted in these financial statements. These developments include the following which may be relevant to the Group.

2.3 已頒佈但尚未生效之香港財務報告準則

截至發出此等財務報表日期，香港會計師公會已頒佈一系列新訂或經修訂準則，有關準則於截至2026年6月30日止年度尚未生效，且尚未於此等財務報表中採納。以下變動與本集團有關。

	Effective for accounting periods beginning on or after 於以下日期或之後開始之會計期間生效
Amendments to HKFRS 9, *Financial instruments* and HKFRS 7, *Financial instruments: disclosures – Contracts referencing nature-dependent electricity*	1 January 2026
香港財務報告準則第9號之修訂，*金融工具*及香港財務報告準則第7號，*金融工具：披露－依賴自然能源生產電力的合約*	2026年1月1日
Amendments to HKFRS 9, *Financial instruments* and HKFRS 7, *Financial instruments: disclosures – Amendments to the classification and measurement of financial instruments*	1 January 2026
香港財務報告準則第9號之修訂，*金融工具*；及香港財務報告第7號之修訂，*金融工具：披露－金融工具的分類及計量之修訂*	2026年1月1日
Annual improvements to HKFRS Accounting Standards – Volume 11	1 January 2026
香港財務報告準則會計準則之年度改進－第11卷	2026年1月1日
HKFRS 18, *Presentation and disclosure in financial statements*	1 January 2027
香港財務報告準則第18號，*財務報表的呈列及披露*	2027年1月1日
HKFRS 19, *Subsidiaries without public accountability: disclosures*	1 January 2027
香港財務報告準則第19號，*不具公共問責性的附屬公司：披露*	2027年1月1日

The Group is in the process of making an assessment of what the impact of these developments is expected to be in the period of initial application. So far it has concluded that the adoption of them is unlikely to have a significant impact on the consolidated financial statements, except for the application of HKFRS 18 which is expected to affect the presentation and disclosure of the Group's consolidated financial statements in future.

本集團現正在評估該等變動於首次採用期間預期產生的影響。本集團目前認為，採納該等調整不太可能對綜合財務報表造成重大影響，惟香港財務報告準則第18號預期將影響日後本集團綜合財務報表的呈列及披露。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES

Investments in associates and joint ventures

An associate is an entity in which the Group has a long term interest of generally not less than 20% of the equity voting rights and over which it is in a position to exercise significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies.

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.

The Group's investments in associates and joint ventures are stated in the consolidated statement of financial position at the Group's share of net assets under the equity method of accounting, less any impairment losses. Adjustments are made to bring into line any dissimilar accounting policies that may exist. The Group's share of the post-acquisition results and other comprehensive income of associates and joint ventures is included in the consolidated statement of profit or loss and consolidated other comprehensive income, respectively. In addition, when there has been a change recognised directly in the equity of the associate or joint venture, the Group recognises its share of any changes, when applicable, in the consolidated statement of changes in equity. Unrealised gains and losses resulting from transactions between the Group and its associates or joint ventures are eliminated to the extent of the Group's investments in the associates or joint ventures, except where unrealised losses provide evidence of an impairment of the assets transferred. Goodwill arising from the acquisition of associates or joint ventures is included as part of the Group's investments in associates or joint ventures.

2.4 重大會計政策概要

於聯營公司及合資公司的投資

聯營公司指本集團於其擁有一般不少於20%股本投票權的長期權益，並可對其實施重大影響的實體。重大影響指對投資對象的財務及經營政策有參與決策的權力，但並非對該等政策形成控制或共同控制。

合資公司乃一種合營安排，據此，對安排擁有共同控制權的各方享有該合資公司淨資產的權利。共同控制指通過訂約協定共享安排的控制權，僅在相關活動決策須經共享控制權的各方一致同意的情況下存在。

本集團於聯營公司及合資公司的投資乃在綜合財務狀況表列賬為本集團應佔資產淨值(根據權益會計法計算，扣除所有減值虧損)。倘出現任何不相符的會計政策，即會作出調整加以修正。本集團應佔聯營公司及合資公司的收購後業績及其他全面收入乃分別於綜合損益表及綜合其他全面收入列賬。此外，倘直接於聯營公司或合資公司的權益確認變動，本集團應於綜合權益變動表確認其任何應佔的變動(如適用)。本集團與其聯營公司或合資公司之間交易產生的未變現盈虧以本集團於聯營公司或合資公司的投資為限對銷，惟尚未變現虧損提供已轉讓資產減值的證據，則作別論。收購聯營公司或合資公司所產生的商譽計入本集團於聯營公司或合資公司的部分投資。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Investments in associates and joint ventures (Continued)

If an investment in an associate becomes an investment in a joint venture or vice versa, the retained interest is not remeasured. Instead, the investment continues to be accounted for under the equity method. In all other cases, upon loss of significant influence over the associate or joint control over the joint venture, the Group measures and recognises any retained investment at its fair value. Any difference between the carrying amount of the associate or joint venture upon loss of significant influence or joint control and the fair value of the retained investment and proceeds from disposal is recognised in profit or loss.

Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The consideration transferred is measured at the acquisition date fair value which is the sum of the acquisition date fair values of assets transferred by the Group, liabilities assumed by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange for control of the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree that are present ownership interests and entitle their holders to a proportionate share of net assets in the event of liquidation at fair value or at the proportionate share of the acquiree's identifiable net assets. All other components of non-controlling interests are measured at fair value. Acquisition-related costs are expensed as incurred.

When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in host contracts of the acquiree.

If the business combination is achieved in stages, the previously held equity interest is remeasured at its acquisition date fair value and any resulting gain or loss is recognised in profit or loss.

2.4 重大會計政策概要(續)

於聯營公司及合資公司的投資(續)

倘對聯營公司的投資成為對合資公司的投資，或對合資公司的投資成為對聯營公司的投資，留存權益不會重新計量，而是繼續按權益法將投資列賬。在所有其他情況下，若本集團失去對聯營公司的重大影響力或合資公司的共同控制權，則會按公允價值計量及確認任何留存投資。失去對聯營公司的重大影響力或對合資公司的共同控制權時，聯營公司或合資公司的賬面值與留存投資公允價值及出售所得款項之間的差額於損益確認。

業務合併與商譽

業務合併以收購法入賬。轉讓之代價乃以收購日期的公允價值計算，該公允價值為本集團轉讓的資產於收購日期的公允價值、本集團所承擔被收購方前擁有人的負債，及本集團發行以換取被收購方控制權的股權之總和。就各項業務合併而言，本集團選擇是否以公允價值或被收購方可識別資產淨值的應佔比例，計算於被收購方的非控股權益(屬現時擁有人權益並賦予擁有人權利於清盤時按比例分佔其資產淨值)。非控股權益的所有其他組成部分按公允價值計量。收購相關成本於產生時列為費用。

當本集團收購一項業務時，會按照合約條款、收購日期的經濟環境和相關狀況評估所承接金融資產和負債，以作出適當分類及指定，其中包括對被收購方於主合約所持嵌入式衍生工具進行分離。

如果業務合併分階段完成，過往所持股權權益按收購日期的公允價值重新計量，而由此產生的任何損益在損益中確認。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Business combinations and goodwill (Continued)

Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability is measured at fair value with changes in fair value recognised in profit or loss. Contingent consideration that is classified as equity is not remeasured and subsequent settlement is accounted for within equity.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred, the amount recognised for non-controlling interests and any fair value of the Group's previously held equity interests in the acquiree over the identifiable net assets acquired and liabilities assumed. If the sum of this consideration and other items is lower than the fair value of the net assets acquired, the difference is, after reassessment, recognised in profit or loss as a gain on bargain purchase.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. The Group performs its annual impairment test of goodwill as at 30 June. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units ("CGUs"), or groups of CGUs, that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the Group are assigned to those units or groups of units.

Impairment is determined by assessing the recoverable amount of the CGU (group of CGUs) to which the goodwill relates. Where the recoverable amount of the CGU (group of CGUs) is less than the carrying amount, an impairment loss is recognised. An impairment loss recognised for goodwill is not reversed in a subsequent period.

2.4 重大會計政策概要(續)

業務合併與商譽(續)

收購方將轉讓的任何或有代價按收購日期的公允價值確認。分類為資產或負債的或有代價按公允價值計量，而公允價值的變動則於損益內確認。分類為權益的或有代價不會重新計量，其後結算在權益內列賬。

商譽起初按成本計量，即已轉讓總代價、已確認非控股權益及本集團先前持有被收購方股權的公允價值總額，超出所收購可識別資產淨值及所承擔負債的差額。如代價及其他項目的總和低於所收購資產淨值的公允價值，於重新評估後其差額將於損益內確認為議價收購收益。

初始確認後，商譽按照成本減任何累計減值虧損計量。商譽須每年進行減值測試，倘事件發生或情況變動顯示賬面值可能已減值時，則應更頻繁地進行減值測試。本集團於每年的6月30日對商譽進行年度減值測試。就減值測試而言，不論本集團其他資產或負債有否分配至本集團各現金產生單位(「現金產生單位」)或現金產生單位組別，因業務合併所得商譽乃自收購日期起分配至該等現金產生單位或現金產生單位組別，而該等現金產生單位或現金產生單位組別預期將受惠於合併帶來的協同效益。

減值是通過評估商譽相關的現金產生單位(或現金產生單位組別)的可收回金額而釐定。若現金產生單位(或現金產生單位組別)的可收回金額低於其賬面值，將確認減值虧損。就商譽確認的減值虧損不會在其後期間撥回。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Business combinations and goodwill (Continued)

Where goodwill has been allocated to a CGU (or group of CGUs) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on the disposal. Goodwill disposed of in these circumstances is measured based on the relative value of the operation disposed of and the portion of the CGU retained.

Fair value measurement

The Group measures its equity investments and certain debt investments at fair value at the end of each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

2.4 重大會計政策概要(續)

業務合併與商譽(續)

若獲分配商譽的現金產生單位(或現金產生單位組別)的部分業務被出售，則於釐定出售盈虧時，與所出售業務有關之商譽計入該業務賬面值。在此等情況下出售之商譽，按所出售業務與其現金產生單位所保留部分對應的比例計量。

公允價值計量

本集團於各報告期末按公允價值計量股本投資及若干債務投資。公允價值為市場參與者於計量日期在有序交易中出售資產可能收取或轉讓負債可能支付的價格。公允價值計量假設出售資產或轉讓負債的交易於該資產或負債的主要市場進行，或在無主要市場的情況下，則於對該資產或負債最有利的市場進行。主要市場或最有利市場是本集團可進入的市場。資產或負債的公允價值計量採用市場參與者進行資產或負債定價時所使用的假設，即市場參與者以自身最佳經濟利益行事。

非金融資產的公允價值計量須考量市場參與者產生經濟效益的能力，即最大限度使用該資產達致最佳用途或將該資產售予可最大限度使用該資產達致最佳用途的另一市場參與者時所產生的經濟效益。

本集團使用適合不同情況的估值方法，而其有足夠資料計量公允價值，從而盡量利用相關可觀察輸入數據，並盡量減少使用不可觀察輸入數據。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Fair value measurement (Continued)

All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — based on quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 — based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly

Level 3 — based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the consolidated financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Impairment of non-financial assets

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than inventories, deferred tax assets and financial assets), the asset's recoverable amount is estimated. An asset's recoverable amount is the higher of the asset's or CGU's value in use and its fair value less costs of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the CGU to which the asset belongs.

2.4 重大會計政策概要(續)

公允價值計量(續)

以公允價值計量或在綜合財務報表中披露的全部資產和負債乃基於對公允價值計量整體而言屬重大的最低層輸入數據，按下文所述公允價值層級分類：

第一層 — 基於活躍市場中相同資產或負債的報價(未調整)

第二層 — 基於可直接或間接觀察對公允價值計量而言為重要的最低層輸入數據的估值方法

第三層 — 基於無法觀察對公允價值計量而言為重要的最低層輸入數據的估值

對於按經常性基準在綜合財務報表中確認的資產和負債，本集團在各報告期末通過重新評估分類決定層級是否已發生轉撥(基於對公允價值計量整體屬重大的最低層輸入數據)。

非金融資產減值

當存在減值跡象，或當資產須進行年度減值測試(存貨、遞延稅項資產及金融資產除外)，則估計資產的可收回金額。資產的可收回金額以資產或現金產生單位的使用價值與其公允價值較高者減出售成本計算，並按個別資產釐定，除非資產所產生現金流入不能獨立於其他資產或資產組別的現金流量，在該情況下，則釐定資產所屬的現金產生單位的可收回金額。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Impairment of non-financial assets (Continued)

An impairment loss is recognised only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to the consolidated statement of profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

An assessment is made at the end of each reporting period as to whether there is an indication that previously recognised impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognised impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortisation) had no impairment loss been recognised for the asset in prior years. A reversal of such an impairment loss is credited to the consolidated statement of profit or loss in the period in which it arises.

2.4 重大會計政策概要(續)

非金融資產減值(續)

減值虧損僅在資產賬面值超過其可收回金額時予以確認。評估使用價值時，估計未來現金流量乃以反映市場當時所評估貨幣時間值及資產特定風險的除稅前折現率折現至其現值。減值虧損於其產生期間在綜合損益表內與減值資產功能一致的支出類別扣除。

本集團於各報告期末，均會評估是否有跡象顯示過往確認之減值虧損可能不再存在或已減少。倘存在該等跡象，則會估計其可收回金額。先前就資產(不包括商譽)確認之減值虧損，僅於用以釐定該資產之可收回金額之估計有變時予以撥回，但撥回金額不得高於假設過往年度並無就該資產確認減值虧損而應釐定之賬面值(扣除任何折舊／攤銷)。其減值虧損之撥回於產生期間計入綜合損益表。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Related parties

A party is considered to be related to the Group if:

(a) the party is a person or a close member of that person's family and that person:

(i) has control or joint control over the Group;

(ii) has significant influence over the Group; or

(iii) is a member of the key management personnel of the Group or of a parent of the Group;

or

(b) the party is an entity where any of the following conditions applies:

(i) the entity and the Group are members of the same group;

(ii) one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);

(iii) the entity and the Group are joint ventures of the same third party;

2.4 重大會計政策概要(續)

關聯方

倘出現下列情況，有關方被視為與本集團有關聯：

(a) 作為一位人士或該人士之近親的一方，且該人士：

(i) 控制或共同控制本集團；

(ii) 對本集團有重大影響力；或

(iii) 為本集團或本集團母公司的主要管理層成員；

或

(b) 有關方為符合下列任何一項條件的實體：

(i) 該實體與本集團屬同一集團的成員公司；

(ii) 該實體為另一實體(或另一實體的母公司、附屬公司或同系附屬公司)的聯營公司或合資公司；

(iii) 該實體與本集團為同一第三方的合資公司；

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Related parties (Continued)

(b) the party is an entity where any of the following conditions applies: (Continued)

(iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity;

(v) the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group;

(vi) the entity is controlled or jointly controlled by a person identified in (a);

(vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and

(viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to the consolidated statement of profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalised in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognises such parts as individual assets with specific useful lives and depreciates them accordingly.

2.4 重大會計政策概要(續)

關聯方(續)

(b) 有關方為符合下列任何一項條件的實體：(續)

(iv) 該實體為一名第三方實體的合資公司，而另一實體為該第三方實體的聯營公司；

(v) 該實體為本集團或與本集團有關連的實體就員工福利而設的離職福利計劃；

(vi) 該實體由(a)項所確認的人士控制或共同控制；

(vii) (a)(i)項所確認的人士對該實體具有重大影響力或為該實體(或該實體的母公司)的主要管理層成員；及

(viii) 該實體，或其所屬集團之任何成員，向本集團或本集團之母公司提供主要管理層服務。

物業、廠房及設備與折舊

物業、廠房及設備按成本減累計折舊及任何減值虧損列賬。物業、廠房及設備項目的成本，包括其購買價及使該資產達致其營運狀況及地點以作其擬定用途時任何直接應佔成本。

物業、廠房及設備項目投產後所產生支出(如維修及保養費用)，一般於其產生期間自綜合損益表中扣除。在確認標準達成的情況下，重大檢查支出於資產賬面值撥充資本作為重置成本。如物業、廠房及設備的主要部分須分階段重置，則本集團將該等部份確認為個別資產，並訂出具體的可使用年期及據此計提折舊。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Property, plant and equipment and depreciation (Continued)

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

Buildings	Over the shorter of 50 years and the remaining lease terms
Leasehold improvements	shorter of 20% and the remaining lease term
Furniture, fixtures and office equipment	20%
Medical equipment	10%-20%
Computer	33.3%
Motor vehicle	33.3%

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each financial year end.

An item of property, plant and equipment including any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognised in the consolidated statement of profit or loss in the year the asset is derecognised is the difference between the net sales proceeds and the carrying amount of the relevant asset.

2.4 重大會計政策概要(續)

物業、廠房及設備與折舊(續)

折舊以直線法計算，按每項物業、廠房及設備項目之估計使用年期撇銷其成本至其剩餘價值。為此而使用的主要年折舊率如下：

樓宇	50年及餘下租賃期（以較短者為準）
租賃物業裝修	20%及餘下租賃期（以較短者為準）
傢俱、裝置及辦公室設備	20%
醫療設備	10%-20%
電腦	33.3%
汽車	33.3%

倘一項物業、廠房及設備項目各部分的可使用年期並不相同，則該項目的成本須在各部份之間合理分配，而各部份須單獨計算折舊。剩餘價值、可使用年期及折舊方法至少於各財政年度結算日評估，並在適當情況下調整。

物業、廠房及設備項目(包括初始確認的任何主要部份)於出售時或於預期使用或出售不會產生未來經濟利益時終止確認。於終止確認資產的年度在綜合損益表確認的任何出售或報廢損益，為有關資產的銷售所得款項淨額與賬面值的差額。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Property, plant and equipment and depreciation (Continued)

Intangible assets (other than goodwill)

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year end.

Intangible assets with indefinite useful lives are tested for impairment annually either individually or at the CGU level. Such intangible assets are not amortised. The useful life of an intangible asset with an indefinite life is reviewed annually to determine whether the indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from indefinite to finite is accounted for on a prospective basis.

Brand names

Brand names with indefinite useful lives are stated at cost less any impairment losses, and are not amortised.

Customer relationships

Customer relationships are stated at cost less any impairment losses and are amortised on the straight-line basis over their estimated useful economic lives of 5 years.

Licence

Licence is stated at cost less any impairment losses and is amortised on the straight-line basis over its estimated useful economic life of 5 years.

Software

The development cost is stated at cost less any impairment losses and is amortised on the straight-line basis over its estimated useful economic life of 3 years.

2.4 重大會計政策概要(續)

物業、廠房及設備與折舊(續)

無形資產(商譽除外)

單獨收購的無形資產於初始確認時按成本計量。通過業務合併收購的無形資產的成本為收購日期的公允價值。無形資產的可使用年期評定為有限期或無限期。有限期的無形資產隨後按可使用經濟年期攤銷，並於有跡象顯示無形資產可能出現減值時評估減值。具有限可使用年期的無形資產的攤銷期及攤銷方法至少於各財政年度末檢討一次。

無限可使用年期的無形資產個別地或按現金產生單位層面每年進行減值測試。該等無形資產不予攤銷。無限年期的無形資產之可使用年期會每年檢討，以釐定無限年期評估是否繼續獲得支持。否則，可使用年期評估由無限變更為有限及以未來適用法基準入賬。

品牌名稱

具有無限使用年期的品牌名稱按成本減任何減值虧損列賬，且並不予以攤銷。

客戶關係

客戶關係按照成本減任何減值虧損列賬，並根據其估計可使用經濟年期5年以直線法攤銷。

牌照

牌照按成本扣除任何減值虧損列賬，並於其5年估計可使用經濟年期內按直線法攤銷。

軟件

開發成本按照成本減任何減值虧損列賬，並根據其估計可使用年期3年以直線法攤銷。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Leases

The Group assesses at contract inception whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Group as a lessee

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. At inception or on reassessment of a contract that contains a lease component and non-lease components, the Group adopts the practical expedient not to separate non-lease components and to account for the lease component and the associated non-lease components (e.g., property management services for leases of properties) as a single lease component.

(a) Right-of-use assets

Right-of-use assets are recognised at the commencement date of the lease (that is the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:

Leased properties	2 to 7 years
Office equipment	5 years

2.4 重大會計政策概要(續)

租賃

本集團在合約開始時評估合約是否為租賃或包含租賃。倘合約為換取代價而授予在一段期間內可識別資產的使用控制權，則該合約為租賃或包含租賃。

本集團作為承租人

本集團就所有租賃應用單一確認及計量方法，惟短期租賃及低價值資產租賃除外。本集團確認租賃負債以作出租賃付款，而使用權資產指使用相關資產的權利。在包含租賃部分和非租賃部分的合約開始時或對有關合約重新評估時，本集團採納可行權宜方法，不將非租賃部分分開，而將租賃部分和相關的非租賃部分(如物業租賃的物業管理服務)作為單一租賃部分入賬。

(a) 使用權資產

使用權資產於租賃開始日期(即相關資產可供使用日期)確認。使用權資產按成本減任何累計折舊及任何減值虧損計量，並就租賃負債之任何重新計量作出調整。使用權資產之成本包括已確認租賃負債金額、已發生初始直接成本及於開始日期或之前支付之租賃付款減已收取之任何租賃優惠。使用權資產於租賃期及資產估計使用年期(以較短者為準)內以直線法折舊如下：

租賃物業	2至7年
辦公室設備	5年

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Leases (Continued)

The Group as a lessee (Continued)

(b) Lease liabilities

Lease liabilities are recognised at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for termination of a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognised as an expense in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate) or a change in assessment of an option to purchase the underlying asset.

The Group's lease liabilities are presented separately in the consolidated statement of financial position.

2.4 重大會計政策概要(續)

租賃(續)

本集團作為承租人(續)

(b) 租賃負債

租賃負債於租賃開始日期按於租賃期內作出之租賃付款現值確認。租賃付款包括固定付款(包括實質固定付款)減任何應收租賃優惠、取決於某一指數或比率之可變租賃付款及預期根據在剩餘價值擔保中將支付之金額。租賃付款亦包括本集團合理確定行使購買選擇權之行使價，並倘租賃期反映了本集團行使終止選擇權，則須就終止租賃支付罰款。並非取決於某一指數或比率之可變租賃付款於觸發付款之事件或狀況出現期間確認為開支。

於計算租賃付款現值時，由於租賃中所隱含之利率不易釐定，因此本集團於租賃開始日期使用其增量借貸利率。於開始日期後，租賃負債金額增加，以反映利息增加及就所付之租賃付款減少。此外，倘出現修改、租賃期變動、租賃付款變動(例如指數或比率變動所產生之未來租賃付款變動)或購買相關資產之選擇權之評估更改，租賃負債之賬面值將重新計量。

本集團之租賃負債於綜合財務狀況表中分開呈列。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Leases (Continued)

The Group as a lessee (Continued)

(c) Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to its short-term leases (that is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the recognition exemption for leases of low-value assets to leases of office equipment that are considered to be of low value.

Lease payments on short-term leases and leases of low-value assets are recognised as an expense on a straight-line basis over the lease term.

The Group as a lessor

When the Group acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to the ownership of an underlying assets to the lessee. If this is not the case, the lease is classified as an operating lease.

When the Group is an intermediate lessor, the sub-leases are classified as a finance lease or as an operating lease with reference to the right-of-use asset arising from the head lease. If the head lease is a short-term lease to which the Group applies the exemption, then the Group classifies the sub-lease as an operating lease.

2.4 重大會計政策概要(續)

租賃(續)

本集團作為承租人(續)

(c) 短期租賃及低價值資產租賃

本集團將短期租賃確認豁免應用於其短期租賃(即自開始日期起計租期為12個月或以下，並且不包含購買選擇權的租賃)。低價值資產租賃的確認豁免亦應用於被視為低價值的辦公室設備租賃。

短期租賃的租賃付款及低價值資產租賃於租期內按直線法確認為一項開支。

本集團作為出租人

倘本集團作為出租人，其於租賃開始時釐定各租賃為融資租賃或經營租賃。倘租賃轉移相關資產所有權附帶之絕大部分風險及回報至承租人，則租賃分類為融資租賃。否則，租賃分類為經營租賃。

倘本集團為中介出租人，分租賃乃參考主租賃產生的使用權資產，分類為融資租賃或經營租賃。倘主租賃乃短期租賃而本集團應用豁免，則本集團將分租賃分類為經營租賃。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Investments and other financial assets

Initial recognition and measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income, and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Group's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient of not adjusting the effect of a significant financing component, the Group initially measures a financial asset at its fair value, plus in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under HKFRS 15, *Revenue from contracts with customers,* in accordance with the policies set out for "Revenue recognition" below.

Except for investment in equity securities, in order for a financial asset to be classified and measured at amortised cost or fair value through other comprehensive income, it needs to give rise to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

The Group's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortised cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows, while financial assets classified and measured at fair value through other comprehensive income are held within a business model with the objective of both holding to collect contractual cash flows and selling. Financial assets which are not held within the aforementioned business models are classified and measured at fair value through profit or loss.

2.4 重大會計政策概要(續)

投資及其他金融資產

初始確認及計量

金融資產於初始確認時分類為其後按攤銷成本計量、按公允價值計入其他全面收入及按公允價值計入損益。

於初步確認時的金融資產分類取決於金融資產的合約現金流量特徵以及本集團管理金融資產的業務模式。除了並不包含重大融資成分或本集團對其採用可行權宜方法不調整重大融資成分影響的貿易應收款項外，本集團按公允價值加上(倘金融資產並非按公允價值計入損益)交易成本初步計量金融資產。並不包含重大融資成分或本集團對其採用可行權宜方法的貿易應收款項，乃根據香港財務報告準則第15號*客戶合約收入*按下文「收入確認」所載之政策釐定的交易價格計量。

除了於股本證券之投資外，為使金融資產按攤銷成本或按公允價值計入其他全面收入分類及計量，金融資產須產生純粹為支付本金及尚未償還本金的利息的現金流量。現金流量不僅為支付本金及利息之金融資產按公允價值計入損益進行分類及計量，不論其業務模式如何。

本集團管理金融資產的業務模式指其如何管理其金融資產以產生現金流量。業務模式確定現金流量是否來自收集合約現金流量、出售金融資產，或兩者兼有。按攤銷成本進行分類及計量的金融資產乃以目的為持有金融資產以收取合約現金流量之業務模式持有，而按公允價值計入其他全面收入進行分類及計量的金融資產乃於以持有作收取合約現金流量及出售為目標的業務模式內持有。並非以上述業務模式持有的金融資產乃按公允價值計入損益進行分類及計量。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Investments and other financial assets (Continued)

Initial recognition and measurement (Continued)

All regular way purchases and sales of financial assets are recognised on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

Subsequent measurement

The subsequent measurement of financial assets depends on their classification as follows:

Financial assets at amortised cost (debt instruments)

Financial assets at amortised cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognised in the consolidated statement of profit or loss when the asset is derecognised, modified or impaired.

Financial assets at fair value through other comprehensive income (debt instruments)

For debt investments at fair value through other comprehensive income, interest income, foreign exchange revaluation and impairment losses or reversals are recognised in the consolidated statement of profit or loss and computed in the same manner as for financial assets measured at amortised cost. The remaining fair value changes are recognised in other comprehensive income. Upon derecognition, the cumulative fair value change recognised in other comprehensive income is recycled to the consolidated statement of profit or loss.

Financial assets designated at fair value through other comprehensive income (equity investments)

Upon initial recognition, the Group can elect to classify irrevocably its equity investments as equity investments designated at fair value through other comprehensive income when they meet the definition of equity under HKAS 32, *Financial Instruments: Presentation,* and are not held for trading. The classification is determined on an instrument-by-instrument basis.

2.4 重大會計政策概要(續)

投資及其他金融資產(續)

初始確認及計量(續)

所有以常規方式進行的金融資產買賣概於交易日期(即本集團承諾購買或出售該資產的日期)確認。常規方式買賣指按照一般市場規例或慣例訂定的期間內交付資產的金融資產買賣。

後續計量

金融資產的後續計量視乎其以下分類而定：

按攤銷成本計量的金融資產(債務工具)

按攤銷成本計量的金融資產其後使用實際利率法計量，並可能受減值影響。當資產取消確認、修訂或減值時，收益及虧損於綜合損益表中確認。

按公允價值計入其他全面收入的金融資產(債務工具)

就按公允價值計入其他全面收入的債務投資而言，利息收入、匯兑重估及減值虧損或撥回於綜合損益表中確認，並按與以攤銷成本計量的金融資產相同的方式計量。其餘公允價值變動於其他全面收入中確認。終止確認時，於其他全面收入中確認的累計公允價值變動將重新計入綜合損益表。

指定按公允價值計入其他全面收入的金融資產(股本投資)

於初始確認時，本集團可選擇於股本投資符合香港會計準則第32號*金融工具：呈報*項下的股本定義且並非持作買賣時，將其股本投資不可撤回地分類為指定以公允價值計入其他全面收入的股本投資。分類乃按個別工具基準釐定。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Investments and other financial assets (Continued)

Subsequent measurement (Continued)

Financial assets designated at fair value through other comprehensive income (equity investments) (Continued)

Gains and losses on these financial assets are never recycled to the consolidated statement of profit or loss. Dividends are recognised as other income in the consolidated statement of profit or loss when the right of payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably, except when the Group benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in other comprehensive income. Equity investments designated at fair value through other comprehensive income are not subject to impairment assessment.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the consolidated statement of financial position at fair value with net changes in fair value recognised in the consolidated statement of profit or loss.

This category includes derivative instruments and equity investments which the Group had not irrevocably elected to classify at fair value through other comprehensive income. Dividends on equity investments classified as financial assets at fair value through profit or loss are also recognised as other income in the consolidated statement of profit or loss when the right of payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

2.4 重大會計政策概要(續)

投資及其他金融資產(續)

後續計量(續)

指定按公允價值計入其他全面收入的金融資產(股本投資)(續)

該等金融資產的收益及虧損概不會被重新計入綜合損益表。當支付權確立、與股息有關之經濟利益可能流入本集團且股息金額能夠可靠計量時，股息於綜合損益表中確認為其他收入，惟當本集團於作為收回金融資產一部分成本的所得款項中獲益時則除外，於此情況，該等收益於其他全面收入入賬。指定為按公允價值計入其他全面收入的股本投資不受減值評估影響。

按公允價值計入損益的金融資產

按公允價值計入損益的金融資產須以公允價值於綜合財務狀況表列賬，並將公允價值的變動淨額於綜合損益表列賬。

此類別包括本集團並無不可撤銷地選擇按公允價值計入其他全面收入進行分類的衍生工具及股本投資。分類為按公允價值計入損益的金融資產之股本投資的股息在支付權確立、與股息有關之經濟利益可能流入本集團且股息金額能夠可靠計量時，亦於綜合損益表中確認為其他收入。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e., removed from the Group's consolidated statement of financial position) when:

- the rights to receive cash flows from the asset have expired; or
- the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

2.4 重大會計政策概要(續)

終止確認金融資產

金融資產(或(如適用)金融資產的一部分或一組類近金融資產的一部分)主要在下列情況終止確認(即由本集團綜合財務狀況表內剔除):

- 自該資產收取現金流量的權利已屆滿;或
- 本集團已轉讓其收取來自該資產的現金流量的權利,或已根據「轉遞」安排就向第三者承擔責任全數支付已收取現金流量,且無重大延誤,並且(a)本集團已轉讓該資產的絕大部分風險及回報,或(b)本集團並無轉讓或保留該資產的絕大部分風險及回報,惟已轉讓該資產的控制權。

倘若已轉讓其自資產收取現金流量的權利或訂立轉遞安排,本集團會評估其有否保留該資產所有權的風險及回報以及其程度。當並無轉讓或保留該資產的絕大部分風險及回報,亦無轉讓該資產的控制權,則本集團繼續按其持續參與該資產的程度確認已轉讓資產。就此而言,本集團亦確認相關負債。已轉讓資產及相關負債的計量基準反映本集團保留的權利及責任。

以對所轉讓資產提供擔保的形式作出的持續參與按該資產原賬面值與本集團可能須償還的代價的最高金額兩者的較低者計量。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Impairment of financial assets

The Group recognises an allowance for expected credit losses ("ECLs") for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

General approach

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12 months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

At each reporting date, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information.

2.4 重大會計政策概要(續)

金融資產減值

本集團對並非持作按公允價值計入損益的所有債務工具確認預期信貸虧損(「預期信貸虧損」)撥備。預期信貸虧損乃基於根據合約到期的合約現金流量與本集團預期收取的所有現金流量之間的差額而釐定，並以原實際利率的近似值折現。預期現金流量將包括出售所持抵押的現金流量或組成合約條款的其他信貸提升措施。

一般方法

預期信貸虧損分兩個階段確認。就初始確認以來信貸風險並無顯著上升的信貸敞口而言，會就未來12個月內可能發生的違約事件所產生的信貸虧損計提預期信貸虧損撥備(12個月預期信貸虧損)。就初始確認以來信貸風險顯著上升的信貸敞口而言，須就預期於敞口的餘下年期產生的信貸虧損計提減值撥備，而不論違約的時間(全期預期信貸虧損)。

於各報告日期，本集團評估金融工具的信貸風險自初步確認以來是否顯著上升。於評估時，本集團將金融工具於報告日期發生違約的風險與金融工具於初始確認日期發生違約的風險進行比較，並考慮無需過多成本或精力即可獲得之合理且可支持的資料，包括歷史及前瞻性資料。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Impairment of financial assets (Continued)

General approach (Continued)

For debt investments at fair value through other comprehensive income, the Group applies the low credit risk simplification. At each reporting date, the Group evaluates whether the debt investments are considered to have low credit risk using all reasonable and supportable information that is available without undue cost or effort. In making that evaluation, the Group reassesses the external credit ratings of the debt investments. In addition, the Group considers that there has been a significant increase in credit risk when contractual payments are more than 30 days past due.

The Group considers a financial asset in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Debt investments at fair value through other comprehensive income and financial assets at amortised cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables which apply the simplified approach as detailed below.

2.4 重大會計政策概要(續)

金融資產減值(續)

一般方法(續)

就按公允價值計入其他全面收入的債務投資而言，本集團應用低信貸風險簡化法。於各報告日期，本集團運用一切毋須花費不必要成本或精力即可得之合理且可證明的資料，評估債務投資是否被視為具有低信貸風險。於評估時，本集團重新評估債務投資的外部信貸評級。此外，倘合約款項逾期超過30日以上，則本集團認為信貸風險大幅上升。

倘內部或外部資料反映，在計及本集團持有的任何信貸提升措施前，本集團不大可能悉數收取未償還合約款項，則本集團認為金融資產違約。倘無法合理預期收回合約現金流量，則撇銷金融資產。

按公允價值計入其他全面收入的債務投資及按攤銷成本計量的金融資產根據一般方法須予減值，並按以下為計量預期信貸虧損的階段分類，惟應用簡化法(於下文詳述)的貿易應收款項除外。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Impairment of financial assets (Continued)

General approach (Continued)

Stage 1 – Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs

Stage 2 – Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs

Stage 3 – Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs

Simplified approach

For trade receivables that do not contain a significant financing component or when the Group applies the practical expedient of not adjusting the effect of a significant financing component, the Group applies the simplified approach in calculating ECLs. Under the simplified approach, the Group does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

For trade receivables that contain a significant financing component and lease receivables, the Group chooses as its accounting policy to adopt the simplified approach in calculating ECLs with policies as described above.

2.4 重大會計政策概要(續)

金融資產減值(續)

一般方法(續)

階段1 – 金融工具的信貸風險自初始確認後並未顯著增加，且虧損撥備按相等於12個月預期信貸虧損金額計量

階段2 – 金融工具的信貸風險自初始確認後顯著增加，惟其並非已發生信貸減值的金融資產，且虧損撥備按相等於全期預期信貸虧損金額計量

階段3 – 金融資產於報告日期為信貸減值(惟其並非購買或原已發生信貸減值的金融工具)，且虧損撥備按相等於全期預期信貸虧損金額計量

簡化法

就不包含顯著融資組成部份或倘本集團應用不調整顯著融資組成部份影響的實際權宜方法的貿易應收款項，本集團應用簡化法計算預期信貸虧損。根據簡化法，本集團並無追蹤信貸風險的變動，反而於各報告日期根據全期預期信貸虧損確認虧損撥備。本集團已根據其以往信貸虧損經驗，建立撥備矩陣，並就債務人及經濟環境的特定前瞻性因素作出調整。

就包括顯著融資組成部份之貿易應收款項及租賃應收款項，本集團選擇連同上文所述的政策採納簡化法計算預期信貸虧損作為其會計政策。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as loans and borrowings.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

Subsequent measurement of financial liabilities at amortised cost (loans and borrowings)

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognised in the consolidated statement of profit or loss when the liabilities are derecognised as well as through the effective interest rate amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is recognised in the consolidated statement of profit or loss.

Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognised in the consolidated statement of profit or loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the consolidated statement of financial position if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

2.4 重大會計政策概要(續)

金融負債

初始確認及計量

金融負債於初步確認時分類為貸款及借款。

所有金融負債初步按公允價值確認及(就貸款及借款以及應付款項而言)扣除直接應佔交易成本。

按攤銷成本計量之金融負債(貸款及借款)的後續計量

於初步確認後，計息貸款及借款其後以實際利率法按攤銷成本計量，惟折現影響不重大除外，而在此情況則按成本列賬。在終止確認負債時及於按實際利率進行攤銷過程中，收益及虧損會在綜合損益表中確認。

計算攤銷成本時將計及收購時的任何折讓或溢價，以及組成實際利率一部分的費用或成本。實際利率攤銷於綜合損益表中確認。

終止確認金融負債

當負債項下責任已解除、取消或期滿，即會終止確認金融負債。

倘一項現有金融負債以來自同一貸款方而大部分條款不同的另一項金融負債所取代，或現有負債的條款大幅修改，則該項置換或修改視作終止確認原有負債及確認新負債處理，而相關賬面值的差額於綜合損益表中確認。

抵銷金融工具

當目前擁有可強制執行的合法權利以抵銷已確認金額，且有意按淨額結算或同時變現資產及償還負債，方會抵銷金融資產及金融負債，並於綜合財務狀況表中呈列淨額。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Derivative financial instruments

Derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at fair value. Derivatives are carried as assets when the fair value is positive and as liabilities when the fair value is negative. Any gains or losses arising from changes in fair value of derivatives are taken directly to the consolidated statement of profit or loss.

Shares held under the share award scheme

Where shares are acquired by the share award scheme from the market or by electing for scrip in lieu of cash dividends, the total consideration of shares acquired from the market (including any directly attributable incremental costs) or under the scrip dividend scheme is presented as shares held for the share award scheme and deducted from total equity.

Upon vesting, the related costs of the vested awarded shares purchased from the market and shares acquired under the scrip dividend scheme (dividend shares) are credited to shares held for the share award scheme, with a corresponding decrease in the share-based payment reserve for awarded shares and a decrease in retained profits for dividend shares.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined on the weighted average basis. Net realisable value is based on estimated selling prices less any estimated costs to be incurred to disposal.

Cash and cash equivalents

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short-term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired, less bank overdrafts which are repayable on demand and form an integral part of the Group's cash management.

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including term deposits, and assets similar in nature to cash, which are not restricted as to use.

2.4 重大會計政策概要(續)

衍生金融工具

衍生金融工具初步按衍生合約訂立日期之公允價值確認，其後按公允價值重新計量。衍生工具於其公允價值為正數時列賬為資產，並於公允價值為負數時列為負債。任何產生自衍生工具公允價值變動的收益或虧損直接計入綜合損益表。

股份獎勵計劃項下預留的股份

如透過股份獎勵計劃從市場收購股份或以選擇以股代息代替現金股息，則從市場獲得的股份或以股代息計劃項下的股份的總代價(包括任何直接應佔增量成本)乃呈列為股份獎勵計劃項下預留的股份並從總權益中扣除。

歸屬後，從市場購買的已歸屬獎勵股份及根據以股代息計劃(股息股份)取得的股份的相關成本計入股份獎勵計劃項下預留的股份，並相應減少獎勵股份的以股份為基礎之付款儲備，以及減少股息股份的留存利潤。

存貨

存貨按成本值與可變現淨值兩者中之較低者入賬。成本按加權平均基準計算。可變現淨值乃根據估計售價減出售將產生的任何估計成本計算。

現金及現金等價物

就綜合現金流量表而言，現金及現金等價物包括手頭現金、活期存款及可隨時轉換為已知數額現金、價值變動風險極微及一般自購入後三個月內到期的短期高流通性投資，減須按要求償還並構成本集團現金管理一部分的銀行透支。

就綜合財務狀況表而言，現金及現金等價物包括用途不受限制的手頭現金與銀行現金(包括定期存款)及性質類似現金的資產。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Provisions

A provision is recognised when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

When the effect of discounting is material, the amount recognised for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is recognised in the consolidated statement of profit or loss.

A provision for reinstatement costs is recognised when a contractual obligation under the terms of an operating lease has arisen to reinstate a leased property at the end of the lease. Reinstatement costs are provided at the value of the expected costs to settle the obligation at the end of the reporting period using estimated cash flows and an equivalent asset is recognised and depreciated over the term of the operating lease. The estimated future costs of reinstatement are reviewed, and adjusted if appropriate, at least at each financial year end. Changes in the estimated future costs are added to or deducted from the cost of the corresponding asset.

Onerous contracts

An onerous contract exists when the Company has a contract under which the unavoidable costs of meeting the obligations under the contract exceed the economic benefits expected to be received from the contract. Provisions for onerous contracts are measured at the present value of the lower of the expected cost of terminating the contract and the net cost of fulfilling the contract. The cost of fulfilling the contract includes both the incremental costs of fulfilling that contract and an allocation of other costs that relate directly to fulfilling that contract.

Income tax

Income tax comprises current and deferred tax. Income tax relating to items recognised outside profit or loss is recognised outside profit or loss, either in other comprehensive income or directly in equity.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries/jurisdictions in which the Group operates.

2.4 重大會計政策概要(續)

撥備

倘因過往事件產生現時債務(法定或推定)及將來可能需要有資源流出以償還債務，則確認撥備，惟有關債務數額能夠可靠估計。

倘折現之影響重大，則確認之撥備金額為預期需用作償還債務之未來支出於報告期末之現值。因時間流逝而產生之貼現現值增幅於綜合損益表確認。

於經營租賃條款下因須在租賃期末復原租賃物業而產生合約債務時，確認復原成本撥備。復原成本採用預計現金流量按報告期末償還債務預計成本值計提撥備，同時就經營租賃期確認一項等值資產並對其計提折舊。復原的預計未來成本至少須於每個財政年度末檢討及調整(如適用)。預計未來成本的變動會增添至相關資產的成本，或從相關資產的成本中扣除。

虧損性合約

當本公司訂立之合約之合約義務履行所不可避免之成本超過預期從該合約獲得之經濟效益，即代表存在虧損性合約。虧損性合約之撥備按終止合約之預期成本與履行合約所產生之淨成本兩者中較低者之現值計量。履行合約之成本包括履行合約之增量成本及與履行合約直接相關之其他成本之分攤金額。

所得税

所得税包括即期及遞延税項。與在損益以外確認的項目相關的所得税於損益以外確認，即其他全面收入或直接於權益確認。

即期税項資產及負債乃按預期自税務機構退回或付予税務機構的金額根據截至報告期末已實施或實質上已實施的税率(及税法)計算，並考慮本集團經營所在國家／司法權區的現行詮釋及慣例。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Income tax (Continued)

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of taxable temporary differences associated with investments in subsidiaries, associates and joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, and the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences, the carryforward of unused tax credits and unused tax losses can be utilised, except:

- when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

2.4 重大會計政策概要(續)

所得稅(續)

遞延稅項採用負債法就報告期末資產及負債的稅基與財務報告所列的賬面值兩者間的所有暫時差額計提撥備。

遞延稅項負債乃就所有應課稅暫時差額而確認，惟下列情況除外：

- 遞延稅項負債乃因初次確認商譽或一項交易(並非業務合併)的資產或負債而產生，並於交易時並不影響會計利潤或應課稅損益；及
- 就與於附屬公司、聯營公司及合資公司的投資有關的應課稅暫時差額而言，暫時差額的撥回時間可予控制，而該等暫時差額於可見將來可能不會撥回。

遞延稅項資產乃就所有可扣稅暫時差額以及未動用稅項抵免及任何未動用稅項虧損的結轉予以確認。遞延稅項資產乃於有未來應課稅利潤可動用以抵銷可扣稅暫時差額以及未動用稅項抵免及未動用稅項虧損的結轉的情況下予以確認，惟下列情況除外：

- 與可扣稅暫時差額有關的遞延稅項資產乃因在一項並非業務合併的交易中初次確認資產或負債而產生，並於交易時並不影響會計利潤或應課稅損益；及

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Income tax (Continued)

- in respect of deductible temporary differences associated with investments in subsidiaries, associates and joint ventures, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and future taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are reassessed at the end of each reporting period and are recognised to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if and only if the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

Government grants

Government grants are recognised at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognised in the consolidated statement of profit or loss on a systematic basis over the periods that the costs, which it is intended to compensate, are expensed.

2.4 重大會計政策概要(續)

所得稅(續)

- 就與於附屬公司、聯營公司及合資公司的投資有關的可扣稅暫時差額而言，遞延稅項資產僅於暫時差額於可見將來有可能撥回及有未來應課稅利潤可動用以抵銷暫時差額的情況，方予確認。

本集團會於各報告期末檢討遞延稅項資產的賬面值，並在不再可能有足夠應課稅利潤以動用全部或部分遞延稅項資產時，相應扣減該賬面值。未確認的遞延稅項資產會於各報告期末重新評估，並在可能有足夠應課稅利潤以動用全部或部分遞延稅項資產的情況予以確認。

遞延稅項資產及負債按照於報告期末已實施或實質上實施的稅率(及稅法)，以預計於變現資產或償還負債的期間內適用的稅率計量。

倘及僅當本集團具有在法律上可強制執行的權利以抵銷即期稅項資產與即期稅項負債，且遞延稅項資產及遞延稅項負債乃與同一稅務機關就同一應課稅實體或有意於往後各預期將結付或收回大額遞延稅項負債或資產的期間內按淨額基準結算即期稅項負債與資產或同時變現資產及清償負債的不同應課稅實體有關，則遞延稅項資產可與遞延稅項負債抵銷。

政府補貼

倘可合理保證將能收取補貼且將符合所有附帶條件，則政府補貼按其公允價值確認。倘補貼與開支項目相關，則於支銷擬用於補償的成本期間按系統基準於綜合損益表確認。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Revenue recognition

Revenue from contracts with customers

Revenue from contracts with customers is recognised when control of goods or services is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services.

When the consideration in a contract includes a variable amount, the amount of consideration is estimated to which the Group will be entitled in exchange for transferring the goods or services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

When the contract contains a financing component which provides the customer with a significant benefit of financing the transfer of goods or services to the customer for more than one year, revenue is measured at the present value of the amount receivable, discounted using the discount rate that would be reflected in a separate financing transaction between the Group and the customer at contract inception. When the contract contains a financing component which provides the Group with a significant financial benefit for more than one year, revenue recognised under the contract includes the interest expense accreted on the contract liability under the effective interest method. For a contract where the period between the payment by the customer and the transfer of the promised goods or services is one year or less, the transaction price is not adjusted for the effects of a significant financing component, using the practical expedient in HKFRS 15.

2.4 重大會計政策概要(續)

收入確認

客戶合約收入

當客戶合約收入按反映本集團預期有權獲得以交換該等貨品或服務的代價金額轉移至客戶時，確認客戶合約收入。

倘合約代價包括可變金額時，則代價金額估計為本集團就交換向客戶轉讓貨品或服務而有權收取的代價金額。可變代價於合約開始時估計並加以限制，直至已確認累計收入金額的重大收入撥回不太可能發生(倘可變代價的相關不確定因素其後得以解決)為止。

倘合約包括向客戶提供一年以上有關向客戶轉讓貨品或服務之重大融資利益的融資成分，則收入按應收金額的現行價值計量，並於合約開始時運用將於本集團與客戶之間的獨立融資交易中反映的折現率折現。倘合約包括提供本集團一年以上重大財務利益的融資成分，則根據該合約確認的收入包括根據實際利率法合約責任附有的利息開支。對於客戶付款與承諾貨品或服務轉移期間為一年或以下的合約，乃不就重大融資成分的影響運用香港財務報告準則第15號的實際權宜方法對交易價格進行調整。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Revenue recognition (Continued)

Details of the Group's revenue recognition policy is described as below:

(a) Revenue from the provision of healthcare solution services is recognised upon the provision of the relevant services or on a time proportion basis over the terms of the fixed-fee service contracts (including annual retainer and capitation plans). Further details are explained in the accounting policy for "fixed-fee service contracts" below;

(b) Revenue from the below services are recognised as services are rendered:

- medical and dental services;
- healthcare management services; and
- administrative support services.

(c) dividend income, when the shareholders' right to receive payment has been established;

(d) interest income, on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset; and

(e) rental income under operating leases is recognised on the straight-line basis over the terms of the relevant leases.

2.4 重大會計政策概要(續)

收入確認(續)

本集團之收入確認政策詳述如下：

(a) 提供醫療保健解決方案服務的收入於提供相關服務時或在固定費用服務合約(包括年度定額收費及按人數承包計劃)履約期內按時間比例基準確認。進一步詳情於下文有關「固定費用服務合約」的會計政策闡釋；

(b) 下列服務的收入於提供服務時確認：

- 醫療及牙科服務；
- 醫療保健管理服務；及
- 行政支持服務。

(c) 股息收入：在股東收取相應款項的權利確立時確認；

(d) 利息收入：按應計基準及以實際利率法，透過採用將金融工具在預期年期或較短期間(如適用)的估計未來現金收入貼現至金融資產的賬面淨值之比率予以確認；及

(e) 經營租賃項下的租金收入：以直線法於有關租賃的期限內確認。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Fixed-fee service contracts

The Group has certain medical, dental and other service contracts, in which the Group agrees to provide specific services over the terms of the contracts for a fixed fee in which the level of services depends on uncertain future events (the "Fixed-fee Service Contracts"). The Fixed-fee Service Contracts are in general of one to two years and the Group receives the related service fees upfront. The Contract Customers cannot recover the service fee upon the expiration of the respective fixed-fee service contract periods irrespective of whether the plan members utilised any services under the Fixed-fee Service Contracts.

At the end of each reporting period, tests are performed to ensure the adequacy of the contract liabilities under the Fixed-fee Service Contracts. In performing these tests, the current best estimates of future contractual cash flows under the Fixed-fee Service Contracts are used. Any deficiency is immediately charged to the consolidated statement of profit or loss by establishing a provision for losses.

Fees received or receivable under the Fixed-fee Service Contracts are recognised on a time proportion basis (i.e., straight-line basis) over the terms of the Fixed-fee Service Contracts. At the time of revenue recognition, plan members may not utilise any services under the Fixed-fee Service Contracts and hence, no direct cost will be incurred by the Group in association with the professional services rendered by the doctors, dentists and auxiliary service providers. Accordingly, expenses incurred in connection with the Fixed-fee Service Contracts are charged to the consolidated statement of profit or loss as incurred.

For certain contracts, the Group accepts significant insurance risk by agreeing to compensate the customer if a specified uncertain future event adversely affects the customer. The Group also mitigates the risk by using other contracts to transfer part of the risk to insurance companies. As the coverage period of each of the Group's insurance and reinsurance contracts would be one year or less, they are expected to meet the eligibility criteria and be measured using the premium allocation approach. Those insurance and reinsurance contracts are considered to be insignificant to the Group's consolidated financial statements.

2.4 重大會計政策概要(續)

固定費用服務合約

本集團持有若干醫療、牙科及其他服務合約，本集團於此等合約中約定於合約期內以固定費用提供特定服務，而服務程度取決於未來的不確定事項(「固定費用服務合約」)。固定費用服務合約一般為期一至兩年，且本集團預收相關服務費。於相關固定費用服務合約屆滿後，不管計劃會員有否使用固定費用服務合約項下的任何服務，合約客戶均不能收回該服務費。

於各報告期末，本集團會進行測試以確保固定費用服務合約之合約負債足夠。進行此等測試時，對於固定費用服務合約下的未來合約現金流量，應使用當前的最佳估計。任何不足額隨即透過設立虧損撥備於綜合損益表內扣除。

於固定費用服務合約下的已收或應收費用，應按照時間比例基準(即按直線基準)在固定費用服務合約的履約期內確認。於確認收入時，計劃會員可能並未使用固定費用服務合約下的任何服務，因此，本集團並不會發生與醫生、牙醫及輔助服務提供者提供專業服務相關的直接成本。因此，與固定費用服務合約相關的費用於發生時從綜合損益表中扣除。

就若干合約而言，倘某項特定不確定未來事件對客戶造成不利影響，而本集團同意向該客戶作出賠償，則本集團承擔重大保險風險。本集團亦透過利用其他合約以轉移部分風險至保險公司來減低風險。由於本集團每份保險及再保險合約之承保期將為一年或更短，該等合約預計將符合條件標準，並將採用保費分配法進行計量。保險及再保險合約於本集團綜合財務報表中被視為微不足道。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Contract liabilities

A contract liability is recognised when a payment is received or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services. Contract liabilities are recognised as revenue when the Group performs under the contract (i.e., transfers control of the related goods or services to the customer).

Share-based payments

The Company operates share option schemes, a share award scheme and warrants scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. Employees (including directors), consultants and a business partner of the Group receive remuneration in the form of share-based payments, whereby employees, consultants and a business partner render services as consideration for equity instruments ("equity-settled transactions").

In situations where the share-based payment transactions are with employees of the Group, the cost of equity-settled transactions is measured by reference to the fair value of the equity instruments at the date at which they are granted, taking into account the terms and conditions upon which these equity instruments are granted. In situations where the share-based payment transactions are with non-employees of the Group, the cost of equity-settled transactions is measured by reference to the fair value of goods or services received, unless that fair value cannot be estimated reliably. If the Group cannot estimate reliably the fair value of the goods or services received, the Group measures the goods or services received, indirectly, by reference to the fair value of the equity instruments granted.

The fair value of the share options granted is determined by an external valuer using a binomial model, further details of which are given in note 36 to the consolidated financial statements.

2.4 重大會計政策概要(續)

合約負債

合約負債於本集團轉移相關貨品或服務前收到客戶付款或到期付款(以較早者為準)時確認。當本集團根據合約履行合約時(即向客戶轉移相關貨品或服務的控制權),合約負債確認為收入。

以股份為基礎的付款

本公司設有購股權計劃、股份獎勵計劃及認股權證計劃,向為本集團業務成就作出貢獻的合資格參與者提供獎勵及報酬。本集團僱員(包括董事)、顧問及業務夥伴按以股份為基礎的付款方式收取薪酬,僱員、顧問及業務夥伴以提供服務作為權益工具的代價(「以權益結算之交易」)。

若以股份為基礎的付款交易以本集團的僱員為對象,則以權益結算之交易的成本參照權益工具於授出當日的公允價值計量,並考慮此等權益工具的授出條款及條件。若以股份為基礎的付款交易並非以本集團僱員為對象,則以權益結算之交易的成本參照所接收的貨品或服務的公允價值計量,除非無法可靠估計其公允價值。若本集團無法可靠估計所接收貨品或服務的公允價值,則本集團將參照授出的權益工具的公允價值間接計量所接受貨品或服務。

所授出購股權的公允價值由外部估值師使用二項式模型確定,進一步詳情載於綜合財務報表附註36。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Share-based payments (Continued)

The cost of equity-settled transactions is recognised either in employee benefit expense or other expenses, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognised for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the consolidated statement of profit or loss for a period represents the movement in the cumulative expense recognised as at the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

The Group shall revise the estimates of the amount for the goods or services received if subsequent information indicates that the number of equity instruments expected to vest differs from previous estimates. For awards that do not ultimately vest because non-market performance and/or service conditions have not been met, no expense is recognised. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

2.4 重大會計政策概要(續)

以股份為基礎的付款(續)

以權益結算之交易的成本乃於績效及／或服務條件達成的期間於僱員福利開支或其他開支中確認，並相應增加權益。從各報告期末至歸屬日對於以權益結算之交易所確認的累計費用，反映歸屬期屆滿的程度以及本集團對於最終將歸屬的權益工具數量的最佳估計。當期綜合損益表借記或貸記的金額代表當期期初和期末所確認的累計費用變動。

釐定獎勵獲授當日之公允價值時，並不計及服務及非市場績效條件，惟在有可能符合條件的情況，則評估為本集團對最終將會歸屬權益工具數目最佳估計一部分。市場績效條件反映於獎勵獲授當日之公允價值。獎勵之任何其他附帶條件(但不帶有服務要求)視作非歸屬條件。非歸屬條件反映於獎勵之公允價值，除非同時具服務及／或績效條件，否則獎勵即時支銷。

倘若隨後的信息顯示預期歸屬的股本工具數目與過往估計不同，本集團應修訂對所收到的貨品或服務之估計金額。因非市場績效及／或服務條件未能達成而最終無歸屬之獎勵並不確認為支出。凡獎勵包含市場或非歸屬條件，無論市場條件或非歸屬條件獲履行與否，而所有其他績效及／或服務條件均獲履行，則交易仍被視為一項歸屬。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Share-based payments (Continued)

Where the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified, if the original terms of the award are met. In addition, an expense is recognised for any modification that increases the total fair value of the share-based payments, or is otherwise beneficial to the employee as measured at the date of the modification.

Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. This includes any award where non-vesting conditions within the control of either the Group or the employee are not met. However, if a new award is substituted for the cancelled award, and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of earnings per share.

Other employee benefits

Pension schemes

The Group operates a defined contribution Mandatory Provident Fund retirement benefit scheme (the "MPF Scheme") under the Hong Kong Mandatory Provident Fund Schemes Ordinance for those employees who are eligible to participate in the MPF Scheme. Contributions are made based on a percentage of the employees' basic salaries and are charged to the consolidated statement of profit or loss as they become payable in accordance with the rules of the MPF Scheme. The assets of the MPF Scheme are held separately from those of the Group in an independently administered fund. The Group's employer contributions vest fully with the employees when contributed into the MPF Scheme.

2.4 重大會計政策概要(續)

以股份為基礎的付款(續)

倘修訂以權益結算之獎勵的條款，在未符合獎勵原有條款的情況下，確認最低費用，猶如條款並無修訂。此外，倘修訂導致以股份為基礎的付款的總公允價值增加，或對僱員有利，會於修訂日計量及確認相應費用。

若以權益結算之獎勵遭撤銷，則被視為於撤銷當日已歸屬，而尚未就該獎勵確認的任何費用須即時予以確認，其中包括受本集團或其僱員控制的非歸屬條件未獲履行的任何獎勵。然而，倘有一項新獎勵取代已撤銷獎勵，並於授出當日被指定為替代獎勵，則已撤銷獎勵及新獎勵均被視作原有獎勵之修訂(見上段所述)。

尚未行使購股權之攤薄影響於計算每股盈利時反映為額外股份攤薄。

其他僱員福利

退休金計劃

本集團根據香港強制性公積金計劃條例，為所有合資格參與之僱員提供定額供款強制性公積金退休福利計劃(「強積金計劃」)。供款乃根據僱員基本薪金之百分比計算，並於有關款項根據強積金計劃之規則須予支付時計入綜合損益表。強積金計劃之資產乃獨立於本集團之資產，並由獨立管理之基金持有。本集團之僱主供款於向強積金計劃作出供款時全數歸於僱員。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Other employee benefits (Continued)

Pension schemes (Continued)

The employees of the Group's subsidiaries which operate in Chinese Mainland are required to participate in a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute certain percentages of their payroll costs to the central pension scheme. The contributions are charged to the statement of profit or loss as they become payable in accordance with the rules of the central pension scheme.

The employees of the Group's subsidiaries which operate in Macau are required to participate in a social security fund operated by the government of the Macao Special Administrative Region. These subsidiaries are required to contribute certain fixed amounts of their payroll costs to the social security fund. The contributions are charged to the consolidated statement of profit or loss as they become payable in accordance with the rules of the social security fund.

Dividends

Final dividends are recognised as a liability when they are approved by the shareholders in a general meeting. Proposed final dividends are disclosed in the notes to the consolidated financial statements.

Interim dividends are simultaneously proposed and declared, because the Company's memorandum and articles of association grant the directors the authority to declare interim dividends. Consequently, interim dividends are recognised immediately as a liability when they are proposed and declared.

2.4 重大會計政策概要(續)

其他僱員福利(續)

退休金計劃(續)

本集團於中國內地營運的附屬公司之僱員須參加當地市政府管理的中央退休金計劃。該等附屬公司須按薪酬成本的若干百分比對中央退休金計劃供款。根據中央退休金計劃的規則，供款於成為應付款項時自損益表中扣除。

本集團於澳門經營之附屬公司之僱員須參與由澳門特別行政區政府營運之社會保障基金。此等附屬公司須按其薪金成本中之若干固定金額向社會保障基金作出供款。有關供款在根據社會保障基金之規則須予支付時自綜合損益表扣除。

股息

末期股息於股東在股東大會上批准時確認為負債。擬派末期股息於綜合財務報表附註中作出披露。

中期股息則即時建議及宣派，因為本公司組織章程大綱及公司細則已授予董事宣派中期股息的權利。因此，中期股息於建議及宣派時即時確認為負債。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Foreign currencies

These consolidated financial statements are presented in Hong Kong dollars, which is the Company's functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange ruling at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognised in the consolidated statement of profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.

In determining the exchange rate on initial recognition of the related asset, expense or income on the derecognition of a non-monetary asset or non-monetary liability relating to an advance consideration, the date of initial transaction is the date on which the Group initially recognises the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of the advance consideration.

The functional currencies of certain subsidiaries outside Hong Kong, associates and a joint venture are currencies other than the Hong Kong dollar. As at the end of the reporting period, the assets and liabilities of these entities are translated into Hong Kong dollars at the exchange rates prevailing at the end of the reporting period and their statements of profit or loss are translated into Hong Kong dollars at the weighted average exchange rates for the year. The resulting exchange differences are recognised in other comprehensive income and accumulated in the exchange fluctuation reserve. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognised in the consolidated statement of profit or loss.

Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising on acquisition are treated as assets and liabilities of the foreign operation and translated at the closing rate.

2.4 重大會計政策概要(續)

外幣

綜合財務報表以港元呈列，港元亦為本公司的功能貨幣。本集團各下屬實體可自行決定其功能貨幣，而各實體財務報表內項目採用該功能貨幣計量。本集團各實體的外幣交易在初始確認時，採用其各自的功能貨幣於交易日的即期匯率入賬。以外幣計值之貨幣資產和負債採用各報告期末匯率將外幣金額折算為功能貨幣金額。由此產生的結算或貨幣項目折算差額，均於綜合損益表確認。以外幣按歷史成本計量之非貨幣項目，採用初始交易日期之匯率折算。

在釐定有關預付代價的非貨幣資產或非貨幣負債終止確認時初始確認相關資產、開支或收入使用的匯率時，初始交易日期即本集團初始確認預付代價產生的非貨幣資產或非貨幣負債的日期。倘支付或收取多筆預付款，則本集團對支付或收取的每一筆預付代價釐定交易日期。

若干香港以外附屬公司、聯營公司及一間合資公司的功能貨幣為港元以外貨幣。於報告期末，該等實體的資產及負債採用報告期末的匯率折算為港元，而其損益表採用該年度的加權平均匯率折算為港元。就此產生的匯兑差額，確認為其他全面收入並在匯兑波動儲備中累計。出售海外業務時，將與該海外業務相關的其他全面收入部份於綜合損益表中確認。

因收購海外業務產生的商譽及任何因收購而產生的資產及負債賬面值之公允價值調整，均被視為該海外業務的資產及負債並採用收盤匯率進行折算。

2.4 SUMMARY OF MATERIAL ACCOUNTING POLICIES (Continued)

Foreign currencies (Continued)

For the purpose of the consolidated statement of cash flows, the cash flows of subsidiaries outside Hong Kong are translated into Hong Kong dollars at the exchange rates ruling at the dates of the cash flows. Frequently recurring cash flows of overseas subsidiaries which arise throughout the year are translated into Hong Kong dollars at the weighted average exchange rates for the year.

3. ACCOUNTING JUDGEMENTS AND ESTIMATES

The preparation of the Group's consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

Estimation uncertainty

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.

Impairment of goodwill and indefinite-lived intangible assets

The Group determines whether goodwill and indefinite-lived intangible assets are impaired at least on an annual basis. This requires an estimation of the value in use of the cash-generating units to which the goodwill and indefinite-lived intangible assets are allocated. Estimating the value in use requires the Group to make an estimate of the expected future cash flows from the cash-generating units and also to choose a suitable discount rate in order to calculate the present value of those cash flows. The carrying amount of goodwill and the indefinite-lived intangible assets at 30 June 2026 was HK$76,520,000 (2025: HK$156,604,000) and HK$39,557,000 (2025: HK$37,892,000), respectively. Further details of impairment testing are set out in note 18 to the consolidated financial statements.

2.4 重大會計政策概要(續)

外幣(續)

就綜合現金流量表而言，香港以外附屬公司的現金流量採用現金流量產生日期的即期匯率折算為港元。海外附屬公司於全年產生的經常性現金流按該年度加權平均匯率折算為港元。

3. 會計判斷及估計

編製本集團綜合財務報表時，管理層須作出會影響所呈報收入、開支、資產及負債之報告金額及其相關披露及或有負債披露之判斷、估計及假設。有關該等假設及估計之不確定性或會導致日後須就受影響之資產或負債賬面值作出重大調整。

估計不確定因素

於報告期末有關未來之主要假設及其他估計不確定性之主要來源，會使下一個財政年度內的資產及負債賬面值有重大調整的風險，詳見下文論述。

商譽及無限年期無形資產之減值

本集團至少每年釐定商譽及無限年期無形資產有否減值。為此需估計商譽及無限年期無形資產所分配的現金產生單位的使用價值。估計使用價值需要本集團估算現金產生單位之預期未來現金流量，並選擇合適的折現率計算該等現金流量的現值。於2026年6月30日，商譽及無限年期無形資產的賬面值分別為76,520,000港元(2025年：156,604,000港元)及39,557,000港元(2025年：37,892,000港元)。減值測試的進一步詳情載於綜合財務報表附註18。

4. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has three reportable operating segments as follows:

(a) Hong Kong & Macau Corporate Healthcare Solution Services segment engages in the provision of corporate healthcare solutions to Contract Customers in Hong Kong and Macau;

(b) Hong Kong & Macau Clinical Healthcare Services segment engages in the provision of medical and dental services, medical imaging and laboratory services, health check-up, and other auxiliary services in Hong Kong and Macau; and

(c) Chinese Mainland Clinical Healthcare Services segment engages in the provision of health check-up service and selected outpatient services in Chinese Mainland.

Management monitors the results of the Group's operating segments separately for the purpose of facilitating decision-making process of resources allocation and performance assessment. Segment performance is evaluated based on reportable segment profit/ loss, which is a measure of adjusted profit/loss before tax. The adjusted profit/loss before tax is measured consistently with the Group's profit before tax excluding interest income, other income and gains, and share of profits and losses of joint ventures and associates as well as head office and corporate expenses.

Segment assets exclude goodwill, investments in joint ventures and associates, financial assets at fair value through profit or loss, financial assets at amortised cost, investments at fair value through other comprehensive income, other assets and other unallocated head office and corporate assets as these assets are managed on a group basis.

Segment liabilities exclude derivative financial instrument, and other unallocated head office and corporate liabilities as these liabilities are managed on a group basis.

Inter-segment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

4. 經營分部資料

就管理而言，本集團基於其產品及服務組織業務單位運營，且有如下三個可呈報經營分部：

(a) 香港及澳門企業醫療保健解決方案服務分部為位於香港及澳門的合約客戶提供企業醫療保健解決方案；

(b) 香港及澳門臨床醫療保健服務分部包括於香港及澳門提供醫療及牙科服務、醫學影像及化驗服務、體檢及其他輔助服務；及

(c) 中國內地臨床醫療保健服務分部為在中國內地提供體檢服務及選定門診服務。

管理層分別監控本集團各經營分部的業績，以促進資源分配及業績評估的決策程序。分部表現基於可呈報分部利潤／虧損評估，為經調整除稅前利潤／虧損的指標。經調整除稅前利潤／虧損按與本集團除稅前利潤一致的方式計量，當中不包括利息收入、其他收入及收益、分佔合資公司及聯營公司損益以及總辦事處及公司開支。

分部資產不包括商譽、於合資公司及聯營公司的投資、按公允價值計入損益的金融資產、按攤銷成本計量的金融資產、按公允價值計入其他全面收入的投資、其他資產及其他未分配總辦事處及公司資產，因此等資產按組合基準進行管理。

分部負債不包括衍生金融工具以及其他未分配總辦事處及公司負債，因此等負債按組合基準進行管理。

分部間銷售及轉讓乃參考按當時現行市價向第三方銷售的售價處理。

4. OPERATING SEGMENT INFORMATION (Continued)

4. 經營分部資料(續)

Year ended 30 June 2026

截至2026年6月30日止年度

		Hong Kong and Macau 香港及澳門		Chinese Mainland 中國內地	
		Corporate Healthcare Solution Services 企業醫療保健解決方案服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Total 總計 HK$'000 千港元
Segment revenue:	**分部收入：**				
External sales	外部銷售	**264,721**	**412,780**	**39,470**	**716,971**
Inter-segment sales	分部間銷售	**1,537**	**149,250**	**696**	**151,483**
		266,258	**562,030**	**40,166**	**868,454**
Reconciliation:	*調節：*				
Elimination of inter-segment sales	分部間銷售抵銷				**(151,483)**
Revenue	收入				**716,971**
Segment results	**分部業績**	**42,943**	**16,411**	**(7,419)**	**51,935**
Reconciliation:	*調節：*				
Interest income	利息收入				**4,422**
Other income and gains	其他收入及收益				**8,181**
Share of profit/(losses) of:	分佔利潤／(虧損)：				
Joint ventures	合資公司				**(1,426)**
Associates	聯營公司				**930**
Corporate and other unallocated expenses, net	公司及其他未分配開支淨額				**(128,793)**
Loss before tax	除税前虧損				**(64,751)**
Income tax expense	所得税費用				**(7,974)**
Loss for the year	年內虧損				**(72,725)**

4. OPERATING SEGMENT INFORMATION (Continued)

Year ended 30 June 2026 (Continued)

4. 經營分部資料(續)

截至2026年6月30日止年度(續)

		Hong Kong and Macau 香港及澳門		Chinese Mainland 中國內地	
		Corporate Healthcare Solution Services 企業醫療保健解決方案服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Total 總計 HK$'000 千港元
Segment assets	**分部資產**	**224,831**	**217,575**	**56,303**	**498,709**
Reconciliation:	*調節：*				
Elimination of intersegment receivables	分部間應收款項抵銷				**(42,561)**
Corporate and other unallocated assets	公司及其他未分配資產				**534,565**
Total assets	總資產				**990,713**
Segment liabilities	**分部負債**	**120,792**	**205,878**	**50,542**	**377,212**
Reconciliation:	*調節：*				
Elimination of intersegment payables	分部間應付款項抵銷				**(42,700)**
Corporate and other unallocated liabilities	公司及其他未分配負債				**3,878**
Total liabilities	總負債				**338,390**
Other segment information:	**其他分部資料：**				
Depreciation and amortisation	折舊及攤銷	**15,608**	**75,986**	**5,933**	**97,527**
Capital expenditure*	資本開支*	**1,463**	**10,546**	**13,875**	**25,884**

* Capital expenditure consists of additions to property, plant and equipment and deposits paid for purchases of items of property, plant and equipment.

* 資本開支包括添置物業、廠房及設備及購買物業、廠房及設備項目支付的保證金。

4. OPERATING SEGMENT INFORMATION (Continued)

Year ended 30 June 2025

4. 經營分部資料(續)

截至2025年6月30日止年度

		Hong Kong and Macau 香港及澳門		Chinese Mainland 中國內地	
		Corporate Healthcare Solution Services 企業醫療保健解決方案服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Total 總計 HK$'000 千港元
Segment revenue:	**分部收入：**				
External sales	外部銷售	264,774	423,187	38,988	726,949
Inter-segment sales	分部間銷售	1,707	135,076	–	136,783
		266,481	558,263	38,988	863,732
Reconciliation:	*調節：*				
Elimination of inter-segment sales	分部間銷售抵銷				(136,783)
Revenue	收入				726,949
Segment results	**分部業績**	44,997	20,063	7,576	72,636
Reconciliation:	*調節：*				
Interest income	利息收入				5,235
Other income and gains	其他收入及收益				5,983
Share of profit/(losses) of:	分佔利潤／(虧損)：				
Joint ventures	合資公司				(1,983)
Associates	聯營公司				1,528
Corporate and other unallocated expenses, net	公司及其他未分配開支淨額				(42,900)
Profit before tax	除稅前利潤				40,499
Income tax expense	所得稅費用				(8,583)
Profit for the year	年內利潤				31,916

4. OPERATING SEGMENT INFORMATION (Continued)

Year ended 30 June 2025 (Continued)

4. 經營分部資料(續)

截至2025年6月30日止年度(續)

		Hong Kong and Macau 香港及澳門		Chinese Mainland 中國內地	
		Corporate Healthcare Solution Services 企業醫療保健解決方案服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Total 總計 HK$'000 千港元
Segment assets	**分部資產**	245,794	287,261	34,814	567,869
Reconciliation:	*調節：*				
Elimination of intersegment receivables	分部間應收款項抵銷				(20,199)
Corporate and other unallocated assets	公司及其他未分配資產				547,655
Total assets	總資產				1,095,325
Segment liabilities	**分部負債**	125,650	218,208	18,048	361,906
Reconciliation:	*調節：*				
Elimination of intersegment payables	分部間應付款項抵銷				(20,199)
Corporate and other unallocated liabilities	公司及其他未分配負債				1,819
Total liabilities	總負債				343,526
Other segment information:	**其他分部資料：**				
Depreciation and amortisation	折舊及攤銷	15,729	86,763	3,314	105,806
Capital expenditure*	資本開支*	1,647	3,146	403	5,196

* Capital expenditure consists of additions to property, plant and equipment and deposits paid for purchases of items of property, plant and equipment.

* 資本開支包括添置物業、廠房及設備及購買物業、廠房及設備項目支付的保證金。

4. OPERATING SEGMENT INFORMATION (Continued)

Geographical information

During the year ended 30 June 2026, the Group operates within three geographical locations, Hong Kong, Macau and Chinese Mainland. Further details of the geographical information in respect of revenue from external customers are set out in note 5 to the consolidated financial statements.

Non-current assets

The non-current asset information above is based on the locations of the assets and excludes rental deposits, financial instruments and deferred tax assets.

4. 經營分部資料(續)

地域資料

截至2026年6月30日止年度，本集團於三個地區(即香港、澳門及中國內地)經營業務。有關來自外部客戶的收入的相關地域資料之進一步詳情載於綜合財務報表附註5。

非流動資產

上述非流動資產資料乃基於資產之位置，不包括租賃按金、金融工具及遞延稅項資產。

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Hong Kong	香港	**323,055**	490,390
Chinese Mainland	中國內地	**25,663**	11,585
Macau	澳門	**3,444**	3,906
TOTAL	**總計**	**352,162**	505,881

4. OPERATING SEGMENT INFORMATION (Continued)

Information about major customers

Revenue from two major customers from the Corporate Healthcare Solution Services segment is set out below:

4. 經營分部資料(續)

主要客戶資料

來自兩名主要客戶(來自企業醫療保健解決方案服務分部)的收入載列如下：

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Customer A	客戶A	**44,645**	50,239
Customer B	客戶B	**25,860**	35,842

5. REVENUE

An analysis of the Group's revenue is as follows:

5. 收入

本集團收入之分析如下：

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Revenue from contracts with customers within the scope of HKFRS 15	**香港財務報告準則第15號範圍內之客戶合約收入**		
Provision of corporate healthcare solution services in Hong Kong and Macau	**於香港及澳門提供企業醫療保健解決方案服務**	**264,721**	264,774
Medical	醫療	**244,032**	247,174
Dental	牙科	**20,689**	17,600
Provision of clinical healthcare services in Hong Kong and Macau	**於香港及澳門提供臨床醫療保健服務**	**412,780**	423,187
Medical	醫療	**360,423**	370,899
Dental	牙科	**52,357**	52,288
Chinese Mainland Clinical Healthcare Business	**中國內地臨床醫療保健業務**	**39,470**	38,988
TOTAL	**合計**	**716,971**	726,949
Timing of revenue recognition:	收入確認時間：		
At a point in time	於某時間點	**588,075**	594,324
Overtime	一段時間內	**128,896**	132,625
TOTAL	**合計**	**716,971**	726,949

5. REVENUE (Continued)

Revenue from contracts with customers

(i) Disaggregated revenue information

5. 收入(續)

客戶合約收入

(i) 經分拆之收入資料

For the year ended 30 June 2026 **截至2026年6月30日止年度**

Segments 分部		Corporate Healthcare Solution Services 企業醫療保健解決方案服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Total 合計 HK$'000 千港元
Type of services	**服務類型**			
Medical services	醫療服務	**244,032**	**399,893**	**643,925**
Dental services	牙科服務	**20,689**	**52,357**	**73,046**
Total revenue from contracts with customers	客戶合約收入總額	**264,721**	**452,250**	**716,971**
Geographical markets	**地理市場**			
Hong Kong	香港	**253,020**	**409,944**	**662,964**
Chinese Mainland	中國內地	**–**	**39,470**	**39,470**
Macau	澳門	**11,701**	**2,836**	**14,537**
Total revenue from contracts with customers	客戶合約收入總額	**264,721**	**452,250**	**716,971**

5. REVENUE (Continued)

Revenue from contracts with customers (Continued)

(i) Disaggregated revenue information (Continued)

5. 收入(續)

客戶合約收入(續)

(i) 經分拆之收入資料(續)

For the year ended 30 June 2025 截至2025年6月30日止年度

Segments 分部		Corporate Healthcare Solution Services 企業醫療保健解決方案服務 HK$'000 千港元	Clinical Healthcare Services 臨床醫療保健服務 HK$'000 千港元	Total 合計 HK$'000 千港元
Type of services	**服務類型**			
Medical services	醫療服務	247,174	409,887	657,061
Dental services	牙科服務	17,600	52,288	69,888
Total revenue from contracts with customers	客戶合約收入總額	264,774	462,175	726,949
Geographical markets	**地理市場**			
Hong Kong	香港	252,366	420,261	672,627
Chinese Mainland	中國內地	–	38,988	38,988
Macau	澳門	12,408	2,926	15,334
Total revenue from contracts with customers	客戶合約收入總額	264,774	462,175	726,949

5. REVENUE (Continued)

Revenue from contracts with customers (Continued)

(i) Disaggregated revenue information (Continued)

The following table shows the amounts of revenue recognised in the current reporting period that were included in the contract liabilities at the beginning of the reporting period and recognised from performance obligations satisfied in previous periods:

5. 收入(續)

客戶合約收入(續)

(i) 經分拆之收入資料(續)

下表呈列於本報告期間確認並計入報告期初合約負債及就於過往期間達成的履約責任確認的收入金額：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Revenue recognised that was included in contract liabilities at the beginning of the reporting period:	計入報告期初合約負債確認的收入：		
Provision of corporate healthcare solution services	提供企業醫療保健解決方案服務	**22,870**	18,433

(ii) Performance obligations

Information about the Group's performance obligations is summarised below:

Provision of corporate healthcare solution services

The Group provides healthcare solution services by entering into (i) capitation plan contract; (ii) annual retainer contract; and (iii) fee for service contract with Contract Customers. The performance obligation is satisfied over time as services are rendered. Payment is either paid upfront for capitation plan contract and annual retainer contract or billed based on each treatment incurred for fee for service contract which is generally due within 30 to 60 days.

Provision of clinical healthcare services

The performance obligation is satisfied at a point in time when services are rendered; and payment is mainly on cash or credit card settlement.

The amounts of transaction prices allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) which amounted to HK$19,689,000 (2025: HK$27,371,000) as at 30 June 2026 are expected to be recognised within one year.

(ii) 履約責任

有關本集團履約責任的資料概述如下：

提供企業醫療保健解決方案服務

本集團透過與合約客戶訂立(i)按人數承包計劃合約；(ii)年度定額收費合約；及(iii)服務收費合約而提供企業醫療保健解決方案服務。履約責任隨著服務的提供而於一段時間內達成。按人數承包計劃合約及年度定額收費合約方面為提前付款，而服務收費合約方面則根據每次療程就付款開立一般於30至60日內到期的發票。

提供臨床醫療保健服務

履約責任於提供服務之時間點達成；且主要通過現金或信用卡結付款項。

於2026年6月30日分配予餘下履約責任(未達成或部分未達成)的交易價金額19,689,000港元(2025年：27,371,000港元)預期於一年內確認。

6. OTHER INCOME AND GAINS

An analysis of the Group's other income and gains is as follows:

6. 其他收入及收益

本集團的其他收入及收益分析如下：

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Dividend income from investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資的股息收入	**495**	467
Dividend income from investments at fair value through profit or loss	按公允價值計入損益的投資的股息收入	**138**	–
Rental income	租金收入	**988**	2,963
Bank interest income	銀行利息收入	**4,404**	4,904
Fair value gain on financial assets at fair value through profit or loss, net	按公允價值計入損益的金融資產的公允價值收益淨額	**2,933**	2,661
Administrative support fees income	行政支援費收入	**468**	411
Interest income from finance lease	融資租賃的利息收入	**19**	107
Others	其他	**3,158**	2,668
		12,603	14,181

7. (LOSS)/PROFIT BEFORE TAX

The Group's (loss)/profit before tax is arrived at after charging/(crediting):

7. 除税前(虧損)／利潤

本集團除税前(虧損)／利潤乃扣除／(計入)下列各項後得出：

		Notes 附註	2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Auditor's remuneration:	核數師酬金：			
– Audit service	－核數服務		**2,482**	2,450
– Non-audit service	－非核數服務		**175**	175
Cost of inventories consumed	已耗存貨成本		**59,858**	56,733
Professional services expenses	專業服務開支		**262,639**	256,997
Depreciation of property, plant and equipment	物業、廠房及設備折舊	14	**40,965**	44,414
Depreciation of right-of-use assets	使用權資產折舊	15(a)	**56,229**	61,392
Amortisation of other intangible assets	其他無形資產攤銷	17	**333**	–
Employee benefit expense (including directors' remuneration (note 9))	僱員福利開支(包括董事酬金(附註9))			
Salaries, allowances, bonuses and other benefits	薪金、津貼、獎金及其他福利		**171,650**	168,209
Equity-settled share-based payment expense (including employees, professional consultants and other business partner)	以權益結算以股份為基礎的付款開支(包括僱員、專業顧問及其他業務夥伴)	36, 37	**1,752**	1,859
Pension scheme contributions (defined contribution schemes)	退休金計劃供款(定額供款計劃)		**10,621**	9,077
			184,023	179,145
Write-off of items of property, plant and equipment	撇銷物業、廠房及設備項目		**3,786**	2,132
Impairment of items of property, plant and equipment	物業、廠房及設備項目減值		**13,864**	–
Gain on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的收益		**–**	(39)
Gain on disposal of leases	出售租賃的收益		**(2,740)**	(331)
Impairment of goodwill	商譽減值	16	**82,000**	7,553
Impairment loss of investment in an associate	投資於一間聯營公司的減值虧損	20	**902**	300
Lease payments not included in the measurement of lease liabilities	並不包括在租賃負債計量之租賃付款	15(c)	**1,661**	1,709
Fair value gain on financial assets at fair value through profit or loss, net**	按公允價值計入損益的金融資產的公允價值收益淨額**		**(2,933)**	(2,661)

** The net fair value gain was credited in the line item of "other income and gains" in the consolidated statement of profit or loss. The net fair value loss was debited in the line item of "other expenses" in the consolidated statement of profit or loss.

** 公允價值收益淨額在綜合損益表內的「其他收入及收益」單行項目中貸記。公允價值虧損淨額在綜合損益表內的「其他開支」單行項目中借記。

8. FINANCE COST

8. 融資成本

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Interest on lease liabilities	租賃負債之利息	**6,304**	7,345

9. DIRECTORS' REMUNERATION

Directors' remuneration for the year, disclosed pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, section 383(1)(a), (b), (c) and (f) of the Hong Kong Companies Ordinance and Part 2 of the Hong Kong Companies (Disclosure of Information about Benefits of Directors) Regulation, is as follows:

9. 董事酬金

本年度董事酬金根據香港聯合交易所有限公司證券上市規則、香港公司條例第383(1)(a)、(b)、(c)及(f)條及香港公司(披露董事利益資料)規例第2部披露如下:

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Fees	袍金	**2,212**	2,210
Other emoluments:	其他酬勞:		
Salaries, allowances and other benefits	薪金、津貼及其他福利	**15,185**	15,318
Equity-settled share-based payment expense	以權益結算的以股份為基礎的付款開支	**960**	830
Pension scheme contributions	退休金計劃供款	**36**	36
		16,181	16,184
		18,393	18,394

Certain directors were granted share options and share awards, in respect of their services to the Group, under the share option schemes and the share award scheme of the Company, further details of which are set out in notes 36 and 37 to the consolidated financial statements, respectively.

若干董事就彼等向本集團提供服務而根據本公司的購股權計劃及股份獎勵計劃獲授購股權及股份獎勵,有關進一步詳情分別載於綜合財務報表附註36及37。

The fair values of such options and awards, which have been recognised in the consolidated statement of profit or loss over the vesting period, were determined as at the dates of grant and the amount included in the consolidated financial statements is included in the above directors' remuneration disclosures.

該等購股權及獎勵的公允價值於授出日期釐定,乃於歸屬期內在綜合損益表中確認,而計入綜合財務報表的金額包括在上述的董事酬金披露。

9. DIRECTORS' REMUNERATION (Continued)
9. 董事酬金(續)

(a) Independent non-executive directors
(a) 獨立非執行董事

		Fees 袍金 HK$'000 千港元	Salaries, allowances and other benefits 薪金、津貼及其他福利 HK$'000 千港元	Discretionary bonuses 酌情花紅 HK$'000 千港元	Equity-settled share-based payment expense 以權益結算的以股份為基礎的付款開支 HK$'000 千港元	Pension scheme contributions 退休金計劃供款 HK$'000 千港元	Total remuneration 酬金總額 HK$'000 千港元
2026	**2026年**						
Mr. Lee Luen Wai, John	李聯偉先生	**290**	**–**	**–**	**–**	**–**	**290**
Mr. Yeung Tak Bun	楊德斌先生	**240**	**–**	**–**	**–**	**–**	**240**
Mrs. Chan Kung Wai Ying (Note a)	陳龔偉瑩女士（附註a）	**147**	**–**	**–**	**–**	**–**	**147**
Dr. Li Kwok Tung, Donald (Note b)	李國棟醫生（附註b）	**94**	**–**	**–**	**–**	**–**	**94**
		771	**–**	**–**	**–**	**–**	**771**
2025	**2025年**						
Mr. Lee Luen Wai, John	李聯偉先生	290	–	–	–	–	290
Mr. Yeung Tak Bun	楊德斌先生	240	–	–	–	–	240
Dr. Li Kwok Tung, Donald (Note b)	李國棟醫生（附註b）	240	–	–	–	–	240
		770	–	–	–	–	770

Note a: Mrs. Chan Kung Wai Ying was appointed as independent non-executive director on 21 November 2025.

附註a： 陳龔偉瑩女士於2025年11月21日獲委任為獨立非執行董事。

Note b: Dr. Li Kwok Tung, Donald was retired as independent non-executive director on 21 November 2025.

附註b： 李國棟醫生於2025年11月21日退任獨立非執行董事。

9. DIRECTORS' REMUNERATION (Continued)
9. 董事酬金(續)

(b) Non-executive directors
(b) 非執行董事

		Fees 袍金 HK$'000 千港元	Salaries, allowances and other benefits 薪金、津貼及其他福利 HK$'000 千港元	Discretionary bonuses 酌情花紅 HK$'000 千港元	Equity-settled share-based payment expense 以權益結算的以股份為基礎的付款開支 HK$'000 千港元	Pension scheme contributions 退休金計劃供款 HK$'000 千港元	Total remuneration 酬金總額 HK$'000 千港元
2026	**2026年**						
Ms. Cheng Chi Man (Note c)	鄭志雯女士(附註c)	**147**	**–**	**–**	**–**	**–**	**147**
Dr. Lee Kar Chung, Felix (Note d)	李家聰博士(附註d)	**94**	**–**	**–**	**–**	**–**	**94**
		241	**–**	**–**	**–**	**–**	**241**
2025	**2025年**						
Dr. Lee Kar Chung, Felix (Note d)	李家聰博士(附註d)	240	–	–	–	–	240
		240	–	–	–	–	240

Note c: Ms. Cheng Chi Man was appointed as a non-executive Director with effect from 21 November 2025.

附註c： 鄭志雯女士於2025年11月21日獲委任為非執行董事。

Note d: Dr. Lee Kar Chung, Felix was re-designated from an executive Director to a non-executive Director with effect from 24 November 2023 and was retired as independent non-executive director on 21 November 2025.

附註d： 李家聰博士自2023年11月24日起由執行董事調任非執行董事並於2025年11月21日退任獨立非執行董事。

(c) Executive directors
(c) 執行董事

		Fees 袍金 HK$'000 千港元	Salaries, allowances and other benefits 薪金、津貼及其他福利 HK$'000 千港元	Discretionary bonuses 酌情花紅 HK$'000 千港元	Equity-settled share-based payment expense 以權益結算的以股份為基礎的付款開支 HK$'000 千港元	Pension scheme contributions 退休金計劃供款 HK$'000 千港元	Total remuneration 酬金總額 HK$'000 千港元
2026	**2026年**						
Dr. Sun Yiu Kwong	孫耀江醫生	**240**	**4,945**	**–**	**–**	**–**	**5,185**
Dr. Sun Man Kin, Michael	孫文堅醫生	**240**	**4,740**	**300**	**480**	**18**	**5,778**
Ms. Kwok Cheuk Kwan, Jacquen	郭卓君女士	**240**	**4,800**	**400**	**480**	**18**	**5,938**
Mr. Tsang On Yip, Patrick	曾安業先生	**240**	**–**	**–**	**–**	**–**	**240**
Dr. Lee Pak Cheung, Patrick	李柏祥醫生	**240**	**–**	**–**	**–**	**–**	**240**
		1,200	**14,485**	**700**	**960**	**36**	**17,381**
2025	**2025年**						
Dr. Sun Yiu Kwong	孫耀江醫生	240	4,950	–	–	–	5,190
Dr. Sun Man Kin, Michael	孫文堅醫生	240	5,168	–	415	18	5,841
Ms. Kwok Cheuk Kwan, Jacquen	郭卓君女士	240	5,200	–	415	18	5,873
Mr. Tsang On Yip, Patrick	曾安業先生	240	–	–	–	–	240
Dr. Lee Pak Cheung, Patrick	李柏祥醫生	240	–	–	–	–	240
		1,200	15,318	–	830	36	17,384

9. DIRECTORS' REMUNERATION (Continued)

(c) Executive directors (Continued)

During the year, no remuneration was paid or payable by the Group to the directors as an inducement to join or upon joining the Group or as compensation for loss of office (2025: Nil).

There was no arrangement under which a director waived or agreed to waive any remuneration during the year (2025: Nil).

During the year, professional services fees were paid/payables to Dr. Sun Man Kin, Michael and Dr. Lee Pak Cheung, Patrick, the executive directors of the Company, in relation to the rendering of healthcare services to the Group. Further details of which are set out in note 42(b) to the consolidated financial statements.

9. 董事酬金(續)

(c) 執行董事(續)

年內，本集團概無已付或應付董事酬金作為加入本集團或加入本集團後的獎勵或作為離職補償(2025年：無)。

年內概無董事放棄或同意放棄任何酬金的安排(2025年：無)。

於本年度，就孫文堅醫生及李柏祥醫生(均為本公司執行董事)為本集團提供醫療保健服務而有已付／應付彼等的專業服務費。進一步詳情載於綜合財務報表附註42(b)。

10. FIVE HIGHEST PAID EMPLOYEES

The five highest paid employees during the year included three (2025: three) directors, details of whose remuneration are set out in note 9 above. Details of the remuneration for the year of the remaining two (2025: two) highest paid employees who are neither a director nor chief executive of the Company are as follows:

10. 五名最高薪酬僱員

年內，五名最高薪酬僱員包括三名(2025年：三名)董事，彼等的酬金詳情載於上文附註9。年內餘下兩名(2025年：兩名)既非本公司董事亦非行政總裁的最高薪酬僱員的酬金詳情如下：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Salaries, allowances and other benefits	薪金、津貼及其他福利	**3,745**	3,974
Discretionary bonuses	酌情花紅	**730**	360
Equity-settled share-based payment expense	以權益結算的以股份為基礎的付款開支	**360**	369
Pension scheme contributions	退休金計劃供款	**36**	36
		4,871	4,739

10. FIVE HIGHEST PAID EMPLOYEES (Continued)

The number of non-director and non-chief executive highest paid employees whose remuneration fell within the following bands is as follows:

10. 五名最高薪酬僱員(續)

最高薪酬非董事及非行政總裁僱員在下列組別的人數如下：

		Number of employees 僱員人數	
		2026 2026年	2025 2025年
HK$2,000,001 to HK$2,500,000	2,000,001港元至2,500,000港元	**1**	2
HK$2,500,001 to HK$3,000,000	2,500,001港元至3,000,000港元	**1**	–
		2	2

Share options and share awards were granted to a non-director and non-chief executive highest paid employee in respect of his services to the Group, further details of which are included in the disclosures in notes 36 and 37 to the consolidated financial statements, respectively.

一名非董事亦非行政總裁的最高薪酬僱員就彼向本集團提供服務而獲授購股權及股份獎勵，有關進一步詳情分別載於綜合財務報表附註36及37。

The fair values of such options and awards, which have been recognised in the consolidated statement of profit or loss over the vesting period, were determined as at the dates of grant and the amount included in the consolidated financial statements is included in the above non-director and non-chief executive highest paid employees' remuneration disclosures.

該等購股權及獎勵的公允價值於授出日期釐定，乃於歸屬期內在綜合損益表中確認，而計入綜合財務報表的金額包括在上述的非董事及非行政總裁最高薪酬僱員之酬金披露。

11. INCOME TAX

Hong Kong Profits Tax has been provided at the rate of 16.5% (2025: 16.5%) on the estimated assessable profits arising in Hong Kong during the year except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax regime effective from the year of assessment 2018/2019.

The first HK$2,000,000 of assessable profits of this subsidiary is taxed at 8.25% and the remaining assessable profits are taxed at 16.5%.

Taxes on profits assessable elsewhere have been calculated at the rates of tax prevailing in the countries/jurisdictions in which the Group operates.

The amount of income tax charged to the consolidated statement of profit or loss represents:

11. 所得稅

香港利得稅已於年內對香港產生的估計應課稅利潤按16.5%(2025年：16.5%)的稅率計提撥備，但本集團一間附屬公司除外，該附屬公司為由2018/2019課稅年度起生效的兩級利得稅率制度下的合資格實體。

該附屬公司的首2,000,000港元應課稅利潤按8.25%稅率繳稅，其餘應課稅利潤按16.5%稅率繳稅。

其他地區應課稅利潤的稅項按本集團業務所在國家／司法權區的現行稅率計算。

於綜合損益表扣除之所得稅金額代表：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Current – Hong Kong	即期－香港		
Charge for the year	年內支出	**9,228**	12,101
Over-provision in prior years	過往年度超額撥備	**(671)**	(23)
Current – Elsewhere	即期－其他地區		
Charge for the year	年內支出	**249**	1,168
Deferred (note 33)	遞延(附註33)	**(832)**	(4,663)
Total tax charge for the year	年內稅項支出總額	**7,974**	8,583

11. INCOME TAX (Continued)

A reconciliation of the tax expense applicable to profit before tax using the Hong Kong statutory tax rate (the statutory tax rate for the jurisdiction in which the majority of the Company's subsidiaries are domiciled) to the tax charge at the Group's effective tax rate is as follows:

11. 所得稅(續)

本集團以香港法定稅率(即本公司大多數附屬公司註冊成立所在司法權區的法定稅率)計算適用於除稅前利潤的稅務開支與以實際稅率計算的稅務開支對賬如下：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
(Loss)/profit before tax	除稅前(虧損)／利潤	**(64,751)**	40,499
Tax at the Hong Kong statutory tax rate of 16.5% (2025: 16.5%)	按香港16.5%(2025年：16.5%)的法定稅率所計稅額	**(10,684)**	6,682
Difference in tax rates for specific jurisdictions or enacted by local tax authority, net	特定司法權區或當地稅務機關實施稅率之差異淨額	**(1,231)**	(171)
Adjustments in respect of current tax of previous periods	就過往期間的當期稅項作調整	**(671)**	(23)
Income not subject to tax	無須繳納稅項之收入	**(1,669)**	(1,451)
Expenses not deductible for tax	不可扣稅之支出	**16,827**	1,791
Tax losses utilised from previous periods	自過往期間動用之稅項虧損	**(809)**	(1,889)
Tax losses not recognised	未確認之稅項虧損	**5,879**	2,943
Others	其他	**332**	701
Tax charge at the Group's effective rate	按本集團實際稅率計算之稅項支出	**7,974**	8,583

12. DIVIDENDS

12. 股息

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Dividends recognised as distribution during the year:	年內確認為分派的股息：		
Final 2025 – HK1.90 cents (2024: HK2.00 cents) per ordinary shares	2025年末期股息－每股普通股1.90港仙（2024年：2.00港仙）	**15,408**	16,219
Less: Dividend for shares held under the share award scheme	減：股份獎勵計劃項下預留的股份的股息	**(142)**	(229)
		15,266	15,990
Interim 2026 – HK1.40 cents (2025: HK1.40 cents) per ordinary share	2026年中期股息－每股普通股1.40港仙（2025年：1.40港仙）	**11,353**	11,353
Less: Dividend for shares held under the share award scheme	減：股份獎勵計劃項下預留的股份的股息	**(53)**	(108)
		11,300	11,245
		26,566	27,235
Dividend proposed after the end of the reporting period:	報告期末後擬派股息：		
Proposed final 2026 – HK1.40 cents (2025: HK1.90 cents) per ordinary share	建議2026年末期股息－每股普通股1.40港仙（2025年：1.90港仙）	**11,353**	15,408

The proposed final 2026 dividend of HK1.40 cents per ordinary share for the year is subject to the approval of the Company's shareholders at the forthcoming annual general meeting.

年內建議2026年末期股息每股普通股1.40港仙須待本公司股東於應屆股東週年大會上批准。

13. (LOSSES)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY

The calculation of the basic (losses)/earnings per share amount is based on the (loss)/profit for the year attributable to ordinary equity holders of the Company of (HK$74,639,000) (2025: HK$31,440,000), and the weighted average number of ordinary shares of 792,374,015 (2025: 789,223,228) in issue during the year, as adjusted to exclude the shares held under the share award scheme.

The calculation of the diluted (losses)/earnings per share amount is based on the (loss)/profit for the year attributable to ordinary equity holders of the Company of (HK$74,639,000) (2025: HK$31,440,000). The weighted average number of ordinary shares used in the calculation is the number of ordinary shares of 792,374,015 (2025: 789,223,228) in issue during the year and excluded the shares held under the share award scheme, as used in the basic (losses)/earnings per share calculation, and the weighted average number of ordinary shares of Nil (2025: Nil) assumed to have been issued at no consideration on the deemed vesting of the respective share awards schemes.

The weighted average number of ordinary shares for the years ended 30 June 2026 and 2025 have been adjusted to reflect the bonus element in respect of scrip dividend during the year.

13. 本公司普通權益持有人應佔每股(虧損)／盈利

每股基本(虧損)／盈利金額乃基於本公司普通權益持有人應佔年內(虧損)／利潤(74,639,000)港元(2025年：31,440,000港元)及年內已發行普通股加權平均股數792,374,015股(2025年：789,223,228股)(不包括股份獎勵計劃項下預留的股份)計算。

每股攤薄(虧損)／盈利金額乃基於本公司普通權益持有人應佔年內(虧損)／利潤(74,639,000)港元(2025年：31,440,000港元)計算。計算所用的普通股加權平均股數為計算每股基本(虧損)／盈利所用的年內已發行792,374,015股(2025年：789,223,228股)普通股，並不包括股份獎勵計劃項下預留的股份，以及假設於各股份獎勵計劃視為已歸屬時，按無償方式發行的普通股加權平均股數為零股(2025年：零股)。

截至2026年及2025年6月30日止年度的普通股加權平均數已作調整，以反映年內已分派的以股代息的紅利元素。

14. PROPERTY, PLANT AND EQUIPMENT

14. 物業、廠房及設備

		Notes 附註	Buildings 樓宇 HK$'000 千港元	Leasehold improvements 租賃物業裝修 HK$'000 千港元	Furniture, fixtures and office equipment 傢俱、裝置及辦公室設備 HK$'000 千港元	Medical equipment 醫療設備 HK$'000 千港元	Computer 電腦 HK$'000 千港元	Total 合計 HK$'000 千港元
30 June 2026	**2026年6月30日**							
At 30 June 2025 and at 1 July 2025:	於2025年6月30日及於2025年7月1日：							
Cost	成本		57,125	117,822	8,049	136,440	40,058	359,494
Accumulated depreciation	累計折舊		(6,334)	(74,086)	(6,515)	(60,800)	(33,831)	(181,566)
Net carrying amount	賬面淨值		50,791	43,736	1,534	75,640	6,227	177,928
At 1 July 2025, net of accumulated depreciation	於2025年7月1日，經扣除累計折舊		50,791	43,736	1,534	75,640	6,227	177,928
Additions	添置		–	15,141	487	3,601	2,895	22,124
Written off	撇銷		–	(2,878)	(452)	(437)	(19)	(3,786)
Depreciation provided during the year	年內計提折舊	7	(926)	(18,505)	(682)	(16,410)	(4,442)	(40,965)
impairment	減值		(13,864)	–	–	–	–	(13,864)
Exchange realignment	匯兌調整		–	2	1	6	37	46
At 30 June 2026, net of accumulated depreciation and impairment	於2026年6月30日，經扣除累計折舊及減值		36,001	37,496	888	62,400	4,698	141,483
At 30 June 2026:	於2026年6月30日：							
Cost	成本		57,125	123,825	5,648	131,909	39,401	357,908
Accumulated depreciation and impairment	累計折舊及減值		(21,124)	(86,329)	(4,760)	(69,509)	(34,703)	(216,425)
Net carrying amount	賬面淨值		36,001	37,496	888	62,400	4,698	141,483

Impairment loss

In June 2026, the Group assessed the recoverable amounts of buildings and as a result the carrying amount of the buildings was written down to their recoverable amount of HK$36,001,000. An impairment loss of HK$13,864,000 was recognised. The estimates of recoverable amount were based on the buildings' fair values less costs of disposal, using market comparison approach by GW Financial Advisory Services Limited. The fair value on which the recoverable amount is based on is categorised as level 3 measurement.

減值虧損

於2026年6月，本集團對樓宇的可收回金額進行評估，樓宇的賬面值因此已撇減至其可收回金額36,001,000港元，並確認減值虧損13,864,000港元。可收回金額乃由盛德財務諮詢服務有限公司採用市場比較法，並根據樓宇的公允價值減出售成本估計。可收回金額依據的公允價值分類為第三級計量。

14. PROPERTY, PLANT AND EQUIPMENT (Continued)

14. 物業、廠房及設備(續)

		Notes 附註	Buildings 樓宇 HK$'000 千港元	Leasehold improvements 租賃物業裝修 HK$'000 千港元	Furniture, fixtures and office equipment 傢俱、裝置及辦公室設備 HK$'000 千港元	Medical equipment 醫療設備 HK$'000 千港元	Computer 電腦 HK$'000 千港元	Motor vehicle 汽車 HK$'000 千港元	Total 合計 HK$'000 千港元
30 June 2025	**2025年6月30日**								
At 30 June 2024 and at 1 July 2024:	於2024年6月30日及於2024年7月1日：								
Cost	成本		57,125	123,064	7,903	145,917	38,074	552	372,635
Accumulated depreciation	累計折舊		(5,407)	(63,037)	(5,948)	(54,033)	(30,777)	(552)	(159,754)
Net carrying amount	賬面淨值		51,718	60,027	1,955	91,884	7,297	–	212,881
At 1 July 2024, net of accumulated depreciation	於2024年7月1日，經扣除累計折舊		51,718	60,027	1,955	91,884	7,297	–	212,881
Additions	添置		–	5,440	302	2,180	3,717	–	11,639
Write-off	撇銷		–	(1,829)	(10)	(290)	(3)	–	(2,132)
Disposal	出售		–	–	–	(68)	–	–	(68)
Depreciation provided during the year	年內計提折舊	7	(927)	(19,902)	(715)	(18,072)	(4,798)	–	(44,414)
Exchange realignment	匯兌調整		–	–	2	6	14	–	22
At 30 June 2025, net of accumulated depreciation and impairment	於2025年6月30日，經扣除累計折舊及減值		50,791	43,736	1,534	75,640	6,227	–	177,928
At 30 June 2025:	於2025年6月30日：								
Cost	成本		57,125	117,822	8,049	136,440	40,058	–	359,494
Accumulated depreciation and impairment	累計折舊及減值		(6,334)	(74,086)	(6,515)	(60,800)	(33,831)	–	(181,566)
Net carrying amount	賬面淨值		50,791	43,736	1,534	75,640	6,227	–	177,928

15. LEASES

The Group as a lessee

The Group has lease contracts for its medical centres, office properties and office equipment. The leases are negotiated for terms ranging from two to seven years.

(a) Right-of-use assets

The carrying amounts of the Group's right-of-use assets and the movements during the year are as follows:

15. 租賃

本集團作為承租人

本集團就其醫務中心、辦公室物業及辦公室設備訂有租賃合約。租賃乃按二至七年期磋商。

(a) 使用權資產

本集團使用權資產的賬面值及年內變動如下：

		Note 附註	**Leased properties 租賃物業 HK$'000 千港元**	**Office equipment 辦公室設備 HK$'000 千港元**	**Total 合計 HK$'000 千港元**
As at 1 July 2025	於2025年7月1日		**93,116**	**3,390**	**96,506**
Additions	添置		**53,505**	**–**	**53,505**
Depreciation charge	折舊支出	7	**(55,321)**	**(908)**	**(56,229)**
Disposal	出售		**(6,225)**	**–**	**(6,225)**
Exchange realignment	匯兑調整		**672**	**–**	**672**
As at 30 June 2026	於2026年6月30日		**85,747**	**2,482**	**88,229**

		Note 附註	Leased properties 租賃物業 HK$'000 千港元	Office equipment 辦公室設備 HK$'000 千港元	Total 合計 HK$'000 千港元
As at 1 July 2024	於2024年7月1日		102,894	4,298	107,192
Additions	添置		53,637	–	53,637
Depreciation charge	折舊支出	7	(60,484)	(908)	(61,392)
Disposal	出售		(3,265)	–	(3,265)
Lease modification	租賃修改		262	–	262
Exchange realignment	匯兑調整		72	–	72
As at 30 June 2025	於2025年6月30日		93,116	3,390	96,506

15. LEASES (Continued)
15. 租賃(續)

The Group as a lessee (Continued)
本集團作為承租人(續)

(b) Lease liabilities
(b) 租賃負債

The carrying amount of lease liabilities and the movements during the year are as follows:
租賃負債的賬面值及年內變動如下：

		Lease liabilities 租賃負債 HK$'000 千港元
Carrying amount at 1 July 2025	於2025年7月1日的賬面值	**108,376**
New leases	新租賃	**53,505**
Disposal	出售	**(8,965)**
Accretion of interest recognised during the year	年內確認的利息增加	**6,304**
Payments	付款	**(62,388)**
Exchange realignment	匯兑調整	**726**
Carrying amount at 30 June 2026	於2026年6月30日的賬面值	**97,558**
Analysed into:	分析作：	
Current portion	即期部分	**43,733**
Non-current portion	非即期部分	**53,825**
		97,558

		Lease liabilities 租賃負債 HK$'000 千港元
Carrying amount at 1 July 2024	於2024年7月1日的賬面值	120,695
New leases	新租賃	53,637
Lease modification	租賃修改	262
Disposal	出售	(3,596)
Accretion of interest recognised during the year	年內確認的利息增加	7,345
Payments	付款	(69,951)
Exchange realignment	匯兑調整	(16)
Carrying amount at 30 June 2025	於2025年6月30日的賬面值	108,376
Analysed into:	分析作：	
Current portion	即期部分	55,519
Non-current portion	非即期部分	52,857
		108,376

The maturity analysis of lease liabilities is disclosed in note 45 to the consolidated financial statements.
租賃負債的到期分析於綜合財務報表附註45披露。

15. LEASES (Continued)

The Group as a lessee (Continued)

(c) The amounts recognised in profit or loss in relation to leases are as follows:

15. 租賃(續)

本集團作為承租人(續)

(c) 有關租賃於損益確認的金額如下：

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Interest on lease liabilities	租賃負債的利息	**6,304**	7,345
Depreciation charge of right-of-use assets	使用權資產的折舊支出	**56,229**	61,392
Expense relating to short-term leases and other leases with remaining lease terms ended on or before 30 June (note 7)	有關短期租賃及餘下租期於6月30日或之前屆滿的其他租賃之開支(附註7)	**1,661**	1,709
Total amount recognised in profit or loss	於損益確認的總額	**64,194**	70,446

(d) The total cash outflow for leases are disclosed in note 40(c) to the consolidated financial statements.

(d) 租賃的現金流出總額於綜合財務報表附註40(c)披露。

The Group as a lessor

本集團作為出租人

(e) Finance Lease Receivables

In 2022, one of the Group's lease was sublet under finance leases. The term of finance leases entered into is 4 years.

(e) 應收融資租賃

於2022年，本集團一項租賃乃根據融資租賃分租。所訂立之融資租賃平均期限為4年。

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Current finance lease receivables	即期應收融資租賃	**–**	1,876

15. LEASES (Continued)

The Group as a lessor (Continued)

(e) Finance Lease Receivables (Continued)

Amounts receivable under finance leases

15. 租賃(續)

本集團作為出租人(續)

(e) 應收融資租賃(續)

融資租賃項下應收款項

		Minimum lease payments 最低租賃付款		Present value of lease payments 租賃付款之現值	
		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元	**2026 2026年 HK$'000 千港元**	2025 2025年 HK$'000 千港元
Not later than one year	不超過一年	–	1,905	–	1,876
		–	1,905	–	1,876
Less: unearned finance income	減：未賺取融資收入	–	(29)	–	–
Present value of minimum lease payments receivable	應收最低租賃付款之現值	–	1,876	–	1,876

16. GOODWILL

16. 商譽

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Goodwill	商譽	**76,264**	156,604

On 30 September 2025, the Group acquired a 60% equity interest in 廣州市美嘉醫生集團有限公司 ("美嘉"), a company incorporated in the PRC that operates medical clinics in Guangzhou, for cash consideration of RMB1 (equivalent to HK$1). The acquisition was undertaken to expand the Group's healthcare service network in the Greater Bay Area.

於2025年9月30日，本集團以現金代價人民幣1元(相當於1港元)收購廣州市美嘉醫生集團有限公司(「美嘉」)的60%股權，該公司為於中國註冊成立並在廣州營運醫療診所的公司。進行該收購事項旨在擴展本集團在大灣區的醫療保健服務網絡。

16. GOODWILL (Continued)

At the acquisition date, the fair value of the identifiable net liabilities assumed was HK$2,397,000. The non-controlling interest (40%) was measured at its proportionate share of the recognised amounts of the acquiree's identifiable net liabilities and was recognised as a deficit of HK$959,000. Goodwill of HK$1,438,000 was recognised,

The goodwill is attributable mainly to the skills and technical talent of 美嘉 work force and the synergies expected to be achieved from integrating 美嘉 into the Group's existing medical business. None of the goodwill recognised is expected to be deductible for tax purposes.

16. 商譽(續)

於收購日期，所承擔可識別負債淨額的公允價值為2,397,000港元。非控股權益(40%)按其分佔被收購方可識別負債淨額已確認金額之比例計量，並確認為虧絀959,000港元。確認商譽1,438,000港元。

商譽主要來自美嘉員工團隊的技能及技術人才以及預期將美嘉整合至本集團現有醫療業務所產生協同效應。已確認的商譽預期不可作抵扣稅項之用。

17. OTHER INTANGIBLE ASSETS

17. 其他無形資產

		Licence 牌照 HK$'000 千港元	Brand names* 品牌名稱* HK$'000 千港元	Customer relationships 客戶關係 HK$'000 千港元	Software 軟件 HK$'000 千港元	Total 合計 HK$'000 千港元
30 June 2026	**2026年6月30日**					
As at 1 July 2025	於2025年7月1日	**–**	**37,892**	**–**	**–**	**37,892**
Addition	添置	**527**	**–**	**–**	**1,998**	**2,525**
Amortisation during the year	年內攤銷	**–**	**–**	**–**	**(333)**	**(333)**
As at 30 June 2026	於2026年6月30日	**527**	**37,892**	**–**	**1,665**	**40,084**
At 30 June 2026	於2026年6月30日					
Cost	成本	**527**	**37,892**	**9,472**	**7,283**	**55,174**
Accumulated amortisation	累計攤銷	**–**	**–**	**(9,472)**	**(5,618)**	**(15,090)**
Net carrying amount	賬面淨值	**527**	**37,892**	**–**	**1,665**	**40,084**
30 June 2025	**2025年6月30日**					
Cost at 1 July 2024 and at 30 June 2025, net of accumulated amortisation	於2024年7月1日及2025年6月30日的成本，扣除累計攤銷	–	37,892	–	–	37,892
At 30 June 2025	於2025年6月30日					
Cost	成本	–	37,892	9,472	5,285	52,649
Accumulated amortisation	累計攤銷	–	–	(9,472)	(5,285)	(14,757)
Net carrying amount	賬面淨值	–	37,892	–	–	37,892

* Brand names are regarded as having indefinite useful lives as they are expected to generate net cash inflows to the Group indefinitely. As at 30 June 2026, brand names with indefinite useful lives were tested for impairment (note 18).

* 品牌名稱乃視為具有無限可使用年期，原因為其預期可以無限期為本集團產生淨現金流入。於2026年6月30日，具有無限可使用年期的品牌名稱已進行減值測試(附註18)。

18. IMPAIRMENT TESTING OF GOODWILL AND INDEFINITE-LIVED INTANGIBLE ASSETS

Goodwill and indefinite-lived intangible assets acquired through business combinations were allocated to the following cash-generating units for impairment testing:

- Hong Kong medical services cash-generating unit; and
- Hong Kong dental services cash-generating unit.

As at 30 June 2025, the respective carrying amounts of goodwill and indefinite-lived intangible assets allocated to each of the cash-generating units were as follows:

18. 商譽及無限年期的無形資產減值測試

商譽及通過業務合併收購的無限年期的無形資產乃分配至以下現金產生單位進行減值測試：

- 香港醫療服務現金產生單位；及
- 香港牙科服務現金產生單位。

於2025年6月30日，分配至各現金產生單位的商譽及無限年期的無形資產的各自賬面值如下：

		Hong Kong medical services 香港醫療服務 2025 2025年 HK$'000 千港元	Hong Kong dental services 香港牙科服務 2025 2025年 HK$'000 千港元	Total 合計 2025 2025年 HK$'000 千港元
Carrying amounts of goodwill	商譽的賬面值	133,502	23,102	156,604
Carrying amounts of indefinite-lived intangible assets	無限年期的無形資產的賬面值	37,892	–	37,892

The Group considers the higher of fair value less cost to disposal and the value in use when determining the recoverable amounts for impairment test.

於釐定減值測試的可收回金額時，本集團會考慮公允價值減出售成本及使用價值之較高者。

Change in identification of cash-generating units

As part of its impairment assessment at 30 June 2026, the Group reassessed how the assets of its medical services business in Hong Kong are grouped into cash-generating units in light of the changes in customer behaviour, service-line performance and the manner in which those assets generated cash inflows.

識別現金產生單位方法變動

作為其於2026年6月30日進行的減值評估一部分，本集團因應客戶行為、業務線表現及香港醫療服務業務的資產產生現金流入的方式之變動，重新評估該等資產如何分組至現金產生單位。

18. IMPAIRMENT TESTING OF GOODWILL AND INDEFINITE-LIVED INTANGIBLE ASSETS (Continued)

Change in identification of cash-generating units (Continued)

Previously, the relevant specialist service assets were grouped with the core general practice and specialist medical centre assets within the Hong Kong Medical Services cash-generating unit. Following the reassessment, the core general practice and specialist medical centre assets remain grouped within that cash-generating unit. The assets comprising SkinCentral, each physiotherapy centre and each laboratory and diagnostic imaging centre are grouped separately based on the level at which they generate cash inflows that are largely independent of those generated by other assets or group of assets. The related impairment and consequential reallocation of goodwill are disclosed below.

Allocation of goodwill and indefinite-lived intangible assets

As a result of the above reassessment, the Group reallocated the goodwill previously allocated to the Hong Kong Medical Services cash-generating unit to the affected cash-generating units or groups of cash-generating units for impairment testing.

Before that reallocation, the cash-generating unit to which goodwill and indefinite-lived intangible assets has been allocated was tested for impairment. An impairment loss of HK$76,000,000 and HK$6,000,000, were recognised in Hong Kong Medical Services CGU and Hong Kong Dental Services CGU, respectively.

18. 商譽及無限年期的無形資產減值測試(續)

識別現金產生單位方法變動(續)

此前，相關專科服務資產與核心全科醫療及專科醫療中心資產一同歸入香港醫療服務現金產生單位。經重新評估後，核心全科及專科醫療中心資產仍歸入該現金產生單位。組成善肌、各物理治療中心以及各化驗及影像診斷中心的資產，按其產生大致獨立於其他資產或資產組別所產生現金流入的水平分別歸組。相關減值及相應重新分配商譽的方式披露如下。

分配商譽及無限年期無形資產

基於上述重新評估，本集團已將先前分配至香港醫療服務現金產生單位的商譽，重新分配至受影響的現金產生單位或現金產生單位組別，以進行減值測試。

在重新分配前，已就獲分配商譽及無限年期無形資產的現金產生單位進行減值測試。香港醫療服務現金產生單位及香港牙科服務現金產生單位分別確認減值虧損76,000,000港元及6,000,000港元。

18. IMPAIRMENT TESTING OF GOODWILL AND INDEFINITE-LIVED INTANGIBLE ASSETS (Continued)

Allocation of goodwill and indefinite-lived intangible assets (Continued)

As at 30 June 2026, the remaining goodwill and indefinite-lived intangible assets have been allocated for impairment testing to the following cash-generating units or groups of cash-generating units:

18. 商譽及無限年期的無形資產減值測試(續)

分配商譽及無限年期無形資產(續)

於2026年6月30日，剩餘商譽及無限年期無形資產已分配至以下現金產生單位或現金產生單位組別以進行減值測試：

CGUs/Group of CGUs	現金產生單位／現金產生單位組別	Goodwill 商譽 HK$'000 千港元	Indefinite-lived intangible assets 無限年期無形資產 HK$'000 千港元
General practice and specialist medical centres	全科醫療及專科醫療中心	**43,016**	**–**
General practice and specialist dental centres	全科醫療及專科醫療牙科中心	**17,102**	**–**
SkinCentral	善肌	**9,267**	**37,892**
Physiotherapy centres	物理治療中心	**–**	**–**
Laboratory and diagnostic imaging centres	化驗及診斷影像中心	**5,219**	**–**
MeiJia clinics	MeiJia診所	**1,660**	**–**
Total	總計	**76,264**	**37,892**

The recoverable amount of the CGUs would be approximately 5% lower than their carrying amount if either of the following individual assumptions changed: 1) the revenue growth rate was 0.33% lower in the first forecast year; or 2) the discount rate was 0.83% higher. Other reasonably possible changes in the key assumptions used in the value-in-use calculation would not alter management's conclusion regarding the impairment test results as at 30 June 2026.

倘下列任何一項獨立假設有變，則該等現金產生單位的可收回金額將較其賬面值低約5%：1)首個預測年度的收入增長率降低0.33%；或2)折現率提高0.83%。在計算使用價值時所用關鍵假設如有任何其他可能合理出現的變動，亦不會改變管理層就2026年6月30日的減值測試結果作出的結論。

18. IMPAIRMENT TESTING OF GOODWILL AND INDEFINITE-LIVED INTANGIBLE ASSETS (Continued)

Allocation of goodwill and indefinite-lived intangible assets (Continued)

The recoverable amounts of the Hong Kong medical services and Hong Kong dental services cash-generating units have been determined based on a value in use calculation using cash flow projections based on financial budgets approved by senior management covering a five-year period. The basis used to determine the value assigned to the budgeted revenue is the average revenue achieved in the year immediately before the budget year, taking into account the expected growth rate. The growth rates and discount rates applied to the cash flow projections are as follows:

18. 商譽及無限年期的無形資產減值測試(續)

分配商譽及無限年期無形資產(續)

香港醫療服務及香港牙科服務現金產生單位的可收回金額根據使用價值進行計算而釐定，乃基於高級管理層所批准涵蓋五年期間的財政預算計算現金流預測。用於釐定預算收入相關價值的基準指緊接預算年度前一年所取得的平均收入，同時計及預期增長率。應用於現金流預測的增長率及折現率如下：

		2026 **2026年**	2025 2025年
Hong Kong medical services	香港醫療服務		
Growth rate	增長率	**1.2%-2.5%**	3.0%-3.6%
Discount rate	折現率	**15%**	15%
Hong Kong dental services	香港牙科服務		
Growth rate	增長率	**2.5%**	2.3%-3.0%
Discount rate	折現率	**15%**	15%

Assumptions were used in the value in use calculations of the cash-generating units for 30 June 2026 and 30 June 2025. The following describes each key assumption on which management has based on its cash flow projections to undertake impairment testing of goodwill and indefinite-lived intangible assets:

於2026年6月30日及2025年6月30日計算現金產生單位使用價值時採用了假設。管理層乃基於以下主要假設利用現金流量預測進行商譽及無限年期的無形資產減值測試：

Growth rate – The growth rate is determined with reference to the growth rate for the relevant unit, adjusted for expected business, market development and economic condition.

增長率－增長率經參考有關單位的增長率而釐定，並就預期業務、市場發展及經濟條件予以調整。

Discount rate – The discount rate used is before tax and reflects specific risks relating to the relevant unit which is determined with reference to the weighted average cost of capital of the Group.

折現率－所採用的折現率為除稅前並反映參考本集團資本成本加權平均值所釐定的有關單位的特定風險。

Other key assumptions for the value in use calculations relate to the estimation of cash outflows for key operating costs. Such estimation is based on historical performance and/or amounts stipulated in underlying contracts, where applicable.

使用價值計算的其他關鍵假設與主要經營成本的現金流出量的估計有關。該等估計乃根據過往表現及／或相關合約(如適用)所訂明之金額作出。

19. INVESTMENTS IN JOINT VENTURES

19. 於合資公司的投資

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Share of net assets	應佔淨資產	**3,753**	5,179

Particulars of the Group's joint ventures as at 30 June 2026 are as follows:

本集團合資公司於2026年6月30日的詳情如下：

Name 名稱	Place of registration/ incorporation and business 註冊／註冊成立及營業地點	Percentage of effective interest 有效權益百分比 Ownership interest 擁有權權益	Voting power 表決權	Profit sharing 利潤分成	Principal activities 主要業務
Acton Digital PET-CT Centre Limited ("Acton") 仁信數碼正電子中心(「仁信」)	Hong Kong 香港	32.5	32.5	32.5	Provision of medical imaging and laboratory services 提供醫學影像及化驗服務

The above investments are indirectly held by the Company.

上述投資由本公司間接持有。

19. INVESTMENTS IN JOINT VENTURES (Continued)

The following table illustrates the aggregate financial information of the Group's joint ventures that are not individually material:

19. 於合資公司的投資(續)

下表說明個別不屬重大的本集團合資公司的匯總財務資料：

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Share of the joint venture's loss and total comprehensive loss for the year	應佔合資公司虧損及年內全面虧損總額	**(1,426)**	(1,983)
Aggregate carrying amount of the Group's investments in the joint ventures	本集團於合資公司的投資賬面總值	**3,753**	5,179

20. INVESTMENTS IN ASSOCIATES

20. 於聯營公司的投資

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Share of net assets	應佔淨資產	**4,884**	5,454
Impairment*	減值*	**(2,432)**	(1,530)
		2,452	3,924

* As at 30 June 2026, the recoverable amount of the Group's interest in certain associates was assessed to be less than its carrying amount. Accordingly, the Group recognised an impairment loss of HK$902,000 (2025: HK$300,000).

* 於2026年6月30日，本集團於若干聯營公司權益的可收回金額評估為低於其賬面值。因此，本集團確認減值虧損902,000港元(2025年：300,000港元)。

20. INVESTMENTS IN ASSOCIATES (Continued)

Particulars of the associates are as follows:

20. 於聯營公司的投資(續)

聯營公司的詳細情況如下：

Name 名稱	Place of registration/ incorporation and business 註冊／註冊成立及營業地點	Percentage of ownership interest attributable to the Group 本集團所佔擁有權權益百分比		Principal activities 主要業務
		2026 2026年	2025 2025年	
Causeway Bay MRI Centre Limited 銅鑼灣磁力共振中心有限公司	Hong Kong 香港	**20**	20	Provision of medical imaging and laboratory services 提供醫學影像及化驗服務
Sunny Wealth Consultants Limited 朗寶顧問有限公司	Hong Kong 香港	**30**	30	Provision of surgical services 提供手術服務
Tiger Era Limited 賢鋒有限公司	Hong Kong 香港	**30**	30	Provision of surgical and consultation services 提供手術及諮詢服務
UMP Eyecare and Optometry Centre Limited ("UMP Eyecare") 聯合醫務眼科保健及視光中心有限公司(「聯合眼科」)	Hong Kong 香港	**50**	50	Provision of medical services and sale of spectacles 提供醫療服務及銷售鏡片
UMP Medical Centre (Tsing Yi On Tao) Limited 聯合醫務中心(青衣安濤)有限公司	Hong Kong 香港	**20**	20	Provision of medical services 提供醫療服務
Paeon ProCare Day Surgery Centre Limited 倍康日間手術中心有限公司	Hong Kong 香港	**25**	25	Provision of day surgery services 提供日間手術服務
深圳醫信兒科門診部有限公司*#	PRC 中國	**20**	20	Provision of medical services 提供醫療服務
Omni Care Medical Centre Limited	Hong Kong 香港	**25**	25	Provision of medical services 提供醫療服務

* The associate is a limited liability company under PRC law and registered as wholly-foreign owned enterprise under PRC law.

\# The Company is under the process of liquidation as at 30 June 2026.

* 該聯營公司為中國法律下的有限責任公司並根據中國法律註冊為外商獨資企業。

\# 該公司於2026年6月30日正處於清盤程序。

The above investments are indirectly held by the Company.

上述投資由本公司間接持有。

20. INVESTMENTS IN ASSOCIATES (Continued)

The Group has discontinued the recognition of its share of losses of associates, Paeon ProCare Day Surgery Centre Limited, UMP Eyecare and Omni Care Medical Center Limited (2025: Paeon ProCare Day Surgery Centre Limited, and UMP Eyecare), because the share of losses of these associates exceeded the Group's interests in these associates and the Group has no obligation to take up further losses. The amount of the Group's unrecognised share of losses of these associates for the current year and cumulatively were HK$1,280,588 (2025: HK$1,074,320), HK$5,910,000 (2025: HK$3,748,000) respectively.

20. 於聯營公司的投資(續)

本集團已終止確認其應佔聯營公司倍康日間手術中心有限公司、聯合眼科及滙賢醫社醫務中心有限公司(2025年：倍康日間手術中心有限公司及聯合眼科)的虧損，因為應佔此等聯營公司的虧損已超出本集團於此等聯營公司的權益，而本集團並無責任承擔進一步虧損。本集團於本年度及累計未確認的應佔該等聯營公司虧損金額分別為1,280,588港元(2025年：1,074,320港元)及5,910,000港元(2025年：3,748,000港元)。

The following table illustrates the aggregate financial information of the Group's associates that are not individually material:

下表說明個別不屬重大的本集團聯營公司的匯總財務資料：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Share of the associates' profit and total comprehensive income for the year	年內應佔聯營公司利潤及全面收入總額	**930**	1,528
Aggregate carrying amount of the Group's investments in the associates	本集團於聯營公司的投資總賬面值	**2,452**	3,924

21. FINANCIAL ASSETS AT AMORTISED COST

21. 按攤銷成本計量的金融資產

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Financial assets at amortised cost	按攤銷成本計量的金融資產	**6,240**	6,240
Impairment	減值	**(6,240)**	(6,240)
		–	–

As at 30 June 2026, the balance after the provision of impairment is nil (2025: Nil).

於2026年6月30日，計提減值撥備後的結餘為零(2025年：零)。

22. INVESTMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

22. 按公允價值計入其他全面收入的投資

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Investments at fair value through other comprehensive income	**按公允價值計入其他全面收入的投資**		
Unlisted equity investments, at fair value*	非上市股本投資，按公允價值計量*	**25,024**	26,434
Listed equity investment, at fair value*	上市股本投資，按公允價值計量*	**11,995**	13,838
		37,019	40,272

* The above investments were designated at fair value through other comprehensive income as the Group considers these investments to be strategic in nature.

* 以上投資已指定為按公允價值計入其他全面收入，因為本集團認為此等投資在性質上屬策略投資。

During the year, the Group received dividends in the approximate amounts of HK$nil (2025: HK$Nil) and HK$495,000 (2025: HK$467,000) from an unlisted equity investment and a listed equity investment, respectively.

年內，本集團從一項非上市股本投資及一項上市股本投資分別收到股息約零港元(2025年：零港元)及495,000港元(2025年：467,000港元)。

23. INVENTORIES

23. 存貨

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Pharmaceutical supplies	醫藥供應	**15,275**	14,612

24. TRADE RECEIVABLES

24. 貿易應收款項

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Trade receivables	貿易應收款項	**125,360**	120,684

The Group's trading terms with its contract customers are mainly on credit. The credit period is generally one month, extending up to two months for certain customers. Each contract customer has a maximum credit limit. The Group seeks to maintain strict control over its outstanding receivables and has a designated policy to monitor and minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest bearing.

本集團與其合約客戶之貿易條款主要以信貸方式進行。信貸期一般為一個月，對若干客戶可延長至兩個月。每名合約客戶均設有最高信用額度。本集團力求對未償還應收款項維持嚴格控制，並設有指定政策，以監測並將信貸風險減至最低。逾期結餘由高級管理層定期審視。本集團並無就該等貿易應收款項餘額持有任何抵押品或其他信貸提升保障。貿易應收款項不計息。

Included in the Group's trade receivables are trade receivables due from related companies of HK$8,771,000 (2025: HK$10,446,000), which have the same credit period as other Contract Customers. Chow Tai Fook Enterprises Limited ("CTFE") is a major beneficial shareholder of these related companies in which Mr. Tsang On Yip, Patrick, an executive director of the Company, is a director of CTFE.

本集團的貿易應收款項包括應收關聯公司的貿易應收款項8,771,000港元(2025年：10,446,000港元)，該等款項的信貸期與其他合約客戶相同。周大福企業有限公司(「周大福企業」)是該等關聯公司的主要實益股東，而本公司執行董事曾安業先生為周大福企業的董事。

24. TRADE RECEIVABLES (Continued)

An aging analysis of the trade receivables as at the end of the reporting period, based on the invoice date, is as follows:

24. 貿易應收款項(續)

於報告期末的貿易應收款項按發票日期的賬齡分析如下：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Within 1 month	1個月內	**75,217**	75,446
1 to 2 months	1至2個月	**19,649**	19,373
2 to 3 months	2至3個月	**21,423**	20,539
Over 3 months	3個月以上	**9,071**	5,326
		125,360	120,684

A credit loss analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Generally, trade receivables are written off if past due for more than two years and are not subject to enforcement activity. As at 30 June 2026 and 2025, the Group assessed that the loss allowance under the application of HKFRS 9 was immaterial.

於各報告日期採用撥備矩陣進行信貸虧損分析，以計量預期信貸虧損。撥備率乃基於具有類似虧損模式的多個客戶分部組別的逾期天數。該計算反映了概率加權結果、貨幣時間價值及於報告日可獲得的有關過去事件、當前狀況及未來經濟狀況預測的合理可支持性資料。一般而言，貿易應收款項倘逾期超過兩年且不受執行活動規限將予以撇銷。於2026年及2025年6月30日，本集團評估應用香港財務報告準則第9號項下之虧損撥備並不重大。

25. DEPOSIT, PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

25. 保證金、預付款項、其他應收款項及其他資產

		Note 附註	30 June 2026 2026年 6月30日 HK$'000 千港元	30 June 2025 2025年 6月30日 HK$'000 千港元
Prepayments	預付款項		**5,749**	5,372
Deposits paid for purchases of items of property, plant and equipment	購買物業、廠房及設備項目支付的保證金		**4,409**	623
Deposits	保證金	(a)	**27,141**	29,376
Other receivables	其他應收款項	(a)	**7,893**	14,052
			45,192	49,423
Less: Portion classified as non-current assets	減：分類為非流動資產的部分		**(18,749)**	(12,367)
Current portion	流動部分		**26,443**	37,056

Note:

(a) The above balances relate to deposits and other receivables for which there was no recent history of default nor past due amounts as at 30 June 2026 and 2025. The loss allowance was assessed to be minimal.

附註：

(a) 上列結餘是關於在2026年及2025年6月30日並無近期違約記錄及並無逾期金額之保證金及其他應收款項。虧損撥備經評定屬甚低。

26. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

26. 按公允價值計入損益的金融資產

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Listed equity investments, at fair value	上市股本投資（按公允價值計量）	**2,302**	2,045
Unlisted but quoted investment funds, at fair value	非上市但有報價的投資基金（按公允價值計量）	**34,271**	36,819
		36,573	38,864

The above investments were classified as financial assets at fair value through profit or loss.

上述投資分類為按公允價值計入損益的金融資產。

27. BALANCES WITH ASSOCIATES AND JOINT VENTURES

27. 與聯營公司及合資公司的結餘

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Due from associates	應收聯營公司款項	**4,193**	5,620
Impairment	減值	**(1,127)**	(1,127)
		3,066	4,493
Due to associates	應付聯營公司款項	**399**	522
Due from joint ventures	應收合資公司款項	**424**	26

The balances with associates and joint ventures are unsecured, interest-free and repayable on demand. Except for the amounts due from associates which are individually impaired, the expected credit losses were assessed to be minimal.

The above provision for impairment of amounts due from associates has been made for individually impaired amounts of HK$1,127,000 (2025: HK$1,127,000) with a carrying amount before provision of HK$1,238,000 (2025: HK$4,080,286), of which the related debtors were in financial difficulties and only a portion of the receivables is expected to be recovered.

與聯營公司及合資公司之結餘為無抵押、免息及按要求償還。除應收聯營公司款項為個別減值外，預期信貸虧損經評定為甚微。

以上應收聯營公司款項的減值撥備為已就個別減值款項1,127,000港元（2025年：1,127,000港元）而作出，撥備前的賬面值為1,238,000港元（2025年：4,080,286港元），相關債務人出現財政困難，因此，預期僅能收回部分應收款項。

28. BALANCES WITH RELATED COMPANIES

28. 與關聯公司的結餘

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Due from related companies	應收關聯公司款項	**10,715**	10,252
Due to related companies	應付關聯公司款項	**14,683**	9,497

The balances with related companies are unsecured, interest-free and repayable on demand.

與關聯公司之結餘為無抵押、免息及按要求償還。

Particulars of the amounts due from related companies, disclosed pursuant to section 383(1)(d) of the Hong Kong Companies Ordinance and Part 3 of the Hong Kong Companies (Disclosure of Information about Benefits of Directors) Regulation, are as follows:

應收關聯公司款項詳情，根據香港公司條例第383(1)(d)條及香港公司(披露董事利益資料)規例第3部披露如下：

Name	名稱	At 30 June 2026 於2026年6月30日 HK$'000 千港元	Maximum amount outstanding during the year 年內最高未償還款項 HK$'000 千港元	At 30 June 2025 於2025年6月30日 HK$'000 千港元	Maximum amount outstanding during the year 年內最高未償還款項 HK$'000 千港元	At 1 July 2024 於2024年7月1日 HK$'000 千港元
Healthcare Assets Management Limited ("HAML") and its subsidiaries#	醫療資產管理有限公司(「醫療資產管理」)及其附屬公司#	**1,155**	**1,155**	1,096	6,420	1,074

28. BALANCES WITH RELATED COMPANIES (Continued)

HAML and its subsidiaries are jointly controlled by a subsidiary of CTFE. Mr. Patrick Tsang, an executive director of the Company, is the Co-Chief Executive Officer of CTFE.

The amounts due from related companies are unsecured, interest-free and repayable on demand.

28. 與關聯公司的結餘(續)

醫療資產管理及其附屬公司受周大福企業的一間附屬公司共同控制。本公司執行董事曾安業先生為周大福企業的聯席行政總裁。

應收關聯公司款項為無抵押、免息及須應要求償還。

29. CASH, BANK BALANCES AND DEPOSITS

29. 現金、銀行結餘及存款

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Time deposits	定期存款		
– Maturing within 3 months	— 3個月內到期	**96,667**	35,424
– Maturing after more than 3 months	— 超過3個月後到期	**119,942**	52,751
Cash at banks and on hand	銀行存款及手頭現金	**112,926**	212,912
Pledged deposits	抵押存款	**1,785**	1,749
Cash, bank balances and deposits	現金、銀行結餘及存款	**331,320**	302,836
Less: Time deposits – maturing after more than 3 months	減：定期存款—超過3個月後到期	**(119,942)**	(52,751)
Less: Pledged deposits (note)	減：抵押存款(附註)	**(1,785)**	(1,749)
Cash and cash equivalents in the consolidated statement of cashflows	於綜合現金流量表的現金及現金等價物	**209,593**	248,336

Note: As at 30 June 2026, the Group has pledged deposits with an aggregate carrying amount of HK$1,785,000 (2025: HK$1,749,000) in connection with surety bonds issued by a bank in favour of independent third parties for potential damages of dental equipment and potential disruption of medical services.

附註：於2026年6月30日，本集團已抵押賬面總值合共1,785,000港元(2025年：1,749,000港元)的存款，乃涉及由一間銀行就潛在牙科設備損壞及潛在醫療服務干擾而向有關獨立第三方發出的履約保證。

29. CASH, BANK BALANCES AND DEPOSITS (Continued)

At the end of the reporting period, the cash and bank balances of the Group denominated in Renminbi ("RMB") amounted to HK$23,018,000 (2025: HK$24,830,000). The RMB is not freely convertible into other currencies, however, under Chinese Mainland's Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Short term time deposits are made for varying periods of between one day and six months depending on the immediate cash requirements of the Group, and earn interest at the respective short term time deposit rates. The bank balances and time deposits are deposited with creditworthy banks with no recent history of default.

29. 現金、銀行結餘及存款(續)

於報告期末，本集團以人民幣(「人民幣」)計值的現金及銀行結餘為23,018,000港元(2025年：24,830,000港元)。人民幣不可自由轉換為其他貨幣，然而，根據中華人民共和國外匯管理條例以及結匯、售匯及付匯管理規定，本集團獲准透過獲授權進行外匯業務的銀行將人民幣兑換成其他貨幣。

銀行存款按基於每日銀行存款利率的浮動利率計息。短期定期存款的期間不定，由一日至六個月不等，視乎本集團的即時現金需要，按各短期定期存款利率賺取利息。銀行結餘及定期存款存放於信譽良好且近期並無違約記錄的銀行。

30. TRADE PAYABLES

An aging analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

30. 貿易應付款項

於報告期末的貿易應付款項按發票日期的賬齡分析如下：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Within 1 month	1個月內	**35,868**	33,751
1 to 3 months	1至3個月	**31,253**	26,020
Over 3 months	3個月以上	**4,212**	1,813
		71,333	61,584

The trade payables are non-interest-bearing and are normally settled on terms ranging from 30 to 90 days.

貿易應付款項為免息且一般於30至90天內結算。

31. OTHER PAYABLES AND ACCRUALS

31. 其他應付款項及應計費用

		Notes 附註	30 June 2026 2026年6月30日 HK$'000 千港元	30 June 2025 2025年6月30日 HK$'000 千港元
Contract liabilities	合約負債	(a)	**19,689**	27,371
Other payables	其他應付款項	(b)	**18,094**	15,927
Accruals	應計費用	(b)	**18,325**	15,990
Deposits received	已收保證金		**1,859**	3,292
Amount due to non-controlling shareholders of subsidiaries	應付附屬公司非控股股東款項	(c)	**5,001**	4,951
			62,968	67,531

Notes:

(a) Details of contract liabilities are as follows:

附註：

(a) 合約負債的詳情如下：

		30 June 2026 2026年6月30日 HK$'000 千港元	30 June 2025 2025年6月30日 HK$'000 千港元
Advances received from customers	**從客戶收到的墊款**		
Provision of corporate healthcare solution services to Contract Customers	向合約客戶提供企業醫療保健解決方案服務	**16,685**	23,216
Provision of clinical healthcare services	提供臨床醫療保健服務	**3,004**	4,155
		19,689	27,371

(b) Other payables and accruals are non-interest-bearing and are normally repayable on demand.

(b) 其他應付款項及應計費用不計息，且一般按要求償還。

(c) The amounts due to non-controlling shareholders of subsidiaries are unsecured, interest-free and repayable on demand.

(c) 應付附屬公司非控股股東的金額為無抵押、不計息及按要求償還。

32. LOANS FROM NON-CONTROLLING SHAREHOLDERS OF SUBSIDIARIES

32. 來自附屬公司非控股股東的貸款

		30 June 2026 2026年6月30日 HK$'000 千港元	30 June 2025 2025年6月30日 HK$'000 千港元
Loans from non-controlling shareholders	來自非控股股東的貸款	**46,379**	53,174

The loans from non-controlling shareholders of subsidiaries are unsecured, interest-free and repayable on demand.

來自附屬公司非控股股東的貸款為無抵押、不計息及按要求償還。

33. DEFERRED TAX

The movements in deferred tax assets and liabilities during the year are as follows:

33. 遞延稅項

年內的遞延稅項資產及負債變動如下：

Gross deferred tax assets

遞延稅項資產總額

		Depreciation in excess of related depreciation allowance 超出相關折舊撥備的折舊 HK$'000 千港元	Future benefit of tax losses 稅項虧損之未來得益 HK$'000 千港元	Reinstatement cost 復原成本 HK$'000 千港元	Total 合計 HK$'000 千港元
At 30 June 2024 and at 1 July 2024	於2024年6月30日及於2024年7月1日	3,128	22,379	–	25,507
Deferred tax credited to the consolidated statement of profit or loss during the year (note 11)	年內於綜合損益表計入的遞延稅項(附註11)	19	742	1,580	2,341
At 30 June 2025 and at 1 July 2025	於2025年6月30日及於2025年7月1日	**3,147**	**23,121**	**1,580**	**27,848**
Deferred tax (charged)/credited to the consolidated statement of profit or loss during the year (note 11)	年內於綜合損益表(扣除)／計入的遞延稅項(附註11)	**1,244**	**(3,281)**	**90**	**(1,947)**
At 30 June 2026	於2026年6月30日	**4,391**	**19,840**	**1,670**	**25,901**

33. DEFERRED TAX (Continued)
Gross deferred tax liabilities

33. 遞延税項(續)
遞延税項負債總額

		Depreciation allowance in excess of related depreciation 超出相關折舊的折舊撥備 HK$'000 千港元	Fair value adjustments arising from business combinations 業務合併產生的公允價值調整 HK$'000 千港元	Total 合計 HK$'000 千港元
At 30 June 2024 and at 1 July 2024	於2024年6月30日及於2024年7月1日	9,648	7,597	17,245
Deferred tax credited to the consolidated statement of profit or loss during the year (note 11)	年內於綜合損益表計入的遞延税項（附註11）	(2,322)	–	(2,322)
At 30 June 2025 and at 1 July 2025	於2025年6月30日及於2025年7月1日	**7,326**	**7,597**	**14,923**
Acquisition of a subsidiary	收購附屬公司	**–**	**132**	**132**
Deferred tax credited to the consolidated statement of profit or loss during the year (note 11)	年內於綜合損益表計入的遞延税項（附註11）	**(2,778)**	**–**	**(2,778)**
At 30 June 2026	於2026年6月30日	**4,548**	**7,729**	**12,277**

At 30 June 2026, the Group has unrecognised tax losses arising in Hong Kong of HK$65,638,000 (2025: HK$75,043,000), subject to the agreement by the Hong Kong Inland Revenue Department, that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose. The Group also has unrecognised tax losses arising in Chinese Mainland of HK$32,097,000 (2025: HK$10,137,000), subject to the agreement by the relevant taxation authority, that will expire in five years for offsetting against future taxable profits of the companies in which the losses arose. Deferred tax assets have not been recognised in respect of these losses due to unpredictability of future taxable profit streams.

於2026年6月30日，本集團在香港產生的未確認税項虧損為65,638,000港元（2025年：75,043,000港元）（有待香港税務局同意），該等税項虧損可無限期用作抵銷產生虧損的公司的未來應課税利潤。本集團亦有在中國內地產生的未確認税項虧損32,097,000港元（2025年：10,137,000港元）（有待相關税務機關同意），該等税項虧損將於五年內屆滿，可用作抵銷產生虧損的公司的未來應課税利潤。由於無法預測未來應課税利潤來源，因此並無就該等虧損確認遞延税項資產。

33. DEFERRED TAX (Continued)

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Chinese Mainland. The requirement is effective from 1 January 2008 and applies to earnings after 31 December 2007. Withholding tax rate may be applied if there is a tax treaty between Chinese Mainland and the jurisdiction of the foreign investors. For the Group, the applicable rate is 10%. The Group is therefore liable for withholding taxes on dividends distributed by those subsidiaries established in Chinese Mainland in respect of earnings generated from 1 January 2008.

At 30 June 2026, no deferred tax has been recognised for withholding taxes that would be payable on the unremitted earnings that are subject to withholding taxes of the Group's subsidiaries established in Chinese Mainland. In the opinion of the directors, it is not probable that these subsidiaries will distribute such earnings in the foreseeable future. The aggregate amount of temporary differences associated with investments in subsidiaries in Chinese Mainland for which deferred tax liabilities have not been recognised totalled approximately HK$72,378,000 at 30 June 2026 (2025: HK$59,501,000).

33. 遞延稅項(續)

根據中國企業所得稅法，於中國內地成立之外商投資企業向外國投資者宣派之股息須按10%徵收預扣稅。此規定由2008年1月1日起生效，並適用於2007年12月31日後之盈利。倘中國內地與外國投資者所在司法權區之間訂立稅務條約，則可能採用預扣稅率。本集團適用的預扣稅率為10%。因此，本集團須為於中國內地成立的附屬公司就2008年1月1日起產生之盈利分派股息而繳納預扣稅。

於2026年6月30日，並無就因本集團於中國內地成立的附屬公司的未匯出盈利(須繳納預扣稅者)而應付的預扣稅確認遞延稅項。董事認為，該等附屬公司於可見將來將不大可能分派有關盈利。於2026年6月30日，與投資於中國內地的附屬公司有關的未確認遞延稅項負債的暫時性差異合共約為72,378,000港元(2025年：59,501,000港元)。

34. PROVISION

34. 撥備

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
At the beginning of the year	於年初	**12,039**	13,427
Additions during the year	年內增加	**892**	109
Amount utilised during the year	年內動用金額	**(1,144)**	(1,501)
Exchange realignment	匯兑調整	**18**	4
		11,805	12,039
less: Portion classified as non-current liabilities	減：分類為非流動負債之部份	**(8,179)**	(6,622)
Current portion	流動部份	**3,626**	5,417

Pursuant to the terms of the respective tenancy agreements entered into by the Group, the Group is required to return certain of its leased properties to the conditions as stipulated in the respective tenancy agreements at the expiration or sooner determination of the corresponding lease terms as appropriate. The provision for reinstatement costs was estimated based on certain assumptions and estimates made by the directors with reference to quoted prices and/or other available information. The assumptions and estimates are reviewed on an ongoing basis and revised as appropriate.

根據本集團所訂立的有關租賃協議的條款，於相關租期屆滿時或提早終止時（視乎情況適當而定），本集團須將其若干租賃物業恢復至有關租賃協議訂明的狀態。復原成本撥備乃基於董事參考報價及／或其他可得資料所作出的若干假設及估計而預測。假設及估計會予以持續檢討並作出適當修訂。

35. SHARE CAPITAL
Shares

35. 股本
股份

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Authorised: 5,000,000,000 (2025: 5,000,000,000) ordinary shares of HK$0.001 (2025: HK$0.001) each	法定： 5,000,000,000股 （2025年：5,000,000,000股） 每股面值0.001港元 （2025年：0.001港元） 的普通股	**5,000**	5,000
Issued and fully paid: 810,955,244 (2025: 810,955,244) ordinary shares of HK$0.001 (2025: HK$0.001) each	已發行及繳足： 810,955,244股 （2025年：810,955,244股） 每股面值0.001港元 （2025年：0.001港元） 的普通股	**811**	811

The movements in the Company's authorised and issued share capital during the years ended 30 June 2026 and 2025 are as follows:

本公司於截至2026年及2025年6月30日止年度之法定及已發行股本變動如下：

		Number of ordinary shares 普通股數目	Nominal value of ordinary shares 普通股面值 HK$'000 千港元
Authorised: At 1 July 2024, at 30 June 2025, at 1 July 2025 and at 30 June 2026	法定： 於2024年7月1日、於2025年6月30日、於2025年7月1日及於2026年6月30日	5,000,000,000	5,000
Issued and fully paid: At 1 July 2024, 30 June 2025, 1 July 2025 and at 30 June 2026	已發行及繳足： 於2024年7月1日、2025年6月30日、2025年7月1日及於2026年6月30日	810,955,244	811

36. SHARE OPTION SCHEMES

The Company adopted a share option scheme (the "Scheme") for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations.

Eligible participants of the Schemes include the Company's directors, including independent non-executive directors, other employees of the Group, consultants of the Group, suppliers of goods or services to the Group, customers of the Group, the Company's shareholders, and any non-controlling shareholder in the Company's subsidiaries. The Scheme became effective on 27 November 2015 and, unless otherwise cancelled or amended, will remain in force for 10 years from that date.

The maximum number of unexercised share options currently permitted to be granted under the Schemes is an amount equivalent, upon their exercise, to 10% of the shares of the Company in issue at any time. The maximum number of shares issuable under share options to each eligible participant in the Schemes within any 12-month period is limited to 1% of the shares of the Company in issue at any time. Any further grant of share options in excess of this limit is subject to shareholders' approval in a general meeting.

Share options granted to a director, chief executive or substantial shareholder of the Company, or to any of their associates, are subject to approval in advance by the independent non-executive directors. In addition, any share options granted to a substantial shareholder or an independent non-executive director of the Company, or to any of their associates, in excess of 0.1% of the shares of the Company in issue at any time or with an aggregate value (based on the closing price of the Company's shares at the date of grant) in excess of HK$5 million, within any 12-month period, are subject to shareholders' approval in advance in a general meeting.

36. 購股權計劃

本公司採納購股權計劃(「計劃」),目的為向對本集團營運成功有所貢獻的合資格參與者提供獎勵及報酬。

計劃合資格參與者包括本公司董事(包括獨立非執行董事)、本集團其他僱員、本集團的顧問、向本集團提供貨品或服務的供應商、本集團客戶、本公司的股東以及本公司附屬公司的任何非控股股東。計劃於2015年11月27日生效,除非以其他方式取消或修訂,否則自該日期起維持有效10年。

目前獲准按計劃授出的未行使購股權最高數目相等於獲行使時本公司於任何時間已發行股份10%。根據購股權可於任何12個月期間內向計劃各合資格參與者發行的股份最高數目,限於本公司於任何時間已發行股份1%。任何超出此限額的進一步授出購股權須獲股東大會上股東批准。

向本公司董事、行政總裁或主要股東或任何彼等聯繫人授出的購股權須預先獲得獨立非執行董事批准。此外,向本公司主要股東或獨立非執行董事或任何彼等聯繫人授出任何購股權(超過本公司任何時間已發行股份0.1%或總值(基於本公司股份於授出日期的收市價)於任何12個月期間內超過5百萬港元),須預先於股東大會上獲股東批准。

36. SHARE OPTION SCHEMES (Continued)

The offer of a grant of share options under the Scheme may be accepted upon payment of a nominal consideration of HK$1 in total by the grantee. The exercise period of the share options granted under the Scheme is determinable by the directors, and commences after a vesting period and ends on a date which is not later than 10 years from the date of offer of the share options.

The exercise price of share options under the Scheme is determinable by the directors, but may not be less than the higher of (i) the nominal value of the shares; (ii) the closing price of the Company's shares as stated in the Stock Exchange's daily quotation sheets on the date of offer of the share options; and (iii) the average of the closing prices of the Company's shares as stated in the Stock Exchange's daily quotation sheets for the five trading days immediately preceding the date of offer.

Share options do not confer rights on the holders to dividends or to vote at shareholders' meetings.

The following share options under the Scheme were outstanding during the year:

36. 購股權計劃(續)

根據計劃提出授予購股權可能自承授人支付象徵式代價合共1港元後獲批准。根據計劃獲授購股權的行使期可由董事釐定，於歸屬期後開始，於購股權要約日期起不少於10年的日期。

計劃項下購股權的行使價由董事釐定，惟不得低於(i)股份的面值；(ii)聯交所每日報價表內所示本公司股份於購股權要約日期的收市價；及(iii)聯交所每日報價表內所示本公司股份於緊接購股權要約日期前五個交易日的平均收市價(以較高者為準)。

購股權並無授予持有人獲派股息或於股東大會上投票之權利。

年內，計劃項下尚未行使的購股權如下：

		2026 2026年		2025 2025年	
		Weighted average exercise price 加權平均行使價 HK$ per share 每股港元	**Number of options 購股權數目 '000 千份**	Weighted average exercise price 加權平均行使價 HK$ per share 每股港元	Number of options 購股權數目 '000 千份
At the beginning of the year	於年初	**0.77**	**11,200**	0.87	12,700
Lapsed during the year	年內失效	**0.77**	**(1,000)**	1.56	(1,500)
At the end of the year	於年末	**0.77**	**10,200**	0.77	11,200

No share options were exercised during the years ended 30 June 2026 and 2025.

截至2026年及2025年6月30日止年度內並無購股權獲行使。

36. SHARE OPTION SCHEMES (Continued)

The exercise prices and exercise periods of the share options outstanding under the Scheme as at the end of the reporting period are as follows:

36. 購股權計劃(續)

於報告期末計劃項下尚未行使購股權的行使價及行使期如下：

2026 / **2026年**

Number of options 購股權數目 '000 千份	**Exercise price 行使價 HK$ per share 每股港元**	**Exercise period**	**行使期**
4,080	0.772	26 May 2022 to 25 May 2029	2022年5月26日至2029年5月25日
3,060	0.772	26 May 2023 to 25 May 2029	2023年5月26日至2029年5月25日
3,060	0.772	26 May 2024 to 25 May 2029	2024年5月26日至2029年5月25日
10,200			

2025 / 2025年

Number of options 購股權數目 '000 千份	Exercise price 行使價 HK$ per share 每股港元	Exercise period	行使期
4,480	0.772	26 May 2022 to 25 May 2029	2022年5月26日至2029年5月25日
3,360	0.772	26 May 2023 to 25 May 2029	2023年5月26日至2029年5月25日
3,360	0.772	26 May 2024 to 25 May 2029	2024年5月26日至2029年5月25日
11,200			

36. SHARE OPTION SCHEMES (Continued)

No share options were granted under the Scheme during the years ended 30 June 2026 and 30 June 2025. During the years, the Group recognised a share-based payment expense of HK$Nil (2025: HK$Nil).

The Company has not granted any share options under the 2023 Share Option Scheme since its adoption.

The expected life of the options is not necessarily indicative of the exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.

No other feature of the options granted was incorporated into the measurement of fair value.

At the end of the reporting period, the Company had 10,200,000 share options outstanding under the Scheme. The exercise in full of the outstanding share options would, under the present capital structure of the Company, result in the issue of 10,200,000 additional ordinary shares of the Company and additional share capital of approximately HK$10,200 and share premium of approximately HK$7,874,400 (before issue expenses).

At the date of approval of these consolidated financial statements, the Company had 10,200,000 share options outstanding under the Scheme, which represented approximately 1.26% of the Company's shares in issue as at that date.

36. 購股權計劃(續)

截至2026年6月30日及2025年6月30日止年度內並無根據計劃授出購股權。本集團於年度內確認以股份為基礎的付款開支零港元(2025年：零港元)。

本公司自採納以來並無根據2023年購股權計劃授出任何購股權。

購股權的預期年期並不一定反映可能產生的行使模式。預期波幅反映假設過往波幅可反映未來趨勢(亦可能未必反映實際結果)。

概無於公允價值計量納入已授出購股權的其他特點。

於報告期末，本公司根據計劃有10,200,000份尚未行使購股權。根據本公司目前資本架構，悉數行使尚未行使購股權將導致發行本公司10,200,000股額外普通股及增加股本約10,200港元及股份溢價約7,874,400港元(扣除發行開支前)。

於此等綜合財務報表獲批准日期，本公司根據計劃有10,200,000份尚未行使購股權，相當於本公司於該日的已發行股份約1.26%。

37. SHARE AWARD SCHEME

On 30 June 2016, the Company adopted a share award scheme (the "Share Award Scheme") for the purpose of recognising the contributions by certain eligible participants and providing them with incentives in order to retain them for the continual operation and development of the Group and to attract suitable personnel for the growth and further development of the Group.

The Board resolved to amend the Share Award Scheme with effect from 24 November 2023 (the "Amendment Date").

Eligible participants of the Share Award Scheme include the Company's directors, senior management and other employees of the Group, and service provider(s) of the Group. The Share Award Scheme shall be valid and effective for a further term of 10 years commencing on the Amendment Date.

The maximum number of shares currently permitted to be granted under the Share Award Scheme is limited to 10% of the issued share capital of the Company as at the Amendment Date. The maximum number of shares which may be awarded to each eligible participant in the Share Award Scheme is limited to 1% of the issued share capital of the Company in each year.

The eligible participant for participation in the Share Award Scheme (the "Selected Participant") is selected and the number of shares to be awarded under the Share Award Scheme is determined by the board of directors. The shares to be awarded under the Share Award Scheme will be purchased by a trustee (the "Trustee") from the open market out of cash contributed by the Group and be held on trust for the Selected Participant until such shares are vested with the Selected Participant in accordance with the provisions of the Share Award Scheme.

The Trustee shall not exercise the voting rights in respect of any shares held on trust for the Group or the Selected Participant.

During the year, the Group purchased 2,100,000 (2025: 440,000) of its own shares through the Trustee from the open market. The total amount paid to acquire the shares was approximately HK$976,000 (2025: HK$180,000) and has been deducted from equity. As at 30 June 2026, such shares were classified as treasury shares of the Company as they were not yet vested.

37. 股份獎勵計劃

於2016年6月30日，本公司採納股份獎勵計劃(「股份獎勵計劃」)，旨在肯定若干合資格參與者所作貢獻及就此給予獎勵，以留聘彼等為本集團持續經營及發展，並吸引合適人員推動本集團增長及進一步發展。

董事會議決修訂股份獎勵計劃，於2023年11月24日(「修訂日期」)生效。

股份獎勵計劃的合資格參與者包括本公司董事、高級管理層及本集團其他僱員及本集團之服務供應商。股份獎勵計劃自修訂日期起10年內維持有效。

根據股份獎勵計劃現時獲准授出的最高股份數目以本公司於修訂日期已發行股本的10%為限。根據股份獎勵計劃可授予各合資格參與者的最高股份數目以為本公司各年內已發行股本的1%為限。

參與股份獎勵計劃的合資格參與者(「獲選參與者」)由董事會選定，而根據股份獎勵計劃將予授出的股份數目由董事會釐定。根據股份獎勵計劃將予授出的股份將由受託人(「受託人」)以本集團注入的現金從公開市場購入，並以信託形式代獲選參與者持有，直至該等股份根據股份獎勵計劃條文歸屬予相關獲選參與者為止。

受託人不得行使以信託形式為本集團或獲選參與者持有的任何股份的表決權。

年內，本集團透過受託人自公開市場購入其本身股份2,100,000股(2025年：440,000股)。收購股份所支付的總金額約為976,000港元(2025年：180,000港元)，已自權益中扣除。於2026年6月30日，由於有關股份尚未歸屬，故已分類為本公司的庫存股份。

37. SHARE AWARD SCHEME (Continued)

During the year, 3,650,000 (2025: 3,900,000) share awards have been granted and 3,650,000 (2025: 4,400,000) share awards have been vested under the Share Award Scheme and Nil (2025: Nil) shares of the Company were scrip dividends with respect to shares of the Company held under the Share Award Scheme.

The movements in the Company's shares held under the Share Award Scheme during the years ended 30 June 2026 and 2025 are as follows:

37. 股份獎勵計劃(續)

年內，根據股份獎勵計劃授出3,650,000份(2025年：3,900,000份)股份獎勵及歸屬3,650,000份(2025年：4,400,000份)股份獎勵而並無(2025年：無)本公司股份為股份獎勵計劃項下預留之本公司股份的相關代息股份。

本公司股份獎勵計劃項下預留的股份於截至2026年及2025年6月30日止年度之變動如下：

		Number of ordinary shares 普通股數目	Shares held under the Share Award Scheme 股份獎勵計劃項下預留的股份 HK$'000 千港元
At 1 July 2024	於2024年7月1日	11,429,863	15,842
Purchases of shares for the share award scheme	就股份獎勵計劃購買股份	440,000	180
Issuance of share awards immediately vested	發行即時歸屬的股份獎勵	(3,900,000)	(1,619)
At 30 June 2025	於2025年6月30日	7,969,863	14,403
At 1 July 2025	於2025年7月1日	**7,969,863**	**14,403**
Purchases of shares for the share award scheme	就股份獎勵計劃購買股份	**2,100,000**	**976**
Issuance of share awards immediately vested	發行即時歸屬的股份獎勵	**(3,650,000)**	**(1,752)**
At 30 June 2026	於2026年6月30日	**6,419,863**	**13,627**

As at 30 June 2026, Nil (2025: 500,000) awarded shares are outstanding and these awarded shares were included in 6,419,863 (2025: 7,969,863) shares of the Company held under the Share Award Scheme.

於2026年6月30日，並無(2025年：500,000股)獎勵股份為尚未行使，該等獎勵股份已包括在股份獎勵計劃項下預留的6,419,863股(2025年：7,969,863股)本公司股份中。

37. SHARE AWARD SCHEME (Continued)

Details of the awarded shares outstanding as at 30 June 2026 and 2025 were set out as follows:

37. 股份獎勵計劃(續)

於2026年及2025年6月30日，發行在外的獎勵股份詳情如下：

30 June 2026

2026年6月30日

Date of grant 授出日期	Share price as at the date of grant 於授出日期的股份價格 HK$ 港元	Grant price 授出價格 HK$ 港元	Number of awarded shares 獎勵股份數目					Vesting period 歸屬期
			As at 1 July 2025 於2025年7月1日	Granted during the year 年內授出	Vested during the year 年內歸屬	Forfeited during the year 年內沒收	As at 30 June 2026 於2026年6月30日	
27 February 2026 2026年2月27日	0.48	–	–	3,650,000	(3,650,000)	–	–	Immediately vested 即時歸屬

The Group recognised a share-based payment expense of HK$1,752,000 (2025: HK$1,859,000) during the year ended 30 June 2026.

本集團於截至2026年6月30日止年度內確認以股份為基礎的付款開支1,752,000港元（2025年：1,859,000港元）。

37. SHARE AWARD SCHEME (Continued)
30 June 2025

37. 股份獎勵計劃(續)
2025年6月30日

Date of grant 授出日期	Share price as at the date of grant 於授出日期的股份價格 HK$ 港元	Grant price 授出價格 HK$ 港元	Number of awarded shares 獎勵股份數目 As at 1 July 2024 於2024年7月1日	Granted during the year 年內授出	Vested during the year 年內歸屬	Forfeited during the year 年內沒收	As at 30 June 2025 於2025年6月30日	Vesting period 歸屬期
5 March 2024 2024年3月5日	0.51	–	700,000	–	(500,000)	(200,000)	–	500,000 awarded shares vested on 30 June 2025 500,000股獎勵股份於2025年6月30日歸屬
28 February 2025 2025年2月28日	0.415	–	–	3,900,000	(3,900,000)	–	–	Immediately vested 即時歸屬
			700,000	3,900,000	(4,400,000)	(200,000)	–	

38. RESERVES

The amounts of the Group's reserves and the movements therein for the current and prior years are presented in the consolidated statement of changes in equity on pages 175 to 176 of the consolidated financial statements.

Capital contribution reserve

Capital contribution reserve represents (i) the fair value of the shares of the then ultimate holding company that were used to satisfy the consideration of the Group's acquisition of equity interests in certain subsidiaries and additional interests in certain subsidiaries in 2014; (ii) the waiver of amounts due to the then ultimate holding company and a major beneficial shareholder of the Company for the acquisition of a subsidiary; and (iii) the waiver of other payable by a former non-controlling shareholder.

Share-based payment reserve

The share-based payment reserve comprises the fair value of share options and share awards granted which are yet to be exercised, as further explained in the accounting policy for share-based payments in note 2.4 to the consolidated financial statements. The amount will either be transferred to the share premium account when the related share options or share awards are exercised, or be transferred to retained profits or to profit or loss should the related share options or share awards expire or be forfeited, respectively.

Details of the Company's share option schemes are included in note 36 and share award scheme are included in note 37 to the consolidated financial statements, respectively.

Legal reserve

The legal reserve represents (i) the transfer of the profit generated from subsidiaries incorporated in Macau from retained profits to the legal reserve in accordance with article 377 of the Macao Commercial Code until the legal reserve balance reaches half of the capital of the relevant subsidiaries; and (ii) pursuant to the relevant laws and regulation in Chinese Mainland, a portion of the profit of the Company's subsidiaries in Chinese Mainland has been transferred to legal reserve which is restricted to use. The legal reserve is not distributable.

38. 儲備

本集團於本年度及過往年度的儲備金額及其變動呈列於綜合財務報表第175至176頁的綜合權益變動表。

出資儲備

出資儲備指(i)當時最終控股公司於2014年用以償付本集團收購若干附屬公司股權及若干附屬公司之額外權益之代價的股份的公允價值；(ii)豁免就收購一間附屬公司應付當時最終控股公司及一名本公司主要實益股東的款項；及(iii)一名前非控股股東豁免其他應付款項。

以股份為基礎的付款儲備

以股份為基礎的付款儲備包括已授出但尚未行使的購股權及股份獎勵之公允價值，於綜合財務報表附註2.4中以股份為基礎的付款交易之會計政策中有進一步闡述。該金額可於有關購股權或股份獎勵獲行使時轉撥至股份溢價賬或於有關購股權或股份獎勵過期或被沒收時分別轉撥至留存利潤或損益。

本公司之購股權計劃之詳情載於綜合財務報表附註36而股份獎勵計劃之詳情載於綜合財務報表附註37。

法定儲備

法定儲備指(i)將在澳門註冊成立的附屬公司的利潤依照《澳門商法典》第377條由留存利潤轉為法定儲備，直至法定儲備結餘達該等附屬公司股本的一半為止；及(ii)根據中國內地的相關法律法規，本公司於中國內地的附屬公司已將部份利潤轉撥至用途受限制的法定儲備。法定儲備不可分派。

39. PARTLY-OWNED SUBSIDIARIES WITH MATERIAL NON-CONTROLLING INTERESTS

Details of the Group's subsidiary that has material non-controlling interests are set out below:

39. 具有重大非控股權益的非全資附屬公司

具有重大非控股權益的本集團附屬公司詳情載列如下：

		2026 **2026年**	2025 2025年
Percentage of equity interest held by non-controlling interests: SkinCentral Limited ("SkinCentral")	非控股權益持有的股權百分比：善肌聯合皮膚中心有限公司（「善肌」）	**40%**	40%

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Profit for the year allocated to non-controlling interests: SkinCentral	分配予非控股權益的年內利潤：善肌	**2,565**	2,294
Dividend paid to non-controlling interests: SkinCentral	已付非控股權益的股息：善肌	**2,000**	7,600
Accumulated balances of non-controlling interests at the reporting date: SkinCentral	於報告日期非控股權益的累計結餘：善肌	**12,103**	11,537

39. PARTLY-OWNED SUBSIDIARIES WITH MATERIAL NON-CONTROLLING INTERESTS (Continued)

The following table illustrates the summarised financial information of the above subsidiary, modified for fair value adjustments on acquisition. The amounts disclosed are before any inter-company eliminations:

39. 具有重大非控股權益的非全資附屬公司(續)

下表說明以上附屬公司的財務資料概要，並且就收購事項的公允價值調整作出修訂。所披露金額尚未經過任何公司間抵銷：

2026	**2026年**	**SkinCentral 善肌 HK$'000 千港元**
Revenue	收入	**64,034**
Profit for the year	年內利潤	**6,413**
Total comprehensive income for the year	年內全面收入總額	**6,413**
Current assets	流動資產	**13,492**
Non-current assets	非流動資產	**1,276**
Current liabilities	流動負債	**(8,749)**
Non-current liabilities	非流動負債	**–**
Net cash flows from operating activities	經營活動所得現金流量淨額	**11,859**
Net cash flows used in investing activities	投資活動所用現金流量淨額	**(439)**
Net cash flows used in financing activities	融資活動所用現金流量淨額	**(11,406)**
Net increase in cash and cash equivalents	現金及現金等價物增加淨額	**14**

2025	**2025年**	SkinCentral 善肌 HK$'000 千港元
Revenue	收入	61,180
Profit for the year	年內利潤	5,736
Total comprehensive income for the year	年內全面收入總額	5,736
Current assets	流動資產	10,509
Non-current assets	非流動資產	12,277
Current liabilities	流動負債	(17,471)
Non-current liabilities	非流動負債	(709)
Net cash flows from operating activities	經營活動所得現金流量淨額	12,144
Net cash flows used in investing activities	投資活動所用現金流量淨額	(188)
Net cash flows used in financing activities	融資活動所用現金流量淨額	(27,507)
Net decrease in cash and cash equivalents	現金及現金等價物減少淨額	(15,551)

40. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS

(a) Major non-cash transactions

(i) During the year, the Group had non-cash additions to right-of-use assets and lease liabilities of HK$53,505,000 and HK$53,505,000, respectively, in respect of lease arrangements for leased properties (2025: HK$53,637,000 and HK$53,637,000).

(ii) During the year, the Group entered into tenancy agreements in respect of certain of its medical centres and office premises. Pursuant to the terms of respective tenancy agreements entered into by the Group, the Group is required to restore the leased properties to the conditions as stipulated in the tenancy agreements. Accordingly, a reversal for reinstatement costs in respect of the leased properties of the Group amounting to HK$234,000 (2025: provision HK$109,000) was recognised and these costs were included as part of the cost of the property, plant and equipment of the Group and reflected as additions to leasehold improvements of the Group during the current year.

40. 綜合現金流量表附註

(a) 主要非現金交易

(i) 於本年度內，本集團有關於租賃物業之租賃安排的使用權資產及租賃負債的非現金添置分別為53,505,000港元及53,505,000港元（2025年：53,637,000港元及53,637,000港元）。

(ii) 於本年度內，本集團就其若干醫務中心及辦公室物業訂立租賃協議。根據本集團所訂立有關租賃協議的條款，本集團須將租賃物業修復至租賃協議所規定的狀態。因此，已確認本集團租賃物業復原成本撥回234,000港元（2025年：撥備109,000港元），而此等成本納入作為本集團物業、廠房及設備成本的一部分，並於本年度反映為本集團租賃物業裝修的增加。

40. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS (Continued)

40. 綜合現金流量表附註(續)

(b) Changes in liabilities arising from financing activities

(b) 融資活動產生的負債變動

		Lease liabilities 租賃負債 HK$'000 千港元
At 1 July 2024	於2024年7月1日	120,695
Changes from financing cash flows	融資現金流的變動	(62,606)
New leases	新租賃	53,637
Lease modification and disposal	租賃修改及出售	(3,334)
Exchange realignment	匯兑調整	(16)
At 1 July 2025	於2025年7月1日	**108,376**
Changes from financing cash flows	融資現金流的變動	**(56,084)**
New leases	新租賃	**53,505**
Lease modification and disposal	租賃修改及出售	**(8,965)**
Exchange realignment	匯兑調整	**726**
At 30 June 2026	於2026年6月30日	**97,558**

(c) Total cash outflow for leases

The total cash outflow for leases included in the statement of cash flows is as follows:

(c) 租賃的現金流出總額

列入現金流量表的租賃現金流出總額如下：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Within operating activities	經營活動內	**1,661**	1,709
Within financing activities	融資活動內	**56,084**	62,606

41. COMMITMENTS

The Group had the following capital commitments at the end of the reporting period:

41. 承擔

於報告期末，本集團的資本承擔如下：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Contracted, but not provided for:	已訂約但未撥備：		
Medical equipment	醫療設備	**172**	–
Computer equipment and software	電腦設備及軟件	**1,143**	552
Furniture, fixtures and office equipment	傢俱、裝置及辦公室設備	**–**	642
Leasehold improvements	租賃物業裝修	**1,857**	4,943
		3,172	6,137

42. RELATED PARTY TRANSACTIONS

(a) In addition to the transactions, arrangements and balances detailed elsewhere in these consolidated financial statements, the Group had the following material transactions with related parties during the year:

42. 關聯方交易

(a) 除此等綜合財務報表其他地方所詳述的交易、安排及結餘外，於年內，本集團與關聯方進行的重大交易如下：

		Notes 附註	**2026 2026年 HK$'000 千港元**	2025 2025年 HK$'000 千港元
Associates:	**聯營公司：**			
Administrative support fee income	行政支援費收入	(i)	**613**	451
Professional services expense	專業服務費用	(ii)	**2,604**	2,645
Healthcare services income	醫療保健服務收入	(iii)	**655**	499
Joint ventures:	**合資公司：**			
Professional services expense	專業服務費用	(ii)	**26**	169
Related companies*:	**關聯公司*：**			
Administrative support fee income	行政支援費收入	(i)	**5,455**	4,884
Lease payments/property rental and related expenses	租賃付款／物業租金及相關開支	(iv)	**3,067**	3,243
Contract healthcare solution services income	合約醫療保健解決方案服務收入	(v)	**15,243**	19,227
Medical related services expenses to Pedder	仁德醫健的醫療相關服務費用	(vi)	**41,622**	22,614
Medical related services income from Pedder	仁德醫健的醫療相關服務收入	(vii)	**16,045**	21,324

* Certain directors and/or beneficial shareholders of the Company are also directors and/or beneficial shareholders of these related companies, and some of these related companies are a substantial shareholder of the Company's subsidiaries (Note (vi) and (vii)).

* 本公司若干董事及／或實益股東亦為該等關聯公司的董事及／或實益股東，而該等關聯公司有一部分為本公司附屬公司的主要股東（附註(vi)及(vii)）。

Notes:

附註：

(i) The administrative support fee income was related to administrative support services, such as payroll services, rendered by the Group and was charged at terms mutually agreed between the relevant parties.

(i) 行政支援費收入與本集團提供的薪酬服務等管理支持服務相關並以與相關方相互協定的條款收費。

(ii) The professional services expense was related to healthcare services rendered by associates and joint ventures and was charged at terms mutually agreed between the relevant parties.

(ii) 專業服務費用乃聯營公司及合資公司向本集團提供的醫療保健服務並以相關方相互協定的條款收費。

42. RELATED PARTY TRANSACTIONS (Continued)

(a) (Continued)

Notes: (Continued)

(iii) The healthcare services income was related to medical services rendered by the Group and was charged at terms mutually agreed between the relevant parties.

(iv) The lease payments/property rental and related expenses were related to the leasing of certain medical centres or premises for the Group's operation and were charged at terms stipulated in the respective tenancy agreements. Lease payments included depreciation charge of right-of-use assets, interest on lease liabilities and rental expense amounting to HK$2,947,000 (2025: HK$2,952,000), HK$120,000 (2025: HK$292,000) and HK$Nil (2025: HK$Nil), respectively. The corresponding right-of-use assets and lease liabilities as at 30 June 2026 are HK$3,208,000 (2025: HK$2,830,000) and HK$3,293,000 (2025: HK$2,951,000), respectively.

(v) Contract healthcare solution services income was related to the provision of healthcare services to the employees of related companies and was charged at terms mutually agreed between the relevant parties. The amount represents the income of HK$12,603,000 (2025: HK$15,896,000) and HK$2,645,000 (2025: HK$3,334,000) under the 2024 Medical Services Framework Renewal Agreement signed with CTFE ("CTFE Agreement") and the Medical Services Agreement signed with Chow Tai Fook Life Insurance Company Limited ("CTF Life Agreement"), respectively, for the year ended 30 June 2026. Under the CTF Life Agreement, the Group provided corporate healthcare solution and administrative services and clinical services which the gross total transaction amount was HK$55,255,000 for the year ended 30 June 2026 (2025: HK$50,200,000).

(vi) Pedder Healthcare Management Limited, its subsidiary or its holding company or a subsidiary of any such holding company and/or its affiliates ("Pedder Healthcare Group") had, on a non-exclusive basis, provided medical related services to the Group, including (i) medical consultation services to plan members under corporate healthcare benefit plans of the Group (as one of the affiliates of the Group's network of healthcare providers; (ii) medical consultation services to the Group through arranging or procuring its medical practitioners to provide medical services (including inpatient and/or outpatient services) to the Group; (iii) clinical administration and personnel support services; (iv) advisory and consulting support services; and (v) other auxiliary services. The services were charged at terms mutually agreed between the relevant parties. For details, please refer to the announcements of the Company dated 31 July 2026.

(vii) The Group had, on a non-exclusive basis, provided (i) diagnostic, imaging and laboratory tests services; (ii) licensing and/or sub-leases of premises; (iii) medical consultation services to the Pedder Healthcare Group through arranging or procuring its medical practitioners to provide medical services (including inpatient and/or outpatient services) to Pedder Healthcare Group; and (iv) other auxiliary services. The services were charged at terms mutually agreed between the relevant parties. For details, please refer to the announcements of the Company dated 31 July 2026.

42. 關聯方交易(續)

(a) (續)

附註:(續)

(iii) 醫療保健服務收入與本集團提供的醫療服務相關並以相關方相互協定的條款收費。

(iv) 租賃付款／物業租金及相關開支與租賃若干醫務中心或本集團的經營場所有關,並基於相應租賃協議所訂明的條款收費。租賃付款包括使用權資產之折舊支出、租賃負債之利息及租賃開支分別為2,947,000港元(2025年:2,952,000港元)、120,000港元(2025年:292,000港元)及零港元(2025年:零港元)。於2026年6月30日之相應使用權資產及租賃負債分別為3,208,000港元(2025年:2,830,000港元)及3,293,000港元(2025年:2,951,000港元)。

(v) 合約醫療保健解決方案服務收入與向關聯公司的僱員提供的醫療保健服務相關並以相關方相互協定的條款收費。該金額代表於截至2026年6月30日止年度根據與周大福企業簽署的2024年醫療服務框架重續協議(「周大福企業協議」)及與周大福人壽保險有限公司簽署的醫療服務協議(「周大福人壽協議」)所產生的收入分別為12,603,000港元(2025年:15,896,000港元)及2,645,000港元(2025年:3,334,000港元)。根據周大福人壽協議,本集團提供企業醫療解決方案與行政管理服務及臨床服務,其於截至2026年6月30日止年度的交易總額為55,255,000港元(2025年:50,200,000港元)。

(vi) 仁德醫務健康管理有限公司、其附屬公司或其控股公司或任何有關控股公司及／或其聯屬公司的附屬公司(統稱「仁德醫健集團」)已按非獨家方式向本集團提供醫療相關服務,包括(i)向本集團之公司醫療保健福利計劃項下的計劃成員提供醫療諮詢服務(作為本集團醫療保健提供者網絡的聯屬公司之一);(ii)透過安排或促使其醫療從業人員向本集團提供醫療服務(包括住院及／或門診服務)而向本集團提供醫療諮詢服務;(iii)臨床管理及人事支援服務;(iv)顧問及諮詢支援服務;及(v)其他輔助服務。該等服務以相關方相互協定的條款收費。有關詳情,請參閱本公司日期為2026年7月31日之公告。

(vii) 本集團已按非獨家方式提供(i)診斷、影像及化驗服務;(ii)物業的牌照辦理及／或分租事宜;(iii)透過安排或促使其醫療從業人員向仁德醫健集團提供醫療服務(包括住院及／或門診服務)而向仁德醫健集團提供醫療諮詢服務;及(iv)其他輔助服務。該等服務以相關方相互協定的條款收費。有關詳情,請參閱本公司日期為2026年7月31日之公告。

42. RELATED PARTY TRANSACTIONS (Continued)

(b) Other transactions with related parties

Professional services fees paid to the executive directors of the Company in relation to the rendering of healthcare services to the Group are as follows:

42. 關聯方交易(續)

(b) 其他關聯方交易

就為本集團提供醫療保健服務付予本公司執行董事的專業服務費載列如下：

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Dr. Sun Man Kin, Michael	孫文堅醫生	**881**	909
Dr. Lee Pak Cheung, Patrick	李柏祥醫生	**4,138**	3,955
		5,019	4,864

(c) Compensation of key management personnel of the Group

(c) 本集團主要管理人員的報酬

		2026 **2026年** **HK$'000** **千港元**	2025 2025年 HK$'000 千港元
Short-term employee benefits	短期僱員福利	**19,342**	20,716
Post-employment benefits	離職後福利	**122**	135
Equity-settled share-based payment expense	以權益結算的以股份為基礎的付款開支	**1,632**	1,328
Total compensation paid to key management personnel	已付主要管理人員之報酬總額	**21,096**	22,179

Further details of directors' emoluments are included in note 9 to the consolidated financial statements.

關於董事報酬之進一步詳情載於綜合財務報表附註9。

The related party transactions in respect of items (a)(v), (a)(vi), (a)(vii) and (b) above also constitute connected transactions or continuing connected transactions as defined in Chapter 14A of the Listing Rules.

有關上文(a)(v)、(a)(vi)、(a)(vii)及(b)項之關聯方交易亦構成上市規則第十四A章所界定之關連交易或持續關連交易。

43. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at the end of the reporting period are as follows:

43. 金融工具分類

於報告期末，各類金融工具的賬面值如下：

2026

Financial assets

2026年

金融資產

		Financial assets at fair value through profit or loss 按公允價值計入損益的金融資產		Financial assets at fair value through other comprehensive income 按公允價值計入其他全面收入的金融資產			
		Mandatorily designated as such 強制指定為按此方式計量 HK$'000 千港元	Designated as such upon initial recognition 於首次確認時指定為按此方式計量 HK$'000 千港元	Debt investments 債務投資 HK$'000 千港元	Equity investments 股本投資 HK$'000 千港元	Financial assets at amortised cost 按攤銷成本計量的金融資產 HK$'000 千港元	Total 合計 HK$'000 千港元
Investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資	–	–	–	37,019	–	37,019
Trade receivables	貿易應收款項	–	–	–	–	125,360	125,360
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產	–	–	–	–	35,034	35,034
Financial assets at fair value through profit or loss	按公允價值計入損益之金融資產	–	36,573	–	–	–	36,573
Amount due from associates	應收聯營公司款項	–	–	–	–	3,066	3,066
Amount due from a joint venture	應收一間合資公司款項	–	–	–	–	424	424
Amount due from related companies	應收關聯公司款項	–	–	–	–	10,715	10,715
Cash, bank balances and deposits	現金、銀行結餘及存款	–	–	–	–	331,320	331,320
		–	36,573	–	37,019	505,919	579,511

Financial liabilities

金融負債

		Financial liabilities at amortised cost 按攤銷成本計量的金融負債 HK$'000 千港元
Trade payables	貿易應付款項	**71,333**
Financial liabilities included in other payables and accruals	計入其他應付款項及應計費用的金融負債	**24,954**
Loans from non-controlling shareholders of subsidiaries	來自附屬公司非控股股東的貸款	**46,379**
Amount due to associates	應付聯營公司款項	**399**
Amount due to related companies	應付關聯公司款項	**14,683**
Lease liabilities	租賃負債	**97,558**
		255,306

43. FINANCIAL INSTRUMENTS BY CATEGORY (Continued)

43. 金融工具分類(續)

2025

Financial assets

2025年

金融資產

		Financial assets at fair value through profit or loss 按公允價值計入損益的金融資產		Financial assets at fair value through other comprehensive income 按公允價值計入其他全面收入的金融資產			
		Mandatorily designated as such 強制指定為按此方式計量 HK$'000 千港元	Designated as such upon initial recognition 於首次確認時指定為按此方式計量 HK$'000 千港元	Debt investments 債務投資 HK$'000 千港元	Equity investments 股本投資 HK$'000 千港元	Financial assets at amortised cost 按攤銷成本計量的金融資產 HK$'000 千港元	Total 合計 HK$'000 千港元
Investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資	–	–	–	40,272	–	40,272
Trade receivables	貿易應收款項	–	–	–	–	120,684	120,684
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產	–	–	–	–	43,428	43,428
Financial assets at fair value through profit or loss	按公允價值計入損益之金融資產	–	38,864	–	–	–	38,864
Amount due from associates	應收聯營公司款項	–	–	–	–	4,493	4,493
Amount due from a joint venture	應收一間合資公司款項	–	–	–	–	26	26
Amount due from related companies	應收關聯公司款項	–	–	–	–	10,252	10,252
Cash, bank balances and deposits	現金、銀行結餘及存款	–	–	–	–	302,836	302,836
		–	38,864	–	40,272	481,719	560,855

Financial liabilities

金融負債

		Financial liabilities at amortised cost 按攤銷成本計量的金融負債 HK$'000 千港元
Trade payables	貿易應付款項	61,584
Financial liabilities included in other payables and accruals	計入其他應付款項及應計費用的金融負債	24,170
Loans from non-controlling shareholders of subsidiaries	來自附屬公司非控股股東的貸款	53,174
Amount due to associates	應付聯營公司款項	522
Amount due to related companies	應付關聯公司款項	9,497
Lease liabilities	租賃負債	108,376
		257,323

44. FAIR VALUE AND FAIR VALUE HIERARCHY

The carrying amounts and fair values of the Group's financial instruments, other than those with carrying amounts that are reasonably approximate to fair values, are as follows:

44. 公允價值及公允價值等級

本集團的金融資產(賬面值與公允價值合理相若的金融資產除外)的賬面值及公允價值如下：

		Carrying amounts 賬面值		Fair values 公允價值	
		2026	2025	**2026**	2025
		2026年	2025年	**2026年**	2025年
		HK$'000	HK$'000	**HK$'000**	HK$'000
		千港元	千港元	**千港元**	千港元
Financial assets	**金融資產**				
Investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資				
– Unlisted equity investments	－非上市股本投資	**25,024**	26,434	**25,024**	26,434
– Listed equity investment	－上市股本投資	**11,995**	13,838	**11,995**	13,838
Financial assets at fair value through profit or loss	按公允價值計入損益的金融資產				
– Listed equity investments	－上市股本投資	**2,302**	2,045	**2,302**	2,045
– Unlisted but quoted investment funds	－非上市但有報價的投資基金	**34,271**	36,819	**34,271**	36,819
		73,592	79,136	**73,592**	79,136

44. FAIR VALUE AND FAIR VALUE HIERARCHY (Continued)

Management has assessed that the fair values of cash and cash equivalents, pledged deposits, trade receivables, trade payables, other financial assets included in prepayments and other receivables, financial liabilities included in other payables and accruals, lease liabilities, balances with associates, related companies, joint ventures and non-controlling interests approximate to their carrying amounts largely due to the short term maturities/repayable on demand of these instruments or the effect of discounting is not material.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

The fair values of listed equity and debt investments are based on quoted market prices.

The fair value of unlisted investment funds is based on price quoted by financial institutions with reference to quoted price in an active market of the listed securities comprising the fund portfolio being valued.

The fair values of unlisted equity investments are estimated based on either the market approach or recent market transaction price. The market approach is based on price multiple determined with reference to comparable public companies and includes appropriate risk adjustments for lack of marketability.

44. 公允價值及公允價值等級(續)

管理層已評定現金及現金等價物、抵押存款、貿易應收款項、貿易應付款項、計入預付款項及其他應收款項的其他金融資產、計入其他應付款項及應計費用的金融負債、租賃負債、與聯營公司、關聯公司、合資公司及非控股權益的結餘的公允價值與其賬面值相若，主要因此等工具於短時間內到期／按要求償還或因折現影響並不重大。

金融資產及負債的公允價值按自願交易方(而非強迫或清盤銷售)於當前交易中交換該工具的金額入賬。已使用下列方法及假設估計公允價值：

上市股本及債務投資的公允價值基於公開市場報價釐定。

非上市投資基金的公允價值是基於金融機構的報價，並參考構成所估值的基金組合的上市證券在活躍市場的報價。

非上市股本投資之公允價值乃基於市場法或近期交易市價進行估計。市場法以經參考可資比較上市公司及包括因欠缺適銷性而作出的適當風險調整而釐定之價格倍數為基礎。

44. FAIR VALUE AND FAIR VALUE HIERARCHY (Continued)

Below is a summary of significant unobservable inputs to the valuation of financial instruments together with a quantitative sensitivity analysis as at 30 June 2026 and 2025:

44. 公允價值及公允價值等級(續)

下表概述於2026年及2025年6月30日金融工具估值的重大不可觀察輸入數據連同定量敏感度分析：

	Valuation technique 估值技術	Significant unobservable input 重大不可觀察輸入數據	Range 範圍	Sensitivity of fair value to the input 公允價值對輸入數據之敏感度
As at 30 June 2026: 於2026年6月30日：				
Unlisted equity investments A 非上市股本投資A	Market approach 市場法	Enterprise value-to-Sales multiple ("EV/Sales multiple") 企業價值對銷售倍數(「EV/Sales倍數」)	0.44 to 3.76 0.44至3.76	10% increase/decrease in EV/Sales multiple would result in decrease/increase in fair value by HK$31,000/HK$31,000. EV/Sales倍數增加／減少10%將令到公允價值減少／增加31,000港元／31,000港元。
		Discount for lack of marketability ("DLOM") 欠缺適銷性折讓(「欠缺適銷性折讓」)	20% 20%	10% increase/decrease in DLOM would result in decrease/increase in fair value by HK$15,000/HK$15,000. 欠缺適銷性折讓增加／減少10%將令到公允價值減少／增加15,000港元／15,000港元。
Unlisted equity investments B 非上市股本投資B	Market approach 市場法	Enterprise value-to-EBITDA multiple ("EV/EBITDA multiple") 企業價值對EBITDA倍數(「EV/EBITDA倍數」)	10.39 to 20.08 10.39至20.08	10% increase/decrease in EV/EBITDA multiple would result in increase/decrease in fair value by HK$67,000/HK$67,000. EV/EBITDA倍數增加／減少10%將令到公允價值增加／減少67,000港元／67,000港元。
		DLOM 欠缺適銷性折讓	40% 40%	10% increase/decrease in DLOM would result in decrease/increase in fair value by HK$117,000/HK$117,000. 欠缺適銷性折讓增加／減少10%將令到公允價值減少／增加117,000港元／117,000港元。
		Discount for lack of control ("DLOC") 欠缺控制權折讓(「欠缺控制權折讓」)	20% 20%	10% increase/decrease in DLOC would result in decrease/increase in fair value by HK$44,000/HK$44,000. 欠缺控制權折讓增加／減少10%將令到公允價值減少／增加44,000港元／44,000港元。
		Control Premium 控制權溢價	25% 25%	10% increase/decrease in control premium would result in increase/decrease in fair value by HK$18,000/HK$18,000. 控制權溢價增加／減少10%將令到公允價值增加／減少18,000港元／18,000港元。
Unlisted equity investments C 非上市股本投資C	Market approach 市場法	EV/Sales multiple EV/Sales倍數	1.08 to 4.54 1.08至4.54	10% increase/decrease in EV/Sales multiple would result in increase/decrease in fair value by HK$291,000/HK$291,000. EV/Sales倍數增加／減少10%將令到公允價值增加／減少291,000港元／291,000港元。
		DLOM 欠缺適銷性折讓	33% 33%	10% increase/decrease in DLOM would result in decrease/increase in fair value by HK$1,116,000/HK$1,116,000. 欠缺適銷性折讓增加／減少10%將令到公允價值減少／增加1,116,000港元／1,116,000港元。

44. FAIR VALUE AND FAIR VALUE HIERARCHY (Continued)

44. 公允價值及公允價值等級(續)

	Valuation technique 估值技術	Significant unobservable input 重大不可觀察輸入數據	Range 範圍	Sensitivity of fair value to the input 公允價值對輸入數據之敏感度
As at 30 June 2025: 於2025年6月30日：				
Unlisted equity investments A 非上市股本投資A	Market approach 市場法	EV/Sales multiple EV/Sales倍數	0.44 to 3.76 0.44至3.76	10% increase/decrease in EV/Sales multiple would result in increase/decrease in fair value by HK$64,000/HK$64,000. EV/Sales倍數增加／減少10%將令到公允價值增加／減少64,000港元／64,000港元。
		DLOM 欠缺適銷性折讓	20% 20%	10% increase/decrease in DLOM would result in decrease/increase in fair value by HK$13,000/HK$13,000. 欠缺適銷性折讓增加／減少10%將令到公允價值減少／增加13,000港元／13,000港元。
Unlisted equity investments B 非上市股本投資B	Market approach 市場法	EV/EBITDA multiple EV/EBITDA倍數	10.39 to 20.08 10.39至20.08	10% increase/decrease in EV/EBITDA multiple would result in increase/decrease in fair value by HK$308,000/HK$308,000. EV/EBITDA倍數增加／減少10%將令到公允價值增加／減少308,000港元／308,000港元。
		DLOM 欠缺適銷性折讓	40% 40%	10% increase/decrease in DLOM would result in decrease/increase in fair value by HK$222,000/HK$222,000. 欠缺適銷性折讓增加／減少10%將令到公允價值減少／增加222,000港元／222,000港元。
		DLOC 欠缺控制權折讓	20% 20%	10% increase/decrease in DLOC would result in decrease/increase in fair value by HK$83,000/HK$83,000. 欠缺控制權折讓增加／減少10%將令到公允價值減少／增加83,000港元／83,000港元。
		Control Premium 控制權溢價	25% 25%	10% increase/decrease in control premium would result in increase/decrease in fair value by HK$66,000/HK$66,000. 控制權溢價增加／減少10%將令到公允價值增加／減少66,000港元／66,000港元。
Unlisted equity investments C 非上市股本投資C	Market approach 市場法	EV/Sales multiple EV/Sales倍數	1.08 to 4.54 1.08至4.54	10% increase/decrease in EV/Sales multiple would result in increase/decrease in fair value by HK$439,000/HK$439,000. EV/Sales倍數增加／減少10%將令到公允價值增加／減少439,000港元／439,000港元。
		DLOM 欠缺適銷性折讓	33% 33%	10% increase/decrease in DLOM would result in decrease/increase in fair value by HK$474,000/HK$474,000. 欠缺適銷性折讓增加／減少10%將令到公允價值減少／增加474,000港元／474,000港元。

44. FAIR VALUE AND FAIR VALUE HIERARCHY (Continued)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments and property, plant and equipment:

44. 公允價值及公允價值等級(續)

公允價值等級

下表載列本集團金融工具以及物業、廠房及設備的公允價值計量等級：

Assets measured at fair value:
As at 30 June 2026

按公允價值計量的資產：
於2026年6月30日

		Fair value measurement using 公允價值計量採用的基準			
		Quoted prices in active markets (Level 1) 活躍市場報價（第一層） HK$'000 千港元	Significant observable inputs (Level 2) 重大可觀察輸入數據（第二層） HK$'000 千港元	Significant unobservable inputs (Level 3) 重大不可觀察輸入數據（第三層） HK$'000 千港元	Total 合計 HK$'000 千港元
Investments at fair value through other comprehensive income:	按公允價值計入其他全面收入的投資：				
– Unlisted equity investments	－非上市股本投資	–	–	25,024	25,024
– Listed equity investment	－上市股本投資	11,995	–	–	11,995
Financial assets at fair value through profit or loss:	按公允價值計入損益的金融資產：				
– Listed equity investments	－上市股本投資	2,302	–	–	2,302
– Unlisted but quoted investment funds	－非上市但有報價的投資基金	–	34,271	–	34,271
Property, plant and equipment:	物業、廠房及設備：				
– Building	－樓宇	–	–	36,001	36,001
		14,297	34,271	61,025	109,593

44. FAIR VALUE AND FAIR VALUE HIERARCHY (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value:

As at 30 June 2025

44. 公允價值及公允價值等級(續)

公允價值等級(續)

按公允價值計量的資產：

於2025年6月30日

		Fair value measurement using 公允價值計量採用的基準			
		Quoted prices in active markets (Level 1) 活躍市場報價（第一層） HK$'000 千港元	Significant observable inputs (Level 2) 重大可觀察輸入數據（第二層） HK$'000 千港元	Significant unobservable inputs (Level 3) 重大不可觀察輸入數據（第三層） HK$'000 千港元	Total 合計 HK$'000 千港元
Investments at fair value through other comprehensive income:	按公允價值計入其他全面收入的投資：				
– Unlisted equity investments	－非上市股本投資	–	–	26,434	26,434
– Listed equity investment	－上市股本投資	13,838	–	–	13,838
Financial assets at fair value through profit or loss:	按公允價值計入損益的金融資產：				
– Listed equity investments	－上市股本投資	2,045	–	–	2,045
– Unlisted but quoted investment funds	－非上市但有報價的投資基金	–	36,819	–	36,819
		15,883	36,819	26,434	79,136

During the year, there were no transfers of fair value measurements between Level 1 and Level 2 for financial assets (2025: Nil). The movements in fair value measurements within Level 3 are as follows:

於年內，金融資產第一層與第二層之間並無公允價值計量轉撥（2025年：無）。第三層內的公允價值計量的變動如下：

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
Equity investments at fair value through other comprehensive income:	按公允價值計入其他全面收入的股本投資：		
At 1 July	於7月1日	**26,434**	13,448
Fair value gain recognised in other comprehensive income	於其他全面收入確認的公允價值收益	**(1,410)**	12,986
At 30 June	於6月30日	**25,024**	26,434

44. FAIR VALUE AND FAIR VALUE HIERARCHY (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

The Group did not have any financial liabilities measured at fair value as at 30 June 2025 and 2026.

Fair value measurement of property, plant and equipment

(i) Fair value hierarchy

The Group's building was revalued as at 30 June 2026. The valuations were carried out by an independent qualified valuer, of Colliers International Group Inc, whose staff include members of the Hong Kong Institute of Surveyors with recent experience in the location and category of property being valued. The Group's senior management have discussions with Colliers International Group Inc on the valuation assumptions and valuation results when the valuation is performed at each annual reporting date.

(ii) Information about Level 3 fair value measurements

The fair value of the Group's building located in Hong Kong are determined on a recurring basis using the direct market comparison approach, assuming sale of properties in their existing state with vacant possession and by reference to recent comparable sales transactions as available in the market.

44. 公允價值及公允價值等級(續)

公允價值等級(續)

按公允價值計量的負債：

本集團於2025年及2026年6月30日並無任何按公允價值計量的金融負債。

物業、廠房及設備的公允價值計量

(i) 公允價值等級

本集團的樓宇已於2026年6月30日重新估值。該等估值由獨立合資格估值師Colliers International Group Inc進行，該估值師的員工包括香港測量師學會會員，且近期對所估值物業的位置及類別擁有經驗。於各年度報告日期進行估值時，本集團的高級管理層會與Colliers International Group Inc就估值假設及估值結果進行討論。

(ii) 有關第三級公允價值計量的資料

本集團位於香港的樓宇公允價值採用直接市場比較法按經常性基準釐定，當中已假設物業按其現狀交吉出售，並已參考市場上可獲得的近期可資比較銷售交易。

Valuation techniques 估值技術	Unobservable inputs 不可觀察輸入數據	Range 2026 2026年範圍
Direct market comparison approach 直接市場比較法	Adjusted unit rate/square feet (for saleable area) 經調整單位價格／平方呎（就實用面積而言）	HK$9,074 to HK$13,288 9,074港元至13,288港元

45. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Group's principal financial instruments comprise cash and cash equivalents and short term deposits. The main purpose of these financial instruments is to finance the Group's operations. The Group has various other financial assets and liabilities such as trade receivables and trade payables, which arise directly from its operations.

The main risks arising from the Group's financial instruments are credit risk and liquidity risk. The board of directors reviews and agrees policies for managing each of these risks and they are summarised below.

Credit risk

The Group trades only with recognised and creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and the Group's exposure to bad debts is not significant.

With respect to listed equity and debt investments, the Group purchases and holds them only through various creditworthy financial institutions.

Maximum exposure and year-end staging

The tables below show the credit quality and the maximum exposure to credit risk based on the Group's credit policy, which is mainly based on past due information unless other information is available without undue cost or effort, and year-end staging classification as at 30 June. For listed debt investments, the Group also monitors them by using external credit ratings and ensures that investments are only made in debts meeting a certain credit rating to minimise credit risk. The amounts presented are gross carrying amounts for financial assets.

45. 財務風險管理目標及政策

本集團的主要金融工具包括現金及現金等價物以及短期存款。該等金融工具的主要目的是為本集團的營運提供資金。本集團有多類直接由其營運產生的其他金融資產及負債，如貿易應收款項及貿易應付款項。

本集團金融工具產生的主要風險為信貸風險及流動性風險。董事會審閱並同意管理各項該等風險的政策並概述如下。

信貸風險

本集團僅與獲認可兼信譽可靠的第三方進行交易。按照本集團的政策，所有擬按信貸條款進行交易的客戶必須通過信貸核實程序後，方可作實。此外，本集團會持續監察應收款項結餘的情況，其所面對的壞賬風險並不重大。

本集團僅透過信譽良好的財務機構購買及持有上市股本及債務投資。

最高風險及年結階段

下表載列基於本集團的信貸政策的信貸質素及最高信貸風險，主要基於逾期資料(除非其他資料可在無須付出不必要成本或努力的情況下獲得)，及於6月30日的年結階段分類。就上市債務投資而言，本集團亦使用外部信貸評級監察該等投資，並確保該等投資僅以債務形式作出以及符合特定信貸評級以盡量降低信貸風險。所呈列的有關金額指金融資產總賬面值。

45. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

45. 財務風險管理目標及政策(續)

Credit risk (Continued)

信貸風險(續)

Maximum exposure and year-end staging (Continued)

最高風險及年結階段(續)

As at 30 June 2026

於2026年6月30日

		12-month ECLs 12個月預期信貸虧損	Lifetime ECLs 全期預期信貸虧損			
		Stage 1 階段1 HK$'000 千港元	Stage 2 階段2 HK$'000 千港元	Stage 3 階段3 HK$'000 千港元	Simplified approach 簡化法 HK$'000 千港元	Total 合計 HK$'000 千港元
Financial assets at amortised cost:	按攤銷成本計量的金融資產：					
– Normal	－正常	–	–	–	–	–
Trade receivables*	貿易應收款項*	–	–	–	125,360	125,360
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產					
– Normal**	－正常**	35,034	–	–	–	35,034
Amounts due from associates	應收聯營公司款項					
– Not yet past due	－尚未逾期	3,066	–	–	–	3,066
Amounts due from a joint venture	應收一間合資公司款項	424	–	–	–	424
Amounts due from related companies	應收關聯公司款項					
– Not yet past due	－尚未逾期	10,715	–	–	–	10,715
Cash, bank balances and deposits	現金、銀行結餘及存款					
– Not yet past due	－尚未逾期	331,320	–	–	–	331,320
		380,559	–	–	125,360	505,919

45. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

Credit risk (Continued)

Maximum exposure and year-end staging (Continued)

As at 30 June 2025

45. 財務風險管理目標及政策(續)

信貸風險(續)

最高風險及年結階段(續)

於2025年6月30日

		12-month ECLs 12個月預期信貸虧損	Lifetime ECLs 全期預期信貸虧損			
		Stage 1 階段1 HK$'000 千港元	Stage 2 階段2 HK$'000 千港元	Stage 3 階段3 HK$'000 千港元	Simplified approach 簡化法 HK$'000 千港元	Total 合計 HK$'000 千港元
Financial assets at amortised cost:	按攤銷成本計量的金融資產：					
– Normal	－正常	–	–	–	–	–
Trade receivables*	貿易應收款項*	–	–	–	120,684	120,684
Financial assets included in prepayments, other receivables and other assets	計入預付款項、其他應收款項及其他資產的金融資產					
– Normal**	－正常**	43,428	–	–	–	43,428
Amounts due from associates	應收聯營公司款項					
– Not yet past due	－尚未逾期	4,493	–	–	–	4,493
Amounts due from a joint venture	應收一間合資公司款項	26	–	–	–	26
Amounts due from related companies	應收關聯公司款項					
– Not yet past due	－尚未逾期	10,252	–	–	–	10,252
Cash, bank balances and deposits	現金、銀行結餘及存款					
– Not yet past due	－尚未逾期	302,836	–	–	–	302,836
		361,035	–	–	120,684	481,719

45. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

Credit risk (Continued)

Maximum exposure and year-end staging (Continued)

* For trade receivables to which the Group applies the simplified approach for impairment, information based on the provision matrix is disclosed in note 24 to the consolidated financial statements.

** The credit quality of the financial assets included in prepayments, other receivables and other assets is considered to be "normal" when they are not past due and there is no information indicating that the financial assets had a significant increase in credit risk since initial recognition. Otherwise, the credit quality of the financial assets is considered to be "doubtful".

Further quantitative data in respect of the Group's exposure to credit risk arising from trade receivables are disclosed in note 24 to the consolidated financial statements.

At the end of the reporting period, the Group had certain concentrations of credit risk as 9% (2025: 11%) and 36% (2025: 33%) of the Group's trade receivables were due from the Group's largest debtor and the five largest debtors, respectively.

Liquidity risk

The Group monitors and maintains a sufficient level of cash and cash equivalents deemed adequate by management to finance the Group's operations and mitigate the effects of fluctuation in cash flows. Management reviews and monitors the Group's working capital requirements regularly.

45. 財務風險管理目標及政策(續)

信貸風險(續)

最高風險及年結階段(續)

* 就本集團應用簡化減值方法的貿易應收款項，基於撥備矩陣的資料於綜合財務報表附註24披露。

** 計入預付款項、其他應收款項及其他資產的金融資產之信貸質素於其並無逾期且並無資料顯示該等金融資產自初步確認起信貸風險有重大增加時視作「正常」。否則，金融資產之信貸質素視作「存疑」。

本集團產生自貿易應收款項的信貸風險敞口的進一步量化數據披露於綜合財務報表附註24。

於報告期末，本集團承擔若干信貸集中風險，因本集團的貿易應收款項中，分別有9%(2025年：11%)及36%(2025年：33%)為應收本集團最大債務人及五大債務人的款項。

流動性風險

本集團監控及維持管理層認為足夠的現金及現金等價物，以便為本集團的營運提供資金並緩解現金流量波動的影響。管理層定期審視及監控本集團的營運資金需求。

45. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

Liquidity risk (Continued)

The maturity profile of the Group's financial liabilities as at the end of the reporting period, based on the contractual undiscounted payments, is as follows:

45. 財務風險管理目標及政策(續)

流動性風險(續)

於報告期末，本集團按合約未貼現付款釐定的金融負債到期情況載列如下：

		2026 2026年				
		On demand 按要求償還 HK$'000 千港元	Less than 1 year 少於1年 HK$'000 千港元	1 to 5 years 1至5年 HK$'000 千港元	More than 5 years 5年以上 HK$'000 千港元	Total 合計 HK$'000 千港元
Trade payables	貿易應付款項	**71,333**	**–**	**–**	**–**	**71,333**
Financial liabilities included in other payables and accruals	計入其他應付款項及應計費用的金融負債	**24,954**	**–**	**–**	**–**	**24,954**
Loans from non-controlling shareholders of subsidiaries	來自附屬公司非控股股東的貸款	**46,379**	**–**	**–**	**–**	**46,379**
Amounts due to related companies	應付關聯公司款項	**14,683**	**–**	**–**	**–**	**14,683**
Amounts due to associates	應付聯營公司款項	**399**	**–**	**–**	**–**	**399**
Lease liabilities	租賃負債	**–**	**43,733**	**53,825**	**–**	**97,558**
		157,748	**43,733**	**53,825**	**–**	**255,306**

		2025 2025年				
		On demand 按要求償還 HK$'000 千港元	Less than 1 year 少於1年 HK$'000 千港元	1 to 5 years 1至5年 HK$'000 千港元	More than 5 years 5年以上 HK$'000 千港元	Total 合計 HK$'000 千港元
Trade payables	貿易應付款項	1,814	59,770	–	–	61,584
Financial liabilities included in other payables and accruals	計入其他應付款項及應計費用的金融負債	24,710	–	–	–	24,710
Loans from non-controlling shareholders of subsidiaries	來自附屬公司非控股股東的貸款	53,174	–	–	–	53,174
Amounts due to related companies	應付關聯公司款項	9,497	–	–	–	9,497
Amounts due to associates	應付聯營公司款項	522	–	–	–	522
Lease liabilities	租賃負債	–	55,519	52,857	–	108,376
		89,717	115,289	52,857	–	257,863

45. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

Capital management

The primary objectives of the Group's capital management are to safeguard the Group's ability to continue as a going concern and to maintain healthy capital structure in order to support its business and maximise shareholders' value. The Group primarily funds its operations by cash generated from operating activities. As at 30 June 2026, the Group did not have any bank borrowings or outstanding bank loans (2025: nil).

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the years ended 30 June 2026 and 30 June 2025.

The capital of the Group represents equity attributable to owners of the Company.

45. 財務風險管理目標及政策(續)

資本管理

本集團資本管理的首要目標為保障本集團持續經營的能力並維持穩健的資本架構，以支持其業務及為股東創造最大價值。本集團主要通過經營活動產生的現金為其營運提供資金。於2026年6月30日，本集團並無任何銀行借貸或未償還銀行貸款(2025年：無)。

本集團根據經濟環境變化及相關資產的風險特徵管理及調整其資本架構。為維持或調整資本架構，本集團或會調整派付予股東的股息、返還資本予股東或發行新股份。本集團並不受任何外部施加的資本要求規限。於截至2026年6月30日及2025年6月30日止年度，資本管理目標、政策或程序並未發生變動。

本集團的資本即為本公司擁有人應佔權益。

46. STATEMENT OF FINANCIAL POSITION OF THE COMPANY

Information about the statement of financial position of the Company at the end of the reporting period is as follows:

46. 本公司財務狀況表

有關於報告期末本公司財務狀況表的資料如下：

		2026 2026年 HK$'000 千港元	2025 2025年 HK$'000 千港元
NON-CURRENT ASSETS	**非流動資產**		
Investments at fair value through other comprehensive income	按公允價值計入其他全面收入的投資	**11,995**	13,838
Total non-current assets	非流動資產總額	**11,995**	13,838
CURRENT ASSETS	**流動資產**		
Prepayments and other receivables	預付款項及其他應收款項	**190**	211
Financial assets at amortised cost	按攤銷成本計量的金融資產	**–**	–
Financial assets at fair value through profit or loss	按公允價值計入損益的金融資產	**34,271**	36,820
Due from subsidiaries	應收附屬公司款項	**413,229**	388,343
Cash, bank balances and deposits	現金、銀行結餘及存款	**143,784**	62,180
Total current assets	流動資產總額	**591,474**	487,554
CURRENT LIABILITIES	**流動負債**		
Other payables and accruals	其他應付款項及應計費用	**306**	2,144
Due to subsidiaries	應付附屬公司款項	**136,738**	–
Total current liabilities	流動負債總額	**137,044**	2,144
NET CURRENT ASSETS	**流動資產淨額**	**454,430**	485,410
Net assets	資產淨額	**466,425**	499,248
EQUITY	**權益**		
Issued capital	已發行股本	**811**	811
Reserves (note)	儲備(附註)	**465,614**	498,437
Total equity	總權益	**466,425**	499,248

46. STATEMENT OF FINANCIAL POSITION OF THE COMPANY (Continued)

46. 本公司財務狀況表(續)

Notes:

附註：

A summary of the Company's reserves is as follows:

本公司儲備概要如下：

		Share premium account 股份溢價賬 HK$'000 千港元	Shares held under the share award scheme 股份獎勵計劃項下預留的股份 HK$'000 千港元 (note 37) (附註37)	Share-based payment reserve 以股份為基礎的付款儲備 HK$'000 千港元 (note 38) (附註38)	Fair value reserve 公允價值儲備 HK$'000 千港元	Retained profits 留存利潤 HK$'000 千港元	Total 合計 HK$'000 千港元
At 30 June 2024 and 1 July 2024	於2024年6月30日及2024年7月1日	436,751	(15,842)	7,629	(9,665)	109,184	528,057
Profit for the year	年內利潤	–	–	–	–	(320)	(320)
Other comprehensive loss for the year:	年內其他全面虧損：						
Changes in fair value of equity investments at fair value through other comprehensive income	按公允價值計入其他全面收入的股本投資的公允價值變動	–	–	–	(3,167)	–	(3,167)
Total comprehensive income for the year	年內全面收入總額	–	–	–	(3,167)	(320)	(3,487)
Final 2024 dividend	2024年末期股息	–	–	–	–	(16,219)	(16,219)
Interim 2025 dividend	2025年中期股息	–	–	–	–	(11,353)	(11,353)
Purchases of shares for the share award scheme	就股份獎勵計劃購買股份	–	(180)	–	–	–	(180)
Equity-settled share-based payment arrangements	以權益結算的以股份為基礎的付款安排	–	1,619	(1,084)	–	1,084	1,619
At 30 June 2025 and 1 July 2025	於2025年6月30日及2025年7月1日	436,751	(14,403)	6,545	(12,832)	82,376	498,437
Profit for the year	年內利潤	–	–	–	–	(5,323)	(5,323)
Other comprehensive loss for the year:	年內其他全面虧損：						
Changes in fair value of equity investments at fair value through other comprehensive income	按公允價值計入其他全面收入的股本投資的公允價值變動	–	–	–	(1,515)	–	(1,515)
Total comprehensive income for the year	年內全面收入總額	–	–	–	(1,515)	(5,323)	(6,838)
Final 2025 dividend	2025年末期股息	–	–	–	–	(15,408)	(15,408)
Interim 2026 dividend	2026年中期股息	–	–	–	–	(11,353)	(11,353)
Transfer upon disposal of equity securities designated at fair value	出售指定為按公允價值計量的權益證券時轉撥	–	–	–	185	(185)	–
Purchases of shares for the share award scheme	就股份獎勵計劃購買股份	–	(976)	–	–	–	(976)
Equity-settled share-based payment arrangements	以權益結算的以股份為基礎的付款安排	–	1,752	(772)	–	772	1,752
At 30 June 2026	於2026年6月30日	436,751	(13,627)	5,773	(14,162)	50,879	465,614

47. APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements were approved and authorised for issue by the board of directors on 24 September 2026.

47. 批准綜合財務報表

綜合財務報表於2026年9月24日獲董事會批准及授權刊發。

A summary of the results and of the assets, liabilities and non-controlling interests of the Group for the last five financial years, as extracted from the published audited financial statements and restated as appropriate, is set out below.

本集團於過去五個財政年度的業績及資產、負債及非控股權益概要(摘錄自已公佈經審核財務報表及適當地重列)載列如下。

CONSOLIDATED RESULTS 綜合業績

		Year ended 30 June 截至6月30日止年度				
		2026	2025	2024	2023	2022
		2026年	2025年	2024年	2023年	2022年
		HK$'000	HK$'000	HK$'000	HK$'000	HK$'000
		千港元	千港元	千港元	千港元	千港元
Continuing operations	持續經營業務					
Revenue	收入	**716,971**	726,949	748,489	727,167	665,859
(Loss)/profit before tax	除稅前(虧損)/利潤	**(64,751)**	40,499	40,624	64,365	85,980
Income tax expense	所得稅費用	**(7,974)**	(8,583)	(5,407)	(8,630)	(11,946)
(Loss)/profit for the year from continuing operations	來自持續經營業務的年內(虧損)/利潤	**(72,725)**	31,916	35,217	55,735	74,034
(Loss)/profit for the year from discontinued operation	已終止經營業務的年內(虧損)/利潤	**–**	–	–	–	1,197
(Loss)/profit for the year	年內(虧損)/利潤	**(72,725)**	31,916	35,217	55,735	75,231
Attributable to:	以下各方應佔:					
Owners of the Company	本公司擁有人	**(74,639)**	31,440	40,643	60,452	72,168
Non-controlling interests	非控股權益	**1,914**	476	(5,426)	(4,717)	3,063

ASSETS AND LIABILITIES 資產及負債

		As at 30 June 於6月30日				
		2026	2025	2024	2023	2022
		2026年	2025年	2024年	2023年	2022年
		HK$'000	HK$'000	HK$'000	HK$'000	HK$'000
		千港元	千港元	千港元	千港元	千港元
Total assets	總資產	**990,713**	1,095,325	1,106,823	1,121,254	1,037,601
Total liabilities	總負債	**338,390**	343,526	362,548	351,535	300,296
Net assets	資產淨額	**652,323**	751,799	744,275	769,719	737,305
Equity attributable to:	以下各方應佔權益:					
Owners of the Company	本公司擁有人	**640,212**	742,632	725,942	740,547	698,653
Non-controlling interests	非控股權益	**12,111**	9,167	18,333	29,172	38,652
Total equity	權益淨額	**652,323**	751,799	744,275	769,719	737,305

GLOSSARY
詞彙

"2023 Share Option Scheme"	the new share option scheme approved and adopted by the Company on 24 November 2023
「2023年購股權計劃」	本公司於2023年11月24日批准及採納的新購股權計劃
"2026 AGM"	the annual general meeting of the Company to be held on Friday, 20 November 2026
「2026年股東週年大會」	本公司將於2026年11月20日(星期五)舉行的股東週年大會
"Affiliated Clinic(s)"	clinic(s) which is/are not operated by the Group but which has entered or will enter into an agreement directly with the Group to offer Medical Services, Dental Services and/or Auxiliary Services to the Plan Members
「聯屬診所」	並非由本集團經營但已經或將會直接與本集團訂立協議以向計劃成員提供醫療服務、牙科服務及/或輔助服務的診所
"Affiliated Doctor", "Affiliated Dentist", "Affiliated Auxiliary Services Providers"	doctor(s)/dentist(s)/Auxiliary Services Provider(s) who has/have entered or will enter into an agreement directly with the Group to provide services to Plan Members and who, in accordance with the terms of such agreement, has/have received or will receive an amount from the Group based on the volume of Plan Members treated
「聯屬醫生」、「聯屬牙醫」、「聯屬輔助服務提供者」	已經或將會直接與本集團訂立協議以提供服務予計劃成員的醫生/牙醫/輔助服務提供者,根據該等協議條款,彼等已經或將會按接診的計劃成員數目向本集團收取款項
"Articles" or "Articles of Association"	the amended and restated articles of association of the Company currently in force
「細則」或「公司細則」	目前生效的本公司經修訂及重列公司細則
"Audit Committee"	the audit committee of the Board
「審核委員會」	董事會轄下審核委員會
"Auxiliary Services"	includes imaging and laboratory services, physiotherapy, traditional Chinese medicine, dietetic services and nursing care services
「輔助服務」	包括醫學影像及化驗服務、物理治療、中醫、營養服務與護理服務
"Auxiliary Services Provider"	auxiliary services provider(s) who is/are or will be engaged directly by the Group as a consultant to provide Auxiliary Services in the UMP Medical Centres in accordance with the terms of a consultancy agreement with the Group, and the Affiliated Auxiliary Services Providers
「輔助服務提供者」	已經或將會直接獲本集團委聘為顧問以根據與本集團簽訂的顧問協議的條款在聯合醫務中心內提供輔助服務的輔助服務提供者,以及聯屬輔助服務提供者
"BBS"	Bronze Bauhinia Star
「銅紫荊星章」	銅紫荊星章

GLOSSARY
詞彙

"Board" 「董事會」	the board of Directors 董事會
"Chairman" 「主席」	the chairman of the Board 董事會主席
"Chinese Mainland" or "PRC" 「中國內地」或「中國」	the People's Republic of China (excluding, for the purpose of this report, Hong Kong, Macau and Taiwan) 中華人民共和國(就本報告而言，不包括香港、澳門及台灣)
"Chinese Mainland Clinical Healthcare Services" 「中國內地臨床醫療保健服務」	provision of clinical healthcare services to self-paid patients in Chinese Mainland 於中國內地向自費患者提供臨床醫療保健服務
"Co-Chief Executive Officer" 「聯席行政總裁」	the co-chief executive officer of the Company 本公司聯席行政總裁
"Code of Conduct for Securities Transactions by Employees" 「僱員進行證券交易的操守準則」	the Code of Conduct for Securities Transactions by Employees adopted by the Company 本公司所採納的僱員進行證券交易的操守準則
"Company" 「本公司」	UMP Healthcare Holdings Limited, a company incorporated under the laws of the Cayman Islands with limited liability on 5 November 2014 聯合醫務集團有限公司，於2014年11月5日根據開曼群島法例註冊成立的有限公司
"Contract Customers" 「合約客戶」	collectively, insurance companies and corporations which have entered or will enter into corporate plans with the Group for healthcare benefits for Plan Members 已經或將會就計劃成員的醫療保健福利與本集團訂立企業計劃的保險公司及企業的統稱
"Corporate Governance Code" 「企業管治守則」	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules 上市規則附錄C1所載的企業管治守則
"CR Medical" 「華潤醫療」	China Resources Medical Holdings Company Limited, a company incorporated in the Cayman Islands with limited liability and listed on the Main Board of the Stock Exchange (Stock code: 1515) 華潤醫療控股有限公司，於開曼群島註冊成立並於聯交所主板上市的有限公司(股份代號：1515)
"CTFE" 「周大福企業」	Chow Tai Fook Enterprises Limited, a company incorporated under the laws of Hong Kong with limited liability 周大福企業有限公司，根據香港法例註冊成立的有限公司

GLOSSARY
詞彙

"CT Scan"	computed tomography scan, a medical imaging technique used in radiology to get detailed images of the body non-invasively for diagnostic purposes
「電腦斷層掃描」	電腦斷層掃描，是放射學中的一種醫學影像技術，用於無創地獲得人體的詳細影像以作診斷用途
"Dental" or "Dental Services"	include primary dental services such as scaling and polishing and secondary dental services such as crown and bridge, orthodontics, implants and whitening
「牙科」或「牙科服務」	包括基本牙科服務（如洗牙及拋光）以及第二層牙科服務（如牙冠及牙橋、口腔正畸、植齒及牙齒美白）
"Dentists"	dentist who is or will be engaged directly by the Group as a consultant to provide Dental Services in the UMP Medical Centres in accordance with the terms of a consultancy agreement with the Group, and the Affiliated Dentists
「牙醫」	已經或將會直接獲本集團委聘為顧問以根據與本集團簽訂的顧問協議的條款在聯合醫務中心內提供牙科服務的牙醫，以及聯屬牙醫
"Directors"	directors of the Company
「董事」	本公司董事
"Doctors"	doctors who is/are or will be engaged directly by the Group as a consultant to provide Medical Services in the UMP Medical Centres in accordance with the terms of a consultancy agreement with the Group and the Affiliated Doctors
「醫生」	已經或將會直接獲本集團委聘為顧問以根據與本集團簽訂的顧問協議的條款在聯合醫務中心內提供醫療服務的醫生，以及聯屬醫生
"FY2022"	the financial year ended 30 June 2022
「2022財政年度」	截至2022年6月30日止財政年度
"FY2023"	the financial year ended 30 June 2023
「2023財政年度」	截至2023年6月30日止財政年度
"FY2024"	the financial year ended 30 June 2024
「2024財政年度」	截至2024年6月30日止財政年度
"FY2025"	the financial year ended 30 June 2025
「2025財政年度」	截至2025年6月30日止財政年度
"FY2026"	the financial year ended 30 June 2026
「2026財政年度」	截至2026年6月30日止財政年度
"FY2027"	the financial year ended 30 June 2027
「2027財政年度」	截至2027年6月30日止財政年度

"GBS" 「金紫荊星章」	Gold Bauhinia Star 金紫荊星章
"General Practitioners" or "GPs" 「全科醫生」	Doctors trained in general practice and best suited to act as first point of contact for patients, having the required knowledge to refer patients to the appropriate specialists or services required 接受全科訓練的醫生，最適合為患者提供首次診斷，具備所需知識按需要轉介患者至適合專科或服務
"Global Offering" or "IPO" 「全球發售」或「首次公開發售」	the offer of the shares of the Company to the public in Hong Kong and outside the United States of America in offshore transactions in reliance on Regulation S, the details of which are set out in the section headed "Structure of the Global Offering" of the prospectus of the Company dated 17 November 2015 本公司向香港公眾人士及依據S規例在美國境外的離岸交易中發售股份，詳情載於日期為2015年11月17日的本公司招股章程「全球發售的架構」一節中
"Greater Bay Area" or "GBA" 「大灣區」	Guangdong-Hong Kong-Macau Greater Bay Area, a geographical region of China comprising Guangzhou, Shenzhen, Zhuhai, Foshan, Huizhou, Dongguan, Zhongshan, Jiangmen, Zhaoqing, the Special Administrative Regions of Hong Kong and Macau for the purposes of this document 粵港澳大灣區，就本文件而言為廣州、深圳、珠海、佛山、惠州、東莞、中山、江門、肇慶、香港特別行政區及澳門特別行政區所組成的中國地理區域
"Group", "we", "UMP" or "UMP Healthcare Group" 「本集團」、「我們」、「聯合醫務」或「聯合醫務集團」	the Company and its subsidiaries 本公司及其附屬公司
"HK$" 「港元」	Hong Kong dollars, the lawful currency of Hong Kong 香港法定貨幣港元
"Hong Kong" 「香港」	the Hong Kong Special Administrative Region of the PRC 中國香港特別行政區
"Hong Kong & Macau Clinical Healthcare Services" 「香港及澳門臨床醫療保健服務」	provision of clinical healthcare services to Self-paid Patients in Hong Kong and Macau 於香港及澳門向自費患者提供臨床醫療保健服務
"Hong Kong & Macau Corporate Healthcare Solution Services" 「香港及澳門企業醫療保健解決方案服務」	provision of corporate healthcare solutions services in Hong Kong and Macau 於香港及澳門提供企業醫療保健解決方案服務
"JP" 「太平紳士」	Justice of the Peace 太平紳士

GLOSSARY
詞彙

"Listing Date" 「上市日期」	27 November 2015 2015年11月27日
"Listing Rules" 「上市規則」	the Rules Governing the Listing of Securities on the Stock Exchange 聯交所證券上市規則
"Macau" 「澳門」	the Macau Special Administrative Region of the PRC 中國澳門特別行政區
"Medical" or "Medical Services" 「醫療」或「醫療服務」	include general practice and specialist practice 包括全科醫療及專科醫療
"MH" 「榮譽勳章」	Medal of Honour 榮譽勳章
"Model Code" 「標準守則」	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules 上市規則附錄C3所載上市發行人董事進行證券交易的標準守則
"MRI" 「磁力共振成像」	magnetic resonance imaging, a procedure that uses magnetism, radio waves, and a computer to create images of areas inside the body 磁力共振成像，是一種使用磁力、無線電波和電腦來創建身體內部區域影像的程序
"PET-CT" 「正電子電腦斷層掃描」	positron emission tomography-computed tomography, a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an X-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed (co-registered) image 正電子發射電腦斷層掃描，在單一掃描器機架結合正電子發射斷層掃描器(PET)及X光電腦斷層掃描器(CT)，在同一次療程從兩部儀器取得序列影像並將該等影像結合成單一疊加(融合)影像
"Pinyu" 「品裕」	Pinyu Limited, a company incorporated under the laws of the British Virgin Islands with limited liability, which is a substantial shareholder of the Company and an indirect wholly-owned subsidiary of CR Medical 品裕有限公司，根據英屬處女群島法例註冊成立的有限公司，為本公司主要股東並為華潤醫療的間接全資附屬公司
"Plan Members" 「計劃成員」	members of the Group's corporate healthcare benefits plans, who typically include group medical insurance policyholders and employees of corporations and/or their dependants 本集團企業醫療保健福利計劃成員，一般包括集團醫療保險保單持有人及機構的僱員及／或彼等之受養人

"Post-IPO Share Option Scheme"	the post-IPO share option scheme approved and adopted by the Company on 13 November 2015 and terminated by the Board with effect from 24 November 2023
「首次公開發售後購股權計劃」	本公司於2015年11月13日批准及採納的首次公開發售後購股權計劃，並已被董事會終止，自2023年11月24日起生效
"Pre-IPO Share Option Scheme"	the pre-IPO share option scheme approved and adopted by the Board on 18 August 2015
「首次公開發售前購股權計劃」	董事會於2015年8月18日批准及採納的首次公開發售前購股權計劃
"Remuneration Committee"	the remuneration committee of the Board
「薪酬委員會」	董事會轄下薪酬委員會
"RMB"	Renminbi, the lawful currency of the PRC
「人民幣」	中國法定貨幣人民幣
"Self-paid Patients"	patients who visit a UMP Medical Centre operated by the Group and pays for services using cash or credit card
「自費患者」	到本集團經營的聯合醫務中心就診並使用現金或信用卡支付診金的患者
"Share Award Scheme"	the share award scheme approved and adopted by the Board on 30 June 2016 and amended by the Board with effect from 24 November 2023
「股份獎勵計劃」	董事會於2016年6月30日批准及採納的股份獎勵計劃，並經董事會修訂，自2023年11月24日生效
"Share(s)"	ordinary share(s) with a nominal value of HK$0.001 each in the share capital of the Company
「股份」	本公司股本中每股面值0.001港元的普通股
"Shareholder(s)"	holder(s) of Share(s)
「股東」	股份的持有人
"specialist practice" or "specialist services"	the range of specialist practice offered by UMP, including Cardiology, Dermatology, Endocrinology, Diabetes and Metabolism, Family Medicine, Gastroenterology and Hepatology, General Surgery, Internal Medicine, Nephrology, Neurology, Neurosurgery, Obstetrics and Gynaecology, Ophthalmology, Orthopaedics and Traumatology, Otorhinolaryngology (ENT), Paediatrics, Paediatrics Surgery, Radiology, Respiratory Medicine, Rheumatology and Urology, an updated list of which is available on www.ump.com.hk
「專科醫療」或「專科服務」	聯合醫務提供的一系列專科醫療，包括心臟科、皮膚科、內分泌、糖尿病及代謝科、家庭醫學科、腸胃肝臟科、普通外科、內科、腎臟科、腦神經科、神經外科、婦產科、眼科、骨科及創傷科、耳鼻喉科、兒科、小兒外科、放射科、呼吸道系統科、風濕病科及泌尿科，經更新清單於www.ump.com.hk上可供查閱

GLOSSARY
詞彙

"Stock Exchange" 「聯交所」	The Stock Exchange of Hong Kong Limited 香港聯合交易所有限公司
"UMP Medical Centre(s)" 「聯合醫務中心」	medical centre(s) offering Medical Services, Dental Services and/or Auxiliary Services which is/are operated by the Group 提供醫療服務、牙科服務及／或輔助服務的醫務中心，由本集團經營
"UMP Network" 「UMP網絡」	consists of (i) UMP Medical Centres which are operated by the Group and (ii) Affiliated Clinics which are clinics not operated by the Group but each of which has entered into an agreement with the Group to offer Medical Services, Dental Services and/or Auxiliary Services to Plan Members 包括(i)本集團經營的聯合醫務中心及(ii)聯屬診所（並非由本集團經營的診所，惟各自已與本集團訂立協議以向計劃成員提供醫療服務、牙科服務及／或輔助服務）
"%" 「%」	per cent 百分比



UMP Healthcare
聯合醫務集團

business@ump.com.hk
(852) 2824 0231
(852) 2511 1152
https://www.ump.com.hk